<SEC-DOCUMENT>0000950170-24-119796.txt : 20241101
<SEC-HEADER>0000950170-24-119796.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101070019
ACCESSION NUMBER:		0000950170-24-119796
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pediatrix Medical Group, Inc.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		241417006

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDNAX, INC.
		DATE OF NAME CHANGE:	20090102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>md-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-10-31T08:44:36.6684+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:md="http://www.mednax.com/20240930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_04ceb4d0-3c0b-4d07-956f-8b518e80af23" name="dei:AmendmentFlag" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd">false</ix:nonNumeric><ix:nonNumeric id="F_5ee593a4-c36b-4805-94d8-fcc1170c801c" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd">Q3</ix:nonNumeric><ix:nonNumeric id="F_2605e4f0-d7f3-4a91-83c9-443ed058d56a" name="dei:EntityCentralIndexKey" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd">0000893949</ix:nonNumeric><ix:nonNumeric id="F_0364beb5-1d96-41e0-a43e-51dfdf17c9fd" name="dei:CurrentFiscalYearEndDate" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd">--12-31</ix:nonNumeric><ix:nonFraction id="F_97cf0492-ca89-4c00-ab6e-b389cf4c47c8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_03fdf1ea-e076-45b4-a2b0-c8c20cef772a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="C_809640ed-b7ff-4176-8579-f511b0405d13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85aec564-a952-4cd7-9508-5cbe268b1c48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_884a565f-15d0-484c-a843-754c3a3fd51c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8893f8cd-4da1-451b-89f6-37ca8812969d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89ef8a38-8113-41c1-8884-93ceeeec10b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a373077-e7b6-4d74-ad52-6daa978d5cf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bcf80cf-5670-466b-a111-7a4f4df2f96f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d0e1e7a-bcf8-46ca-91e1-c0bdbcb1a4a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8da3915f-acc7-4713-ba2c-89d5082ed5ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91bb3025-d080-4133-988b-b4f0d0b089ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97646255-9ce5-4a28-beb9-59eb7df4e021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98c7bf66-2c4f-46e5-b8f2-acc2d7acc7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c587590-b2d8-42e3-8e9e-97f94e51d556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f3f07b8-2273-400e-9dac-e0d7b41207ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fe3e6f6-dfe4-49b2-b5b9-6a12b9a5ec2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a064a518-736d-4c03-94ce-b34a0a334113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5ff1526-329f-4f0e-adea-d07328710c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a75a21da-6809-46e5-af03-95d29f9164a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a760bed3-e7a4-433b-9d43-3760b6d240a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a97a53d9-d7b3-4f52-bcbd-33dcc1fc5933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adcf8579-3d6b-4b9f-8e99-6447b79239ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b044401a-b565-4c10-a46e-4df13e21403c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0a769b5-fd85-4a51-83ff-76f342c6430e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b33c435b-217f-44e6-b52c-795ccaa7b00b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4c72fe0-fa90-4fdf-a008-6fff4568447e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8197466-b836-40f5-85ec-515f06dd7959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8fc85c6-2e4a-4259-af7d-66c68b0e250a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb151c97-9f7d-4189-b1ec-f8da6602d134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc533806-93ff-49e5-b0c8-9cf97c0129d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc621510-11b6-4741-b375-b503a329d672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd4aca94-0492-4f7f-9862-fa2bf57c6c59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c365d25d-3bf1-4fdb-a10e-5da8bba0e06b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3888977-2554-47aa-831d-fd567a5a82f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4f7fa0c-4852-41a3-8551-93e9d6ff41e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c879f931-4318-47fc-90a7-3a99688432aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccf152cf-ccd9-4e3b-ad6d-b551a5ad3dc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd2b3074-957c-47ae-bd82-52e354aedc65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf9e856d-4f62-44c9-bc0f-62baf73c9b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d17aad46-7efb-49af-8377-5895940b3823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4d03e6c-0505-4dfb-a0aa-1fb8302e51db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8733763-56e3-4062-ae80-9b406c362d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9374888-7c91-4cc7-a16b-1f318051fca5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbb37038-35b4-4678-82a8-8d91cb359de4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc569cc7-6aeb-45b2-a43d-509db2773e16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3929a3a-e631-4b36-ac48-9798696c3593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3d4fda8-e2c4-41b7-b7bb-a79d5f1f5fb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5b15b48-9344-4b59-8c84-5acf6a9e4f95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e677cfe7-2e92-47c1-bdb2-9ea23c33d51c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8baca31-7b2d-488d-8c77-f9c0d2500a82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edc32faf-e353-493b-84f0-3902b6006c98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efbc84c8-00fb-4a9b-8009-81542e40749f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9508b9c-3eec-4609-8305-3008f33d44f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9c9410e-b646-4864-81ca-3b62fc7d8849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fae578a7-d0cf-4d45-9f18-19ac5559973c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc38c255-4fa4-44a0-a508-6debd99e834f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc7ad59c-2e25-40e7-af1a-51976aee8220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc9712c3-f658-44af-9601-750da0b09a7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fffa0abb-f44c-4f13-9801-32f57a3f6d0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0310ccf0-c3d9-49e4-aadd-2e067003de46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03aeeb1a-6712-41b8-b9d7-3904a46932d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03faae58-4912-4ec2-812d-9cda8660c060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_040f5030-8668-48c5-8848-7595226a4f67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04afc832-8f3e-408b-8423-2c62e6af5946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_050e4bfe-b9c5-4ca8-9e26-96b6ce67c09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05ec53de-4d6b-4354-9ca4-75993de13e10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09f36e04-ed7b-4580-81de-9e91190ac2c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a422510-3d44-47cf-88b2-48f0575a1143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a8c0d8a-e7ce-404f-9c3f-9a4becbd6264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b429a49-04e0-4af0-a34e-5f729e65b865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_117ba3bc-14b9-4031-9bd2-9c2358d754ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1202300f-b9c8-495b-8286-dd386fb30e91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14426c2a-51aa-4302-9c65-7d61956fde41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_185f6642-e06e-4f8e-82da-cc97ce9485fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c7a5188-9dfb-4b7b-9117-75232b52d800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eb0559c-65bc-419b-9342-1cc866cf8e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2174c181-c272-4b4a-a55a-328ca7305cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24781c95-cc49-4f39-8985-1dc5dfaea767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2552545a-460b-438d-84d7-f2a85377d43f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2859086d-715d-44f6-833b-c4f773353b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_289f4f19-0840-473e-83b2-ff56e944f693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28fa2519-8122-457f-8ba0-95ed99b3c132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2aac07cf-292c-417d-84aa-0cdee14fc3fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bf9eff0-56e4-43b2-93d7-2aa6cebf3f72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c0855ff-d273-4bff-9e15-451242764f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f2b7c65-5b1c-4fa7-82de-aeef631ca5d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30923953-448c-4331-a85c-b787cb6bd620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30fb370c-634f-4103-9fe0-f5ed7b584e16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31f10005-61d2-425a-98d1-6c46c15c52e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33d9e07d-a996-482e-a2e3-ae221fbaed2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_345a8683-3a40-4392-9de5-24333799ced8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34b50bdd-0dce-4d36-b6db-803f912a1615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_396c2856-16b5-4b29-9a6d-0cf8c4644545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3aaa3335-768e-46db-93e1-0c4ef48e3199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3adf6473-1204-48e7-8491-9b1ef9c81706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f03f9d7-2c71-47ee-a8a2-3847457e8827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40ce43d6-de46-459b-bbd4-173babcdee2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ba766e-800a-4319-b85c-312bb5654756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45ae435c-1042-4b5a-96ae-8bb41d0114d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46499516-3d0b-4a41-8a39-4fc6b1dd499a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4706aab8-b042-4ef2-a16d-8c4b37316242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a193a2f-b90e-43a7-8dd9-49f38c7c982f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c6acf44-78a8-4282-9b87-3142ddf448cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50c28849-d475-4e33-b9af-f6b8058a8d67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51656139-59ae-422c-baf9-a869db14153e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52510259-ebc9-442f-9bd2-61734b97e057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55792ef2-9526-43dd-a1b0-74ec9336243f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5621fe56-862f-40f3-af0a-35de308efe0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5694b95e-c7a4-4c1f-8ca3-731f364b3aab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56ebd4fc-39c1-4956-8a5c-fcae4efff07b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58c12c59-2a6c-435e-913c-34398f795390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59042f13-1f1d-4792-8848-e80880b13fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dd0ed8f-b21b-4d66-9790-efa9a58934b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fc55157-e10f-464a-8e86-f58de13c1556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60eae1e8-e969-481f-9fcc-b8bd60d6c306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_670aadb1-d0ce-4bc5-9e7e-daa0c38d0f03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67b3dbbf-e507-4f3c-9126-f4e687359ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67fa25ce-537a-4741-a50f-8a52146562e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69acc370-b79c-460d-aad7-0050c48e4b39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cd8e851-3986-4e06-8fd3-aaed9f13e169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ee00435-93bf-4611-b09d-2c2deb02faf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f592960-a202-4029-b088-c0a2bc84ee92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70459c21-18a9-41b0-8deb-ec60bf6e856d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_725f7eeb-d657-453d-92fe-1caaa6092c16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73c5246d-4aad-43c5-87f0-58cbadc4d111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ee178e-6d00-479f-9b2a-a97ace384501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79accd32-aa9b-4cab-864d-398239122d36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7db712e2-9eb1-41c5-a6ef-4225a89f28c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Number"><xbrli:measure>md:Number</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" fromRefs="F_554f20a0-098b-4a43-8639-8d7377037c50 F_28c3128d-bf1c-4211-afdf-739d332083af F_20724637-3d05-4be7-a24a-1b65bee504db F_3dbe5509-4bef-474c-989c-13ffc8dc1751"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11e06b6b-0a67-4cde-955c-f3396d047128" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2241f61-e806-40e6-aa87-c672b133c30f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd7b144e-9ba2-4d93-bf15-11218cae2d34" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce9d2b0d-835f-4bf1-9be4-c9be96d6ab80" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dd7ac59-4fc2-40f3-b4ea-1fd66e514502" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ______ to ______</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b1b56b4-dd4f-4f66-8c17-36445719f793" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-12111</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img260272796_0.jpg" alt="img260272796_0.jpg" style="width:134px;height:84px;"/></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fdd7519-930b-416c-bfd6-7afb802dc795" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.71%;box-sizing:content-box;"/>
    <td style="width:3.821%;box-sizing:content-box;"/>
    <td style="width:48.47%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f57c7b35-1d2d-47b1-9c58-1e8082e36911" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_30ae48c3-ca1d-4257-982a-064eb805cf58" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26-3667538</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or organization)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:48.95pt;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="margin-left:48.95pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2592c215-b5f0-4c1b-8136-1af69a28c1b6" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1301 Concord Terrace</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f79dfae1-e4a9-44b9-a76e-751c779c88a2" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sunrise</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_4e884723-f30d-44a3-95fa-eb4bfabcafd9" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5fe3b197-bf69-488b-8637-efa0a2d401d0" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">33323</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d635d11-ffcf-4461-89c0-217e6c605cc1" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">954</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14228d05-76b5-423d-a240-ab51d250ecdf" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">384-0175</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Registrant's telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Former name, former address and former fiscal year, if changed since last report)</span></p>
  <p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.08%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:40.1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="text-indent:31.5pt;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f07bddaf-f86a-410f-8b12-c10cf5778dba" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $.01 per share</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5ed8dfda-ad1b-47ea-9503-5349555800bc" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MD</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.06in;vertical-align:top;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e5ebfe11-dcef-4636-96df-1d309a033e01" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_241d7c5f-9228-4702-a6ca-072698efff81" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2e9cd04-ca25-4300-9f07-44604e9c049c" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.455%;box-sizing:content-box;"/>
    <td style="width:1.946%;box-sizing:content-box;"/>
    <td style="width:55.527%;box-sizing:content-box;"/>
    <td style="width:22.066%;box-sizing:content-box;"/>
    <td style="width:2.006%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ddfe655c-734d-4c67-ab93-11905dc00d51" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9745;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b8ad9e8a-9e8f-48a5-a7dd-e591fd952402" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ea28f89d-79ea-4dd7-8452-c751f89036ca" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No   </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1024017f-4d3a-493e-8a48-fbb355df1e47" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On October 25, 2024, the registrant had outstanding </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc6b57b2-81e0-4302-8e3a-48381b9ff203" contextRef="C_5fc55157-e10f-464a-8e86-f58de13c1556" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,880,487</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock, par value $.01 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.74%;box-sizing:content-box;"/>
    <td style="width:84%;box-sizing:content-box;"/>
    <td style="width:5.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for the Three and Nine Months</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">   </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Ende</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">d </span><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">September 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Equity for the Three and Nine Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">September 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Nine Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">September 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 3.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 4.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1A.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 5.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 6.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.82%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ee52ee2-9f31-4aa2-bce4-1c46ae497012" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27c9a7ba-7b09-475f-9547-200db1062f8d" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0723dd04-4afd-4aa2-9a11-257ce175f57d" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,621</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de1e710-13b8-4dec-b8b5-3eb30ca5c02e" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eceab14-78a1-4200-b5e9-08e0b4df8d59" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286,897</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25d81d9f-2ae1-4410-9e79-7f8eb03cf21e" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,313</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acf7d4b7-f71e-40e6-9660-b083c3717851" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447f4bd5-31bb-44d1-a055-c7060752210e" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af2b016c-026d-45b5-a485-de69fbfded24" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85b1eb99-7b64-40c3-93a6-3dd74fe4377f" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,565</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02dad9e9-5c77-49bd-8d14-630debeba370" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9535f83-2a56-4d29-af51-a616cdab2367" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_155ac861-6fe9-4d8e-9592-d0def4913a8a" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_210a4b02-c60b-4583-9724-53e2390edd4a" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05a1c517-e4f6-42ad-a6c1-4beb8cdc726b" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f5d8a67-5e82-487a-9392-75153552ccfc" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1daed31-a697-4f45-9089-4c3a2d7ad736" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,239,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e237540-56da-45a8-9042-61b7c474f647" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,384,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01326e8f-d52d-49eb-af6e-2a36bdbc2cd1" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_439f3195-c53c-4cdb-8ae1-3a404c3907d7" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating and finance lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfa4cb2c-35e4-4540-a3bb-b6ab9b5ceaa8" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e3e52e4-dfaf-4950-adc6-ddf08c7dabbe" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ecb53e4-5da3-4f3a-847f-6e8d2e42fe62" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbeb7ba6-58e8-4406-9a33-a2e12679fa93" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9bbc4a9-6de1-40fd-bf55-036304836f15" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ddf69ff-0f7c-49b3-9c2e-eade9fb0efb1" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca789bfa-8869-4a9f-aed7-983b545b093b" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,076,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c2a5f1-681d-42bd-aaa4-f401d58efab8" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,219,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND SHAREHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af8ac6a9-851f-4fc2-8c04-363ed15b472f" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951bcb67-1162-4226-8dce-19005ba3ebd7" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt and finance lease liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9db7b7e5-6621-40b6-bcd5-ffdf9fcae932" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1289b31e-755d-4983-b274-f88997dc9c25" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_711c041d-3be0-44d0-9b18-16c3eaf61f7e" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,992</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0af8a90-dfe1-4a9e-a5b2-c9fcdbd5f68a" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dca941a1-f799-45a4-8eae-6f3399e4a4ef" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,319</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54276184-07dc-4d38-9669-c2ee21f36204" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2ac0e77-906c-42ac-b8c9-9f7498e91d41" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">373,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5038700-a890-43e8-afdd-55fe7c7e0e30" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt and finance lease liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a87dc5d-79d6-4186-b7cc-a106b14ebd44" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f90e43a-7a83-49b7-9971-fca9bd0ff6c7" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">618,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80d31965-9c33-44d7-90f9-e0decaec475a" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,940</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75e8824a-9a3d-4df5-9d29-d301d1b28180" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f20ec315-12ee-412d-910e-379923edca01" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_176a7283-424d-4657-bd74-b84f8ddffa77" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10951cf8-3fc1-4619-b4ad-c4d141cd22bd" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,618</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34636e5f-c668-4ad3-afeb-94682f535a65" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d1f36fa-b553-4ab4-a01f-aff53f909e53" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35a1945f-bbd3-41b3-b730-ea6b78239fcc" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c6aabef-6cbb-4abe-af3a-8b3503d947db" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,344,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_795a8fa1-9a7b-4360-ad89-2b34e2c913bc" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,370,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_97cf0492-ca89-4c00-ab6e-b389cf4c47c8;"><span style="-sec-ix-hidden:F_03fdf1ea-e076-45b4-a2b0-c8c20cef772a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Preferred stock; $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e357319-2166-4f67-8790-061db1c8635b" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cc573127-202c-4e2b-b919-c84b18efacbe" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7379d6-4c6e-4170-82f4-5662c72166fd" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b29a17a1-d87f-424d-92d7-bda2cf986c64" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ef769b8-7da8-45e5-8a43-80f927fa219f" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_91a45953-4b7c-446e-8f93-39b6b9d63a20" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;issued</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9dcaabb-31f6-4880-ae23-5f81c61fb685" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ce996b7-fff9-49a2-b8ae-1bed4f29d9a2" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Common stock; $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_596f9e2e-bf35-49f3-8071-75b7e8b0cc70" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1edf0893-e77d-43e3-8d34-cfa8ef02b4af" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f0b1b5c-e35d-463f-a136-b45d03ba2c0c" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6a12b67e-c027-4f41-ac5d-43fe450a541e" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0752bf6-997c-46b0-8917-f7f60f7f810f" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b25846d6-c39a-4b1c-a127-0af316698c99" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,865,841</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c297a4e8-e7c3-4826-bebe-610ef6c73495" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77189fe7-72b2-4a70-9ab9-4cc35652bad9" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,018,023</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba6dd9c8-75ce-4980-bb31-131562681a67" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f237b0ac-e77b-4d9b-a835-13d1fb2ecb97" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7aa934a-e3a3-4419-86fb-cbaa60f5e665" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,010,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71750b27-2106-4bf3-bae5-9a1ac0158596" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d1f70d6-a258-4a68-b805-ee775ff6d6d2" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ab956f3-f1e6-479d-a927-a92a7fc908b2" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,214</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Retained deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1b62756-c8fc-451d-bc2c-ad8c5b525310" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">279,020</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_addcb141-a1f4-4eb1-9557-8d2fea4dd332" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a392af9b-ce57-4091-a983-1afa09dc630d" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d07c75-2761-4ddf-abe8-16dc2f296309" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and shareholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_550cab18-5c53-44be-bf77-a33eccf31e89" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,076,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afd815bb-8909-4b5b-90ba-c7655b2d6e16" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,219,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Income and Comprehensive Income</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.97%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.222%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.302000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.142%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9243fa23-fb42-4b27-9ea6-0f99df60948c" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,158</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90c83378-7db1-435a-8a4a-91ec8fa41540" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,612</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a27342e-354f-431f-b3ec-4511bc111570" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,510,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4148e09-4fd0-4956-9edc-e5eb9a64ae17" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,498,197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Practice salaries and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fc44ed2-4961-4e5b-905f-92e56a33dacf" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">364,888</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d41e3447-bfa6-4dc2-9658-2c9722bce16f" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9c070c-98c5-4a50-9edd-d235556598b6" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,091,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc79784b-8cfb-44cf-ab49-6c5788a907d2" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084,671</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Practice supplies and other operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc22020-7975-46a7-895b-8b814abe0edf" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd2f2598-5318-477c-b452-d56204b4a103" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,319</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3cc6c31-6096-479b-bc09-e0bc95d6e952" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c4132f4-abad-42db-926e-f75c26bea65e" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec5a6bad-dc90-4203-9c35-ec714ea0c840" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d534f0e1-bff6-4721-b593-7bb5982eec09" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,406</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ed8b1ca-2dbe-4336-b6b6-815e94f5e620" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,884</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40383417-04ea-4059-afa1-608dbd56ff3e" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,478</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b195aff-52ff-41b9-9481-608ed38c62bf" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_959dbcf0-2053-41f0-84c3-ff406558c0ac" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8daa1971-61ee-42c2-a896-6376f4ed0db5" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,353</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22bd1254-7128-4c93-bc79-4ba925ad2dc7" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,109</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c338fff3-82fd-4b4c-8443-9180d1c41f4e" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bd3e033-b83f-4073-963c-3a6db9bff28b" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00e641cf-7afc-4fda-8877-f669a6ed2826" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7618d7a-d8d3-449e-8e86-5c9942f901fd" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1f6d519-58cb-4166-b3e4-ec26370c271d" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_534b3cd3-51cd-49f3-9802-b10d0b8584e1" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823e499a-96c0-4c2d-9add-a4f031f97983" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab82f566-1c01-4778-ab80-44d61fb8b541" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b06589ae-e259-40b2-8dbe-f023fa2729d6" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3e2c12b-3119-498e-a87e-45cbd23760f5" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23b7f413-d7cf-4346-a33c-833b72302f52" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04c896d5-66db-49c6-a85e-768885242306" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c90f127b-64d7-48de-afb5-6c56dd786fb2" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c19df50-8fe0-44a0-aee6-a514f5bbf017" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65dc921f-c25b-48c0-b0e5-581130ee283d" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d1c8985-fd2e-49ea-aa92-e519f745849a" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e71fbbbd-cab2-405c-b6fd-193142dc5a11" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23cccf2-5ab6-4529-b2bc-ec1812e865c7" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50acff3c-650c-4a7d-b120-781771c97485" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,932</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba170ca2-33b8-45ad-97b6-431577145271" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a02aad2d-ab9e-403b-acfe-35454b1014f3" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">477,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdbeb39c-b317-4f64-8dcd-a5ba67c91a49" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4e7d4c7-e10d-4b6f-b3e8-258d287ca2bc" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,618,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3d2c6c4-4025-4029-8019-3c31b23bc600" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,379,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb11224e-01bc-407f-8692-4bd0a849d6a1" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,827</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e3ff46-5cc5-47b1-95af-8b30686c24c5" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_312a3c35-3aff-40ea-861e-0cd12793a654" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">108,004</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b43dd7e-3462-4291-a95a-25a2b03c4fc8" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment and other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22b08fa5-35de-4a1a-89d7-015c4b7735e1" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,089</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ced4f766-317c-4be7-97da-ed154d9cc905" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb38734a-9126-445a-9272-1d22e3bbeb78" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,941</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07d126fb-4145-4d57-8ccd-45b503fea900" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4ab45c-10ac-4a23-b7fb-667493ff26df" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_355ef0b6-dc2d-4c25-a2bb-ed24a6e813c4" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92a46e29-248a-4b7c-b91d-5e0b923e416e" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,033</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_181c7469-5198-4034-8b61-9fea8de9abd9" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,994</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity in earnings of unconsolidated affiliate</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e01f941-5a2f-4a95-936e-4079ff03aa7f" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7128dbf0-96cb-4a53-a4bd-771a3ce5272f" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5217329-9c15-48aa-8f0e-52ccf1d70716" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,427</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d5fb3fe-9e51-454a-afe1-f9ce5b52991a" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non-operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d6a78bc-2943-4c66-a9e1-687d35386c73" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62c50ff4-77c4-4f41-87c5-c0cc9307b7c9" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9555e640-a87a-4a1b-96e9-80855f2686a7" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_169748e8-9c7c-4075-8c56-31db1fbac81f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,320</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f7d3a60-1ab8-46cf-8f30-50134cd64532" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8920078f-f3e4-40cb-921f-1788f712e7e4" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1140302e-795c-427d-b113-60a73406f6b7" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,669</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5fdc864-a601-4502-92b2-34f910bd5805" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,491</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax (provision) benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a675820e-6455-4af4-8442-34361ccdeeb8" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,794</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a0cd06f-befa-43c3-b4b0-40201fdea52e" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe4e0f18-1181-464d-ad3d-2657ad4ad2ac" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deed8b59-3cec-448b-9454-67574ae92168" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,612</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_182fff8d-a9ac-4f61-afa3-924ec352549c" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3404cd50-173a-419e-983a-b62cf05caf1a" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57e20d45-7071-4b8f-af49-cbdba2fb95cf" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6547994e-4aed-480e-82c0-7b8d5308e01f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss), net of tax</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Unrealized holding gain on investments, net of tax of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1737a2c6-2a62-4b5c-8f0c-6defa8594de8" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">, $-, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7280c3de-a1f0-411b-8a65-18033418c1b6" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">657</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;and $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_859cd922-276e-433b-8263-81c598c582eb" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae55aa3-a26f-4bb1-8f22-d023a2486cdd" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed1ae2c8-d84b-4954-88fe-11d90385d58f" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa213146-ac7e-4ad1-b699-4071ac7fed97" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a62d6a7-a613-4ba2-885e-8fca7c544aa9" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35644fd7-fc30-4e88-8e8b-aa1f626b00f3" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ac8cb8-90a9-4abb-a36b-9424474ca5ca" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630dd46f-31c3-4975-8f4e-679ff749f5e1" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,544</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5be0016-2c29-4f27-9e75-da2bb1bad174" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per common and common equivalent share data:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_406f60a6-1c7a-4339-8491-06e88e2c75e0" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68ed4890-617f-4240-8e17-3ce46e45d54b" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f245bc-52ed-42ec-b757-a8681961dc73" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_228c1f79-7b3d-46db-a135-d03864992471" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eef37e3e-c3dd-4fda-98b7-308948649d36" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7545d10e-a861-4975-94f3-77160acb52d7" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fe52162-4589-4a0f-829e-302d0f590b13" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c99103b-9654-404a-9bd3-370779079253" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a3e1aff-04ca-4a1e-9bd4-f48cb7fede12" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60e36c40-0425-467b-b8fc-8c47a977547c" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,543</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9936538f-2050-41cc-8405-1dba1ff022b9" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73dfb7ee-bc20-4658-8f55-ad7e1942731b" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82e8b708-da14-4388-bf51-a600d94ed0ee" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7254651a-2f19-4815-aa08-9993bb5d8e87" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,950</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34a29fcf-4433-4bd6-980f-63709abd4069" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_401ebc78-8be9-4239-9a63-65414781766b" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Shareholders' Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Retained</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Shareholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9007875-fb54-491b-8e5b-d0fe57a3dd12" contextRef="C_8893f8cd-4da1-451b-89f6-37ca8812969d" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_881a5d29-115e-4b24-a745-aed0a399b153" contextRef="C_8893f8cd-4da1-451b-89f6-37ca8812969d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08145efc-4c9b-4f5b-8b6c-7d0829b8efe1" contextRef="C_05ec53de-4d6b-4354-9ca4-75993de13e10" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79fd8498-c106-4632-8b7a-ec9392d99799" contextRef="C_30fb370c-634f-4103-9fe0-f5ed7b584e16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,214</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4addcf9-e34f-4425-a9b4-bf994faf5832" contextRef="C_efbc84c8-00fb-4a9b-8009-81542e40749f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c91febd-2c45-4024-8e01-f1f9b186e61b" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b6a21c-ab7c-4b11-92a5-23397dab5df8" contextRef="C_884a565f-15d0-484c-a843-754c3a3fd51c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34eceb20-e58c-4ff2-923a-43d95ceeb4ec" contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_282b6570-c6c0-4291-9af1-90427c00bdaa" contextRef="C_2bf9eff0-56e4-43b2-93d7-2aa6cebf3f72" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fbf4de2-e785-4c6d-bd46-65e9e4cf34f7" contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8daabeca-a4f5-40ee-aa45-9ccb0f6aa33c" contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d458556-469e-42b5-9d01-a2d5b3d447df" contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4972c95e-f110-40f1-ac24-2e1f32e7572f" contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_557e8e15-1399-4afa-b9f7-d604ac0629de" contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a346f2f1-a075-4125-ac53-5c11318dcc96" contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4985001-1706-4c79-8de8-46802bbe089f" contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf5a9758-229d-4d42-abe8-b862d1bfc777" contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6832143b-08e6-44d6-a403-de2f7a8ba19a" contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a97e1f52-62b5-46b3-b26e-b6050e2ffae9" contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d82e574-839e-480a-a6f6-a0514d307dbd" contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e5d9b90-760c-4681-8d2e-567930434513" contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">887</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30789c1d-7ee0-4b58-85b8-dd39eeb89842" contextRef="C_cd2b3074-957c-47ae-bd82-52e354aedc65" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,008</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1293010d-c7c7-4bd7-95f0-69b57d4547e0" contextRef="C_cd2b3074-957c-47ae-bd82-52e354aedc65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8e15f8f-e42a-424a-9e86-3d25cae44a32" contextRef="C_89ef8a38-8113-41c1-8884-93ceeeec10b6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2594f3be-ae58-4367-a5b1-264049affb7f" contextRef="C_fc9712c3-f658-44af-9601-750da0b09a7e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78cc7bce-c5e2-4dec-ab59-f0362da20a67" contextRef="C_8d0e1e7a-bcf8-46ca-91e1-c0bdbcb1a4a4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e0bf102-7c8e-45a7-b5d8-67e985c48867" contextRef="C_8a373077-e7b6-4d74-ad52-6daa978d5cf3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9f06f47-9329-4c13-af4d-97383a3fa759" contextRef="C_cf9e856d-4f62-44c9-bc0f-62baf73c9b06" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca1c6fc-aa50-4513-ab12-a2df85379179" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4712b0fe-fdc0-4581-ada8-5bd3b6a6bf67" contextRef="C_e8baca31-7b2d-488d-8c77-f9c0d2500a82" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f9ad690-afd4-4849-bd79-7b23fa8300d0" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24083caf-a8db-4220-a6cc-5010b7eb64e2" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13f9a7bb-140b-4ce9-9030-d81d7af8e494" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_864f3a2d-3418-496f-9fbb-f0063cb73db2" contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_327bf89c-0d97-491b-85c5-fd72a1708d51" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34004f60-7397-4fef-a9bf-6e12c9acd0b2" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0eca4fb-e5af-4ea3-8347-2f865d3b31f6" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d15e3af2-9c07-40e3-8b0b-682c6dd80aa5" contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25c54fa5-9e9b-48f5-9c1e-5e5531cb5526" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c550671c-3480-4659-9676-82f119d2add7" contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88e438ec-2a52-4f7f-aa51-a50ead7267ec" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aefec75-7239-454b-a74e-1b5469a466aa" contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07c1b30f-e61a-40dd-acda-a0cb4839a886" contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_572567db-b486-41ba-bb96-6b462be89b22" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a7e5428-efdd-40ce-84fa-81034963872e" contextRef="C_31f10005-61d2-425a-98d1-6c46c15c52e5" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c27a870-6c01-4afe-a256-01408fe00979" contextRef="C_31f10005-61d2-425a-98d1-6c46c15c52e5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94972ec0-b477-4715-905f-852e8b9bd6a8" contextRef="C_b4c72fe0-fa90-4fdf-a008-6fff4568447e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,006,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fc5daf7-0230-4cc8-87e9-e08180c5a81b" contextRef="C_98c7bf66-2c4f-46e5-b8f2-acc2d7acc7bb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4168e834-1c15-4445-9d10-8845130fa233" contextRef="C_fae578a7-d0cf-4d45-9f18-19ac5559973c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38b211d4-9d0d-46ec-9f65-9cbedddf3155" contextRef="C_3adf6473-1204-48e7-8491-9b1ef9c81706" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">706,461</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce9303b2-9267-4f86-bbd8-04dcf77f9e2c" contextRef="C_59042f13-1f1d-4792-8848-e80880b13fd6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a697997-ac78-4c6e-b6dd-a9965efd2095" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34ed1fb1-8ec6-4040-979d-ec54f1edd9e6" contextRef="C_85aec564-a952-4cd7-9508-5cbe268b1c48" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cedf1c3-1a50-4384-81d7-bcec090ec2e8" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d26a0d9-261b-4588-b452-ac46067b5cc4" contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94fdd05b-677e-46d3-94c2-4330bbbb6c4f" contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_964c8e93-52cd-4d1f-9fac-17f3abfd959e" contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">896</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cc96f57-2c6d-44b9-8777-f10f408fa3ad" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09e81e1b-7f16-4764-90d4-44bf06f6dec2" contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dead753f-78ef-4673-8d64-a0df18268409" contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f356b541-1188-4829-a8ce-7392136d5c79" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_106b04f9-9d61-4d4d-b0b4-0501935cfe12" contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_122ffad3-94a8-46f9-96ec-91a220cd9391" contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7aa2926-d28b-47d3-a433-f38b41a078cd" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at September 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d76fb465-a47a-416f-8ae0-06cd34da87c7" contextRef="C_9c587590-b2d8-42e3-8e9e-97f94e51d556" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0646d7eb-73a6-445a-9895-01c57b5a4f13" contextRef="C_9c587590-b2d8-42e3-8e9e-97f94e51d556" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd0ecdd2-9a53-4b5e-a42a-44866849f6be" contextRef="C_0b429a49-04e0-4af0-a34e-5f729e65b865" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,010,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c7701c2-fd73-43b8-b0ca-f358c0592b03" contextRef="C_1202300f-b9c8-495b-8286-dd386fb30e91" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a714a7-f1cb-473a-a104-476980c8b7f4" contextRef="C_33d9e07d-a996-482e-a2e3-ae221fbaed2a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">279,020</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_553bd1aa-9480-4035-86d6-47fe00f656ce" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b234f00-bb37-4308-a629-2c2aaaf6f5f0" contextRef="C_24781c95-cc49-4f39-8985-1dc5dfaea767" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8006be46-d43f-4c1c-bc8e-c112e95fe699" contextRef="C_24781c95-cc49-4f39-8985-1dc5dfaea767" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75f51249-6324-4a0f-beb6-26bbff8546f8" contextRef="C_adcf8579-3d6b-4b9f-8e99-6447b79239ec" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983,601</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2eb333e-3810-460a-80db-dd1967da46e9" contextRef="C_0a422510-3d44-47cf-88b2-48f0575a1143" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f158c8f-e3fc-43cd-9f0c-b5535b3f1de8" contextRef="C_b0a769b5-fd85-4a51-83ff-76f342c6430e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,063</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16ecc3d2-b7ae-454a-b1e1-df258b3a6f01" contextRef="C_03faae58-4912-4ec2-812d-9cda8660c060" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f02917-c667-4610-81a9-e0cb95db6a42" contextRef="C_5dd0ed8f-b21b-4d66-9790-efa9a58934b9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28184a9a-b1a4-4da8-9500-3e79e9ab8e35" contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_924981a6-1f5c-4277-81a2-6f1966a86e88" contextRef="C_dc569cc7-6aeb-45b2-a43d-509db2773e16" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a5c2b3-8ea8-456f-babb-a6733b1e24b9" contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock option,<br/>&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7afd49c-1004-4d4b-a597-088cfb2d8ac5" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_753f76ce-6ebd-465d-afda-b58aa8ff10da" contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a967808-cd65-4565-93f8-10330c7d34ab" contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43e6d331-5736-4451-b3a1-3aa2904c1cd6" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36ee32f2-09e2-44f1-84bb-19fca4b3a261" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93eae6bc-e8fe-441d-b60b-d854ba10bae9" contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90e1c45d-1c45-42e8-9ce7-9122608663db" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61b2c33f-01b4-4230-a80c-9fde39d7c9ad" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4beb80f-bb8f-4fd9-9c36-91c84081bb6b" contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe79cb9-25a2-4ff9-b410-02ee93b32571" contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_006cabe5-26c9-48e7-aeba-9426d998e4fe" contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a355f07-d90f-4159-9f92-21d89b4b04c8" contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a28e255-f92c-4c5b-9663-f17f1b53ffe9" contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a603d32-ae24-49a2-9c10-c5bf32a71dbb" contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b5ed819-f71b-4d36-99b9-709320a2492b" contextRef="C_6ee00435-93bf-4611-b09d-2c2deb02faf4" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6886f71-1792-4bc9-baf7-a57ae98445fa" contextRef="C_6ee00435-93bf-4611-b09d-2c2deb02faf4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e44de4-64e5-4af3-8c98-a5b30000a19f" contextRef="C_56ebd4fc-39c1-4956-8a5c-fcae4efff07b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,923</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebd0d21c-bc2f-4ffd-961c-a1ff78e1ddc5" contextRef="C_28fa2519-8122-457f-8ba0-95ed99b3c132" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffc5adea-b61b-468f-99d2-64cd0da3d0e9" contextRef="C_30923953-448c-4331-a85c-b787cb6bd620" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c468695d-547e-48f3-baf1-44391332f59e" contextRef="C_6cd8e851-3986-4e06-8fd3-aaed9f13e169" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">909,771</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef728f33-da10-49e1-9835-84704cc5a663" contextRef="C_2f2b7c65-5b1c-4fa7-82de-aeef631ca5d1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b332763-70d1-4750-b94d-d3ce5e2d5276" contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89f284e1-21db-4da6-a778-893c6f579bb5" contextRef="C_c3888977-2554-47aa-831d-fd567a5a82f3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b13d9adf-5ea7-44b1-8731-af65d89dc0ee" contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock option,<br/>&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c195e58-dcc6-4503-baa0-236a7cfac1f4" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_860d0a94-b36c-4c84-823f-f64b4414bccf" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40113e71-9bb8-4a5a-acd4-edb2042be8cc" contextRef="C_79accd32-aa9b-4cab-864d-398239122d36" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,593</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a748bf60-c3a0-475f-bbc0-15fc38322a3c" contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0acb138c-6536-4b47-8553-e918668b857a" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e824f0fb-10e4-4e35-82c1-5eacb2b4a052" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a80e7efd-83b9-44f9-a848-2bd66e15fd75" contextRef="C_79accd32-aa9b-4cab-864d-398239122d36" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc4087c3-9f95-4ad7-8237-922261c864d7" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6df3fed1-b765-40c5-8c5e-e4c60512390a" contextRef="C_79accd32-aa9b-4cab-864d-398239122d36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372a764f-5d71-4813-a2aa-2d697f8e6353" contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_499d4dff-5e7d-461b-9899-7272b636fa91" contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_246a600f-ebce-42a2-a283-e9e2f49234c7" contextRef="C_79accd32-aa9b-4cab-864d-398239122d36" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4317b774-32eb-421f-bf37-f99a0c412643" contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c426526c-be83-4d52-93b0-5a21d086e56f" contextRef="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a15e0199-e9ce-41c7-b65b-eb617ba8e757" contextRef="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0ba5f67-055a-432b-9f14-d0b289c6f39f" contextRef="C_f9c9410e-b646-4864-81ca-3b62fc7d8849" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de69b6ec-6446-476a-835d-09ae3058a8dc" contextRef="C_40ce43d6-de46-459b-bbd4-173babcdee2c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb4ad4f2-902b-4fce-a99d-03a5dbdb9b03" contextRef="C_d8733763-56e3-4062-ae80-9b406c362d7b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a30e91-3484-46cd-93f7-32ab684d75eb" contextRef="C_75ee178e-6d00-479f-9b2a-a97ace384501" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">942,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b00dbec-1924-4132-b290-f382621adef7" contextRef="C_670aadb1-d0ce-4bc5-9e7e-daa0c38d0f03" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f288d4da-e299-4ae4-824d-419a9c505ceb" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f40430a3-a602-49d1-b3c4-96ed525f0190" contextRef="C_e3929a3a-e631-4b36-ac48-9798696c3593" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d3a1f5-cfa5-4629-aa57-125aa985561b" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued under employee stock option,<br/>&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a57ffeac-9c87-47db-b48a-852f786ac3a0" contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7018933c-fa88-4f31-8fb0-9ebc0eb239d5" contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f4a0c3d-7f6e-49ac-bae9-3274e99ee70a" contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_090239b0-0626-4da8-8822-517e46d7ff4c" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cde5a612-9ad0-4ac7-85ad-57489cd04075" contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6f3ced9-c611-4a38-94cc-7b774f774897" contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6a002df-51a2-4c35-873c-1078621e1416" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_162f8642-91df-4bd9-84ce-9015dc41809c" contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fcb6e73-3ae8-49dd-a26f-f15c4c25ffee" contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eab5345-81f8-41f4-84e2-4de03d7e5a9f" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at September 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e74cfb0-26a3-48d1-9aa3-ab9e732701b5" contextRef="C_a064a518-736d-4c03-94ce-b34a0a334113" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eeb4b47-3385-44c4-bf2a-70e6e4231648" contextRef="C_a064a518-736d-4c03-94ce-b34a0a334113" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f673304-778d-4df7-b108-06404452a7f6" contextRef="C_51656139-59ae-422c-baf9-a869db14153e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">995,847</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57c02a51-427b-4132-b99e-54006970306d" contextRef="C_67b3dbbf-e507-4f3c-9126-f4e687359ae4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6a3e822-a942-4e01-bed1-41fd4fefd79a" contextRef="C_4c6acf44-78a8-4282-9b87-3142ddf448cd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a93635-059e-496c-8618-d36e7d92b466" contextRef="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967,985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">atements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.287%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90fafb30-906c-4f58-9913-34c9c0ed3a7b" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">129,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62a654fd-af25-4157-8bf1-4e7d7f6f523d" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5766d7dc-48ce-4c80-9dc6-37f0815c2b04" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,353</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_466a526e-e7ad-4612-8185-6fec38d984f9" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,109</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premiums, discounts and issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b79a5172-ffd5-4b49-ae85-9a73b6abe55f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb492cfb-7d1d-4820-8870-73c5267eb814" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a8cdc6f-14fd-4873-831d-8af3279c9e0d" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76276fd4-5079-4012-a429-4594c4c9d2d0" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc964d8-d3b4-4ee2-9565-060d9eba7b9a" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_330855a2-8766-495b-9c12-d0129f271be2" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bddfa3e3-f738-4ff0-8de0-5f8933e9a106" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd7d5dd-0662-4126-8a68-0e84611d320b" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c1ebe13-de5e-40a3-be0a-ce95dc078c5e" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,932</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6f1d26d-2a58-48ad-8a80-d13c71af4ec5" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2275e0d5-f9cd-4c3c-8c29-99cd4008701a" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92237417-7b9e-4b42-b485-e96934d5595e" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94dee9be-1e79-41e0-9940-e2372d8b6031" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d8f7c49-d54e-4614-88c6-643f6e4fba0d" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,589</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6869cc85-2c85-4a09-9c68-df5c61ec17a3" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df408842-e026-4287-92b4-73a31dc59508" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c50740f2-d07f-490f-a612-8434b3ae4260" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df5d4a07-6405-4819-b84d-684db45f3b6b" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92678b49-969f-40de-a287-f59139eefa08" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5808cf81-6ed4-4105-af84-f82645aad1f6" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_424c9b57-d00a-4a9c-95a9-7bb05b681447" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_526c4d9e-f485-4ce9-9559-a795808a414d" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39887d58-e611-438b-85ae-59e22c8333ff" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5862071-4aa5-4d8c-a53b-dd1f6261faa5" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_386ed3e7-6ad3-4abb-a5e8-a57bdb5f938f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24636f4e-5284-4262-befe-8489761a1c5d" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99da1697-9173-41c0-ae87-bd71796a5bba" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b13f7e96-91f2-4ded-9913-73f7b7834fba" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b58cbf-3773-44e9-a3e4-aa92008633a8" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8f60f57-a3e0-42c2-87f7-4710968cd96f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities &#8211; continuing operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a0abb09-5bb7-4494-98db-db5b075941e3" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f10dd24a-a77b-4cf1-bf00-7272aada3288" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities - discontinued operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bcfffdc-12cd-48e2-852a-82cc803aedfc" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,882</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0fd93f4-cc37-4611-b666-f1c90e2199a3" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,003</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54368098-a7cc-4b41-b6c3-e2aef86a7d38" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9a5f571-fee5-4bff-b66c-cf49f7ef6f6f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,075</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition payments, net of cash acquired</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93a76fd9-990c-4df5-bd79-a9b9d50a8ab6" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d03f17-cab1-43d2-9aca-57cb7b0b1ff2" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_976af25f-258f-4abc-a243-c387a489399b" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d03b042-4ea3-4034-becf-e90db7b5b619" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities or sales of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cc28736-310b-4ac2-a5ce-3792b6a86c8d" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_addc87a0-da78-455b-a244-05791933c7ab" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1a571d7-c63f-4b00-aab4-ac28e5e4807a" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,582</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cc4b303-bb2b-4832-b877-5cc2118446e2" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39e87c20-927e-4ae9-8236-4238ad7baeb2" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb237aa1-3d42-47fe-af6e-6b772764e37d" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce21890b-943d-4362-b33f-d653f163f55e" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9834bb42-c784-414e-97b9-14fdb87172e1" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings on line of credit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84cce854-06b2-4775-b44d-fb21bc4dcd2d" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d31854de-ae24-4975-9e02-7d2ae57a026f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on line of credit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98997c90-dbbb-4006-8326-59515f2e7c90" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c114055-7aa3-4ec4-969e-a4e0e3d773ca" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15488656-a7d7-4fd3-b401-b1eb98cb882f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4fbe4ca-d21e-4f4d-a966-9c786b38671c" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments on finance lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_705c4743-2cfc-41d0-9082-661b6a32ae6c" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,045</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee6dfdce-0fa9-44af-99ee-ad8b257fe38b" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cb1828a-d550-48a0-bc88-cc86880af45d" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37d4aa4d-a0a0-410e-8dd3-f7435287c510" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,876</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchases of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b101a879-cb91-4329-9f99-5947c607c087" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6924a63a-18cc-4076-a45a-8e65daf1cbf4" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca9ef0d-6941-4f01-b14b-f2b431f1d51b" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_451baa41-c243-4fba-a440-68b7f17caa29" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74a84f51-6211-4d67-9f8d-6b8a7e882a18" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3b5126f-6a6c-44d8-83d1-74019266f789" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7cbcc2e-3b33-4050-aa84-8d2a32af8088" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,573</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfb6dc93-4ba0-4948-9ab7-7db7fb4320e4" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca5fa813-9886-498d-9511-90d211e5162b" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c67660c7-df86-43ef-98b3-6d8266e743b9" contextRef="C_03faae58-4912-4ec2-812d-9cda8660c060" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cabbef7-c1d4-4cd6-8080-e80ec19cb883" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c647b93-81bf-435c-a6db-83de8e79ae01" contextRef="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a832276b-8241-47d8-b463-41f35d1e5289" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dde27613-b583-40e4-87ad-be433f315919" contextRef="C_a75a21da-6809-46e5-af03-95d29f9164a1" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44362b54-de59-4d3a-90c6-7311bd4919c2" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86f400d-8f19-4a04-b519-b5342e696d15" contextRef="C_34b50bdd-0dce-4d36-b6db-803f912a1615" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e413be99-1ab3-403e-8c77-05af2d2b2713" contextRef="C_a97a53d9-d7b3-4f52-bcbd-33dcc1fc5933" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b014ad5-5dbe-4cc2-b8f4-5a9dd3a90264" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.833%;box-sizing:content-box;"/>
        <td style="width:2.778%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:23%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.389%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:23%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06c0d111-f25e-4d77-9956-0fb98e9a6aef" contextRef="C_1c7a5188-9dfb-4b7b-9117-75232b52d800" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,602</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a3af728-8bb0-4ba6-b80e-455c018f0af6" contextRef="C_97646255-9ce5-4a28-beb9-59eb7df4e021" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,878</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbd97f8e-4af0-455d-8451-05ff6b5ba80c" contextRef="C_91bb3025-d080-4133-988b-b4f0d0b089ec" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80b27ef4-b570-4300-a2ad-daab902135dc" contextRef="C_b33c435b-217f-44e6-b52c-795ccaa7b00b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fbe65b1-975b-4e7c-b713-3799b6d51183" contextRef="C_9f3f07b8-2273-400e-9dac-e0d7b41207ad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fabce886-e16e-4049-8026-b40223f5f142" contextRef="C_04afc832-8f3e-408b-8423-2c62e6af5946" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc60bd7d-c03a-4b44-9b3e-98a1dd965b69" contextRef="C_d4d03e6c-0505-4dfb-a0aa-1fb8302e51db" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,673</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0bd4118-b54a-444d-b9d3-df37e2535776" contextRef="C_8bcf80cf-5670-466b-a111-7a4f4df2f96f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_049fcb44-5d9a-4a8e-b95e-553a77bc6427" contextRef="C_c4f7fa0c-4852-41a3-8551-93e9d6ff41e3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,733</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8516f9eb-213c-44d1-9d1b-d3b4a90ef70c" contextRef="C_d9374888-7c91-4cc7-a16b-1f318051fca5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,614</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1dc4727-3e88-4648-99b2-acdbb17af4d1" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,621</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ca08e92-ca6d-4880-bf28-8634240ca9e2" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_df3da8f3-c5d7-4f92-82b6-c905a5f6701c" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_df3da8f3-c5d7-4f92-82b6-c905a5f6701c_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><div><ix:nonNumeric id="F_2deac78c-f340-4383-b25e-685b60749b9a" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_2deac78c-f340-4383-b25e-685b60749b9a_1"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_df3da8f3-c5d7-4f92-82b6-c905a5f6701c_1"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_2deac78c-f340-4383-b25e-685b60749b9a_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.444%;box-sizing:content-box;"/>
        <td style="width:2.222%;box-sizing:content-box;"/>
        <td style="width:12.222%;box-sizing:content-box;"/>
        <td style="width:1.111%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.111%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.889000000000003%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_223bac66-6302-48de-908c-ca680557b952" contextRef="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">711</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64a5002d-e412-4f84-8f09-68a492b90c17" contextRef="C_2c0855ff-d273-4bff-9e15-451242764f8c" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af3aa034-a34a-4551-92f2-05425829d379" contextRef="C_f9508b9c-3eec-4609-8305-3008f33d44f3" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,621</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96af9a3f-409a-470c-a865-b969e6867a6d" contextRef="C_bd4aca94-0492-4f7f-9862-fa2bf57c6c59" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98271640-192b-4e99-be86-c7e6bee9b5b4" contextRef="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f162285d-6436-4673-9871-5657c66b4f87" contextRef="C_2c0855ff-d273-4bff-9e15-451242764f8c" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f069ce59-d1ea-461c-9c11-6cccd63e6a21" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be603f8c-c937-4d4d-8bc6-c12d31716995" contextRef="C_345a8683-3a40-4392-9de5-24333799ced8" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68f61f22-171c-454c-8536-04a826b34bcf" contextRef="C_345a8683-3a40-4392-9de5-24333799ced8" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388,240</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ac39db-6924-4f45-a6e3-21d714ef0041" contextRef="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9e2dcbc-8e32-4706-ae0f-24b6b014888d" contextRef="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:continuation></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ceee724a-0c39-4117-b23d-234b417d2c71" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" escape="true" continuedAt="F_ceee724a-0c39-4117-b23d-234b417d2c71_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85fbe446-c63b-447f-9d5f-6e322127af68" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.29%;box-sizing:content-box;"/>
        <td style="width:1.075%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.151%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.204%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7751a1b2-4eea-4f02-9569-f2a09be425cc" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469,676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e871cb83-ad34-421f-894c-d9fdce8fd846" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,379,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65be70a7-d954-4075-94bf-a491bd61b13c" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,182,779</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0ad1d72-bf43-4376-b265-f973cb46c9fd" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,106,900</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_883a52d3-9438-4ad7-8d74-73f164d249de" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286,897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5826253-2740-4f63-a7b8-1b85ecf15c3a" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,313</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_efa7c735-657d-4f29-a64c-88405dcd4191" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.215%;box-sizing:content-box;"/>
        <td style="width:1.111%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.131%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.222%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.33%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.111%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.329%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.111%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.442%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_261c8b12-cf4c-41c9-9b61-ff27ef0ee09b" contextRef="C_e677cfe7-2e92-47c1-bdb2-9ea23c33d51c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">438,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_617420ae-eae8-444a-a595-bd562156f31c" contextRef="C_67fa25ce-537a-4741-a50f-8a52146562e2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,321</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_571f6c6a-aff9-4636-961c-cbd07e7923c3" contextRef="C_3f03f9d7-2c71-47ee-a8a2-3847457e8827" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,293,353</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ee942b4-6c0e-4cac-8627-9a03c168093e" contextRef="C_dbb37038-35b4-4678-82a8-8d91cb359de4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,290,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce71abcf-721f-42ad-831f-2bc741e32010" contextRef="C_69acc370-b79c-460d-aad7-0050c48e4b39" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,413</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_640a73b3-0379-4f49-bc9d-ede44334d438" contextRef="C_50c28849-d475-4e33-b9af-f6b8058a8d67" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99f2edfe-570b-4914-82db-ce5c5639184b" contextRef="C_a5ff1526-329f-4f0e-adea-d07328710c94" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ac0a52b-2271-42d2-98e5-f3764ef884dd" contextRef="C_44ba766e-800a-4319-b85c-312bb5654756" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,286</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0292ffc-069f-4fe0-8799-7ab0f44e9504" contextRef="C_d17aad46-7efb-49af-8377-5895940b3823" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b7fccc3-1550-45b9-a6ed-c914fbf13c86" contextRef="C_725f7eeb-d657-453d-92fe-1caaa6092c16" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">579</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aacfd200-dc66-4052-9e00-8a1678fced81" contextRef="C_5694b95e-c7a4-4c1f-8ca3-731f364b3aab" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,073</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bc14e35-c384-4a02-a5d6-122f2ab3c390" contextRef="C_73c5246d-4aad-43c5-87f0-58cbadc4d111" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0178574-8205-4504-9450-41cfea327829" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd4f3df4-c51c-4466-afa9-fb4a8d1b9502" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f07c6e5d-0de5-40b1-b644-9aecfb42b030" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,510,555</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd730396-8f14-46f7-83bb-712b9cb45e2f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,498,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_ceee724a-0c39-4117-b23d-234b417d2c71_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2731b9a5-f183-42f9-804a-0fc9f6832f76" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.197%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.198%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.578%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.677999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a60b14-90e2-4241-8eeb-4ed142dfc3cf" contextRef="C_2aac07cf-292c-417d-84aa-0cdee14fc3fb" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdffd6a6-6768-428a-91cc-95bcdd83eb0d" contextRef="C_4a193a2f-b90e-43a7-8dd9-49f38c7c982f" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9e32a25-e195-459b-b7d9-c0beacb70f76" contextRef="C_ccf152cf-ccd9-4e3b-ad6d-b551a5ad3dc6" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cc32d65-6942-46ed-a49d-598165d81b89" contextRef="C_fc7ad59c-2e25-40e7-af1a-51976aee8220" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fb79a2f-28dd-4713-bfc5-add7a87eb153" contextRef="C_e3d4fda8-e2c4-41b7-b7bb-a79d5f1f5fb3" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_736da600-edc9-4ad2-8cca-ec6c426354fa" contextRef="C_9fe3e6f6-dfe4-49b2-b5b9-6a12b9a5ec2b" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7d63c32-89eb-41e9-941a-8e73e57a715c" contextRef="C_c879f931-4318-47fc-90a7-3a99688432aa" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d82ca19a-ee39-4c1c-b801-139b36759a94" contextRef="C_fffa0abb-f44c-4f13-9801-32f57a3f6d0e" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a483f393-3019-4130-a1b9-33062438d8f6" contextRef="C_0a8c0d8a-e7ce-404f-9c3f-9a4becbd6264" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57f007d8-1f24-426e-83ca-acda6fd09652" contextRef="C_040f5030-8668-48c5-8848-7595226a4f67" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_683acf1c-1bec-4a2e-a7c5-45851613f982" contextRef="C_117ba3bc-14b9-4031-9bd2-9c2358d754ba" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b62f6e-36aa-428f-8278-904686bba96c" contextRef="C_c365d25d-3bf1-4fdb-a10e-5da8bba0e06b" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f33d521-ca01-4b5e-ae5b-6d64ba24f960" contextRef="C_8da3915f-acc7-4713-ba2c-89d5082ed5ab" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d5622e9-a873-46d8-bbaa-3c6ecefad317" contextRef="C_7db712e2-9eb1-41c5-a6ef-4225a89f28c2" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c7c2835-17cd-4ed0-aa94-2693c06456cf" contextRef="C_03aeeb1a-6712-41b8-b9d7-3904a46932d1" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02534b3f-51bb-406f-8557-042e1afa6921" contextRef="C_14426c2a-51aa-4302-9c65-7d61956fde41" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a34f64dc-2692-496b-9ed2-c549f8acaa8e" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a2f2de1-22ff-4e07-9efa-1eb0e684feef" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5709941-fe58-46c0-93a9-3eb8715ec5a9" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da27774e-6542-43fa-87e7-63ab614cb9b4" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb4ea482-7965-410d-a381-2c501efa25f2" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5. 	Business Combinations:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company completed the acquisition of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7c7d09a-550d-4caf-9bba-ecf02ff04da3" contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6" name="md:NumberOfMaternalFetalMedicinePracticesAcquired" unitRef="U_Number" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> maternal-fetal medicine practice for total consideration of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d5b35e-12e2-4142-9cc4-53aebf3584f6" contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a95086f-4a94-4498-a881-6a9813c67e35" contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was paid in cash at closing and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_40818292-ba13-4946-ab6c-3c28ca64fe7a" contextRef="C_bb151c97-9f7d-4189-b1ec-f8da6602d134" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as a contingent consideration liability. The acquisition expanded the Company&#8217;s national network of physician practices across women&#8217;s and children&#8217;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d877e25-93be-4565-bebc-ad9d03e99867" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, fixed assets of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0eb7358-0d2b-4d20-abfb-cc0c55ab80e2" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and other intangible assets consisting primarily of physician and hospital agreements of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02eb03f1-453f-42a4-8f77-12942378f218" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99a088e5-08d4-451d-b4a2-6f0512cfef2e" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, during the nine months ended September 30, 2024, the Company recorded fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44a0ceb8-9c76-4097-96f8-4e6966e2b3f0" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42ed736c-c777-43c4-ae8f-e303ba7c97bf" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease right-of-use asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80bffd3f-75d5-41fb-a401-05d4c3a98925" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested the second practice during the third quarter. The total loss on disposal of these two businesses was $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a04c77ab-6525-4269-b493-5afde007a2c6" contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#8217;s market capitalization, multiplying the number of actual shares of common stock outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#8217;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This assessment resulted in a non-cash impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89273fd2-a4c8-4f3c-b741-8cdf617bb498" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70f14755-5750-485c-aaba-ce977f53fc40" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million that increased the Company's book value. An incremental non-cash charge was required to reduce the Company's book value to its previously determined fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the Company recorded the incremental non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afb52448-4616-4583-93e0-df91fcee42dd" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:IncrementalNonCashCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million for a total non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96aaeee7-90fa-41af-96e4-85c524602359" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:NonCashCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">154.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. A </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15afec53-fabe-4a03-a5c3-2b29fb9efb91" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:ChangeInRateOfControlPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% change in the control premium used would have impacted the non-cash impairment charge by approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14efe4c2-7597-4dd1-a521-33838779b83a" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:ChangeInNonCashImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_83c1a651-5f3e-40c0-b0b8-b37ed2938660" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true" continuedAt="F_83c1a651-5f3e-40c0-b0b8-b37ed2938660_1"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.            Accounts Payable and Accrued Expenses:	</span></p><div><ix:nonNumeric id="F_6f7e8fb0-0b81-4b1c-b2c0-d26404fe1861" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_6f7e8fb0-0b81-4b1c-b2c0-d26404fe1861_1"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_83c1a651-5f3e-40c0-b0b8-b37ed2938660_1"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_6f7e8fb0-0b81-4b1c-b2c0-d26404fe1861_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.5%;box-sizing:content-box;"/>
        <td style="width:1.25%;box-sizing:content-box;"/>
        <td style="width:20%;box-sizing:content-box;"/>
        <td style="width:1.25%;box-sizing:content-box;"/>
        <td style="width:20%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e0179b-05a2-4c10-8c02-61aeca790cdd" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,367</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9b2c3de-b671-486b-9237-1bc11a0bb8de" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,588</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_225bd0a1-1400-4ba4-ab3b-fc94c217c6fb" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,554</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcd761e2-2747-442c-8e8a-feb8e9d09017" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,112</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de0bfb08-71b4-4ce3-ac9c-1aa54332d765" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,327</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a45e46-ad29-4873-afb5-22c05418f28d" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,545</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c7e382f-474b-4b79-8df2-4b3457936733" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,966</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e318a0e-b709-4d42-aef4-8fcbdfd44ee0" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,039</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_451b9699-9c87-4723-b06e-6d794dcbe56f" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,789</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f74a41-e9d7-4ee9-8d20-fa749b12c115" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,262</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_242658e0-339f-4898-931f-2fe10e09fea2" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,490</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85c8eff7-15ec-4653-a5ea-62389a27f100" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,252</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bc170b6-981a-42e7-8c6b-4fd66e21d3a4" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333,493</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fc8dbd2-0a5b-4263-a7e2-fc34e75e42e8" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,798</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69fcf467-eed0-4e35-a1ea-898447fd5a35" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2023 to September 30, 2024, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p></ix:continuation></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_0d0a6c88-4db9-4ba5-8e39-6ce21bf40599" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:LineOfCreditAndLongTermDebtTextBlock" escape="true" continuedAt="F_0d0a6c88-4db9-4ba5-8e39-6ce21bf40599_1"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_771cf373-3137-4a8c-bdd7-c1682819013a" contextRef="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275" name="us-gaap:SeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_256ec109-48a8-46c2-908d-60a80a9bca4c" contextRef="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d3a7e01-338f-4ec5-bf80-511948440683" contextRef="C_70459c21-18a9-41b0-8deb-ec60bf6e856d" name="md:DebtInstrumentMaturityYear"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f5c6c44-41c6-4fbb-9071-397a9d0ecc7c" contextRef="C_45ae435c-1042-4b5a-96ae-8bb41d0114d8" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b807895-064e-4893-891a-2620f0925969" contextRef="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c03e249c-8d2c-4b99-8552-0fd6b60e3dc4" contextRef="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">308.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea626ee-095c-4932-8f1a-5f67c8de98d2" contextRef="C_e5b15b48-9344-4b59-8c84-5acf6a9e4f95" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% senior unsecured notes due 2027 (the "2027 Notes"), which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_899a9dc8-949b-47ee-9d4f-9a0e6fda3100" contextRef="C_bc621510-11b6-4741-b375-b503a329d672" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76671459-cbcb-4326-9182-193be94106f5" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1752cc9-11ee-4904-ad66-5192c3f2a275" contextRef="C_6f592960-a202-4029-b088-c0a2bc84ee92" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56d20411-dc8e-4635-b269-37de63cefa43" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dcb71d25-5578-4998-b004-10403784d848" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55bbec7a-5a31-4d10-9276-df0b15f0c38e" contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca" name="md:PurchasePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9a5b84f-740c-41c3-9edf-7098ff7184cd" contextRef="C_55792ef2-9526-43dd-a1b0-74ec9336243f" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_877be97d-4941-454c-a1f2-28118b702712" contextRef="C_58c12c59-2a6c-435e-913c-34398f795390" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42c8b1c1-b2b4-4962-985f-aa47125a37f3" contextRef="C_b044401a-b565-4c10-a46e-4df13e21403c" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ba46954-fcd3-486d-9e9d-2c9cea039e63" contextRef="C_bc533806-93ff-49e5-b0c8-9cf97c0129d7" name="us-gaap:DescriptionOfInterestRateRiskExposure"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_0d0a6c88-4db9-4ba5-8e39-6ce21bf40599_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60f5d1d6-32d1-4318-b5a9-4254a1b16c02" contextRef="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">218.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line at September 30, 2024. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13503252-c020-46ef-a782-620c9d207c3c" contextRef="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1ad7b08-7deb-4147-a3d6-c5257dd065af" contextRef="C_46499516-3d0b-4a41-8a39-4fc6b1dd499a" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d227a5e-fcb7-4251-80c8-e856085bd2cd" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eccf6c99-f520-4c34-84c0-da95a8cfdeea" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.498%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.178%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.978%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.398%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4eaab1c-1c34-41ae-a1e7-b0d3c2024c76" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,891</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c18afdc1-56ee-4b0f-b810-87c515c49856" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,543</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2554557e-f92a-47ce-bed0-f9399057f0c8" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,223</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bd0e605-0872-4a24-b362-dc7ef04412be" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_554f20a0-098b-4a43-8639-8d7377037c50" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">632</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c3128d-bf1c-4211-afdf-739d332083af" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dbe5509-4bef-474c-989c-13ffc8dc1751" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20724637-3d05-4be7-a24a-1b65bee504db" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e79cdbe-f2f5-4dc5-bb32-c759d8e471c4" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,523</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_355fa24e-89f6-4ef6-b2d5-80856bfe532f" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,950</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b44df58-ecd8-4af6-8c02-c8a9e1a7b7f6" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,223</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89c6b747-f615-493c-9fd1-4e6a99c8735f" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddcd6c3c-dace-4aae-832f-ee7dac18f863" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f4bc9af-38d7-48e8-8b26-b29b1a54bb50" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf88c7e6-2a52-422e-82bb-66401ad4566f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d0169f2-4dbe-4cfe-85a0-6bff2c4c2a35" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,201</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><ix:footnote id="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_347e3e6b-5614-48cd-b55a-84c0cf54e9a7" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares are not included because the effect would be antidilutive.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe92d13d-2a4f-4a16-be18-73ac642c3bab" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f226a157-c348-44ff-8442-3d9f81cd9276" contextRef="C_396c2856-16b5-4b29-9a6d-0cf8c4644545" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e7e9d72-d2ee-4888-add7-71e939145d3b" contextRef="C_0310ccf0-c3d9-49e4-aadd-2e067003de46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2fe5dbf-2f23-4411-a066-a79786e8e13d" contextRef="C_809640ed-b7ff-4176-8579-f511b0405d13" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb3b4712-4f72-4849-af36-5f1bcca950e9" contextRef="C_b8197466-b836-40f5-85ec-515f06dd7959" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce70bf30-9075-48a3-a032-91ac2623a00c" contextRef="C_5621fe56-862f-40f3-af0a-35de308efe0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a097956-aeda-46a9-89c1-c58db7f14dad" contextRef="C_60eae1e8-e969-481f-9fcc-b8bd60d6c306" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b47cf04-da52-4cd6-aa33-08ca274f6eee" contextRef="C_3aaa3335-768e-46db-93e1-0c4ef48e3199" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10d13776-b123-445d-880f-4b9dc874e673" contextRef="C_0310ccf0-c3d9-49e4-aadd-2e067003de46" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At September 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f7e257-0613-472a-85cf-3b2acdc7f196" contextRef="C_050e4bfe-b9c5-4ca8-9e26-96b6ce67c09c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At September 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d581b3e9-931b-418c-9785-3e6ec0386d78" contextRef="C_2859086d-715d-44f6-833b-c4f773353b3c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a34b9b8-b2b0-4741-a2ec-9a56fe57329a" contextRef="C_fc38c255-4fa4-44a0-a508-6debd99e834f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2024 and 2023, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_411cfb91-75fa-4375-a6e5-2a73e8a917ec" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b01f9d-546b-4d25-8104-de4cb50dbf3f" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2166a6c3-eaa7-499e-8005-bab65f926a64" contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c84efb4-6c49-470c-976f-2a7f7e40a8fd" contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b93cefb-1a72-41b6-a8a7-a40e8e18196c" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="md:CommonStockRepurchasesTextBlock" escape="true" continuedAt="F_1b93cefb-1a72-41b6-a8a7-a40e8e18196c_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf06eb72-42a3-4d19-856a-9d99bc3b535c" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49507eb3-7aef-4555-b6d8-6f79dfa58207" contextRef="C_1eb0559c-65bc-419b-9342-1cc866cf8e35" name="srt:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0890b37-53ae-4d42-996a-1e56b2b06dbe" contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f486979-c651-48a2-bed2-678baf8b4efa" contextRef="C_b8fc85c6-2e4a-4259-af7d-66c68b0e250a" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e288d0d-888d-43ef-b77f-8d0a3a485e38" contextRef="C_09f36e04-ed7b-4580-81de-9e91190ac2c5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of September 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_1b93cefb-1a72-41b6-a8a7-a40e8e18196c_1"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a62fd7b-e90c-4673-b4d6-34d9fe75b4b7" contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> of Financial Condition and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 20, 2024 (the &#8220;2023 Form 10-K&#8221;). As used in this Quarterly Report, the terms &#8220;Pediatrix&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, Pediatrix Medical Group, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;PMG&#8221;), together with PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2023 Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#8220;NICUs&#8221;), to babies born prematurely or with medical complications; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies, primarily in areas where our affiliated neonatal physicians practice. We also provide services across multiple other pediatric subspecialties.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Economic Conditions and Other Factors</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our operations and performance depend significantly on economic conditions. During the three months ended September 30, 2024, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) decreased as compared to the three months ended September 30, 2023. However, we could experience shifts toward GHC Programs if changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, costs of managed care premiums and patient responsibility amounts continue to rise, and accordingly, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Practice Portfolio Management Plan and Impairment of Long-Lived Assets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, we formalized our physician practice optimization plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. Over the course of many years, we expanded our pediatric service lines and footprint to provide specialized care to more patients, including through our office-based portfolio of practices. This added complexity to our operations over time and, accordingly, increased costs that resulted in operating challenges primarily for our office-based portfolio of practices. Recognizing this and our need to adapt to the current healthcare climate, during the second quarter, we made the decision to return to a hospital-based and maternal-fetal medicine-focused organization. The exits of our pediatric office-based practices are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each impacted individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, during the nine months ended September 30, 2024, we recorded fixed asset impairments of $20.1 million, intangible asset impairments of $7.7 million and operating lease right-of-use asset impairments of $10.6 million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on Disposal of Businesses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, we made the decision to exit our primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  We divested one of our two previously acquired primary and urgent care practices during the second quarter and divested the second practice in the third quarter. The total loss on disposal of these two businesses was $10.6 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill Impairment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment on at least an annual basis, in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. During the second quarter of 2024, we experienced a triggering event resulting from a sustained decline in our stock price that resulted in our market capitalization being lower than the book value of our equity. This impairment assessment resulted in a non-cash impairment charge of $130.0 million. Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $24.2 million that increased the book value of our equity. An incremental non-cash charge was required to reduce the book value of our equity to our previously determined fair value. Accordingly, we recorded the incremental non-cash charge of $24.2 million for a total non-cash charge of $154.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Surprise&#8221; Billing Legislation</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In late 2020, Congress enacted the No Surprises Act (&#8220;NSA&#8221;) legislation intended to protect patients from &#8220;surprise&#8221; medical bills when certain services are furnished by providers who are not in-network with the patient&#8217;s insurer. Effective January 1, 2022, if the patient&#8217;s insurance plan or coverage is subject to the NSA, providers are not permitted to send patients an unexpected or &#8220;surprise&#8221; medical bill that arises from out-of-network emergency care provided at certain out-of-network facilities or at certain in-network facilities by out-of-network emergency providers, as well as nonemergency care provided at certain in-network facilities by out-of-network providers without the patient&#8217;s informed consent (as defined by the NSA). Many states have legislation on this topic and will continue to modify and review their laws pertaining to surprise billing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For claims subject to the NSA, insurers are required to calculate the patient&#8217;s total cost-sharing amount pursuant to rules set forth in the NSA and its implementing regulations which, in some cases, can be calculated by reference to the applicable qualifying payment amount for the items or services received.  The patient&#8217;s cost-sharing amount for out-of-network services covered by the NSA must be no more than the patient&#8217;s in-network cost-sharing amounts. Patient cost-sharing amounts for items and services subject to the NSA count toward the patient&#8217;s health plan deductible and out-of-pocket cost-sharing limits. For claims subject to the NSA, providers are generally not permitted to balance bill patients beyond this cost-sharing amount. An out-of-network provider is only permitted to bill a patient more than the cost-sharing amount allowed under the NSA for certain types of services if the provider satisfies all aspects of an informed consent process set forth in the NSA&#8217;s implementing regulations. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For claims subject to the NSA, including many emergency care services, out-of-network providers will be paid an amount determined by the patient&#8217;s insurer; if a provider is not satisfied with the initial amount paid for the services, the provider can pursue recourse through an independent dispute resolution process. The outcome of each IDR dispute is generally binding on both the provider and payor with respect to the particular claims at issue in that dispute but may not affect an insurer&#8217;s future offers of payment. Accordingly, we cannot predict how these IDR results will compare to the rates that our affiliated physicians customarily receive for their services. These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#8217;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively the &#8220;ACA&#8221;) has altered how health care is delivered and reimbursed in the U.S. and contain various provisions, including the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the FCA and other healthcare fraud and abuse laws. The status of the ACA may be subject to change as a result of political, legislative, regulatory, and administrative developments, as well as judicial proceedings. As a result, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. We cannot say for certain whether there will be additional future challenges to the ACA or what impact, if any, such challenges may have on our business. Changes resulting from various legal proceedings, and any legislative or administrative change to the current healthcare financing system, could have a material adverse effect  on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In addition to the ACA, there could be changes to other GHC Programs, such as a change to the Medicaid program design or Medicaid coverage and reimbursement rates set forth under federal or state law. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for Medicaid benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and/or make it more difficult for people to enroll. Moreover, the expiration of the COVID-19 national emergency and public health emergency declarations in May 2023 may impact the coverage for and access to certain services for Medicaid patients. Expiration of the national emergency and public health emergency declarations will also end waivers for the provision of certain services, and returning our services to a pre-pandemic regulatory state similarly may increase our exposure to legal, regulatory, compliance and clinical risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medicaid Expansion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.  Recently, Democrats in Congress have sought to expand Medicaid or Medicaid-like coverage in states that have not yet expanded Medicaid. They also have sought to reduce payments to certain hospitals in some of these states. Should any of these changes take effect, we cannot predict with any assurance the ultimate effect on reimbursements for our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-GAAP Measures</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In our analysis of our results of operations, we use various GAAP and certain non-GAAP financial measures. We have incurred certain expenses that we do not consider representative of our underlying operations, including transformational and restructuring related expenses. Accordingly, we report adjusted earnings before interest, taxes and depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), defined as net income (loss) before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Earnings per share has also been adjusted (&#8220;Adjusted EPS&#8221;) and consists of diluted net income (loss) per common and common equivalent share adjusted for amortization expense, stock-based compensation expense, transformational and restructuring related expenses and impacts from discrete tax events. For the three months ended September 30, 2024, Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude loss</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">on disposal of businesses and tax effects of goodwill impairment. For the nine months ended September 30, 2024, both Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude loss on disposal of businesses and impairment losses.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis.  These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For a reconciliation of each of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and nine months ended September 30, 2024 and 2023, refer to the tables below (in thousands, except per share data).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.14%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,441</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,391</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(129,549</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,879</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,126</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,033</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,994</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision (benefit)</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,794</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,441</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,120</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,612</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,254</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,211</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,353</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,109</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,560</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,619</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,112</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,679</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,932</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted EBITDA</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,234</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,417</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,302</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,594</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,523</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,950</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income and diluted net income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,441</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,391</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization (net of tax of $446 and $498)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,338</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,493</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation (net of tax of $656 and $791)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,969</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,373</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $4,640)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,920</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax effects of goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,135</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses (net of tax of $15)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,452</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.08</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,114</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,029</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.44</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,371</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended September 30, 2024 and 2023, other than for tax effects of goodwill impairment for the relevant period. Tax effects of goodwill impairment relate to the goodwill impairment recognized in the second quarter of 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.99%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.358%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.259%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.458%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.918%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,223</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,492</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income and diluted net (loss) income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(129,549</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,879</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.77</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization (net of tax of $1,842 and $1,508)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,526</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,522</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.06</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation (net of tax of $1,872 and $2,325)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,616</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,974</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.09</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $10,155)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.37</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment (net of tax of $21,625)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,618</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.59</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets impairments (net of tax of $5,028)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,084</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets impairments (net of tax of $1,920)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,759</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of businesses (net of tax of $2,733)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,199</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,456</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,984</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.02</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,173</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.99</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77,359</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the nine months ended September 30, 2024 and 2023, other than for goodwill impairment for the relevant period. Tax effects for the goodwill impairment approximate 14% due to a portion of the expense being non-deductible.</span></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three Months Ended September 30, 2024 as Compared to Three Months Ended September 30, 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue was $511.2 million for the three months ended September 30, 2024, as compared to $506.6 million for the same period in 2023. The increase in net revenue of $4.6 million, or 0.9%, was primarily attributable to an increase in same-unit revenue, partially offset by a decrease in revenue from non-same unit activity, primarily resulting from practice dispositions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $24.6 million, or 5.2%. The increase in same-unit revenue was comprised of an increase of $15.9 million, or 3.4%, from net reimbursement-related factors and $8.7 million, or 1.8%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from a favorable shift in payor mix and an increase in administrative fees from our hospital partners. The increase in revenue from patient service volumes was related to increases across all of our service lines.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits decreased $3.5 million, or 1.0%, to $364.9 million for the three months ended September 30, 2024, as compared to $368.4 million for the same period in 2023. The $3.5 million decrease was primarily attributable to non-same unit activity, primarily resulting from practice dispositions, partially offset by an increase in clinical compensation expense, including benefits and incentive compensation, all at our existing units.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses decreased $1.9 million, or 6.0%, to $29.4 million for the three months ended September 30, 2024, as compared to $31.3 million for the same period in 2023. The decrease was primarily attributable to non-same unit activity, primarily resulting from practice dispositions, partially offset by a net increase in practice supply and other costs related to our existing units, with increases in professional services, travel and medical supply costs partially offset by a decrease in insurance expense.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $58.1 million for the three months ended September 30, 2024, as compared to $57.4 million for the same period in 2023.  The net increase of $0.7 million was primarily related to increases in incentive compensation based on financial results and salary expense for enhancement of revenue cycle management staffing, partially offset by decreases in overall staffing levels. General and administrative expenses as a percentage of net revenue was 11.4% for the three months ended September 30, 2024, as compared to 11.3% for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense was $6.3 million for the three months ended September 30, 2024, as compared to $9.2 million for the same period in 2023. The decrease of $2.9 million was primarily related to a decrease in depreciation expense related to non-same unit activity, primarily practice dispositions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses were $18.6 million for the three months ended September 30, 2024 and primarily related to revenue cycle management transition activities, position eliminations across various shared services and operations departments and impairment of various right-of-use lease assets resulting from practice dispositions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on disposal of businesses was $0.1 million for the three months ended September 30, 2024.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from operations was $33.8 million for the three months ended September 30, 2024, as compared to $40.3 million for the same period in 2023. Our operating margin was 6.6% for the three months ended September 30, 2024, as compared to 7.9% for the same period in 2023.  The decrease in our operating margin was primarily due to transformational and restructuring related activity, partially offset by net favorable impacts from our same-unit results driven by higher revenue and from non-same unit activity due to practice dispositions. Excluding transformational and restructuring related expenses for the three months ended September 30, 2024, our income from operations was $52.4 million and our operating margin was 10.3% for such period.  We believe excluding the impacts from transformational and restructuring related activity provides a more comparable view of our operating income and operating margin.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses were $8.6 million for the three months ended September 30, 2024, as compared to $9.4 million for the same period in 2023. The net decrease in non-operating expenses was primarily related to an increase in investment income on higher cash balances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our effective income tax rate (&#8220;tax rate&#8221;) was 23.0% for the three months ended September 30, 2024 as compared to 30.6% for the three months ended September 30, 2023.  The tax rates for the three months ended September 30, 2024 and 2023 include net discrete tax expense of $6.5 million and $1.1 million, respectively. Net discrete tax expense for the three months ended September 30, 2024 primarily relates to a reduction in the carrying value of deferred tax assets due to practice portfolio management activities. After excluding discrete tax impacts, during the three months ended September 30, 2024 and 2023, our tax rate was (2.6)% and 27.0%, respectively.  We believe excluding discrete tax impacts provides a more comparable view of our tax rate. The decrease in our tax rate from  27.0% to (2.6)%  for the three months ended September 30, 2024 as compared to the prior year period primarily relates to the tax effects of the non-cash goodwill impairment charge.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net income was $19.4 million for the three months ended September 30, 2024, as compared to $21.4 million for the same period in 2023. Adjusted EBITDA was $60.2 million for the three months ended September 30, 2024, as compared to $50.4 million for the same period in 2023.  The increase in our Adjusted EBITDA was primarily due to net favorable impacts from our same-unit results and practice disposition activity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per common and common equivalent share was $0.23 on weighted average shares outstanding of 84.5 million for the three months ended September 30, 2024, as compared to $0.26 on weighted average shares outstanding of 83.0 million for the same period in 2023. Adjusted EPS was $0.44 for the three months ended September 30, 2024, as compared to $0.32 for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nine Months Ended September 30, 2024 as Compared to Nine Months Ended September 30, 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue was $1.51 billion for the nine months ended September 30, 2024, as compared to $1.50 billion for the same period in 2023. The increase in revenue of $12.4 million, or 0.8%, was primarily attributable to increases in same-unit revenue, partially offset by a decrease in revenue from non-same unit activity, primarily resulting from practice dispositions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $51.5 million, or 3.7%. The increase in same-unit net revenue was comprised of an increase of $29.1 million, or 2.1%, from net reimbursement-related factors and an increase of $22.4 million, or 1.6%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from a favorable shift in payor mix and an increase in administrative fees from our hospital partners. The increase in revenue from patient service volumes was related to increases across all of our service lines.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits increased $7.2 million, or 0.7%, to $1.09 billion for the nine months ended September 30, 2024, as compared to $1.08 billion for the same period in 2023. The $7.2 million increase was primarily attributable to an increase in clinical compensation expense and benefits at our existing units, partially offset by decreases in non-same unit activity, primarily practice dispositions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses decreased $0.2 million, or 0.2%, to $92.9 million for the nine months ended September 30, 2024, as compared to $93.1 million for the same period in 2023. The decrease was primarily attributable to non-same unit activity, primarily practice dispositions, partially offset by a net increase in practice supply and other expenses. The net increase at our existing units was driven by increases in professional services, rent and travel expenses, partially offset by a decrease in insurance expense.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the day-to-day operations of our physician practices and services. General and administrative expenses were $174.9 million for the nine months ended September 30, 2024, as compared to $174.5 million for the same period in 2023. The net increase of $0.4 million is primarily related to increases in salary expense for enhancement of revenue cycle management staffing and incentive compensation based on financial results, partially offset by lower expenses from net staffing reductions, professional services fees, travel expenses, and information technology expenses. General and administrative expenses as a percentage of net revenue were 11.6% for the nine months ended September 30, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense was $25.4 million for the nine months ended September 30, 2024, as compared to $27.1 million for the same period in 2023. The decrease of $1.7 million was primarily related to lower depreciation resulting from fixed asset impairments recognized in the second quarter of 2024.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses were $40.6 million for the nine months ended September 30, 2024 and primarily related to the impairment of various right-of-use lease assets resulting from our practice portfolio management activities, position eliminations across various shared services and operations departments and revenue cycle management transition activities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill impairment was $154.2 million for the nine months ended September 30, 2024, resulting from the triggering event during the second quarter based on a sustained stock price decline.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets impairments were $20.1 million for the nine months ended September 30, 2024, resulting from the practice portfolio management activities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets impairments were $7.7 million for the nine months ended September 30, 2024, resulting from the practice portfolio management activities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on disposal of businesses was $10.9 million for the nine months ended September 30, 2024, resulting from the disposals of the primary and urgent care practices.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Loss from operations was $108.0 million for the nine months ended September 30, 2024, as compared to income from operations of $118.8 million for the same period in 2023. Our operating margin was (7.1)% for the nine months ended September 30, 2024, as compared to 7.9% for the same period in 2023. The decrease in our operating margin was primarily due to the impairment activity recorded during the second quarter and transformational and restructuring related activity, partially offset by net favorable impacts from non-same unit activity. Excluding impairment activity and transformational and restructuring related expenses for the nine months ended September 30, 2024, our income from operations was $125.5 million and our operating margin was 8.3% for such period. We believe excluding the impacts from the impairment and transformational and restructuring related activity provides a more comparable view of our operating income and operating margin.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses were $26.7 million for the nine months ended September 30, 2024, as compared to $28.3 million for the same period in 2023. The net decrease in non-operating expenses was primarily related to an increase in investment income and lower interest expense due to lower debt balances.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our tax rate was 3.8% for the nine months ended September 30, 2024 compared to 29.4% for the nine months ended September 30, 2023. The tax rates for the nine months ended September 30, 2024 and 2023 include net discrete tax expense of $8.5 million and $2.0 million,</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">respectively. After excluding discrete tax impacts, during the nine months ended September 30, 2024 and 2023, our tax rate was 10.1% and 27.2%, respectively. We believe excluding discrete tax impacts on our tax rate provides a more comparable view of our effective income tax rate. The decrease in our tax rate from 27.2% to 10.1% for the nine months ended September 30, 2024 as compared to the prior year period primarily relates to the effects of the non-cash goodwill impairment charge.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $129.5 million for the nine months ended September 30, 2024, as compared to net income of $63.9 million for the nine months ended September 30, 2023. Adjusted EBITDA was $155.3 million for the nine months ended September 30, 2024, as compared to $149.6 million for the same period in 2023.  The increase in our Adjusted EBITDA was primarily due to net favorable impacts in our same-unit results, primarily from an increase in revenue.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per common and common equivalent share was $1.56 on weighted average shares outstanding of 83.2 million for the nine months ended September 30, 2024, as compared to diluted net income per common and common equivalent share of $0.77 on weighted average shares outstanding of 82.5 million for the same period in 2023. Adjusted EPS was $0.99 for the nine months ended September 30, 2024, as compared to $0.94 for the same period in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024, we had $103.8 million of cash and cash equivalents as compared to $73.3 million at December 31, 2023. Additionally, we had working capital of $155.1 million at September 30, 2024, an increase of $60.6 million from working capital of $94.5 million at December 31, 2023. The increase in working capital is primarily due to net favorable impacts in our same-unit results, primarily from an increase in revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Continuing Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by (used in) operating, investing and financing activities is summarized as follows (in thousands):</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.287%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,445</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,078</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33,468</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,752</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,522</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,968</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024, our net cash provided by operating activities for continuing operations was $82.4 million, compared to $73.1 million for the same period in 2023. The net increase in cash provided of $9.3 million was primarily due to increases in cash flow from accounts payable and accrued expenses, partially offset by decreases in cash flow from accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024, cash inflow from accounts receivable was $0.6 million, as compared to $22.1 million for the same period in 2023. The decrease in cash flow from accounts receivable for the nine months ended September 30, 2024 as compared to the prior year period was primarily due to the prior year period reflecting a significant improvement in cash collections.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">DSO is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 51.6 days at September 30, 2024 as compared to 50.5 days at December 31, 2023 and 50.4 days at September 30, 2023.  The change in our DSO was primarily related to revenue cycle management transition activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024, our net cash used in investing activities of $33.5 million consisted primarily of capital expenditures of $18.6 million, net purchases of investments of $9.1 million and acquisition payments of $8.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024, our net cash used in financing activities of $9.5 million primarily consisted of payments on our Term A Loan (as defined below).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, we issued $400.0 million of 5.375% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  We used the net proceeds from the issuance of the 2030 Notes, together with $100.0 million drawn under our Revolving Credit Line (as defined below), $250.0 million of Term A Loan and approximately $308.0 million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the 2027 Notes, which had an outstanding principal balance of $1.0 billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, we amended and restated the Credit Agreement (the "Credit Agreement"), and such amendment and restatement (the &#8220;Credit Agreement Amendment&#8221;), concurrently with the issuance of the 2030 Notes. The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;), among other things, (i) refinanced the prior unsecured revolving credit facility with a $450.0 million unsecured revolving credit facility, including a $37.5 million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a new $250.0 million term A loan facility (&#8220;Term A Loan&#8221;) and  (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders under the Amended Credit Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Amended Credit Agreement bear interest at (i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if we select a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line, based on our consolidated net leverage ratio.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, we may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, we are in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, we had an outstanding principal balance on the Amended Credit Agreement of $218.8 million, composed of the Term A Loan. There was no balance outstanding under the Revolving Credit Line. We had $450.0 million available on our Amended Credit Agreement at September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, we had an outstanding principal balance of $400.0 million on the 2030 Notes. Our obligations under the 2030 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Amended Credit Agreement. Interest on the 2030 Notes accrues at the rate of 5.375% per annum, or $21.5 million, and is payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The indenture under which the 2030 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions.  Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, we may be required to repurchase the 2030 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Amended Credit Agreement and the 2030 Notes. We believe we will be in compliance with these covenants throughout 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at September 30, 2024 was $284.2 million, of which $29.0 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $28.3 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form 10-Q.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2023 Form 10-K, including the section entitled &#8220;Risk Factors.&#8221;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">itative Disclosures about Market Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt.  We borrow under our Amended Credit Agreement at various interest rate options based on the Alternate Base Rate or SOFR rate depending on certain financial ratios. At September 30, 2024, we had an outstanding principal balance of $218.8 million on our Amended Credit Agreement under our Term A Loan. Considering the total outstanding balance, a 1% change in interest rates would result in an impact to income before taxes of approximately $2.2 million per year.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nd Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Controls Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">No changes in our internal control over financial reporting occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1.	Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ceedings	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits, including with payors or other counterparties that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot ensure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to the risk factors previously disclosed in our 2023 Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregiste</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">red Sales of Equity Securities and Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2024, we withheld 22,821 shares of our common stock to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.092%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.018%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.278%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.417%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:14.837%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Period</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number<br/>of Shares<br/>Repurchased </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(a)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average Price<br/>Paid per Share</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number of<br/>Shares Purchased<br/>as part of<br/>the Repurchase<br/>Program</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate Dollar<br/>Value of Shares<br/>that May Yet<br/>Be Purchased<br/>Under the<br/>Repurchase<br/>Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 1 &#8211;  July 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,821 (b)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1 &#8211; August 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 1 &#8211; September 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,821</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which is estimated to be approximately 1.5 million shares for 2024. </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $496.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">million as of September 30, 2024.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares withheld to satisfy nominal minimum statutory withholding obligations in connection with the vesting of restricted stock.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, none of the Company&#8217;s directors or officers </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e3b1151-2293-47e7-af74-a9fda180b0bd" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_ca6047bf-53df-40e8-aa72-5c1e0167731a" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c75b8bcd-059a-42cd-a462-f287f5e7949a" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c20bebc2-d360-4387-a9ad-1602b824a0ca" contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 6. 	Exh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ibits</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.		    	Description								</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:90%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Employment Agreement, dated as of September 30, 2024, by and between PMG Services, Inc. and Kasandra Rossi.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1++</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:-54pt;padding-left:54pt;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interactive Data File</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Schema Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Calculation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Definition Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Label Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Presentation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+  Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">++  Furnished herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.8%;box-sizing:content-box;"/>
    <td style="width:42.2%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">Pediatrix Medical Group, Inc</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  November 1, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;/s/ James D. Swift, M.D.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">             </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;James D. Swift, M.D.</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  November 1, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;/s/ Kasandra H. Rossi</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">        </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Kasandra H. Rossi</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;(Principal Financial Officer and</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Principal Accounting Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>md-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is made and entered into by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PMG SERVICES, INC. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f/k/a Mednax Services, Inc.), a Florida corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">KASANDRA ROSSI</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on September 30, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer is presently engaged in &#x201c;Employer&#x2019;s Business&#x201d; as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employer desires to continue employing Employee and benefit from Employee&#x2019;s contributions to Employer; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employer and Employee previously entered in a Second Amended and Restated Employment Agreement dated April 26, 2023, which will be superseded in its entirety upon the execution of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the mutual covenants and premises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Employee hereby agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employment and Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; commencing on October 1, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and continuing for a period of three (3) years, unless sooner terminated as hereinafter set forth.  Thereafter, the employment of Employee hereunder shall automatically renew for successive one (1) year periods until terminated in accordance herewith.  The Initial Term and any automatic renewals shall be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Duties of Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As of the Effective Date and thereafter during the remaining Employment Period, Employee shall serve as Executive Vice President, Chief Financial Officer and Treasurer of Employer and Pediatrix Medical Group, Inc., a Florida corporation and the parent corporation of Employer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by the Chief Executive Officer of Pediatrix (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee&#x2019;s Supervisor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or the Board of Directors of Pediatrix (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of Pediatrix; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that such duties as assigned shall be customary to Employee&#x2019;s role as an executive officer of Employer and Pediatrix.  Employee&#x2019;s employment shall be full-time and, as such, Employee agrees to devote substantially all of Employee&#x2019;s attention and professional time to the business and affairs of Employer and Pediatrix.  Employee shall perform Employee&#x2019;s duties honestly, diligently, competently, in good faith and in the best interest of Employer and Pediatrix.  During the Employment Period, Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">capacity for any institution other than Employer and Pediatrix, and their respective subsidiaries and affiliates in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Employment Period, it shall not be a violation of this Agreement to (i) serve on civic or charitable boards or committees, or (ii) deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities have been approved by Employee&#x2019;s Supervisor and do not interfere with the performance of Employee&#x2019;s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Place of Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employee shall be based at Employer's offices located in Sunrise, Florida, except for required travel relating to Employer&#x2019;s Business.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Salary and Performance Bonus.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer shall pay Employee during the Employment Period an annual salary of Four Hundred and Twenty-Five Thousand Dollars ($425,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), payable in accordance with Employer&#x2019;s normal business practices for senior executives (including tax withholding), but in no event less frequently than monthly.  Employee&#x2019;s Base Salary shall be reviewed at least annually by the Compensation and Talent Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation and Talent Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and may be increased in its discretion.  After any such increase in Base Salary, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall refer to the increased amount.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employee shall be eligible to receive a cash bonus (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for each year (or prorated with respect to any partial years of employment) during the Employment Period, provided that, except as otherwise provided herein, Employee has remained employed by Employer as of the end of the applicable year (or as of the end of the Employment Period for the final calendar year of the Employment Period).  Employee&#x2019;s target bonus opportunity for any particular year (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be seventy-five percent (75%) of Base Salary.  The amount of bonus payable to Employee for any particular year will be determined by the Compensation and Talent Committee, in its sole discretion, taking into account the performance of Employer and Employee for that particular year (or portion thereof).  All such bonuses shall be paid no later than March 15th of the calendar year immediately following the calendar year in which it is earned.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Benefits.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expense Reimbursement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer shall promptly reimburse Employee for all out-of-pocket expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employer&#x2019;s Business pursuant to the reimbursement standards and guidelines of Employer in effect from time to time, including reimbursement for appropriate professional organizations.  Employee shall account for such expenses and submit reasonable supporting documentation in accordance with Employer&#x2019;s policies in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Employment Period, Employee shall be entitled to participate in such health, welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and programs are applicable to other similarly situated employees of Employer.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leave Time</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Employment Period, Employee shall be entitled to paid vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Plans.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">During the Employment Period, the Chief Executive Officer of Pediatrix shall recommend to the Compensation and Talent Committee that Employee receive, on an annual basis following the Effective Date, and at the same time as other executive officers of Employer, grants of awards (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) pursuant to Pediatrix&#x2019;s Amended and Restated 2008 Incentive Compensation Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2008 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or any other similar plan adopted by Pediatrix (together with the 2008 Plan, each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with a grant value determined by the Compensation and Talent Committee in the same manner as for other executive officers of Employer.  Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and the terms of the applicable Equity Plan and shall be made subject to an award agreement that is consistent with terms applicable to other executive officers of Employer.  Notwithstanding any contrary provision in this Agreement or any Equity Plan then maintained by Pediatrix, if Employee remains continuously employed with Employer through the date of a Change in Control (as defined in the Equity Plan pursuant to which the Equity Award is issued, provided that such event constitutes a &#x201c;change in the ownership or effective control of the corporation, or in the ownership of a substantial portion of the assets of the corporation&#x201d; as defined in Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as necessary to avoid penalties under Section 409A of the Code that are applicable to an Equity Award), then upon such Change in Control (i) all time-based Equity Awards granted to Employee by Pediatrix shall immediately become fully vested, non-forfeitable and, if applicable, exercisable and (ii) all performance-based Equity Awards, if any, for which the applicable performance condition has been met at the time of such Change in Control shall immediately become fully vested, non-forfeitable and, if applicable, exercisable.  For purposes of clarification, except as otherwise provided in an applicable award agreement, the vesting of any performance-based Equity Awards for which the performance condition has not been met at the time of such Change in Control shall not be accelerated or otherwise modified pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> but such Equity Awards may nonetheless be accelerated or otherwise modified as determined by the Compensation and Talent Committee of Pediatrix under the terms of the Equity Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination; Compensation and Benefits Upon Termination.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement for Cause (as defined below).  The termination date for a termination of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be the date specified by Employer in a written notice to Employee of finding of Cause.  If Employee&#x2019;s employment is terminated for Cause, Employer shall pay (i) Employee&#x2019;s Base Salary through the termination date at the rate in effect at the termination date, (ii) reimbursement for reasonable business expenses properly incurred prior to the termination date, subject to Employer policy and the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, and (iii) vacation payout and any other benefits that are vested benefits under applicable Employer benefit plans or that are required by applicable law (the foregoing clauses (i)-(iii), the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement upon the Disability (as defined below) of Employee.  The termination date for a </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">termination of this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be the date specified by Employer in a notice to Employee.  In the event of Employee&#x2019;s Disability, (i) Employee shall continue to receive Employee&#x2019;s Base Salary for ninety (90) days under the Employer&#x2019;s short term disability policy, which may be amended or modified in the Employer&#x2019;s discretion upon written notice to Employee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Disability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and (ii) following such Initial Disability Period, if Employee&#x2019;s Disability continues, the Employer may terminate Employee&#x2019;s employment immediately upon written notice.  If Employee&#x2019;s employment is terminated in connection with Employee&#x2019;s Disability, in addition to the Accrued Obligations and subject to and conditioned on Employee&#x2019;s compliance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, Employee shall be eligible to receive (A) a bonus with respect to Employer&#x2019;s fiscal year in which the termination date occurs, equal to Employee&#x2019;s minimum Target Bonus for the year of termination, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pro-Rated Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) payable within thirty (30) days of the termination date; and (B) all time-based Equity Awards granted to Employee by Pediatrix prior to termination of Employee&#x2019;s employment shall immediately become fully vested, non-forfeitable and, if applicable, exercisable, and all performance-based shares awards, if any, shall remain outstanding and shall vest based upon actual performance determined at the end of the applicable performance period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except as set forth in the award agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Death</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employee&#x2019;s employment under this Agreement shall terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employee&#x2019;s estate.  The date of Employee&#x2019;s death shall be the termination date for a termination of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon Employee&#x2019;s death during the Employment Period, Employer shall pay or provide to the person or entity designated by Employee in a notice filed with Employer or, if no person is designated, to Employee&#x2019;s estate (i) the Accrued Obligations; (ii) a Pro-Rated Bonus; and (iii) the Equity Acceleration, except as set forth in the award agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination by Employer Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement without Cause by giving Employee written notice of such termination.  The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90) days from the date of such notice.  Upon any termination of Employee&#x2019;s employment without Cause pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, in addition to the Accrued Obligations and subject to and conditioned on Employee&#x2019;s compliance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, Employee shall be eligible to receive: (i) a Pro-Rated Bonus; (ii) severance payments equivalent to Employee&#x2019;s monthly Base Salary for a period of twenty-four (24) months after the termination date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), payable in installments in Employer&#x2019;s normal payroll with the first installment payment to occur within sixty (60) days following the termination date; (iii) continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as regular, full-time employees of Employer and their eligible dependents during the Severance Period (or, at Employer&#x2019;s option, Employer may provide health insurance to Employee and Employee&#x2019;s eligible dependents through an insurance carrier(s) selected by Employer in lieu of providing the foregoing coverage, provided the coverage afforded by such insurance is substantially comparable to the foregoing coverage, and Employee shall pay the cost of such insurance up to the amount that would have been paid by Employee under the foregoing coverage and Employer shall pay the excess cost, if any); (iv) an amount equal to the greater of (A) 1.5 times Employee&#x2019;s Average Annual Performance Bonus (as defined below) or (B) 1.5 times </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee&#x2019;s Target Bonus amount, payable within sixty (60) days of the termination date; and (v) the Equity Acceleration.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination by Employee without Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employee may terminate Employee&#x2019;s employment under this Agreement without Good Reason (as defined below) upon not less than ninety (90) days prior written notice to Employer.  Upon receipt of such notice from Employee, Employer may, at its option, accelerate the effective date of Employee&#x2019;s termination of employment at any time in advance of the expiration of such ninety (90) day period (which acceleration shall not constitute Good Reason or a termination by Employer without Cause).  The termination date under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be the date specified by Employer, but in no event more than ninety (90) days after Employer&#x2019;s receipt of notice from Employee as contemplated by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon any termination of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employee shall be entitled to the Accrued Obligations.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination by Employee for Good Reason.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Employee may terminate Employee&#x2019;s employment hereunder for Good Reason.  If Employee desires to terminate Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employee must, within ninety (90) days after the occurrence of events giving rise to the Good Reason, provide Employer with a written notice describing the Good Reason in reasonable detail.  If Employer fails to cure the matter cited within thirty (30) days after the date of Employee&#x2019;s notice, then this Agreement shall terminate as of the end of such thirty (30) day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30) day cure period.  If Employee&#x2019;s employment under this Agreement is terminated pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, then Employee shall be eligible to receive the same payments and benefits, subject to the same conditions, for a termination without Cause as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continuation of Benefit Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Following any termination that results in the expiration of Employee&#x2019;s continued benefit plan coverage, Employee and each of Employee&#x2019;s eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to COBRA.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continuing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The obligations imposed on Employee with respect to non-competition, non-solicitation, confidentiality, non-disclosure and assignment of rights to inventions or developments in this Agreement or any other agreement executed by the parties shall continue, notwithstanding the termination of the employment relationship between the parties and regardless of the reason for such termination.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conditions to Severance; Certain Definitions.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Release.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer shall provide Employee with a general release in the form attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (subject to such modifications as Employer may reasonably request) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) within seven (7) days after Employee&#x2019;s termination date.  Payments or benefits to which Employee may be entitled pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof (other than the Accrued Obligations) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severance Amounts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall be conditioned upon (i) Employee executing the Release within twenty one (21) days after receiving it from Employer (or such longer period as may be set forth in the Release not to exceed forty-five (45) days) and the Release becoming irrevocable upon the </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">expiration of seven (7) days following Employee&#x2019;s execution of it, (ii) Employee agreeing to submit to a reasonable exit interview if requested by Employer, and (iii) Employee&#x2019;s compliance with all post-termination obligations to Employer and its subsidiaries and affiliates and surrendering to Employer all proprietary or confidential information and articles belonging to Employer or its subsidiaries or affiliates.  Payment of the Severance Amounts shall be suspended during the period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Suspension Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that begins on Employee&#x2019;s termination date and ends on the date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Suspension Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that is at least forty-five (45) days after Employee&#x2019;s termination date; provided, however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage (or COBRA reimbursement) that would be required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof during the Suspension Period.  If Employee executes the Release and the Release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As used in this Agreement:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Average Annual Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean an amount equal to the average of the percentage of the Performance Bonus target achieved by Employee for the three (3) full calendar years prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on Employee&#x2019;s Base Salary and Target Bonus in Employee&#x2019;s current position.  For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#x2019;s Target Bonus in each of the three full calendar years prior to termination, and Employee&#x2019;s current Target Bonus was 100% of Base Salary, and Base Salary was $450,000.00, then Employee&#x2019;s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $450,000.00 = $315,000.00).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the occurrence of any of:  (i) Employee&#x2019;s engagement in (A) willful misconduct resulting in material harm to Pediatrix or Employer, or (B) gross negligence; (ii) Employee&#x2019;s conviction of, or pleading nolo contendere to, a felony or any other crime involving fraud, financial misconduct, or misappropriation of Employer&#x2019;s assets; (iii) Employee&#x2019;s willful and continual failure, after written notice from Employee&#x2019;s Supervisor or the Board to (A) perform substantially Employee&#x2019;s employment duties consistent with Employee&#x2019;s position and authority, or (B) follow, consistent with Employee&#x2019;s position, duties, and authorities, the reasonable lawful mandates of Employee&#x2019;s Supervisor or the Board; (iv) Employee&#x2019;s failure or refusal to comply with a reasonable policy, standard or regulation of Employer in any material respect, including but not limited to Employer&#x2019;s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies; or (v) Employee&#x2019;s breach of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof resulting in material harm to Pediatrix or Employer.  No act or omission shall be deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Employee in a good faith belief that such act or omission to act was in the best interests of Employer or Pediatrix or if done at the express direction of the Board.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to the requirements of applicable law, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean (i) Employee&#x2019;s inability to perform Employee&#x2019;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii) a </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">determination by an independent qualified physician selected by Employer and acceptable to Employee (which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional ninety (90) or more days in any one hundred twenty (120) day period.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean:  (i) a material decrease in Employee&#x2019;s Base Salary; (ii) a material decrease in Employee&#x2019;s Target Bonus opportunity; (iii) Employee is assigned any position, duties, responsibilities or compensation that is materially inconsistent with the position, duties, or responsibilities of Employee contemplated herein as of the Effective Date, it being understood that these roles and positions are evolving and responsibilities may change over time and, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice; (iv) Employee experiences a material diminution in Employee&#x2019;s authorities, duties or responsibilities, it being understood that these roles and positions are evolving and responsibilities may change over time and excluding for this purpose any isolated and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice; (v) Employee is required to report to any person other than the senior most executive officer of Pediatrix, the Board, or a duly constituted committee thereof; (vi) the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employee resides or where Employer&#x2019;s headquarters resides as of the Effective Date, except for travel reasonably required in the performance of Employee&#x2019;s duties; or (vii) any other action or inaction that constitutes a material breach of this Agreement by Employer.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successors; Binding Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) acquiring a majority of Employer&#x2019;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment.  In such event, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean Employer as previously defined and any successor to its business and/or assets which executes and delivers the agreement provided for in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law.  This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall not limit Employee&#x2019;s ability to terminate this Agreement in the circumstances described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Benefit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by Employee&#x2019;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  If Employee should die after the termination date and amounts would have been payable to Employee under this Agreement if Employee had continued to live, including under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, then such amounts shall be paid to Employee&#x2019;s devisee, legatee, or other designee or, if there is no such designee, Employee&#x2019;s estate.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided in this Agreement, this Agreement constitutes the entire agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely determinative of the subject matter hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Competition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employer and Employee acknowledge and agree that a strong relationship and connection exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services.  Employer and Employee further acknowledge and agree that the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following:  (1) the use and disclosure of the Confidential Information as described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof; (2) the professional development activities described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof; and (3) the goodwill of Employer, as promoted by Employee as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.  The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such interests.  Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement.  Employee further acknowledges that the goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section.</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee, consultant, independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer&#x2019;s Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto.  Employee acknowledges that, as of the date hereof, Employee&#x2019;s responsibilities will include matters affecting the businesses of Employer listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Employment Period plus (i) eighteen (18) months in the event this Agreement is terminated pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, and (ii) twenty-four (24) months in the event the Agreement is terminated for any other reason.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Hire</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Employee further agrees that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, at any time during the Employment Period and for a period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly employ, or intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a) employ or otherwise engage (i) any person who is a then current </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">employee or exclusive independent contractor of Employer or one of its affiliates, or (ii) any person who was an employee or exclusive independent contractor of Employer or one of its affiliates in the prior six (6) month period, or (b) take any action that would reasonably be expected to induce an employee or independent contractor of Employer or one of its affiliates to leave his or her employment or engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer of Employee).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Solicitation.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee further agrees that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, at any time during the Employment Period and for a period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly solicit or accept business from or take any action that would reasonably be expected to materially interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with (i) hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships, (ii) patients, (iii) referral sources, (iv) vendors, (v) any other clients of Employer or its affiliates, or (vi) prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of soliciting at the time of Employee&#x2019;s termination (including potential acquisition targets).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  At all times during the term of this Agreement, Employer shall provide Employee with access to &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  As used in this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly, verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to:  (i) patients with whom Employer has a physician/patient relationship; (ii) the present or future business of Employer; or (iii) the research and development of Employer.  Without limiting the generality of the foregoing, Confidential Information includes:  (a) the development and operation of Employer&#x2019;s medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b) contractual arrangements between Employer and insurers or managed care associations or other payors; (c) the databases of Employer; (d) the clinical and research protocols of Employer, including coding guidelines; (e) the referral sources of Employer; or (f) other confidential information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in Employer&#x2019;s business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and projections, and computer programs.  The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer&#x2019;s business and its goodwill.  Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might otherwise obtain.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Confidential Information shall not include any information that (i) was known by Employee from a third party source before disclosure by or on behalf of Employer, (ii) becomes available to Employee from a source other than Employer that is not, to Employee&#x2019;s knowledge, bound by a duty of confidentiality to Employer, (iii) becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv) has been independently developed by Employee and may be disclosed by Employee without breach of this Agreement, provided, in each case, that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions.  Pursuant to the Defend Trade Secrets Act of 2016, Employee acknowledges that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition, if Employee files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee&#x2019;s attorney and may use the trade secret information in the court proceeding, if Employee (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any investigation by any such federal government agency.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless disclosure is otherwise required by applicable law or stock exchange rules, Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section.  Employee shall keep the terms of this Agreement strictly confidential and will not, without the prior written consent of Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employee&#x2019;s representatives (such as tax advisors and attorneys) who need to know such information.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employee&#x2019;s employment with Employer, in any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information of any kind, nature, or description, subject to applicable law.  The parties agree that any breach by Employee of any term of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> resulting in material harm to Pediatrix or Employer is a material breach of this Agreement and shall constitute &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; for the termination of Employee&#x2019;s employment hereunder pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.  In the event that Employee is ordered to disclose any Confidential Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement.  In the case of any disclosure required by law, Employee shall disclose only that portion of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or control shall be and remain Employer&#x2019;s sole property (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Upon termination or expiration of this Agreement, or earlier upon Employer&#x2019;s request, Employee shall promptly deliver to Employer all Employer Property, retaining none.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ownership of Work Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee agrees and acknowledges that (i) all copyrights, patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#x2019;s Business (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Work Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code.  To the extent the Work Product may not be considered a work made for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration.  Upon request of Employer, Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#x2019;s successors and assigns, as fully and as entirely as the same might be held by Employee had this assignment not been made.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clearance Procedure for Proprietary Rights Not Claimed by Employer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  In the event that Employee wishes to create or develop, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">other than</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> on Employer&#x2019;s time or using Employer&#x2019;s resources, anything that may be considered Work Product but to which Employee believes Employee should be entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section.  Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently detailed written description of the work under consideration for Employer to make a determination regarding the work.  Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with respect to such request or description.  Employer will determine in its sole discretion, within thirty (30) days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer.  If Employer determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer.  If Employer fails to so notify Employee within such thirty (30) day period, then Employer shall be deemed to have agreed that such work is not considered Work </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Product for purposes of this Agreement.  Employee agrees to submit for further review any significant improvement, modification, or adaptation that could reasonably be related to Employer&#x2019;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer.  Clearance under this procedure does not relieve Employee of the restrictive covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Disparagement.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">During the Employment Period and for a period of ten (10) years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or willingly make any comment that would reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employee&#x2019;s work conditions or circumstances surrounding Employee&#x2019;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Review by Employee.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Employee has carefully read and considered the terms and provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and having done so, agrees that the restrictions set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> are fair and reasonably required for the protection of the interests of Employer.  In the event that any term or provision set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed from this Agreement without, in any manner, affecting the remaining portions hereof.  Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, such relief to be without the necessity of posting a bond.  In the event that, notwithstanding the foregoing, any part of the covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be held to be invalid, overbroad, or unenforceable by an arbitrator or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in any manner, affecting the remaining portions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (all of which shall remain in full force and effect).  In the event that any provision of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> related to time period or areas of restriction shall be declared by an arbitrator or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitrator or court deems reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Survival; Notice of Breach and Right to Cure.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Employer reasonably believes that Employee has breached a provision of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employer shall provide prompt written notice thereof to Employee that explains such reasonably believed breach (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alleged Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Employer agrees to work in good faith with Employee to provide Employee a reasonable opportunity to promptly cure such Alleged Breach.  In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a comment made by Employee that Employer reasonably believes is in breach of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> with respect to the Alleged Breach.  Employer and Employee further agree that Employee shall not be deemed to be in breach of any term of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof unless such breach results in material harm to Pediatrix or Employer.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall survive the termination of this Agreement and Employee&#x2019;s employment with Employer.  In the event of a breach of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> by Employee, as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, Employer retains the right to terminate any continuing payments to Employee provided for in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.  In the event of a breach of any provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> by Employee, as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities constituting such breach shall have been finally terminated, in each case as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof.  The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> are expressly intended to benefit and be enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof.  Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Matters</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In General.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).  For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.  Employer makes no representation or warranty and shall have no liability to Employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Six-Month Delay.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, if at the time of Employee&#x2019;s separation from service within the meaning of Section 409A of the Code, Employer determines that Employee is a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A) that would be considered &#x201c;non-qualified deferred compensation&#x201d;, such payment shall not be payable and such benefit shall not be provided until the date that is within fifteen (15) days after the end of the six-month period beginning on the date of such &#x201c;separation from service&#x201d; or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Employee&#x2019;s estate following Employee&#x2019;s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reimbursements.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by Employer or incurred by Employee during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Separation from Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#x2019;s termination of employment, then such payments or benefits shall be payable only upon Employee&#x2019;s &#x201c;separation from service&#x201d; as defined under Section 409A.  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Later Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and not otherwise exempt from the application of Section 409A, then, if the period during which Employee may consider and sign the Release or the period in which the Employer can make a severance payment spans two calendar years, any payment or benefit described in this Agreement will not be made or begin until the later calendar year.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 280G</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#x2019;s benefit pursuant to the terms of this Agreement or otherwise (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) constitute parachute payments (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) within the meaning of Section 280G of the Code and, but for this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, would be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then prior to making the Covered Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the Excise Tax to (ii) the Net Benefit to Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax.  Only if the amount calculated under (i) above is less than the amount under (ii) above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net Benefit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any such reduction shall be made in accordance with Section 409A and the following:  (i) the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section 409A shall be reduced first, in reverse chronological order; (ii) all other Covered Payments consisting of cash payments, and </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. &#167; 1.280G-1 Q/A-24(c) does not apply, and that in either case do not constitute nonqualified deferred compensation subject to Section 409A, shall be reduced second, in reverse chronological order; (iii) all Covered Payments consisting of cash payments that constitute nonqualified deferred compensation subject to Section 409A shall be reduced third, in reverse chronological order; and (iv) all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg. &#167; 1.280G-1 Q/A-24(c) applies shall be the last Covered Payments to be reduced.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any determination required under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be made in writing in good faith by an independent accounting firm selected by Employer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accountants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Employer and Employee shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of making the calculations and determinations required by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Accountants may rely on reasonable, good-faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code.  The Accountants&#x2019; determinations shall be final and binding on Employer and Employee.  Employer shall be responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is possible that after the determinations and selections made pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Overpayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or less than the amount intended or required to be provided after application of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Underpayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:21.429%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.428947960528431%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that:  (A) the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B) it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date of Employee&#x2019;s receipt of the Overpayment until the date of repayment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:21.429%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.428947960528431%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that:  (A) the Accountants, based upon controlling precedent or substantial authority, determine that an Underpayment has occurred or (B) a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by Employer to or for the benefit of Employee together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee until the payment date.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Withholding.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All amounts payable under this Agreement shall be subject to applicable income and employment tax withholding.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dispute Resolution; Injunctive Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If any controversy or claim arises out of or relating to this Agreement, or any alleged breach hereof, Employee and Employer shall first try to resolve such controversy or claim through mediation using the services of the American Arbitration Association.  If any such controversy or claim cannot be resolved by mediation pursuant to the foregoing, Employee and Employer agree that such controversy or claim shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that if Employee and Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer shall bear all costs associated with such mediation and, if necessary, arbitration, including but not limited to all costs of the mediator and arbitrator, and shall reimburse Employee on a monthly basis for Employee&#x2019;s reasonable legal and other expenses, including all fees, incurred in connection with any such mediation and, if necessary, arbitration, provided, however, that if Employer ultimately prevails in any arbitration (as determined by the arbitrator), the arbitrator shall have the power to require Employee to reimburse Employer for all or a portion of the advanced legal fees and other expenses as determined by the arbitrator (and, if the arbitrator finds that Employer prevailed on certain claims and Employee prevailed on others, the arbitrator shall have the power to require Employee to reimburse Employer for a portion of the advanced legal fees and other expenses determined by the arbitrator based on those claims on which Employer prevailed).  The mediation and, if necessary, arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually agreed by the parties, and shall be conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect.  Judgment on any award rendered by the arbitrator may be entered and enforced by any court having jurisdiction thereof.  Any such mediation and, if necessary, arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrator.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the party shall be entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable service of process.  Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i) they are not subject to the jurisdiction of such courts, (ii) they are immune from any legal process issued by such courts and (iii) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum.  In the event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all of Employee&#x2019;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided, however, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer all such advanced legal fees and other expenses.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given when (i) delivered by hand, (ii) delivered by </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">electronic mail that is confirmed by non-automated means, or (iii) when delivered or delivery is refused if sent by registered or certified U.S. mail, return receipt requested, postage prepaid, or via reputable overnight courier, addressed as follows:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:38.8pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">If to Employer:</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PMG Services, Inc.</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1301 Concord Terrace</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sunrise, FL 33323</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Attention: General Counsel</font></p><p style="margin-left:2.187%;text-indent:-5.387%;padding-left:5%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Email: maryann.moore@pediatrix.com</font></p></td>
    <td style="text-indent:18pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">If to Employee:</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Kasandra Rossi</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">c/o PMG Services, Inc.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1301 Concord Terrace</font></p><p style="text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sunrise, FL 33323</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Email: kasandra.rossi@pediatrix.com</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Benefits; Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns.  Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer.  This Agreement may be assigned by Employer upon notice to Employee.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The invalidity of any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or clauses, or section or sections had not been inserted.  If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Nothing contained herein shall be construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Third Party Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#x2019;s heirs, personal representative(s) and/or legal representative) any rights or remedies under or by reason of this Agreement.  No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">representations are not set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The remainder of this page has been left blank intentionally.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the undersigned have executed this Agreement effective as of the Effective Date.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EMPLOYER:</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PMG SERVICES, INC.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EMPLOYEE:</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Mary Ann E. Moore</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mary Ann E. Moore</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, General Counsel, Chief Administrative Officer &amp; Secretary</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Kasandra Rossi</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Kasandra Rossi</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PEDIATRIX MEDICAL GROUP, INC.</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Shirley A. Weis</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shirley A. Weis</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair, Compensation and Talent</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Committee</font></p></td>
    <td style="text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature Page to Third Amended and Restated Employment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BUSINESS OF EMPLOYER</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively referred to herein as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer&#x2019;s Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(1) Neonatology, including hospital well baby care;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(2) Maternal&#x2011;Fetal Medicine, including general obstetrics services;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(3) Pediatric Intensive Care, including Pediatric Hospitalist Care;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(4) Newborn hearing screening services;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(5) Pediatric Surgery; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(6) Pediatric Emergency Medicine; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">References to Employer&#x2019;s Business in this Agreement shall include such other medical service lines, practice management services and other businesses in which Employer is engaged during the Employment Period; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that to be considered a part of Employer&#x2019;s Business, Employer must have engaged in such other service line, practice management service or other business at least six (6) months prior to the termination date of this Agreement.  For purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, businesses of Employer shall include the businesses conducted by Employer&#x2019;s subsidiaries, entities under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended.  Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for financial reporting purposes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and clarifications regarding the scope of Employer&#x2019;s Business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hospital Services.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer and Employee acknowledge that, as of the date hereof, Employer does not currently operate hospitals, hospital systems or universities.  Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer&#x2019;s Business where such hospitals, hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#x2019;s Business.  Therefore, the parties desire to clarify their intent with respect to the limitations on Employee&#x2019;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall not be deemed to restrict Employee&#x2019;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer&#x2019;s Business.  Furthermore, even if a hospital, hospital system or university provides medical services that are included in Employer&#x2019;s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the hospital&#x2019;s, hospital system&#x2019;s or university&#x2019;s provision of medical services that are Employer&#x2019;s Business.  For the avoidance of doubt, Employer and Employee agree that if Employee becomes the Chief Operating Officer, Chief Legal Officer, Chief Compliance Officer, General Counsel or Chief Executive Officer of a hospital system or health system, or other</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A&#x2011;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">executive officer of similar level to the foregoing, that Employee shall not be in breach of the provisions of this Agreement.  Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or university that are included in Employer&#x2019;s Business so long as such hospital, hospital system or university is located at least ten (10) miles from a medical practice owned or operated by Employer or its affiliate.  Subject to paragraph B below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">De Minimus Exception.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer agrees that a medical service line (other than those listed in items (1) through (8) above), practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#x2019;s Business if such medical service line, practice management service or other business constitutes less than three percent (3%) of Employer&#x2019;s annual revenues.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Divested Lines of Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer agrees that any medical service line (including those listed in items (1) through (8) above), practice management, or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity, or otherwise after the Effective Date shall not be considered to be a part of Employer&#x2019;s Business effective as of the effective date of such divestiture.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Ownership Interests.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It shall not be deemed to be a violation of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for Employee to:  (i) own, directly or indirectly, one percent (1%) or less of a publicly&#x2011;traded entity that has a market capitalization of $1 billion or more; (ii) own, directly or indirectly, five percent (5%) or less of a publicly&#x2011;traded entity that has a market capitalization of less than $1 billion; or (iii) own, directly or indirectly, less than ten percent (10%) of a privately&#x2011;held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A&#x2011;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FORM OF RELEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GENERAL RELEASE OF CLAIMS</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Kasandra Rossi (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), for himself or herself and his or her family, heirs, executors, administrators, legal representatives and their respective successors and assigns, in exchange for the consideration received pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.[&#x25cf;] of that certain Third Amended and Restated Employment Agreement, dated as of September 30, 2024, by and between Employee and Employer, to which this release is attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), does hereby release and forever discharge PMG Services, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), its subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Released Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Employee&#x2019;s employment or termination thereof, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment.  Employee acknowledges that Employer encouraged Employee to consult with an attorney of Employee&#x2019;s choosing, and through this General Release of Claims encourages Employee to consult with Employee&#x2019;s attorney with respect to possible claims under the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and that Employee understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans.  Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that Employee may have as of the date hereof.  Employee further understands that by signing this General Release of Claims Employee is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof.  Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any actions to enforce rights to receive any payments or benefits which may be due Employee pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.[&#x25cf;] of the Employment Agreement, or under any of Employer&#x2019;s employee benefit plans, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv) any claims for benefits under any directors&#x2019; and officers&#x2019; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v) any rights as a holder of equity securities of Employer, (vi) any claims that cannot be waived as a matter of law, (vii) any claims Employee may have to government&#x2011;sponsored and administered benefits such as unemployment insurance, workers&#x2019; compensation insurance (excluding claims for retaliation under workers&#x2019; compensation laws), state disability insurance, and paid family leave benefits, and (viii) any benefits that vested on or prior to the termination date pursuant to a written benefit plan sponsored by Employer and governed by the Employee Retirement Income Security Act of 1974, as amended.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee represents that Employee has not filed against the Released Parties any complaints, charges, or lawsuits arising out of Employee&#x2019;s employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that Employee will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), provided, however, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived Employee&#x2019;s rights under ADEA.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any investigation by any such federal government agency; however, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other individual remedies, provided that, for purposes of clarity, this limitation on monetary recovery does not apply to whistleblower proceedings before the United States Securities and Exchange Commission.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee hereby acknowledges that Employer has informed Employee that Employee has up to twenty&#x2011;one (21) days to sign this General Release of Claims and Employee may knowingly and voluntarily waive that twenty&#x2011;one (21) day period by signing this General Release of Claims earlier.  Employee also understands that Employee shall have seven (7) days following the date on which Employee signs this General Release of Claims within which to revoke it by providing a written notice of Employee&#x2019;s revocation to Employer.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of Florida applicable to contracts made and to be performed entirely within such State.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee acknowledges that Employee has read this General Release of Claims, that Employee has been advised that Employee should consult with an attorney before Employee executes this general release of claims, and that Employee understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This General Release of Claims shall take effect on the eighth day following Employee&#x2019;s execution of this General Release of Claims unless Employee&#x2019;s written revocation is delivered to Employer within seven (7) days after such execution.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[DO NOT SIGN]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, 20</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>md-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, James D. Swift, M.D., certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: November 1, 2024</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">James D. Swift, M.D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Executive Officer</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Executive Officer)</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>md-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, Kasandra H. Rossi, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: November 1, 2024</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Kasandra H. Rossi	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Kasandra H. Rossi</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">          Principal Accounting Officer)</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>md-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification Pursuant to 18 U.S.C Section 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Pediatrix Medical Group, Inc. on Form 10-Q for the quarter ended September 30, 2024 (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pediatrix Medical Group, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Pediatrix Medical Group, Inc. and will be retained by Pediatrix Medical Group, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">November 1, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/ James D. Swift, M.D. 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: /</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Kasandra H. Rossi	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Kasandra H. Rossi</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Principal Accounting Officer)</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img260272796_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img260272796_0.jpg
M_]C_X1FB17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D ,C R,CHP-SHR-R Q-3HS.#HS-
M  .@ 0 #     0 !  "@ @ $     0  !D"@ P $     0   ^D
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   8:         !(     0   $@
M   !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( &0 H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDDE*22224I)
M)))2DDE"VVJFI]USQ756TOL>XPUK6C<Y[G'Z+6M24U.L]8Q.CX3LO))(G;76
MWZ3W'\QJQ:'_ %WZJT7L?1TC'<2:V.9ZEI:?H;VVM?\ ^Z__ !2Y[.ZMU'ZU
M_66H="H:^C 874ORM*Y#AOR75GW?3?1LK]]OZ/\ 25*]F]7^O/0;J1FW8?4G
M7F&XE0=ZI$_F"NK'=[W?HZ_;=[_\$K!P^W&YRQPEN8Y#ZAX<+*>;P<OC@8XQ
MDG,<4LV6'%BAQ>F$,4<GIG_?X'2R,CZZ]&8<FXT=7Q6&;=K?3M:T?2(;6UC?
M^AD?U%N]*ZKB=6PVYF(Z6.T<T_2:X?2KL _.7+=)Z[]9_K$;G8%^+A/QW;;<
M2P'U&^;M]=SG-_,W_H_?_@U1Z5U3*^K/UHR<3JE+:L7-8+7.HUK:Z9%C6#_!
M_P _^C;^D_X)02E\PG"6.41?JCPBOZR/OF'/CF9XCAGC'&,T(<&#)")X9QR#
M'Z<?]2?!!]#246/98QME;@]CP'-<TR"#JUS7!208U))))*4DDDDI22222G__
MT/54DDDE*22224I))))2ER/^,*ZZZGIO1*7^F>K93:[']MC7,&O_ %VZJS_K
M:ZY<G_C!QLAF)@]:QF^I9T?(;<YO;82PN<?^NU4[_P#@][U/RE>_"^YX?[]?
MJ_\ GL>>_;E7U_N_I?\ -1=1QZ?JQUSIW4*&>GTMU(P;@V3LCZ+W<[MWLM_T
MEGH6_GJS]7*V]3ZUU#K=I%H99Z&$X:M# #[V?]9]/_MV[_2+:HNZ;UWI;;&A
MN1A9;)+7?]2[]RVIX_KU6KB,'I/4^B]=R^D].ZD[!%[_ %<1EPWUO#OHB7AS
M/4V?H]_I>]].Q0Y:E* R'AE&1!XOWOT>+^LS9I8,_P!T&28PG%>,3D"<$QP_
MT;BX.+@E#Y/E_P VZ'UD97T+ZV=+ZY0137G../U#7:PM]C?5L_L.]3_T%J1>
MCXK?K%U;JG5<BL_8+J_L>.'<D#;-K)^@]GI^I_(LN_X)8>1@9_7/K7B=(SNH
M'J(PR;LXU#;75M/Z2ENS8WU/YJE[ZV>Q]WI_X*Q=_DWX'1>FFPM;3C8[896W
M23^;76/W['*QS!X<>,2UE[=2/^JXO3_S5T<F'!#FH1D,GN5C.0:88X^'BYCA
MX^'BXI>AROJ7?<,'(Z?>=UG3[W4@_P GP_[<]5=$N?\ J9C7MZ?=GY B[J%S
MK_#VGZ+O[;O4>S_@UT"IXK]N/E^'1J<I?L8[O;2_W?T/^8I)))/9U))))*4D
MDDDI_]'U5))))2DDDDE*22224I1>QEC'5V-#V/!:YKA((.CFN:5)))3Q]GU,
MZKTO)?D?53J'V-EIE^'?+JI_DN+;OZK-]/J_]V%7S/JS]=>M.K9U7,Q**JSI
M90TFP3SLAE3O_!ZUU5/6^D7Y[^G4YE+\VLD.H:\%TM_G&Q^<^O\ PC/\&KRG
MGFR$<.6$9$CYLD 9\/3U?]TP^QCD*UX;^4'T6/ZKQO3/JQ]8^@MLIZ3?BNKM
M=+[;&D6.C1I?['_1_,K]5[/\]7:?JMFYN0S)^L.9]L-?T,:O2H?UM*_[>VJO
M_A+'KI4E5E#B-SE*?]^1DM'*8^IE*-WP2E*6/_$6    $ : !.DDGMA222HY
M_6^D=.MKIS\RG&LMU8RQX:2)V[]?HL_X1WL1$3(U$$GL$$@;FF\DDD@E2222
M2G__TO3VYN&Z[T&WUNNDM](/:72-7-V3N]J%^UNE?:?LOVRC[3.WT/59ZF[]
MWT]V_<O)>HXN1D_6[,Q\/V961G6U5O!+2"]SF/+K&>]K/3<_U?\ @UI]=_Q>
M9/2>F/SJ\EF6R@;KZO2],AOYSZ_?;O\ 3_/W;/T:T#R6&)@)YN&60#A'#^D6
MH.9R$2,<=B!]1OH^I*ME]3Z;A%K<W+IQBX2T76-K)'\GU'-7"_5[ZV9F-]4>
MI&QQNR>F>FS%L>=QC(/I8[7[OYS[/:+/^L_HUS?3</IO4;K<KK75AB.<[5SF
MNMOM=$E[G1M97_KL8FPY WD]R1$<9X?1'CE/]+Y?\),N;%0X "9CB]1X8Q^K
M[#C9>)F5^KB75Y%4QOJ<'MGPW,+FHKG-8TO>0UK02YQ,  <DE>-_:6_5SJM>
M9T/J#<U@&YSFM=7O:#^DQ<JEWTM[?H/_ .N?HK&+6_Q@=<NZAU"KIN.7'$KK
MJL](?X2VX"VO>W\_96^KTF?Z1$_#R<D1&7HF#+BD.&4>']Z"AS8X)$CU1('"
M#?%Q=I/HE/5.FY>^O#RZ<BQK22VJQCW#^RQSEQ'^+SK?6.H=8LISLRW)J&(Y
MX9801N#Z6[]&M_-<Y5[/\6W4\3 ^WU9C/M]#?5%%;"V'-]VRG+:_?ZO[C_1^
MG^Y]-"_Q8D'K]Y'!PWQ_VY0GQPX8X,YQS&70:F/J@1_WRPY,IRXA./!9/723
M<Z+]2787UCIM=U'&LHQ;G/K96_\ 6'EN[;795&UCO^Y'O>N_OOHQZG79%C::
MF_2LL<&M']9SO:O,NB-;_P".4\P)^VYNL?R<I ^LF1G_ %C^M3^G5'<VN]V)
MB4N/Z-IK)9?>[:#^<RVVRS9ZGH_HT<N">;+$3R>F.(9)2JN$*AECCQRX(:F9
M@(]Y/I]'4NG9-3[L?*INJJ$V65V-<UHY][V.+6*3<["?6^QN14ZNN-[P]I#9
M^CO=/M7FO7/J'F=$Z;9U&G,&0UC=F4QK#4?3>0Q^HLL]:K<[])79^8I_4WI#
MNK] ZYTVIS*GY#\<![FRT;3ZGN:W^HHCRF'VSECFXH"48D\/RW*,9?\ 27CF
M,G&,<L=2,3+?MLFZ+]8NIO\ KG]GR>H/=T\9&4W8]S?2V-%_H^^/H-VU^G[U
MZ'9E8U5;;;+F,J?&Q[G -,C<W:XG:[VKQK"Z%;G];/0V6L;9ZEU/JN:2R:19
MN=L^EM?Z*['Z_8AQ/JCTO#L+7NQKJ*BX#0EE%]>YH/\ 54O-8,<LN&$9")F!
M&HQ_1]7ZQ9@S3&/)*0OA)._7]Q[9EU-E7K,L:ZH@D6-(+8')WCVKAOKC]57=
M3ZJWJ&/U#%I;D4M#V9-FV&MG;;1M#_4J>UWT?9[_ /"?I/9S_2^C?63ZR8%6
M%C$5]+PP65^HXUT;Y<]WL8+'Y%VZSZ?I[*_^#1/\8&&<2[IF);M?9C=-KI<X
M#0EA>P[=WYOM2P<O[6<1AF'&>($ <7##IQ*R9O<Q7+&>'TZG2Y>#Z9B,QNF=
M-Q<>R]HJQZJZ6W6$-#MK16TZG;[]J/3DXV1N]"UENV-VQP=$\;MI5#*Z7C]6
M^KW[.O V7X[&AT3M<&M=5:T?\%8UMB\R^K_6,KZK=3RA95+]EF/D8XT'JUSZ
M#M"/:R[\_P#T%UGIJMBY;WHY#&7ZV)OA_>9LF;VC"QZ)?I?NOK-N?@T.<R[)
MJJ<W5S7O:T@<^X.*."")&H/!7F/U.^KUOUAZI9UKJP%^/787V&P#]/?]+9M_
M[CX_[G\W_-8_\WZJ]/3.8PQQ2$!+CD!Z_P!V,OW5V')+)'B(X0?E[T__TZ/4
M,ZSIWUOR\^L!S\;/LL#28#@'NWLW:[?487,70_6#_&'AY_1[\'!Q[F793#5:
M^X,#6,<-MVW8^SU'[/8S_MS_ (-9>(UK_P#&(YCP'-?U"]KFG4$$7!S7!=VS
MZE?59E_KMZ=5OF0UQ<ZN?_"[W.H_\#6MS&3! XCEA*4HPC*)C_T9.?AAED,G
M!(1!D0;_ .Y>.Z%]6L_*^IO5+V,/JYQJLQ*SR]F,[U@YO_AC?;73_8L_FUD?
M5[*^K%?J5=>PGWASIJR*W6 MTAU-M-5E7YS?I;=_[Z]B63U'ZI_5[J5YR,O"
M8Z]WTK&.=4YQ_>L-#ZO4=_QBAASX)R#()".0\0.(\,X?H_U?W667*4(<!!,!
MP^L<49/"LROJ-D]5HPL7HE]V/D'TS8+K1:7N,-]/']?W4M_PKW6UO_X/]&I?
M7[IE_3.N5=4H;MQ[A4:7Q[&74 -;2?\ K=-3V?Z3]+_HUWO2_J[T7I+G/Z?B
M,IL<(-IE[X_=]:YUENS^3O5W)QL?+H?CY53+Z+!#ZK&AS3!GW-=_*3?OL8Y8
MR@)R@ 8R&27'*7%_C<*?NQ.,QD8B5\0,(\(C6SQ.9_C-P[.F6-HQ;J\^RLM
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-!         (  3A"24T$ @      !      X0DE-!#
M  (! 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "
M0      X0DE-!$0      !     "   "0    D      .$))300>       $
M     #A"24T$&@     #20    8              ^D   9     "@!5 &X
M= !I '0 ; !E &0 +0 Q     0                         !
M      9    #Z0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #Z0    !29VAT;&]N9P  !D     &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^D
M4F=H=&QO;F<   9      W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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MW7/%=5;2^Q[C#6M:-SGN<?HM:U)34ZSUC$Z/A.R\DDB=M=;?I/<?S&K%H?\
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MO_0JHW#RLKHMF6ZJW)ZGC]4JS.MX): YYHVL?C8M+?T5]'H-IOQ/?9]J_?\
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M]).CUWV/R_R^5!Z;;]7ZJ27RJDFI?JI)?*J22G__V3A"24T$(0      5P
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M0R0T5%8)XF/"@Z/41(2D)97#Q$;PX62%)K4G_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M                              __T+_
M
M
M
M
M
M        #__1O\
M
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M;;:%?S^V[3'S3X]SFSS+<5W*Y:<ER/IT_8]Z[/:3X?Z+5H1?Y>@]"TUIU?\
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MI2I*B4E1$I*DF1I4DRZDI)E[2/Y#&LD?&G%X/8T?Z!_
M
M
M                  #_TK_
M
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MY#6@
M
M                                   /_]._P
M
M
M          #1GF'ZA/'CAA4*;V#D"LBV+,A^\T&I\2=BSLRL4NH/W6;:MK63
M55 6?_ZY.4CO22_=FY"T&V-GT]I/-]1U,;2'!13PE5GBH+K2Z92\$?-:6TD-
MR-[LO,_GS>J6F;;WKE<)<-;,;E2A:PP]-"FTN*XK)?W5%2X6X]K*E&2D5..8
M'JC\FN7#MIC\Z_7K#4DQ3K3.K,$G2HD&?!4?1+.9Y"DFYETI2>WS6G_+AFHB
M6W#:5XCO&G]$9+D"C5C#M[A?WLTFT_I([5#P88RZY,N?Y']T#E+R4A1S*WME
MF^=PP;S"[A&4X3Z[6CY5*U2>/#*'%7P;C*O-$;HW E4
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M[6O.VN82IU*<G&<))QE&47A*,HO!QDFFFFDTU@SR1_#Y
M
M
M            !__4O\
M
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MG"KJ>%62Z*-GF%9/Q3IVLH?VMO0??M>B=Z@3B#6O7&',*))*)IW9^$FLS/\
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M!1JTY=:PE!XPJ1A4C*"SL,6<Z
M
M                                                    _]6_P
M
M
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M"
M
M                          '_UK_
M
M                                                      #U]O;U
M5!56=[>64&GI:6OF6MO;6<IB#6U=97QU2Y]A839*DMLL,M(6XZZXHDI21J49
M$1C]TZ<ZM2-*DG*4FDDEBVWL22Z6WN1ZK*RO,RO*679=2G7N+B<:=*G3BYSJ
M5)R480A"*<I3E)J,8I-MM)+$ID>J-ZF=URUR>;J34]C.I^.&+6A&VI!/P9^V
M;JN=_8LGOF5=KB*QIPN^IK7"(_!,N2GW@V6HDBM$:+IY#05_?I2O)KQJDGZF
M/TS]5)?4QV8N5\'=![IEAR6RBGK76=*%?55Y3VXX3AEU*:VV]%[4Z\H[+FO%
MOIH4GV7'.O#N.A$Y0    #?KAOZ<?(GF=8,6&&TB<.U:S+5'M]MYA'E1<8:-
MASLEQ,;C((G[F8CHI/D0R\IM9$B3(C$I*CU746L,HTY!PN)=I7:V4H8.7@<N
MB"\+VM>E3(V<]>]-ROY#VTK7/;CW]G$H\5++;:497#Q6,95Y/R+6D]CXZOER
MCC*E2JX-%KGB1Z77%SB8S6W=7C"-F;3B)9=>VAL*'#M+2'.0753^(4:DJA4R
M4J[O*<C(5+)!]CLQXBZCA6?ZWSO/G*E.?8T'_=4VTFOIY;Y^''R>E1133SK[
MWW-_G1.KE]W=O*<GGBEE]E*5.G*#Z+FMBJMTVL.)3:HN2XH4(,D<&GD60
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MK8TRRJTN[6_M:=[8U85J-:,9TZE.2G"<)+&,X2BW&49)IQDFTT\4\#PA^CT
M  !F/0N^MG<:]G8]MK4N0O8_EF/O=#(^]ZIO:EY:3L<<R.N)24RZ^6E))?84
M9&1DEQM3;S;3J,?FN566<V4["_AQTY^?%]$HOHDNA^8\4VGHO,?EQI'FOI&Z
MT5K6U5S97*\"J4:B3X*]">#=.M3;;A-)K!N$U*G*<)7I.$G-#6_-?4<3/\/6
MU3Y93E$K-E:^D2D/VN%9&ZR:^SN,DJD5TOL<=K)Y()+S:5(42)#+[+48M2Z<
MO--W[M;CRJ<L73J8;)Q_DDMTH]#ZTTW_ )W^\!R&U5R!UM/36>)U[*OQ5+&]
M46J=U03PQZ5"O3QC&O1Q;IR:DG*E.G.>Y UTX4
M
M
M '__U[_
M
M                              "J3ZR_J-/9_>W/$;2=_P!,"QN=[GN;
M*:J1\W,LGKI'<O!($ID^BJRL?07U041_[S,1Y7@S&,Y'=>76D%:4HY_F4/;9
MK&C%^HB_5M>NDO2]4=N^6RY7N(]UNGIK+J'.S7]M_P#<KN'%E=O4C_E;><=E
MY.+W5[B+]I7]U0EQ[9U<*5>8=:+.@   _1AAZ2\S&C,NR)$AUMAAAAM;KS[S
MJR;:99:;(U*4I1DE*4D9F9]"!M16+V)'XJ5*=*G*K5DHQBFVVTDDEBVV]B26
MUM[$BR=Z=_HKKMF:+=',FIDQ(+I1K;%=#.K=B393:NC\2?M-UHTN,(,NBRHF
ME)</YJ9RT='8:N-ZNYCJFY9=IV2;VJ5?>EUJET/ZM[/6I[)%4W>?[^\;*I<:
M"Y%5HSJ+BIW&<)*4(O=*&7IXQF]Z=W)."VNWC+&%=6:Z>FJ,>JJZBH*JNHZ2
MHAQZZIIZB%&K:JLKXC9,Q8-?7PTH:99:01(;:;024D1$1$0XO4J5*U1U:LG*
M4GBVVVVWO;;VMOK*EKZ^O<SO*N8YE6G<7%>4IU*M6<JE2I.3QE.<Y-RE*3>+
ME)MM[6SV0_!Y0                     (UN=?IEZ3YH5,W(2C1=<[RBPS1
M2;1I8#?6V6PSV1*K8%6QV%:1.B4MH?-12XY$GR7O*)<=W<M+ZTS+3E14<76M
M6_*I-[NMTWZE^#TKZ5CM4K>[MWM-?\AKVGECG+-=/3EC5R^K-^UIO&52SJ/'
MWO4VN3@DZ-5M\<.-JI"FAR*XV[>XL['LM8;CQA_'[Z(2I-98,FN7CN54QNFU
M&R'%;GM2B7#=Z&1*(DN-K)33[;3Z'&DR)RC.<OSRS5[ET^.#WK=*+Z8R70UY
MSWIM-,O<Y7\U=$<X=*TM7:%NU<VT_)J0>$:]O5P3E1N*6+=.K''=BXS6$Z<I
MTY1F\$#*'1@   V;XD<J=C</MRT&V]>R5/HCJ369AB<B0ZS3YQB$E]#EICEJ
M2"423422=B2>Q2H\A#;R4J[30K"Y_D5GJ#+IV%VL,=L)=,)]$EZ#72L5X3DG
M.ODYI;GAH2YT5J>'"Y>V6UQ&*=6TN8IJG7IXX8X8N-2&*56E*=-M8J2OK:'W
MAK[D;JG$-PZQMBM<3S"M1+82YY:+&GL&C\FUQZ[BMJ5Y$Z#(2N/):[C+N3W(
M4MM2%JBUFF67>3WU3+[V/#4IO#P-=$HOIC);4_/V[#_.%S&Y>ZFY6:ROM#:M
MH]C>V,W%X8N%6#VTZU*32XZ56#4Z<L$\'A)1DI167ACS2
M
M
M       /_]"_P
M
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M[7BI12[>4E=7(R41*29&DR(R,CZD9'XD9&0C>4&M-/!G^@?P
M
M
M        _]&_P
M
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M61\G^7N6Z R!)T[*FNTJ\*C*XN)^57N)[_*JU&Y)-O@APTXOAA%+ 0RITH
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MCG) X
M
M                         __2O\
M
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M6,E*C%2N;D1$1$1$1$70B+P(B+V$1".A0]OVL_T
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MH^9XP
M
M                       __]._P
M
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M:-6A/LZT7"2Z))I^<S)TZM.K'CI24EUIIKST>8/F?L
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MU/7.6T^"QU/3=:6"PC&^H<$+I>#M(RHW#;>,JE6K@L(DU8YN0&
M
M
M        #__4O\
M
M                                (4_71WVO6'$VNU543_=<BWYEC%!(
M;;<\N2>"8@;61Y:\RM/SNBY7U(@O)]BVI+B3/H9D?2.6.5*]SYWU18PM(\7]
M.>,8?0XY+PQ1/K_CPY;QU=SHJZRO:?':Z;MG63:QC[[N>*A;)K=LI^^:L7OC
M.E!K;M5-P2'+U0 /0WN4XWC*#7D%W75)DW'?*/)?[I[D:2YY34F/51R7*>;Z
MD?5;+*R(B,S\!F,NR#.,UP]XV\YQ?JL.&']>6$?,QQ. <S>]'R&Y12J6NM-2
M6M.\I.496=O)W=XIQ6/!4M[959T)2W1=PJ,,=\TDVMC^&GJ*X;POSFWW5CVF
MRW%L*3C]QB^N9.4WDG$,7Q-J>^46YS9B.Q"ES+%<II#U6PTER$IMLYB7%=5H
M(;K0[N^9:_LO>V:YDK"UISBZBI4^VJ5&EQ=GQ2G"-/AQC-OAJ)MQP6QE&?\
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M+F]_57RKE9Q_R[1'(/3."V3ETB#8XOGV!S[G&K##\NI'RE4N2G07:K9N4?\
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M72QW\/O2=:;6YSIP;W)J\2(SG^>\
M
M                                              /_U;_
M
M
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M#I*YT'KK.-%7;;GE5Y<6O$_5JC5E",_%4BE-/I4DS*0\)IX
M
M
M   '_]:_P
M
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M?TLN'@?U1SGFQG;R+0&8W,&E4K0["&W!XUVJ<G%[^*-.4YKZD^O'92O<
M           _>-&?F/)8C-*>=4EQ?:GIT2VRV;S[SBE="2AM"5..+49)0DC4
MHR21F6.S;-\KR'+JN;YU<4[6UH1XJE6K)0A!8X8RE)I+%M)+>VTEBVD?>VMK
MB\KQMK6#J5)[HQ6+?3N74MK>Y)-O8>S/ZG5A&1>5;6)$74_$ZB$M3!]23T,E
M2W6UJ+Q/M8);9ETE,N$95]\W.^/=W4JN1<J(.C2VQEF%:'MD]N^VH36%.+2V
M5*\74:ELI4IQ4GUC(>7U&BE<YZ^TGO5*+\B.SU<EZ=I]$6HXKTTXO ];+F2I
MSOG2WEO.$E+:.O1+;+*/!J/':01(;:07S6VFTDA)>"2(BZ""V8YEF&;WU3,\
MVKU+FYK2<JE6K.52I.3WRG.;<I/PMLZ73ITZ4%2I14(Q6"C%)12ZDE@DO E@
M99PO<N18WY,&V4O(:5!(;2U*=/ZIPFD-&TV4&P7U4I"/V/HP^2TDA!-M&SW&
ML:-G^CLISU.K*/8W#_O(+:W]/'8I^;A+8DI)'*.8')O2.OHSNJ]/WGF$MUU1
MBE*3PP7;0V1KK=BY.-7"*C&K".PVOQO*:++8/U0HIR932/**3'<(F9\!UYOO
M0Q/A]3-M7@M)*(U-K-"_*<<2DU#A^>:;S/(*W!>PQIMX1J1VPEX,>B6_R98/
M8VL5M(*Z]Y9:IY>W?9YS2X[:<L*5S3QE1J-IM1QP3IU,$\:<U&3X9.''!*;^
M@&!.>@              &NW)K'46NO4W:&XY2L7M8<LY#JE$^5;:.IJ)<2,1
M>!FY(=AN+(_UK77Y!TGEI?\ 8YG6L)/96AQ+ZJF]R\<92;^I+!_^/+6GY)YC
MYKHBO)1I9Q9JM3Q>UW%E-N,(+=Y5"O<3EAMPI+H6R/@=L+A  /H,=RK(,3F'
M.Q^TDUSRR)+Z&S2Y%EH2E24(FPGB4R\2>Y1H)Q"NU7SD]%$1E[<OS*_RJY5Y
MEU65&I'IB\/,:W23Z8R33Z4S:-'ZVU;R_P \I:DT7F%;+;VENJT9N+:Q4G"I
M';"K2DTN.E5C.G-+"<)+87:?14]7/4G]GS7O'??;O]'MMB-KD>.X[L60ZZY@
MCZ+/(G\BA4.03))J>JSCHL&FX\I]3L4F>U+[[!M]SF,S_7UK5U'V>>I4:EQ"
M$NU2PI2DL:;XO62? I-^DQDWY"P1P?G_ -[O(;GGX[/FQ&GEE[GEI:7*OZ<.
MSL:U6*E93[98OWM6F[6-:K-?X=SJRD_>\'&!:,C28TV-'F0Y#$N)+8:DQ949
MUM^-)C/MDZQ(COM&:5H6DR4A:3,C(R,CZ#,QE&45*+Q3VIK<T;E2JTJ]*->A
M)3A-*491:<91:Q336QIK:FMC6U'[C^GT
M
M                                               /_]>_P
M
M
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M.:2<J56#\JG5ABN*$DG@U)8QE&3RP/>;@
M
M                                              '_T+_
M
M
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M-K27./2E/5&E:N["%Q;S:[:UK88NE5BO/A->14CY47O2V2&9.G@
M
M
M  ?_T;_
M
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M*G00
M
M             #__TK_
M
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MR6O&YM+NG"K1JP>,9TYQ4HR7C3W/!I[&DTT?1C[&3
M
M                                                 #__T[_
M
M
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MEVO(Q?!;K3^JWD.Q).#8W.V52*LLOSV*X1*^J\NM4][C6*Z%7M+\Z01SS2U
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M<RQE.UQ>Q0N-LZ2V)7'%%*4KC9:''<"UL
M
M                                         /_4O\
M
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M_IN   "T1\/%GZ9&*<E-6O.DE=3D."9_6L&KYSZ<AK9N.W;J$_0:.LKR4?\
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MWKN_\PY:,U='*K^>&7YHXTJF+\FG5QPHU>I+B?9S>Q<$N*6/ CH"BILL>
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M&O**S*V_PU_!8+"YIQ6-11Z(5X.-:."X8N4J:;=-F[XV8[N
M
M                                                     !__U;_
M
M
M      @?]?SF:YQQXCGIG$+;W+9_)]RUPALXSQHG4^JX##:ME6Z3;/J@YK<B
M+1H)9%WMS9"VS[XY])3=T_EPM8\P/VCS"GQ6.2<-;:O)G=2;][0\/ XRK/#<
MZ<$UA,CUWC=<O2^C/R'93X;O-N*EL>V-NDNWEX.).-)=:J2:VQ*$8M6*[
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M<-63I2DVE&G7J2?I47/Q) N^
M
M                               __]:_P
M
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M':X1KI=$:L3<0;$=I
M
M                      /_U[_
M
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M;GU,M5RV'3^E:9D0FRZ%T(<!YH9*[3-89O27M=RL)>"I!8?VHX-=;4F4D?\
M(OREGI?F1:\T,MI866H::IUVELA?VT%!XX;(]O;JG./3.=*O)[<2> <N*YP
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MURJ4ITI/Z6W;+.X[:6I@
M
M                        '__0O\
M
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MB7VQ*L_T)
M
M              '_T;_
M
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M(+M;^JT!#$]OK\YV0W/</V"0/+'/??V52RBM+VVU]+UNE)[/ZDL8^!.*+O\
M_CQYQQUARWK<L,VJ\68:<>-!2?E5,OK2;IX8[7[VK.=&71"E*VCTD%PZ<6(
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MKS\%2I1A*HGX8U.*+\*,SC)&[@
M
M                            !__2O\
M
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MLM+S"^7NFZ>6G.0&GJ#CA.ZHU+N;]=[ZK5*T&_%2E3BO!%$@@VTD8
M        <S3U0-8MZ@]0;EMA+$?W2&G<V39=6Q"22&XM3LE3>R*B,PDO8VW&
MMFD-?Z!)]OM%U/)#.WJ'E)I_,Y/BE[SITI/KG;XV\V_"Y4FWX<2JKFSE*R7F
M3G-A%81]\U*D5U1KX5XI>!1J)+P&APZF<\  E*]%C/#U]ZF?%RQ6^;,3(<ER
MG YK?=VHE%G> 6N+US#GT2*=)B.I+_/0D<-[R65?E;DKGE%+&5&G2KKP=A7I
M59/^I&2?@;.N<BLQ_)O-7**K>$:LZE%^'M:-2G%?UY1?C2.B1G&;XGK;$,CS
MW.KVOQC#\2J)E[D5]:/>3"K*R T;LA]U1$:E*\"2VTVE2W%FEMM*EJ2DZ?+:
MVKWEQ"UM8N=2HU&,5O;?_P#&_<M[V%JFG]/YUJO.[73>G;:=W?7M2-&A1IK&
M=2I-X12Z$NF4FU&,4Y2:BFU16]0_G%DO-S=+^2H*?3:GPPYM'J?#Y3G1R#3N
MO).;DMRPVHV_JI:J;;>E=IF33:&(J5N$QYKDGM(Z9HZ:RU47A*O4PE5FNE]$
M5]+'<NMXRP6."_T1]V'N]Y3W?]!1RJ7!7SJ_X*N8W,5LG52?!0I-I2][VZE*
M-/'!SDZE9QBZG!'0,;424   "SUZ#_#AR##O>9&=578_9M6F$Z49F,]%HKR<
M5 SC.(Q++P\Y:54T-U)D?8BP(R-#C:CXIS1U"I2CIVUELCA.MAU[X0\ST[7U
M'4RHS_D8YZ1N*]OR*T[6QC1=.ZS5Q>QSP4[2TEAZU-756+Q6,K9I\4)(LJCC
M95&      !"CZZV IR+BAB&;L,$J;KK;=&Z_(-)&;-#E5+.HY[:5>TN^=]3#
M/QZ?-\2Z].G->:-IVV0T[E+;1JQ_JRC*+_M<)!CO^:>69<H;+/J<<:F6YA2;
M?52N*56E->;5[#SBI". %.H   76?2#S!66<"M1,/.F]+Q"PSS#Y2S5U,DU^
M;3K&M:Z?)Y<&7%;(OH)(_E$E.7MQ[XTK;I[Z;G!^9.37]EHO,[F>=/..[WDU
M.;XIV4[NVD_J+JK."\RE4IKS"3,;J2E
M
M                                  #_T[_
M
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M3\,:5O7V?UIQ?F(D_P!U6R5;7-]>R6/8V4DO!*I6H[?ZL9+S67@A603Y
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M5J3]17EYSA3_ )<2X3_C[OW<<H,RL)/%V^;5FO!&I:V;2_K*;\TFY'3"=H
M
M
M ?_4O\
M
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M<9O25(0[)<247]6:DKZES-W+QC1IXQI0ZH];^FEOEYD<6HH_SI]Y?G[F_/\
MYA5,_J<=#*;/BHY=;2?V*AQ8NK42;C[XN&E4K-8X)0I*4H4H,WJ&KD=@
M    U/YW1$S>&'*-E:242-&;(ED1].G= QB1.0KQ^@ILC(8#5,>+3=\G]HJ/
MSHMG(.\!15?DAJR$MN&57LOZE"<E]&)0C$53_/:   %I/T!9*EZ;W[#-1&AC
M9N.R4H^5*I>+$TM1_P#:3*2+_L'<N5$O_MUW'JJ1?GQ__D6Q?\=]5O1.HJ..
MR-]1EA]50P^CPKSB?D=7+#P
M
M                          __U;_
M
M                                  #X':T,['5VR:]*36J?@.80R02>
M\UG*QZ2P223X=>O=TZ=1E<AJ=CGEE6>S@KT7YU2+,=G$.URFZI[^*C47GPDC
ME B^<IX   "T[\+Q8M-;4Y;U)K(GINOM7V+;?0NJFJO([6,\LC]OS3F(+_*(
M+]^"C*61:?N,-D:]S'S94Z37L'YQ+KNEU4LWSFCTRHT)?U9U$_9(N/BNLF\
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MBK*GI>PJ8N:QB\RKP>RO-/!JVIO_ "U*2QD_;ZBXW3A1F7'.B"0
M!J7SSFHK^%W*%]Q78ES2&PH1&?0NJ[/'GJUM/CU^F4Z2?\HP&JI*&F[YO[34
M7GQ:_E./=X.O&VY'ZKJ2>&.5WD?-G1E!>>Y8%"<15/\ />   %IGT!XIHTGO
MB;VGVR-ITL4E>/0SB8DTZI)>'R>>77Q^7Y/E[GRHC_\ ;+J7752\Z"_G+9?^
M/"DUH74%?UU_2C_5MXO_ ,1/F.K%A@
M
M                                 ?_6O\
M
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MNWTR4(K^E4BG]#$C;WNLTCE/=YU%4Q\JM"WH176ZUW0IR\Z#D_$BD&(RE$
M  6X/0CHEUW$/-K=ULTKR+?&528[AET)V!787CU8UT^CVR&Y)=1W_E;2X-/U
M:C]77EYRA37HXEQ?_'_E[MN35_>S6#N<VKM/KA"VLX+SIJ9-8.E$Y@
M
M                                                         __7
MO\
M
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MH
M
M    /__0O\
M
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MA:#T['2&B,GTK'#_ .W65M;/#IE1HPIR?A<I1;;Z6\3*(]QM@
M
M                                                    ?__1O\
M
M
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MN9QEU*IV2I>.:6]E[L2E/] (
M
M                            !__2O\
M
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MV<A-:K1^O:%.ZGPVF8I6U7%[(RDUV-1]"X:F$6WLC"<V=#D5$EE@
M        %1'UO=&+UWRDJMLUT+R<>WIBD6RD/MH[&/Y;X4RSC>1QT)3\TC5"
M^I$M:O UN/NJ,NO51Q]YFY6[//(W\%A"ZBG_ $X81E_9X'X6V4V=^_0,M-<V
M*.L+:'#;9_;QFVE@O?5LHT:R71MI>]ZC>^4JDF]N+<,(YP0A/RD1X\N/(B2V
M&9424RN/*BR&D/1Y,=PNCC$AEPC2M"B\%)41D?RD/O;W5S:556M*DJ4UZJ$G
M%^>FF9C(M19_I?,8YOIJ^KY?=034:UM6J4*J3WI3IRC+!X;5C@^E&&<EX_:S
MR-Q<A%3(QV6Z\I]U_&I**]MS]A\I#!5DAM^&TT1D2S3'C-J,^OSO$QNV7<Q,
M]M,(W?!<Q^F7#/#J4HX+S91DR8>@^_GSGTOP6VIU;:@MTUCV]-4+GA2PX85[
M=0AX7.M0KS>W%]4H_'GTP=Y\H]*M[8T?FVNLXL*6UE8KFN%7MI(PW-*_)8$9
MJ44AAI^,NJ<C3V'6I;#JIS"4FM3)),V5F4V^7'.W)L_T]0>:4ZE*O1795&L*
MBQ@L%)M83;E'ADWP;9<74?ZNNX[_ ,N/*?G'R7RJ?,*QOLKS;+8JPO9PX;ZE
MVEO%1IU:E2,J=S*5>W=*K.:MFIU75PPX<#%>Q?3RYMZL4_\ RNXS[4./%-7O
M%CBF/JV#4,H3[7G;? 5V<9"/]-3I%\G7J.O6>K=-7V'O>]I8OHE+LWYT^%_0
M+--+]YWN_P"L%'\B:LR_BGNA<5E95&^I4[Q4*C?@46S4BXH[O'IKE;?T]I1V
M+/\ K:^XKY=9-:\>G[)%FH0XGQ+IXI&?IU:=:/'2DI+K337GH[78YA89G;J[
MRVO3N*4MTZ4XU(/Q2@VGYYZL?L]@   "(S,B(NIGX$1>TS^@0'\,YX%QAY';
M16P6N]$;=S)J1T-$V@U[E-A5I0KP)U^W9BG%:1\GF.O)3^J,9=9WD]CC[[NJ
M5/#HE4BGYV.+\Q'/-1\W.5FD(R>J-1Y;8..^%:]MX5,>I4W4[23\$8M^ WSU
MMZ*_.3-V2L<KQ?"-,4*&5S)5QL_.:EGW6O90;TF4_5X=]5Y;/8@E&:9;3'3I
MU4:$_.+5[OF-IJA-4K:<[JHW@HTJ;>+>Q).7"GB_6X^ C9K+O_\ =STI3J>\
M+^YSFI33QC96LU%-==:[]ZTG'I<H3FDMV+V%?;<JL1L]E9 55/7F]%C=O+Q[
M&[Q7F5%)DN.U4AUEJV35Q4M3D(FOJ=FQU+G)<2RMMIQ/5!D+ ]"\MJF5Z>MZ
M>:U'2K58*I5IP2XH59I-Q<Y<49<"PIO"FDW%M/I/\PG>T[^><\^N<>;:YT_E
M\;>SE*-O8JYJ2JNE96\>"DHTX."A*I+CN)KM)Q=6M4:BE+A6/$2'&8RH<5+4
M*(MEAAZ/!8:AMRVXKANQCL/=R2<E:%*,TNR#6O\ TAU&RR7*\OEVEK12FL<)
M/&4UBL'A*3;BGTQBU'P$%M0ZZU;JG&.>7U2M3>'M::A2V/%/LJ:C3;71)Q<O
M"?@,H:F?5X)A61[*S?#M=X? 7:Y9GF4T&&XQ6-]>^PR#)[5JEIX2321F7FR'
MVT=>A].O4>#-<RL\FRRXSC,9]G;VM*I6J2];3IQ<YOS(Q;/9E]A=9I?T,LLH
M\=:XJ0I4X]<ZDE&*\V32.IQH;4=#H/2FJ-*8SVJH]5Z^Q3!8,A+9-+GEC=*S
M6/VLA)?_ %TQUM<I]1GU4XXI1F9F8HQU5J"ZU7J6_P!2WOV6^KU:\EOX>TFY
M**\$$U&/4DD6YZ=R:WT[D-GD-I]CLZ-.DGNQX(J+D_#)IR?6VV99& ,R
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ML>E)6T4UT2G''>G90'9BSX
M
M                           __]._P
M
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M4P]*R1_=HT<\]UK+45S'&WRJ'&L5L=Q43C27]&/:5-GI91AUE[@5:EA(
M          !ZN\NZC&J6WR*_L8E114%9/NKJVGO)CP:RIJXJYMC83'U^"&F6
M4+<<6?@22,Q^*M6G1IRK56HQ@FVWN22Q;?@2/)?WUGE=C6S+,:D:-O;PG5JU
M)O",*=.+E.<F]BC&*;;Z$BB'SDY/V7+;D7FFU7#E,8JVZC%];U,GN2NHP&B>
M<12I<95U\M^8M;UE+;ZF29$EU"3-"4](LZGSN>?YQ5OWBJ?I::?13CN\U[9/
MPR9_G^Y]\U;KG%S+OM72XHVB:H65.6^G:4FU2Q71*HW*O46W"I5FD\$C4,:^
M<:  \N!!FVDZ'65L61.L;&7'@P(,1I;\J9-EO%'BQ8S#9&I;CBU)0A"2,S,R
M(O$?J$93DH06+;P26]M[D?:WMZ]W7A:VT'4J59*$(Q3<I2DTHQBEM;;:22VM
MLOQ\-=!Q^,W&K5.G_*83=8_CC,[,7XYH<3,SC('%7>6O%(3XNMHFONQXZS/K
MY#;22Z$DB*5FG,J62Y+0R[U4(XS\,Y>5/Q[6TO D?Z%N27+RGRMY7Y1HS!*O
M;45*Y:P?%=5FZMP\?5)59RA!O^[C!;DD;/#-G50
M
M                                           #_]2_P
M
M                                                       (8?7+
MX7N<L>&UUE6)U9S]M<<UVFTL,;CL^;87.,,P"3LO$(Q()2U'*KF&[!AEI)K>
MEP(K*>GF&)']V#F0M!<QJ=A?SX,OSCAMJV+PC"JY?X:J^CR:DG3DV\(TZLY/
M<CAG/_0KUCH>I>6<.*]RSBN*6"VRII>WTUT^5!*:2VRG3A%;SGPBVTK:   #
M?3TX>;^4\"N36*[@KDS[7 [,BQ+;^'0W2+^5.O;22VJQ.*PZI+9V-<XANRK%
MJ4C]G9)E;B6'WR5ROG'RRL>:NBJ^GJW#3NH>VVE9K[%<13X<6MO9U$W3J+;Y
M,N))RC'#HG+#7UWR[U71SNEC.WG[7<TE_>49-<6"W<<&E.F]GE1X6U&4L>DQ
MK_/L/VG@^)[(U_?P,IPC.*"LR?%LAK'#<A6U+<14S(,MDU$2DF:%$2VW$I6V
MHE(6E*TJ25,^;95F.19G<9-FU*5"YM:DJ56G+TT)P;4D^A[5L:Q36#3::9:/
MEN8V6;V%'-,MJ*M;W$(U*<X[I1DL4UYF]/:GL:31]@,>>T             /
MY6A#J%M.H2XVXE2'&UI):%H67:M"T*\#(R\#(_:#2:P9_)1C.+C)8I[&GN:Z
MF47O44XNO\4^3N:897P5QM?94ZYGFL'TMF44L1R"6ZLJ-I?B7=4RDR*TTFKO
M-MEIY1$3R>L7M89&\ASNI;06%&IY=+JX)-^3_0>,?$D^DH,[RG*BIRBYJ7V2
M6U/ARZ[;N[%X>3[WK2D^R3Z[>HIT<,<7&$)O!31HL-7.!   !;X](;G$UR!U
M6UHW85P3NY-14T:- E3I!+FYYKJ&:(-5=I<</O>FUG5J!9&?52TG&DJ4MQY[
MLD'R^U.LVL?R7=R_Q-NE@WOG36Q2\+CLC+S'M;>%S'<TY]0YBZ26@M25L<[R
M:G&,)3?E7=G'"%.KB]LJE#R:5;>VNRJMRE.?#,H.C$V0      ,.[_WMKGC/
MI[/-X[7ND4>#:^HY%S:OEY:IL]\C*/5T--&=4@GY]C*6S"@Q^XO,?=0DS21F
MHMBTGI;.-::BM=,9#3[6ZNYJ$5T16^52;6/#3IQ3G.6&R,6]NXPFH]0Y7I7)
M+C/\XJ=G;VT'*3Z6]T816S&<Y-1@NF32.:%S%Y4; YF\A=@;_P!B.J9L,ML?
M)Q['FY+DFNPK"ZTU1\6PZI4LDEY4*-T)UQ*$>?(4_*6DG7W#.Z3EWH7*>7&D
M;32>3K&%O'&I4PPE6K2VU:T_#.6Y8O@@HP3X8HJNUOJ_,M<ZEN=1YF\)5I80
MACC&E2CLITH^",=[P7%)RFUC)FL0W8U, #]H\>1+D,1(C#TJ5*>:CQHT=I;T
MB1(>63;+##+9&I:UJ,DI2DC,S,B(NH_,YPIP=2HU&,4VVW@DEM;;>Y+I9^HQ
ME.2A!-MO!);6V]R2Z6SI->E5PW1PDX;Z[UG<P68VS<I0O96X7D)0;Q9_E<5E
M;]&XZCJ2BIH+4*F(TJ-"U1EO)Z><8IGY[<Q7S,YBWF=6\G*RH?X:T71V%)O"
M>'1VTW.MM6*4U%^E+1^4&AUH+0]ME5>*5W6]ON7T]M42QA_Y4%&EU-P<EZ8D
M<''3IX              !74]:GG$S75KG#W6=OW6EFB!9[OMZ^1T.OJU$BQI
M-=I>:/J3LO\ 8I]FDNG:P4=@S6F1(;1Q_F5J=0A^SME+RI8.LUT+?&GXWLE+
MP8+I:*U>_+SYA;6KY+Z6K8U:JA/-*D'Z2GLG2L\5ZJIY-6NMF%/LZ;;52I%5
MGAQ8JX   "8'T:^+2]V\CV]M9%7F]K_0*H&4&I]KNC6NQ92E_P AZQ!K+HKW
M-;3MNXI!F:%QHZ5EVOEUZ%RYR)YGG/O^LL:-IA+P.H_2+S,'/P.*QWDS^Y-R
MFEKOF:M89E3XLNT[P5]J\FI>2Q]ZP6._LW&5Q)KTLJ5-26%1%PL2'+H@
M
M
M  /_U;_
M
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ML>3O+BQTA;\,KE+MKRK'^^NZJ3JRQV8QAA&C2Q2?94X8^5B;9#/G7P
M
M
M/__6O\
M
M              -(/4)X5X=SPXTYAI3(#AU>4H+^4^JLQDLJ<7AFQZF*ZBCL
MUJ;)2SAR4N.U]FTA)FN(^[V$3R6EHZ;RCYDYCRLUI;ZEM,9T'[5=44_LUO-K
MCCU<<<%4IM[JD8X^2Y)Z#S)T)8\P]*U\AN<(5OLEO5:^Q5XI\$NOAEBX5%TP
MD\/*2:YK6S-;9MI[8.8ZMV/C\W%LZP+(+'&<HH;!!)D5UM5R#CR$$M)FAUI?
M0G&)#2E-O-*0ZTI3:TJ.YO)<YRS464V^>9-5C7M;JG&I2J1W2A)8KPIK=*+P
M<9)QDDTT5:YKE=_DF95\HS2FZ-Q;SE3J0EOC*+P?@:>]-8J2::;33/AQE#'@
M  !:H]&'UI&,%CXKQ$Y?92;>&MJAX_IC==_,ZMX>TKI%K-?[$LI)^%0D^UJK
MMGE=()=L>2HH1-NPX)]X_NW3S2=?F#R]H8W+QJ7EG37V9[Y5[>*_O>FK22]M
MVS@NUQC4E[R,YZQR^-'1>M:V%!80M;J;^Q]$:-:3_N^BG4?V/TL_:\'"XBVX
MAU"'6EH<;<0EQMQM1+0XA9=R%H6GP,C+Q(R]HKP:<6XR6#1-I--8K:F?V/X?
MT             *DOK$<'7-);*=Y%:YIU(U1MBY><RN%!8_W3!ME3C5+FI4V
MV71J#=&3DR,?TC<DI#/[&@XR%<!YB:8>67OY8LX^T7#\I+="H]K\49[UU2Q6
MQ<**=^^GR%EH75#YE:9HX91G%1NXC!>3:WL\92V+TM*YVU(=$:O:4_)BZ47"
M:.:$%@   V)XP\G-G<3MJ5.TM8V)-RF"3 R/')JW54&9XXZ\EV=CU]&;,NYM
M?:2V7D]'&'20ZT9+3XY?),[OL@OHWUC+:MDHOTLX],9+JZGO3VHZ3RJYJ:JY
M0:MHZLTK5PG'R*U&3?8W-%M.5&K%;XO#&,EY5.:4XM-%V3BARTU1R^UI$V#K
M6R)F?&3&BYGA%A(8/)L&O'6S4JMMX[?3O9<-*U0IS:?*DMI,T]KB'6FY+9#G
M]AJ&R5W92P:V3@_30EU/P/U,MTEX4TKT^4/.'2/.;2\-1Z7J\-2'#&YM9M=O
M:U6O25(K?&6#=*JEP58IM824X1V?&<.JGKK>WJL?JK*]OK.OI:2E@2[6XN+:
M9'KJNJJZ^.J7/L;*PF*0TPPPTA3CSSJTH0DC4HR(C,?:WMZ]W7A:VL)5:M22
MC"$$Y2E*3PC&,5BY2DVDDDVV\$?*M6HVU&=Q<35.G33E*4FHQC%+%RDW@DDM
MK;>"6UE('UDO61E<HY5UQEXRW4VMXZULXXN<YS%-^!8;NL*^02D1(:%$AUC&
M6'4$XTTX25SUI2\\E+*6VU6:]W3NZ0T/"GK76M.,\XG'&A0>$HV49+>]ZE<R
M3P;6*I)N,6Y.34!^>'.^>K9U-*:4J..60>%6JL4[II[EN:H)K%)[:CPE)**2
M==(3!(R   !G+C9QYV1RIW9@.B-452K/,,]N6:YEYQ#OU-H:IHCDWN4WS[1*
M-F!6Q$.S);A$:NQ!I;2MU2$*U?6>KLFT)IJ[U3GU3@M[2#DULXIR>R%*">^I
M4FU"*W8O%M13:V#2VFLTU?GUMI[)X<=>XDHI^IA'?.I-]$(1QE)[\%@DVTGT
MP>*7&?7G$+0FO= ZRC&G'L'J$L3+=]EMJTRS)9JSF9+E]V;?7NEV,M;CZT]Q
MI:0:&&NUEIM":6M>:US?F%JN[U9G4O;KJ>*@FW&E36RG2A]+3@E%=,GC*6,I
M-NU+1^E<LT5IVVTYE2]JMXX.37E5)O;.I/Z:<L6^A+"*\E)+8D:@;,
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M-)27.G5-'#T]/*Z<UUXPJWN#Z,.*C;M[\:M3#[%,LCCLI9R
M
M                                                       '_]>_
MP
M
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M*7"N;7/#-^8$YY1E*E9Y2G]CQPJ5\'LE7:>'#TQI1;BGMDYR47&$L27.#
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MC1H4(1ITZ<(J,(4X1480A%8*,8Q244MB221[(?L]0
M
M                                                 ?_0O\
M
M
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MT_"GK35E+"^FL;:A-?Y>+7V2HGNKR7I8O[%%[?;'A3LS"%9*H
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MZD'A;0:WTZ$G/>I5Y0DX$,)F:C-2C-2E&9F9F9F9F?4S,S'-R$#;;Q9_@
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ML%QU:DL93DTL6\$E%**RJ/>;<
M
M                                   ?_]&_P
M
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M\NM*\KM+T-):0MU0MJ.V4G@ZM:HTN.M7G@G4JSP6+P2BDH0C&G&,8YI&2-X
M
M
M           __]*_P
M
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ME)MO[8>DSH
M
M                       ?_]._P
M
M                                             -/N8/!3C;SCPC^1
MV^<%CVD^!'D-XGL&C-BGV-@S\CYRG\8R<FW%I:-?1QV!*;?A/*)*GXSAI0:>
MA\O.:.L^6.9_E'2MTZ<)M=K0GC.WKI=%2EBECAL4XN-2*;49K%XZ3K7E]I;7
M]A[QU%;J<HI]G6AA&M2;Z:=3!O#':X24H2>'%%X(I;<\/0VY3\157.<:ZA2N
M16CH:GY9Y9A%/(/.<4K4F;G7.M?QC?DH;91W&[95BI45*$&](.'W$T5D?*SO
M/:%Y@*GEF<263YI+!=E6FNPJR_[%=\,6V]U.IP5&WPP[3#B(+<P^0&KM%N=_
MED7F>7QQ?:4HOM:<?^[16,L$M\Z?'#!<4N#' A-]@DL<&
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MVD(]6ZTU'K?,GF>HKF5:2QX(>EI4HO#R:5->3!8)8O;*>"E4E.6,G[ 8PU8
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M/<XAA*/%#_!6TUM3HT9K&M.+W5JZWJ,H4:4UB3#CH9-(
M
M
M#__4O\
M
M                          BEYF^C?POYENVF47&&.ZCVU8>?(<VGJ9NO
MQ^SM;!SYY2LRQQ;2ZNX-:^TWY$B,B:M)=B)K9>)=WY<=XKF1RYC"QMKG\H9?
M#!>];IRJ1C%=%&IBJM'!>EC&3I)[73D<?USR0T+KB4[NO0]Y7LL7[XM\(2D^
MNK#!TZN+WMQ51K8IHJU<J_0 YNZ!=M+S5M76<G=?Q#=>8LM:MK@["9@HZ]BK
M75UHXJ6X^KV$Q1R;,_$C,R\2*<NA.]CRRU9&%MGE2627<L$XW/E6[E]+<Q7
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M
M
M                  ?_U;_
M
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M6HW3MJC\2ACX#57)N"_,C$%N)NN,>Z^QGKYLFGU]D.306R+VJ588TS+8)/\
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M$1%["(;,=T226"/] _H
M
M                                        '__6O\
M
M
M
M
M
M                   /_]>_P
M
M
M
M
M                                                          __
MT+_
M
M
M
M
M                                    #__1O\
M
M
M
M
M
M               /_]*_P
M
M
M
M
M                                                      __T[_
M
M
M
M
M
M                                #__4O\
M
M
M
M
M
M           /_]6_P
M
M
M
M
M                                                  __UK_
M
M
M
M
M
M                            #__7O\
M
M
M
M
M
M       /_]"_P
M
M
M
M
M                                              __T;_
M
M
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M:POLNK0KT*BQA4IRC.$EUQE%M->)GTP\1Z@
M
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M7-K.-2G42E&<&I1E%[4XR3::?0T\&>T'P/L
M                                        ?__2O\
M
M                                                           ,
M9;EW%KK0&L,TW%MC)(>)Z_P&F?O,BNYAFHFH[:DLQH<*,WU<D2Y;ZVHL*(RE
M3K[[C;+:5+6DCS>G-.YQJS.[;3N0T7<7=W-0IP72][;>Z,(Q3E.3PC&"<I-)
M,Q6>9WEFG,IKYWG-54;:VBYSD^A;DDM\I2;48Q6V4FHI-LY^/J2^K)O'GSEE
MICT.PM];<;JRR7_(_4-;/4P=TQ%?[H.2;.DP5=MI9N=J7D15*7#@GT1&0IPG
M94BV?DSR$TQRIL(7E2$+W.9Q]MNY1QX&UY5.V4E[736U.6"J5=\VH\-.%;W-
M+G'G_,6\G;0E*URN$O:[:+PXDGLG7:^R3>]1VPI[H)O&<HGAWHXZ     ;W<
M&O41Y%\"<\CY'JC)'[7!+&>P_G>G<AFRG\!S:&7:W)6Y!(U?4^S)LB*-;PDI
M?;,DI<\^/YD=SEO,_E!H_FKE3L\^HJG=0BU0NZ:2KT7T>5_>4\?34IMP>UKA
MGA./0^7_ #,U/R[S%7.3U7.WDTZMM-MT:JZ=GJ)X>EJ1PDMB?%'&+Z$O#?F!
MJ+F]I#']W:@LEKKYZCJ\JQ:P<9+),!S"(PV[;8EDD9DS)+[/F(<9>3^QR&%M
M2&C-MQ(J/YB\O-0<LM35M,ZAAY</*I58X]G7HMM0JTV_4O!II[834H2VIEDV
MB-:Y+K[(*>?Y++R9>34IRPXZ-1).5.:72L4T]THM26QFU(T4V\
M
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MJ=I;UUBNB4)+9*G..WAG![)+S4W%IO.0U@V
M                                       /_]._P
M
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M*HM[6'10%0)9D
M                                                           !
M0F]?3FY9\C.5]GH7%KE;FGN,MA-Q)J%$D&<#(-MD@H^PLBFMH,DN.5SQ'012
M<)7E>[2G&C(ICA':KW4N6='1^@X:JOJ>&8YW&-5MKRJ=KOMZ:ZE47M\L,.+C
M@I8]G$KN[Q>O:NI]8ST[:5,;+*FZ>">R=QNK3?6X/VF./I>&;7IV0."4Y'@
M       )Y_0-YRV7'#E-7: RVX6C37)BU@8NJ)+D**#C.W74>Y8%DD)M9FEM
M5F[V4,TD$GS?/B.NJ-,)!"*_>LY84=8Z&GJS+Z?_ -QR6,JN*7E5+1;:].77
MV:QKPQQX>&I&*QJ,D1W=>8%72^KHZ<O)_P"!S62IX-[(7.ZC-=7:/"C+##'B
M@V_(1?5%598@
M               '_]2_P
M
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MG.:SXJE6WIJI)[Y5*:[*I+S9PD_--S!S@WD
M
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M-=,V
M     !__U;_
M
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M&SXO'[RM_P"3 LM[O+F^4F5\6Y2NL/%[[K_RXDP CT=K
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ME=5XWE6FIRC"+4(TJ$E'"$8K8YR>[';O)G1' [F
M                 $??JL3),#TYN8;\0UDZO2F30U^6HTJ]VL?*KYI&9?K?
M)=<[B^4NI'[1UKD13A5YPZ=C4W*\IOS8XR7T4CF_."<Z?+'.Y0W^]:B\R6"?
MT&SFCBZ(JO            Z6_I2N2G?3EX>JF=3>+2N-MHZ]?W*RIUJ#[?\
M[!+?04N\^%"/.'42I[O?E3SW@Y?VL2T_D^YOECDCGO\ >L/.VX?0P)!1R4Z2
M
M !__UK_
M
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MM9<=*M"-2$ENE&<5*+7C33*?+FWK6=S4M+B/#4I2E"2?1*+<9+S&FCTX]!\
M         #I>^E?K"7I_T\>)6$SXYQ)YZDJ<SGQ%-FT[$G;/FR-FS(LEI7BE
MYMRX4AY)^)+)77Q%+?/3.Z>H>;N?YG2?%#WU.C%[TXVT8VR:?4U237@P+4>4
M64SR3EIDUA47#+WO&JUU.NY5VGX4ZF#\.)O^.3G1P
M                              ",GUE/T9?+7[!L?_"%3#M?=S^>O(/N
M]3\7K'*>>'S4YS]RA[M3.;R+D2KT        +UGPU7X@>=?G0["_!SAXJZ[Y
M_P Z]K^K+?\ &+LL%[K/S<W'P^M[A;%A 1())@
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M+<M&93/(M(Y9DU183M;6A3E]7"E%3\^2;-A1J)LH
M                                         '__U[_
M
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MLPA"G!4Z:48Q222V));$DNA(\@?@_0
M                   !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ?B]8Y3SP
M^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^=>U_5EO^
M,798+W6?FYN/A];W"V+" B023
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MMM3AAAOX..2]*SHWBG8L[
M                        #__0O\
M
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M-O;V<,7B]CJ3;D\$H1C*R.$'8
M                 (R?64_1E\M?L&Q_\(5,.U]W/YZ\@^[U/Q>L<IYX?-3G
M/W*'NU,YO(N1*O0        O6?#5?B!YU^=#L+\'.'BKKOG_ #KVOZLM_P 8
MNRP7NL_-S<?#ZWN%L6$!$@DF
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MVG(Y7;M5;JLU.YK88=I4PP2CCM5.FFXTXOPR:4IR)!1R4Z2
M                                                  '_T;_
M
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MJ*>TW.'.#>0
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M6PVB&CFV@
M             '__TK_
M
M              *VWQ.'XGFBOSE:S\%V2B9?<G^</-/U=+\9MR+O>M^1.7_#
MH^X5RD8+,2!(        =4GB_P#BT\>/N&:D^T&O%%>M_EIF_P -NO=ZA;QI
M/Y*Y9\$M_<8&<QJYL
M                           !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ
M?B]8Y3SP^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^
M=>U_5EO^,798+W6?FYN/A];W"V+" B023
M
M                               #_]._P
M
M                               "MM\3A^)YHK\Y6L_!=DHF7W)_G#S3
M]72_&;<B[WK?D3E_PZ/N%<I&"S$@2        '5)XO\ XM/'C[AFI/M!KQ17
MK?Y:9O\ #;KW>H6\:3^2N6?!+?W&!G,:N;
M                                             1D^LI^C+Y:_8-C_
M .$*F':^[G\]>0?=ZGXO6.4\\/FISG[E#W:F<WD7(E7H        7K/AJOQ
M\Z_.AV%^#G#Q5UWS_G7M?U9;_C%V6"]UGYN;CX?6]PMBP@(D$DP
M
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M=I'M=OW5N-#?OPJMKJ(9-P?$_P"?S')430?%_$,?80;B(=[MW,+G+GY*3/\
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M-:%.SPFDU_B5N:Q7J"/]3O+<LJ525*4[G&+:?M'2GAZ\\7_$4>G)_P 6W/\
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M:IG WWE>5J6/;W#_ /EYGC?XA_TWO^\NW/O56G^W'[_A#YR?:+3XU'ZT_/\
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MW^FMOC5,?Q*<K?M]?XO,?XA;TU_^^VT/O3Y&'\(W.;_36WQJF/XE.5OV^O\
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MY(VG1_.30NN,W_(>15ZCN."511J4I4U)0PXE%O8Y)/BX=_"I/<F25#C!U,
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M<@             __]6_P *-/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0
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M&,H22E&2?2I)II]*951<4*UK7G:W,7"I3DXRBU@XRB\)1:Z&FFFNL]8/N?$
M       ,Z\9-\Y3Q@W_J;?N&J6J]U?F=5DA0DO''1=U#;AQ,DQJ2\GJ:6+2M
M=EUT@R\?+>7T\>@U?6VE;'6^D[_2F8_8KZC*GCACP3WTZB7KJ511J1^FBC8=
M*:BN])ZCL]1V/V2TJQGACAQ1W3@WU5(.4'X),ZB>M]@XMMC7V$;/P>R1;X=L
M/%*#-,7LT="]]HLEJVK>L?6@C/L6;+J?,;,^J%=4GXD8H]SG*;[(,VN<DS2'
M9W-G5J4:L>J=.3A)>%8IX/I6U%M&5YE9YSEMOFV7RXZ%S3A5IRZX3BI1?@>#
MVKH>P^T&-/>      !ZRZNJC&Z:VR+(+.#2T-#63[J[N;24S!K*FHJXJYUE9
MV,V0:6V6&&4+=>=6HDH0DU*,B(Q][:VN+RYIV=I"56K5E&$(13E*<Y-1C&*6
MURDVDDMK;P1\J]>C:T)W-S-4Z=.+E*4FE&,8K&4I-[$DDVV]B1SIO5H]0RWY
M]<C)EGCTR=%T'J]VSQ?2U ^3T8IT!<A*+O8=I"=Z&F=>N,M.DA:$J8AMQ8RD
M^:VZMRX'D%RBM^5.CXT+N,99K?<-6\J+!\,L/(MXR6^%!-K%-J51U)I\,HI5
ME<Y.95;F+J>56VDUEUIQ4[6#Q6*Q\JM)>OJM)X/;&"A%[4VXKQW0Y"
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M09%EFF<FM\BR>FJ5M;04(1Z>MRD^F<Y-RG+?*3;>\RL,"9@
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MX(LU$P^Y3\YN8_JNK^-V9&/O6?("Q_6%/\6NBCJ+.2 8
M  9GXX?C#Z&^[/J[[>((UO6/R0S7X'<^XS,[ICY2Y=\)H>ZP.JJ*)RWL
M \.P_<$[]YR?VE0^E'[-#QKT3\5/L<O$_0.2>+^"FH        .IOQ'=\_BE
MQC>[>WSN/6EW>WKU[?,UO6K[>OR].HHQY@1X=>9W'JO[Q?\ U%0MST9+BT?E
M,NNSM7_Z$#84:B;*?%;$V1@.H\-O=A[/S''<"P?&H:IU[E.56L2FIJZ.1]J/
M.F3%)2;CBS2VRRCJXZXI+;:5+4E)Y/)\FS;4&8TLHR2WJ7=U6?#"E2BYSD_
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M#B=G'*'EK:\N--1M:BC/,+GAG=5%MQGAY-*+^UTDVEZZ3G/9Q8*3D<3.K@
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MTL=W:32V.K-;9/:HK"$6TL91ICM!RL
M #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<V
M   Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
M  M,?"\_UM\L_N=:T^V:R$&>_!^8,@^$7/N=,ESW3/SSG/W&A[.9<D%=)-\
M     "LQZY_JR2]&UMMPXXX9*J'N#(JI#>Y,_II1HFZOQBYA$\QA^/S&#[F;
M^TC.I=D2D*)<"&M!M=)4EMV)-7NO\A*>IZU/F+K*CQ9=1EC9T)KR;FK!X.M4
M3]-0I2348O95J)\7M<'&I%3O \XYZ?I3T1I>KPWM6/\ B:T7MH4Y+%4X-;JU
M2+Q<M].#6'ER3A2J,S,^I^)GXF9^TS%DY!(
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MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M2S?-7H/**G^%LY)W+B]E6X6ZF\-\:'2NFMCBL:<65FQ-0BJ
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M5>WEW=9A=U;Z]J2JUJTI3G.3QE*<FW*4GTMMML]"/4>8
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M6VWM;;VMO:V620A"E!4Z:48Q2226"26Q));$DMB2/)'X/T
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ML(QBEL22222V);"K"K5JUZLJ]>3G.;<I2;Q<I-XMMO:VWM;>]GA#ZGS
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M[3GYUF(_@BS43#[E/SFYC^JZOXW9D8^]9\@+']84_P 6NBCJ+.2 8
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MS#YC?9=ICZS9&*\N_%^=-._<KSV=N39[I7YOSS[I:^QKEK$00)?@
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MU&I"+PVX8$<M1Z4U'I*\]X:CLZEI4VX<<?)FEO=.:QA47AA*2\)@H;2:\
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M%K%2C)8IIK:FG@UN.!5:56A5E0KQ<)P;4HR34HM;&FGM33V-/:CP1]3Y@
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MW0YCSAU:]&<O[_-*$N&XJQ["@T\&JM;&*E'PTX\=5?4'-<]HN;*M0
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M:OQ'M.?G68C^"+-1,/N4_.;F/ZKJ_C=F1C[UGR L?UA3_%KHHZBSD@&
M             &9^.'XP^AONSZN^WB"-;UC\D,U^!W/N,S.Z8^4N7?":'NL#
MJJBB<M[     /#L/W!._><G]I4/I1^S0\:]$_%3['+Q/T#DGB_@IJ
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MLY3J3D^F4Y-R;\;)NV5C99;:0L<NI0H4*2X84Z<5"$4NB,8I)+Q(^E'B/4
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MR:N^75VLURIRKY37EA&;VSH3>U4JK6]/^[J8+BP<9)22<H5Q),X2
M  6Z?A:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_P!CS_QV7H79;3$!29(
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M*49)IIIK%--;&FMJ:V-%6%2G.E4E2JIQE%M--8--;&FGM33V-'C#]GX
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M&Y69\F>6-MR[TW&5U!/,[R,9W,]C<>F-"+]93Q\K#T]3BEBUP*,L8X(=B
M       *_/K[\!*[D1QWE\F\"I&SW3QTI)5K=.08Y'-S33,5:Y^4T\ORR(W'
M:(E.W<):C/L93/:2E2Y".V6?=1YKUM(:OCHG-:O_ -MSB:C#B?DT;QX1I374
MJ^RC-+?)TI-I0>,;^\9RYI:FTS+5>74_\?ED7*6"VU;98NI%];I;:L7T151)
M-R6%$D6DE>X         !U2>+_XM/'C[AFI/M!KQ17K?Y:9O\-NO=ZA;QI/Y
M*Y9\$M_<8&<QJYL     !R9,O_G9E'V17?UR=%^&7_Y"A]SA[%%.-[_G*WU<
MO9,^>'L/*      !:8^%Y_K;Y9_<ZUI]LUD(,]^#\P9!\(N?<Z9+GNF?GG.?
MN-#V<RY(*Z2;X   <X#UE=LN[?\ 4CY.VR97GUV&9C%U/4LI7WM06M6TL;"[
M>,T9^SOM(EA(67R..KZ> N.[N>01T]R:R2WX<)W-%W4WTR=S.5:#?BI2IQ7@
MBBK_ )X9R\ZYHYM6QQC0JJWBNI6\8TI+[Y&;?A;(PAVXY.        %@+T(_
M3:K^5^V9_(G<="BST)H^[B,U=#9QB>JMF[6::;M(%#-8=2:)%93,K8L+1E9]
MKSCL*,M+K#LI"8F]Z7G+6T%D$-(:=J\&:YG!N4XO"5M:MN,JD6ML:E9J5.E)
M;8J-2:<91@W(_N]\KJ6L<XEJ;/*?'EUA)*,)+&->XV24&MSITDU.HGLDW3BT
MXN:+W)$22)*2)*4D1$1$1$1$70B(B%6N_:RPD_T         &.-O:FP+>VLL
MWT_M"AC9-@6PL?G8WDM/*(B\^#-1\R3$?Z&IB5&=)N3#E-]'&'VVWFU)<0E1
M9G3V?YKI;.[74.1U70N[2I&I3FNB4>AK=*,EC&<7LE!N,DTVC%YUDV7:ARJX
MR3-J:JV]S!PG%]*?2GT2B\)1DML9)26U(YEO,_B[EG#;DKM'CWEJWIKF$WJC
MQO('&#CMY9A%NTFTP[*&$I^81RX#K*I+;:E)9DD]'-1J94+J^6^N+#F-HNQU
M=EZ45<P]LIXX]E6@^&M2?3Y$T^%M)RAPSPPDBJC7.DKS0^J;O3=[C)T)^1/#
M#M*4O*I5%T>5!KB2QX9<4<<8LU<&\&I        !;I^%I_</.']]\</VG.Q7
M[WY?LNF/%F'HV),_NC_8\_\ '9>A=EM,0%)D@      1D^LI^C+Y:_8-C_X0
MJ8=K[N?SUY!]WJ?B]8Y3SP^:G.?N4/=J9S>1<B5>@       !?Q^'@_1O8U]
MUS:OUT8%47>\^>2O\$M?8R+&>[1\U]+X1<>R1.6(P'?P         #P[#]P3
MOWG)_:5#Z4?LT/&O1/Q4^QR\3] Y)XOX*:@             E,X2^D#S!YMH
MK,HQK%&M7:=G*;=_I?V<U-IJ&SA&KJM["J1MM5C>&I)+)IZ(P4(UI-MV:RH<
M,YE]X3EYRS<[&]N'?9C'9[TMG&<XOJK3Q[.CT8J<NTP>,:<D==T%R5UMKU0N
M[6C[TL9?_$U\8PDO^U##CJ^!Q79XK!U(LM8<4_0*X.\>V:VZV313N3>P8I-/
M/W.TV6FL$9F(Z>8=1JRO<57J85T+]ANGK-1'UZ.$1]"@CKSO7<SM72G;9-5C
MDEI+%*%JVZ[7T]U)*IQ+KHJ@O 2_T?W=- ::4*^:4WFURM\KA+LD_I;=/@P\
M%5U?&344&.X_B=/ QW%J*GQK'ZIA,6KHZ"LA4U/6QDGU3'@5E<AMAE!=3Z(;
M01?J"-EW>7=_<3O+ZK.M5J/&4ZDI3G)]<I2;DWX6SNMM;6UG0C;6E.-*G!81
MA"*C&*ZE&*22\"1[@><^X      &(^0']0V[?N1[(^TV:-@TG\J<L^%V_NT#
M#:C^3U_\'K^Y2.4^+W"H         +A?PN7\P^8WV7:8^LV1BO+OQ?G33OW*
M\]G;DV>Z5^;\\^Z6OL:Y:Q$$"7X             4)O7]X8'QSY;N;LQ*I*)
MJ[D^5GF;9Q&.R#2[6@.-ELFH5V$9(.>Z_'O6U+,O,<F24-I[(Y]+5>Z?S(_;
M#0"TUF%3BOLDX:.U^5.UEC[WGX>!1E0>&Y4X-O&97;WC=#?LQK-Y]90X;3-N
M*KL6R-PL.WC_ $VU56.]SFELB0."4Y'D                    E)]*#T[[
M[G]R$BU-W&L*[0FM':W(]TY1&\V.<BN<?4NIU_2S4=.VRNU,NM)6E1''BHDR
MBZK:::=X;SYYO6O*?2,KBV<9YK>J5.SI/!X2P\NO./VNBFGAZN;A#=*4H]<Y
M/<L[CF/J54:ZE'+K5QG=5%LQCCY-&+]?5P:Q]3!2GO23Z+6.8[0XAC]'B>+5
M%?C^,XS45U!CU%4Q6H-734E1#17U=770V")#3$=AM#33:"(DI21%X$*?KR\N
MLPNZM_?5)5J]><JE2<VY2G.;<I2DWM<I2;;;WMEFMK:V]E;4[.TA&G2I1C"$
M(K",8Q248Q2V))))+H1[D>8^X                     '_U;_  HT_$S_C
MX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M6RZ&TK:Z+TI9:;MDO\/32G)>KJR\JK/K\JHY-8[HX1W)&T T@VP
M  "J5\3=QNC3L0T+RPI:Y!6>/W,W2.>366B4_*I+QB3EV /RE)+JEJ%+CW3'
M>KJ1KG-HZD?:1SP[E&LITLQS705S/R*T%>T$WL4X.-*NEX9QE1EAU4I/K(?=
MZW2\*EEEVL:$?+IR=K6:WN,U*I1;\$91JK'KJ)%/@6&$*         MT_"T_
MN'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?^.R]"[+:8@*3)       C)]9
M3]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
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M?(#^H;=OW(]D?:;-&P:3^5.6?"[?W:!AM1_)Z_\ @]?W*1RGQ>X5
M !<+^%R_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M            "/3U0N'47FYP\V3JB##8>V+1QRV'IZ6X2$N1MDXG$>>JZY#[
MG@VBWC.2Z5]:NI(1+-WH:FT].N<D.8E3EGS$LL^JR:LZK][W:Z[>JTI2PZ72
MDH5HKI=/AW-G->;6B(:]T3=9/3BG=4UVUL^JO33<8X]"J1<J3?0IX[TCFJRH
MLF#)D0IL=^',AOO19<24RY'DQ9,=PVGX\AATB6AQ"R-*T*(C(R,C(C(7/0G"
MK!5*;4HR2::>*:>U--;&FMJ:WE6<X3IS=.HG&46TTU@TUO370UTH_ ?H_(
M              &7M":,V-R4V]@FD-3TB[[.]A7D>EIXO[(B'#;-)R+*[N)3
M:5^[P*^*AZ;.DFDR:8:<7T/IT/7M5:HR?1FGKK4V?U>RM;2#G-]+Z(P@MG%.
MI)J$(^JE)(S>G=/YIJG.K?(,FI]I<7,U&*Z%TRG)]$(13E.71%-G2HX1\/\
M7/![CUAVB==M-RU537U7S?+G(J(UGGV?63#99%EMFE)J-/FJ;0Q#84XOW>(U
M'C$M9-=QTQ\S.86<<SM77&J<W?#VCX*-+'&-"A%OLZ4?$FY3E@N.I*<\%Q8*
MTO06BLKT#IJAI[+%Q<'E5:F&$JU:27'4EX\$HK%\,%&.+PQ-MAH!N0
M                 ?_6O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_XI8D
M .]7\X=G^KJ/XS=E=D2^(S        !U2^,NLF-+\<]$:DCQ2AEK?4.N\,?9
M(NBCG8]BD6MLGWO NKKLAMUUU1EU4M2E'XF**M:YW+4FL,US^<N+WY=W%9/Z
M6I5E**7@46DET))%O.E,JCD6F,OR:*X?>MM1I->&%.,9-^%R3;\+,XC6#/@
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MD4Y5JLZ]:5>H\93;DWUMO%_1/ 'U/F
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MEFLPUAE.7R6*KWEK3?\ 3KPC_*8+5-R[+3.8WD=CHVMQ/^K2G+^0Y5HO7*A
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M_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M       *"WKY\,/[-?+V5MW$JCW+5?)TK3/8!Q6>R!3[.BOMELZB+L+H@Y,A
M]B\;ZF1'[\ZVV7;'/I:UW4N8_P"V?+V.G[^IQ7V2<-"6+\J=LT_>T_#PQC*B
M_N47+;-%=/>*T-^RVM7G5G#AL\VXJRP6R-=-=O#^E)JJONC2V1(+!*(CZ
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M\SMYU4O,57!>#!%;?>-LHVG-6]JQ6'OBE;U/-[&--^?V?GD+PD@<+
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M:C[(^![5E)3W%VDJ9D-.RI1)^0S)@NI_+T+Z L3[C\$LDU!5Z77M5YU.L_\
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M)]93]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
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M/_#0DME:O%_9,'OIT7NZ)5<%CA3G%W9Q6D3R
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M/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
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MV>6>82>"H5Z-1OZBI&7\ACLXM7>Y3=645BZU&I#^O"4?Y3E "^<IX
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MM9K#M+J5=>%7,8W"?_J^>6E<F<QCFG*_);B+QX+=47XZ$I4,/_3)&1QXZ<
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M56/BXZ<(^.2)0]U7,8V^M;[+9O#WS:.2\,J56F\/'PSF_$F7>Q663W
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M\+E_,/F-]EVF/K-D8KR[\7YTT[]RO/9VY-GNE?F_//NEK[&N6L1! E^
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MPG<3PG<U4MM6LUMPQV]G#TM-;,(KB:XI2;WT'*SH@
M         ?_2O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_XI8D .]7\X=G
M^KJ/XS=E=D2^(S        !>L^'*Y(1]H\,KS1=G8I>ROCAG%A71(2W"7)_H
MZV-*D9?C$U2E?.42;0[Z&DNADVVPRDC(C2DJNN^)HV>1\QZ6J*$,*&<T8R<N
MCWQ;J-*K'J^Q=A/PN4GULL&[L6J(YOH:II^K+&ME=5Q2Z>QK-U*;^^=M'P*,
M5U(L(")!)(           #Y'/\YQK6."9GLC,K!NIQ' ,5R#,\GLW>G9 H,9
MJG;JWEF2C+KY;#+BB+KXF73Y1D,IRN]SO-+;)LNAVEQ=U:=&E%>JJ5)*$%YL
MFCQ9EF%KE.7U\TOI<%&VISJU)=4*<7*3\Q)G+ W;M*ZW?N/:FY,B(T7FT]AY
MCL"S8\PW41)66W\B\7!94?3]BC^>3+22(B2A*2(B(B(7HZ9R.VTSIVPTY9[:
M5C;T:$7NQ5*G&'$_#+AQ?6VV5%9]F]?/\\O,\N?LEY6JUI+J=2;G@O L<%X$
M8P&;,2      !)KZ..MU[0]2GBK3G&-^+CF=3=D37#0:FH:-8XS.SN#)>/\
M6D<V!%:0?_M%H+Y1Q3O%9RLCY,9[<<6$JU"-O'K?OFI"A)+^A.3?@3.K<D<K
M>;<TLGH88JE5==^#L*<ZR;_I0BEX6CI#BFXM"  Y6?)O7R]3<C]^ZO6PJ.6O
M-S[.PMII23011L:S2;41%MD?M0MII"VU%X*29&74C(7JZ)S99_HW*<\3Q]^6
M=M6;\-2C";\U-M/J94/JO+7DVJ,QREK#WM=5Z6'@A5E%>8TDUX#!XV<U\
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M5*4)23\*DVGU--%0VJ\K>2:GS')VN'WK<UZ27@A4E%8>!I)KP&#QLY@
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M%1<6 D,         MT_"T_N'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?\
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MQ/-WWQ.KR]TW5\B+PO:L7Z:2_P#AHM>IB_LS6^7M6Y5%*J")YD/
M     RCI';>5:%W!K/=.$O\ D95J_-L=S:F)3BVV)4F@LVYZJR:;?BJ-+;0N
M+*;Z&2V7%H,C)1D,'J;(+'56GKW3>9K&A?4:E&?2TJD7'B7TT&U*+Z))-;C+
MY!G-YIW.[7/;!X5K2K"K'J;A)/A?TLEC&2Z8MHZDVH=H8KNS5FN]OX/+]^Q'
M9F&X[F^//FI!O%69'5M6D>/+2@S[)#).>3(:/YS;J5H41*29"C?4&1W^FL]O
M-/9G'AN+*M4HU%T<5.3BVNN+PQB]SBTUL9;=DN;6>?91;9UE\N*C=TH58/IX
M9Q4DGU-8X270TT]J,BC#F3                            #_T[_  HT_
M$S_CX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
M    23^E-S:<X+\NL.V+>2I*=49FRK7&Y(;"77R1A-],9<;R5F(WW&M^DFM1
MK-)(0IU;+<B,WT.09CC//?EHN:'+^XR>UBO?]L_?%FW@O;H)^UM]$:T'*GM:
MBI2A-^D.I<G]>/E_K2AF=PW[SKKL+E+;[5-KRTNETIJ,]BQ<5**],=(:KM*V
M\K*ZZIK"%;4]O B6E5:UTEF;7V5;81TRX-A F1S4VZR\TM#C3K:C2I)DI)F1
MD8INKT*UK7G;7,'3J4Y.,HR34HRB\)1DGM33333VI[&6A4:U*XI1KT)*<)I2
MC*+3C*+6*::V--/%-;&CSQ\CZ          %83XBCGS78+K.'P?US=MNYYL]
MNKR/=3U?()3N*ZVB2D6=#B4MQD^K4R^EM,R76NXE)KV#2ZV;-@THYN=T#E36
MS3.I<SLXI86MCQ4[-26RK<-.,ZJQWPH1;BGA@ZTL8OBHR1$_O,\Q:67Y5'0.
M65,;B[X9W33^QT$U*%-X;I5I)2:W]G':N&JF4OA9 07        "S9\,EI9S
M(^1&^M\S(IKK=7ZOJ\"JG76^C19+M"^*P5)B.&7SG8]?02V7"2?S42R[B^>@
M0I[Z^I%9Z0RK2M.6$[ZYE7DEO[.VAPX/P2J5X-=;IO#<R5G=3R)W6ILQU%->
M1:4(T8_5UY\6*\*A1DGU*>W>BZ@*V2=@ '/1]>/3KFIO4CVW8M1O=:;<-%A.
MWZ-/9VDXF\HTXWDC_?[%&Y>5-JX9E[.[H?4RZG;EW6-11S_DUE]&4N*IETZU
MI/\ H3[2FO,H5:2\PK6[PV2/)N:-[52PA>PI7,/Z<.";\VK3J/S2'$2*.(
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MBG8GI7SU1,ILI:4&9MJOUH71Q4+3T=CG8J2I*V$]9;=TSE;5U9K%:WS.G_\
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M^7:T4][MZLL9)?<ZS;;Z%5@EN++XA:2I
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M\39QW=O]6Z&Y/TL#S).O,DMM49O)8;[WOY.9NT5YB,V8OI\V/"L8,R,D^O\
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MJJ^EJ1*K>;&EY:1Y@9EE$8\-%U76H]78UO;()>"'$Z;\,&:##JQSD
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ME@E6;J74>;:LSNOG^=U.TN+B6,GNC%;HP@MO#"$<(Q70EM;>+>%QLA@@
M     #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<
MV      Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
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MO*S[5NP<+2R1=3=5E.)2Z,FR+_2\_H,YI?,EDVI<NSAO#WI<T*V/5V56$_\
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M'.<XS'4&:5\YS>JZUS<S<YS?2WT);E%+",8K!1BE%)))&.QES&
M       ;L>G?RNG\+^7>HMZ)>E?R5J[LL<V97Q26XJVUEE72HS!CW5O_ %[L
M5A:;*&T?0CEQ8YF9=.HYIS>T'2YD<OLPTNTNWJ0[2VD_4W-+RZ+Q]2I279S?
MVN<S?.6>L*FA=:66H,7V,)\%=+U5"IY-18=+BGQQ7KX1.FK56E;>5E;=4TZ+
M:5%Q AVE59P7VY,*QK;".F7!G0Y+1FAQIYI:7&UI,R4DR,CZ&*4Z]"M:UYVU
MS%PJ4Y.,HR6$HRB\)1:>U----/<RUBC6I7%*->A)3A-*49)XJ46L4TUO33Q3
MZCSQ\CZ                           ?_U;_  HT_$S_CX:F_-'P/\,>>
MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P           $MW!3UE^6
M7"&)5X/&L8FZ-(5ZD-,:HV)-FJ_D]")75R/KW,6"<F4Q'TZ(BJ;E0$&:UI@^
M8M2QP#FEW<M!<S:D\SG!Y;F<]KNK>*]LEUW%%X0K>&6,*KV)U>%)'9N7W/'6
M.@80R^,E?6$=UO6;\A=5&JL94O!'"=-;7V>+Q+-NA_B(. VTH4)C9\W/N/.2
MN(;;F0\UQ6RRW&/?%D1FW5Y5KUJQ6M@C/H4BPKH/L,U(270SA3JKNA\ULCJ2
MEDD:&;T5N=&K&E4P^FI7#II2^EIU*O@;9*S3W>7Y=9O3C'-I5LLJO>JM.52G
MC]+4HJ;:\,X4_"D2$8]ZDWI^Y/%1,K>9W&F,TX@EI1D.X<(Q&423^1<'*YD)
M])_Z*FR/]0<CN^3/-FRFZ=;3>8R:^UVE:JOZU*$XOSSI5MS2Y;W<..EGMBE]
M/<TJ;\ZI*+^@?Y?^I/Z?N-1UR;'F=QJDMH3W*30;APC*Y!ETZ]$1,6F3'5'X
M>Q*#/Y.G4+3DSS9O9J%'3>8IO[9:5J2\^K""^B?RYYI<M[6/'5SVQ:^DN:51
M^=3E)_0-&]R?$%^G5K&++1A^8YYO.Z82M#=7K3 ;F##.41=&T/Y!L4J.(;/7
MH:WHBY/1/4TI6HNT=/T[W2N<&=SB\PMJ&5TGZJYKPD\/!3M^WGCU1FH;=[2V
MF@9YWD>664PDK*O6S"HO4T*,DL?#.MV4<.MQ<O GN(!>8'Q#7*[?,&UP[0U1
M7\8<%L$/1'K7';1W)=N6$-PC;6G^7DAB*S5]Z>BTG45[$IE1F29RR\3E?R][
MHN@]*U:>8ZJJ2SNZA@U"I%4[2+^X*4G5PW>VU)0DMKI(CGK7O*ZPU%3G8Z=A
M'*;>6*<H2X[EK[LU%4\=_M<(SB]U1D UA83[:?-M+6=,L[.RER)]C8V$EZ;/
MGSI;QR)<V;,DJ4XZZZXI2W''%&I2C,S,S,S$KZ5&E;THT*$5"$$HQC%)1C%+
M!))8))+8DMB6XCE4J5*U25:M)SG-MRDVVVV\6VWM;;VMO:V>(/H?@
M -N>"?%V[YC\J]/Z#JV995>5Y-&F9U9Q"4E5!KBA/ZL9S=&_T[6W$5[3S40W
M#(ERG&&2/N<21\_YI:XMN76A,QU77:[2A3:H1?\ >7$_(H0PWM.HTYX;H*4M
MR9NG+[25?6^K[+3E%/@K5$ZLEZBA#RJLL>AJ":CCOFXQWM'3PI::JQRFJ<>H
MH$6JHZ&L@4U-5PFDL0JVJJXJ(-= B,I\$-,LH0VVDO DD1"DJYN:]Y<U+NZF
MZE6K*4YRD\7*4FY2DWTMMMM]9:_0H4;6A"VMXJ%.G%1C%;%&,5A%)=2221[,
M? ^H &MW+_CQ1\KN,^YN/E\<=IG96%6-346$I!K9I,MA*1<X3D*T)(S,J^WC
M0IAI3XJ)LT_*-RY>ZONM!ZURW5MIBW95HSG%;YTGC"M3_P#,I2G#P<6)J^M=
M-6^L-*WVF[G!*ZI2C%O=&HO*I3_H5(PEX<,#E[9?B>18%EF3X-E]5*HLKPW(
M;G%<FI)J"1,J,@Q^Q<J;BLE(+J1.,2&7&ED1^U)B[[+[^SS6PH9IE]15;>YI
MPJTYQW3IU(J<)+P2BTUXRIF]L[G+KRKE][!TZU"<J=2+WQG"3C*+\*DFF?.C
MV'E        #>+@_Z@_(K@1GB\ITWD2)F*7,F.O.]59*J5-P'.8S)>42["M:
M6A<6>TCPBVD);<AKZ12G8ZG6'.8<SN4FC^:V5*QU'1X:]-/L+JG@J]!O;Y,F
MFI4V_34IIPEO2C-1FM_T#S)U-RZS'WYD=7BHU&NUMYXNC52ZXIKAFEZ6I'"2
MW-N.,7=?X6^M7PTY=P:FCM<OA:#V_*:CLS-:[6MX%3"G6;G1"F,)SV3Y%9;H
M6X?9'94J-.<]ON*2\3K5YD]VOF-R^JU+JA;O-LOBVU<VL)3<8]=:@N*I2:6V
M37'27VUD\-"<]M#ZTIPMZU=9=>O!.A<244Y=5*L\(5$WN7D5']K1+TE25))2
M3)25$2DJ29&E23+J1D9>TC$?&FG@SM*>.U'^@    _E:T-H4XXI*$(2I:UK4
M24(0DNY2E*5X$1%XF9C^I-O!;6S^-I+%D:/*#U=N!_%2+8QLNW32[ S:"EY"
M-:Z<?A;%R]<U@OGU]B[4OE5U3Q'TZHN+*(?0^J25[!VC1'=^YIZ[G">7Y;.T
MMI8?XF[4K>EPOU45./:U5X:-.IX<#EFK.='+S1\)0O;^-S<1Q]HMFJU3%>IE
MPOLZ;\%6<"H[ZA7K;<B^:T*XUGA4=S0O'ZP\Z).PG'+9V9EV=UYJ[";V'F+2
M&%.QG$^*ZB TS%,E&W).;V-N%/\ Y1]V?1_+6I3SK,W^5<VA@XUJD$J5"77;
MT6Y823W59N539C#LL6B&7,KGUJ?7<)Y58+\G9;+%.E"3=2JO^]526,7]K@HP
MVX2[3!,A5$E#A    2H<!O5SY0\$)M?C=-;JVKHM,DEV6ELWLI:ZJ PZ[YDI
M[7^0&EZ3025&:U=L=#L):U*<?A/.=%IX7S6[O^A^:=.=Y<4_>&:8>3>48KBD
MTMBKT]D:\=R\IQJ))*-6*V/KW+KG/JWE[.-K0G[\R_'RK6K)\*72Z,]LJ,M^
MY.FVVY4Y/:KN'"+U)^+W/+'42=1Y>51L*#!3+RG3F8KB5&Q,>[$D4J3'KB<4
MW:5Z%&72RK''F4DI"7_(>4;*:SN9O)G7'*N\<-06_:6DI84KNCC.WJ=2<L$Z
M51_:ZBC)X-QXHKB<]-!<TM)<P[;BR:OP7,5C4MJN$:T.MJ..%2"]?3<H[5Q<
M,GPK?P<H.C     %7[XE#B([FFJ=;\Q,3JS?N]12&M;[1>C-=S[NN,JM3>Q"
MYEK(O]357C[L4B+Q,[;N/YK9F4WNYES!CEN?7G+N_GA2S!.XMDWL5Q2CA5@O
M#5H14O\ Y?#>]L3>])HN5_D]KK:SAC4LGV%PUO["I+&G)^"G5;C_ .=CN13$
M%CQ!D          W4XA>H/RJX/WJ['0^R)==CDZ8B;D.M,E:5D>L\F=(DI6Y
M9XM*6E+$A:4I0J?6NQ9G81(*22.J1S7F%RDT)S.M51U59J=:"PIW--]G<TUU
M1JI/BBL6U3J*=/%X\&.TWO17,G5^@;CM=/73C2D\9T)^70J?54V]C>[C@X3P
MV<6!9NX[?$RZ.R6) JN3FE\UUA?FEMF7E>LGHN?X3(>(OV6?(IK)R#;U[1_K
M8[!62R^5P^OA"C6'<KU/95)U]$YE1OJ6UJE<IT*R71%3BITJC^FEV*\!*W3/
M>JR"ZA&CJNQJVE3<ZE!JM2;Z6XR<*D%X%VK\)*O@7J]^FSL6.P_2<MM9U!O)
M29Q\]5?ZTD,+/Z9M]&PH581&D_ U$HTG[249=#/A.:]WSG-D\W"YR"YJ8=-#
ML[E/PKWO.I_/X#K^7<Z>5N9Q4K?.:$,>BMQT&O'VT8?S>$S*KU!N!B6#D'S6
MXFFV2/,[4\B-1K?[?;T*,BW-PS_T21U_4&N+E)S4<N#]FLTQ_5]WAY_98?1,
MX^9/+M1XOR]E^'PVWQ\[M,37G9WK.^FMJV)(>L>3N*9?.:2HX]1K&JR;8LN>
MZDNOD1Y^+0Y%<V9_(N5-:;_T^O0;=DG=PYSYY44:.25;>+WSN94[=176XU9Q
MJ/Q1A)^ UK-N>?*W*(.57-J=>2W1H1G6;\"=.+@O'*27A(0.6WQ+M_=0+/%.
M&6I7\/.2AZ,UMK<2*NSR"(A9&W[WCVMZAV57,OH,B<9D6=C,;,CZ.02,2;T!
MW+K2VJPO^8^8*XX<&[6TXHTWX*EQ-1J.+W.-.G3?55.!ZR[U%S7ISL]#6;H8
MXKWQ<\,IKPPH1<H)]*<YS773*P>SMI;&W1F][LG;&:Y'L'.\EE'+N\HRFSD6
MMK-<(NQEGSI!F3;#*")J-&9)#++:4MM(0VE*2FYDF1Y/IO+*639#;4[2UHK"
M%*E%1BNMX+?)O;*3QE)MRDVVV1.S;-\SSV_J9IG%>=S<57C*I4DY2?4L7N26
MR,5A&*P2222/@AE3'            =4GB_\ BT\>/N&:D^T&O%%>M_EIF_PV
MZ]WJ%O&D_DKEGP2W]Q@9S&KFP     ')DR_^=F4?9%=_7)T7X9?_ )"A]SA[
M%%.-[_G*WU<O9,^>'L/*      !:8^%Y_K;Y9_<ZUI]LUD(,]^#\P9!\(N?<
MZ9+GNF?GG.?N-#V<RY(*Z2;X   8=Y!Z5Q7D;I#:>B\V;)6-;2PJ]Q"?()I#
M[U6]9PU(K+Z$VLR+WFNEDQ.BF9^#S*#^0;%I+4M_H[4UCJC+'[=8UH58K'!2
M47Y4)?2U(\4)?2R9A-2Y%9ZGR"\T_?KVJ[I3IM[W%R7DS7TT)83C]-%'+IVY
MJW,-([0S_4.P*Y53FFMLMO,-R2$?>;:+.BGK@//Q'5D7FQG^PGXKZ2[765H<
M09I41G>%I_/,NU-D=IJ'*9]I;7M*%:G+IX9Q4DFNB4<>&4=\9)I[45*YSE%[
MD.;7.2YE'@KVM2=*:^F@VFUUQ>&,7N<6FMC,=C,&,        #Z;#,US#764
M4N;X#E&087F.-S6[*@RC%K>=17]-/:(THE5MK6K;?97T,TF:%EU29I/J1F0\
M699;EV<6-7+,VH4[FWK1X:E*K",Z<XOHE&2<6O&M^T]=C?WN67=._P NK3H5
MZ3XH5*<G"<7UQE%II^)EC;B;\23OC7,*LQ3E5KJKWS1Q$,Q?Z0<5D0L%V<S'
M01).3;P&V54MNXE)$E*4,5JU&9K=D.+ZF<.]?=S32V<5)W^A+R65598OL*J=
M>V;ZH2Q5:DO&ZR6Z,$B3NCN]'J'*Z<+/5]K',:<<%VU-JE72ZY+#LJC\2I-[
MY2;)S]2^O/Z;&T8T7ZI[=R#45Q)2@_J#M? LEJGV%*+YZ9%_BK5Q2([3\#-5
MH77VEU+KTB_G_=6YS9'.789?3S"G'U=K7IR3\5.JZ59X_<O&2!R;O#\K<V@N
MUO9V4WZBXHSBUXYTU4I?^H;B5/J,< [J.F5#YI<766UI)1)MMY:XH)!$?AT5
M#O;&,Z1_J&@C'.[CD]S7MI\%33>9M_265Q47GPIR7T3=J/,[ES7CQPSVP2^F
MNZ$'YTYQ?T#T.6>IYZ>>&179=QS*X]S&F4FM:,3V1C^>RC(B[C)J%@SMB\L_
MH$ALS/V$74>JPY)<W<RFJ=OIR_BW]MMZE!>;*NJ:7FL\]YS8Y:V,'.OGEG)+
M[77A6?G4G-OS$1F\AOB0.&NN84Z%H?&=@\A\F2AQ-?+;JY6L-?J=27:E4Z]S
M%@KDBZF1DEG'EDHB,O,1U(S[5I'N;\QLXJ1JZJKV^44-G$N)7-?#Z6%&78^?
M76'4SE6I>]!H?+(2IZ>I5LSJ^I?"Z%'S9U5VOG47CUHJX<WO4_Y6\\; X6UL
MM8QW642<F;2::P)$NDP""\PONASK>,ZZ[*MYK9=#1*M)#WE*-9Q6XR%J0)Q\
MLN2.@^5=+M,AMW6O91PG>5\)UY)[XP:2C2@^F-*,>)8<;FTF1)U]S9UAS#J<
M&<5E2M(O&%M1QC136YR6+E4DO75'+!X\"BG@1WCKQS,           "W3\+3
M^X></[[XX?M.=BOWOR_9=,>+,/1L29_='^QY_P".R]"[+:8@*3)        #
MEP<U=5N:2Y=\E=5'&5$B85NO8M52M*1Y??C*LGD3,5E);_6I?K78KR2+P(EE
MTZB\;EKGJU-R^R7/N+BE<V=O*;_[G9155?T:BDO,*D]=Y0\AUIFN3X81H75:
M,?J.TDZ;\V#B_--8ANQJ8        ?M&DR(<AF7$?>BRHSJ'H\F,ZMB0P\VK
MO;=9>:,E)4DR(TJ29&1^P?F<(5(.G42E%K!IK%-/H:>]'ZC*4)*<&TUM36QI
M]:9L#3<N^6&.16X./<G^0]#":03;4.FW5LFKBMMD1))#<>#9H01="(NA%\@U
M*YY?:"O*CJW>1Y?5D][G9V\GY\J;9LE#6FL;6"IVV;7M.*Z(W5>*\Y31^-CR
MTY4VZ#;MN3'(&T;,NAMV.YMC34&73IT-,FR40_5'0.A+=\5ODMA!_2V=O'T*
M:/S5UEJ^NL*V:WDU]-<UGZ,S%5_GN<Y7W'E.:99DO>?5?U?R.XN>X_;U5]47
MG.O^49ZTRK*[#_(VU*CA]KIPA[%(P]SF.87G^;KU*OU<Y2]DV6W_ (7+^8?,
M;[+M,?6;(Q 'OQ?G33OW*\]G;DS>Z5^;\\^Z6OL:Y:Q$$"7X   <D,7^%,X
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MUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
M  %X[X>K@B_HG15IRKV)2JA;-Y$5D1G"(LYCRYV-Z28D(L:I\B61*;7DDI#5
MHM/B2H;%:LC2I3B16)WN.:4-4ZIAH3)ZO%991)NLXOR:EZTXR7A5O%NDNJI*
MLGBDF3][M?+V6GM/3UAF=/AN\SBE236V%JFI1?@=>251]<(TGO;18N$/B38
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MU/=:<S!-NC+VN>&"JTI;:=1='E1PQ2QX9*4'MBS5X;P:D
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MGYS&^Q'3/UYR(01[\7YJT[]UO/86Y+_NE?G'._N=M[*L7#!7B39
M      ,1\@/ZAMV_<CV1]ILT;!I/Y4Y9\+M_=H&&U'\GK_X/7]RD<I\7N%0
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M=G->MS#SOWCELG'*;.35&.U=M/:G<37A6*I)[80>Y2G-$-8D8<.
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M?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M9)E6&MM'YKH74=?3N;1\ND\832PC5I-O@JP^EDEM6+X9*4'Y46:Q#=C4P
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M3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_   #DAB_PIG
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MXI8D .]7\X=G^KJ/XS=E=D2^(S                              &\7
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M*3LYTMIC*-'Y'0T_DE/LZ%!8?33D_35)O9Q3F]LGYB2BDEG4:N;
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M316AG.39GI_,ZV39Q1E0N;>3C.$MZ?6GN<6L'&2;C*+4HMIIF.AF#&
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M3K'U7I3.M%YW5R'/J3IUJ3V/:X5(/'AJ4Y8+BA+#8]Z>,9)2C**U_&V&M@
M                           %NGX6G]P\X?WWQP_:<[%?O?E^RZ8\68>C
M8DS^Z/\ 8\_\=EZ%V6TQ 4F2        'X2HL6=%DPIL9B9"F,/19<24RW(C
M2HLALV9$:0PZ1I6VM!FE:%$9&1F1D9&/W3J3I3C5I-QE%IIIX--;4TUM33VI
MGYG"%2#IU$I1DFFFL4T]C372GTHYPWJQ<#K7@CRER'&:BME)TGLEZRSC2-RI
M+KL5.-2IG=9X0]+7U(YF/R'2A.)4M3BXRH<I?3WHB*XSD)S4M^:6AJ-[<37Y
M3LE&A>PV)]HEY-9+UE>*XT\$E-5(+TA6#SBY>5N7NKJMK1B_>%TY5;671P-^
M52;]=1D^%[<7#@F_3D88[:<G             "X7\+E_,/F-]EVF/K-D8KR[
M\7YTT[]RO/9VY-GNE?F_//NEK[&N6L1! E^   ')#%_A3.        %K#X7+
M^?G,;[$=,_7G(A!'OQ?FK3OW6\]A;DO^Z5^<<[^YVWLJQ<,%>)-D
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M/.6V;.A>)UK*JW[WN4O)FM_#/UE6*]-!O;@Y0<H[2.<=A.8@
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M+<91:VIIM-;B$-Q;W%I7G:W=.5*K3;C*$XN,HR3P<91:333V--8H]2/0?$
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M=I#/-$9W4R+/J79U8;8R6+A5ACY-2G+!<4)8;]C3QC)1DG%:YC<#6
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M3J)V3\DN5U/E[I[WUF,$\TO5&5>6Q]E'?&WB^J.^HULE4QVRC"#4Q CN=M
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MS@^.4N(89CU+B>*8Y7QZF@QO'*R'345+5Q$>7%KZNJKT-L,,MI+HEMM!)+Z
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MO.36MM!3G7O+=W5E'=<T$YTTNNI'#CHO=CQI0QV1G+>1BCMAR<
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M:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_V//\ QV7H79;3$!29(
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M56*F)W;^5/;U(<Q,_I^1!OWE3DO326QW+3Z(O&-'Z;BJ+#AIR=OL5[DU
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M/9'IJS67Y!:4K2BO4TH*.+ZY-;9R^FDW)]+,LC &9
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MPS' _P#ZL\N/^?-.?^ @_C5YI_Z#*OO%W_[X?PJ<O/\ 69C]^MO_ &@_PS'
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M\I-.<LZUU7R&O<UG=QIQG[XG2DDJ;DX\/9T:6#?&\<>+HPPZ9)1QHZB
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MS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
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M \)ZP
M
M
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M<8U+2MC.VKX;*E/'TLFMBJT\5&I'9MPDEPSB1[CK9S4
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MI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
M                             #5OF%Q$U#S9TCD6D=P51OU=F7U1QG)H
M+;!9)@6716%MU&7XQ+>(_+DQS6I#K2OV.0PMV.\E33JTGO/+SF#J#EIJ:CJ;
M3U3"</)J4Y8]G7I-ISI5$M\98)I[X249Q:E%,U+6VB\EUYD-7(<[AC"7E4ZB
MPXZ-1)\-2FWNDL<&MTHMQEBFSG2<U>%&Z>"NY+34FWZA2F'%2I^"9Y71I!8G
ML?%FW_+CY!CLMWJ1+22D(G05J\Z(Z?END9&VXY<%RUYE:;YHZ<AJ#3U3:L(U
MZ$FNUMZN&+IU$NC>X32X:D=L>E*LG7>@\]Y?9Y/)LZAL>+I5HI]G7IX[)P?7
MN4X/RH2V/H;U"'032@                -A^,O%7>G+[9E=JG0N"V.8Y'*4
MR]:SDI5$QG$*AQWRWLBS+(74^[U\%OQ_9'5=[JB)F.V\^MMI>H:UUWI?E[DL
M\^U5=1MZ,<5&.^I5GABJ=&FO*J3?4MD5Y4W&"<ELVE-(:@UKFL<GT[;RKU7@
MY/=3IQZ9U9[H076]K?DQ4I-)WR_30])?3/I^XZSE,U4#9W(^[K3C93M>;7^7
M%Q^/+:Z3,6UG7R^Y=?7]#-N1,5TESO%3YM,FW$8JOYT\_=1\V;QV-+BL<FI2
MQI6JEMJ-/95N9+94J=,8+VNENCQ2QJ2L.Y5\F\CY;VRNZF%WFE2.%2X:V03W
MTZ">V$.AR]/4WRPCA",M0X$=D        #__UK_  HT_$S_CX:F_-'P/\,>>
MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P      &6] ?U[Z4^ZWK?
M[<80U_5GR6S/X)<>XS,UISY0V'PBA[K$ZL(HC+?@
M
M
M
M
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M*(RWX
M
M
M
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M'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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M!_7OI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M9\ELS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
M                                         /7VU357]78T=[65]U2W
M$*566U/;0HUC5VE;.95&FU]C7S$K:?8>;4IMUIU"DK29I41D9D/M;W%>TKPN
MK6<J=6G)2A.#<91E%XJ49)IQDGM3333VH^=:C1N*,K>X@JE.:<91DE*,HM8-
M23Q336QIK!HA;VYZ!G!?/\LDYSKA>W.-.22G79#A:(SB-1T'O#Z^Y\XU#D\&
MU3":5^MBU3L1A'0NQLB(R.2.G^];S0RFPCE><JTSJC%)+W]1<ZF"W8SISI.;
M^FJJI)]+9PK.>[IR_P RO'F&5NYRJJ]O^$JJ$,7OPA4A4X5]+3<(KH1Z_67H
M <'\3RJ+FFT[C>')6[B+:=;B[JV$S-Q\W(Z_-8\^MQ&#52)+9*\51ITU]A?B
ME;2D&I)_7.^]CS.O["66Y%3LLEI2Q6-G;N-3;L>$JLZL8O#=*$(26]23P9\\
MJ[N.@;.\5_F\[K-:D>BZK)PV;L8TX4W)?2SE*+Z5AL)JL<QO'L/H:C%L2H:;
M%\9H($:JHL=QZLA4U'35D-LF8E=555<AMB.PTDB2VTTVE*2\"(A&R\O+O,;J
MI?7]6=>O5DY3J5).<YR>URE*3<I2;WMMMG=K6UMK*WA:6=.-&E32C"$(J,(Q
M6Q1C&*2270DL$>Z'F/N !__3O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_
MXI8D .]7\X=G^KJ/XS=E=D2^(S       9;T!_7OI3[K>M_MQA#7]6?);,_@
MEQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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MOX0A7HRE)VE=))5(MMMT\$DMK;V)'2K%,1:8
M
M
M
M
M                                                      '_U;_
M
M
M
M
M
M                                #__6O\
M
M
M
M
M
M           /_]>_P
M
M
M
M
M                                                  __T+_
M
M
M
M
M
M                            #__1O\
M
M
M
M
M
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ML>9&@<SO*>7Y?G%I6KUI*,(1KP<IR>Z,5CM;>Q);6]B-P!STW4
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M\<'AL,;?WFGI[?EE\=?OHXQ_MQF?W*<V_P#;F8?%JOUIBOWK<M?TY9??Z?\
M.9XTSR3T#R*8R"3HG<.O=MQ\4=K6,E>P')ZS)&Z)ZX0^Y5-6:JU:R95(3&D&
MT2^G<3:^GTIC5M1Z,U9H^5&&J<NN,O=PI.FJ].5/C4.'B<>)+'AXHXX;L5UF
MQ9%JG3FIHU9Z>O:-ZJ/"INC4C/@<L>'BX6\,>%X=>#,VC63/
M               :0[M]23@IQXDS*[;')[5M+=UZEMS\9HKA[/LM@.MGVFQ/
MQ/7S-I91U]? DO14G_D'3=-<FN:.KX1K9#DES5I3]+4G!4*4EUQJUW2IR7A4
MF:#GW-'E]IF4J6<9M;TZD=].$G6J)]3IT54FGXXHC\RCXC#TZL?D.,5+^\LX
M:0HTIF8OK"-$CND2NG>VG-+2G>(C]OSVDGT^3KX#K-CW/><%W!2N%96K?15N
M6VOO-*JO.;.;W?><Y96TG&B[NX773H))_?:E-_0/DX/Q*? &6X2'\)Y/5B35
MT-V=KS7KC:2\/G&5;ETA?3_L3U\/9[!D*O<QYL4UC"YRV?@C<7'_ (K2*^B>
M.GWI>7,WA*WOX>.C1_\ #<LV P+UZ/3,S=]F),W7?8!,D*)#+&>ZRSZ QWG\
MCUM0P;&"R1?*M^4A/^E[!J>:]U;G5ED74IY;3NXK>Z%S0D_,A.=.;\48M^ V
M3+N\1RJOY*$[^=M)[E6H5DO-E"$X+QN21)9J3D)HG?=:NWTGN+6FU8++27I:
M\"S3'\G?KTK,B)-K"J7W7XBR,R(VY+:%D9D1I(QQ?/\ 2.J=*5O>^I<NN;"3
M>"[>C4IJ7U+E%1FO#%M>$ZGDVI=/:BI=MD-]0O(K?V-6%1Q^J46W%^"23,PC
M73-@      :8Y!ZBO!'%+Z[Q;)>6^@Z+(\:M[*@R"DL]D8Y$LJ>[IIJZZUJK
M"(\^2VGX[[;C+K:B(TK29'XD.CVG)_FE?VM*^LM/WU6C6A&I3G&WJ.,X32E&
M46HX.,HM--;T\31KGF;R]L[BI:76<VE.K2E*$XRKP4HRBW&49+'8TTTUT-'J
M/[S3T]ORR^.OWT<8_P!N/1^Y3FW_ +<S#XM5^M/A^];EK^G++[_3_G']YIZ>
MWY9?'7[Z.,?[</W*<V_]N9A\6J_6C]ZW+7].67W^G_./[S3T]ORR^.OWT<8_
MVX?N4YM_[<S#XM5^M'[UN6OZ<LOO]/\ G']YIZ>WY9?'7[Z.,?[</W*<V_\
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MW<2ZS8,BU9IK4[JK3U]1O>PX>T[&I&?!Q\7#Q<+>'%PRPQWX/J,ZC5S8
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MWSYWLH_^:_$KDZ)HJ"+,@ *.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D
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M.;%\[X<7]'C+^[_LOZS48JN[XOSO1^ 6WLZQ8?W8?FT?PRO[&D3W"*A(D
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M_K;E8KU[\?\ G]-_<[WV5J36[I/^3SWZNT]C<%KP0-)A
M       !%!ZA?J[\<.!$65B4UT]M;]>A)D5FG<3LXS#U.4EDGX4_8^1]C[5'
M&<0I+C;*F7IKR%(6U$4PHWT=YY1]WW6/-:<<PIKWAE*>$KNK%M3P>$HV]/&+
MK23Q3>,:46FI5%)<+X]S*YT:7Y=0=G4?OS,6L8VU.23CBL4Z\\&J46MJ6$JD
MDTU#A?$J97+WU9.:O,F7:5^<[0L,&UM.6\VSJ+5;\[#<(* YU24*^]T>5/NB
M,NAK^K$R2COZJ:;:+H@K'>7W(3EKRYIPK978QNKV.&-W=*-:MQ=<,5V='P=C
M"#PV2E+>0;UKSCUWKB<Z>87;M[66.%M;MTJ6'5/!\=7P]I*2QW*.XC7'9CE@
M    ![W&LHR;"[ROR;#LBO<3R2H?3*JLAQJWL**\K)*/I9%?;5;C4AEPOD6V
MXD_U1Y;VQLLRM9V68T87%&HL)4ZD(SA)=4H23BUX&F>BUN[NQN(W=C5G1JP>
M,9PDX3B^N,HM-/PID_/";XA7DQHV948AR=9D<D]6MK8BO7TMR'7;HQV$DR0J
M3!R8R;C7G81J<4Q=I]X?5T3]4F$D(H<R^Z/HK4].IF&B6LEOGBU36,K.H^J5
M/;*ACN4J/D16+[&3)&Z#[RFJM/SA9:L3S2TV)S>$;J"ZU4V1JX;\*OE2?][%
M%QWC+RMT/R_UO#VEH+/:S-<<=4U&MX;9G"R7$K=;7FN4&88Y)Z2J^8@NIDAY
M'8ZCH]'6\PI#JJZ]:Z#U5R]SF61ZKM)6U98N#WTZL,<.THU%Y-2#ZT\8OR9J
M,DXJ;NE-8:>UKE<<WTY<1KTGLDMTZ<O65(/RH2\#6#6V+E%IO8D:@;,   '+
M8YG_ (X?*_\ .5WK^%&U%Y/+CYO,A_5UE^+4BI'7/RVSCX==^[U#6H;F:J
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M---/!II[4T]C3VIDL83A5@JE-J49)--/%-/:FFMC36U-'DC\'Z
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M?5 _)0R/_G[4'_B$/XE.2'Z>I_>+O_VX_<1S9_0\_OUM^&']RCZH'Y*&1_\
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M"CZ=4MM/3,*:9-7R'WNI21^PS+Q&HT^^ERKG4X)66:1CZYT+7#QM*\;\Y-^
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M<4JLDOIHPDY1\U(U'.-+ZDT^\,]L+BSQV)UJ-2FGXG.*3\QLPN-D,$ !:9]
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M?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M  !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$PB
M,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
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MJPC6I-]-.HEQ1V[7%XPDUY<9+84,?4L]+_;?IXY[&.Q?D9]HK,;"0QK?;42
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M$1C+:7PM/[OYP?O/CC^W9T("]^7[#ICQYAZ%D3)[H_V3/_%9>C=ENH5^DSP
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M1?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M   !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$P
MB,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
M      !3&^()]-BFU3=-\W=)X\S585G>0M5.]\9J8J6:W',]NW3^I&PX46.7
M8Q%O'NZ-9D24H38FR[U6Y8+)%CO=+YS7.?6SY9ZEK.I<VM-SL:DWC*I0@O+M
MVWME*@O*I[VZ*E'8J*Q@UWD.5M#)ZZU[D-)0H7$U&[IQ6$85I>EK)+8HU7Y-
M3<E5X7M=1X5?!-\B89JXY;TS#C/O35N^<#?6UD^L,PJ\FB1R?7'9MX$=PX][
MC<YULC446T@.2:Z61%U-E]PB\3&M:QTOEVM=+WVE<U6-"^HRIMX8N$FL85(K
MUU*HHU(?311GM,:@O=*Z@M-19<\*MI4C42QP4DMDX/Z6I!RA+Z63.H[K;8&-
M;8UW@FT,,F?5#$=C8?C><8S-,DI5*H<JIV;RJ><0DS)*S8?1WHZGVJZD?B0H
MZSG*;W(<WNLCS*/!<6=:I1J1ZITIN$EXN*+P?2MI;7E>96N<99;YM8RXJ-U3
MA5IOKA4BIQ?G-8GVHQI[P .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#
M\YV=_"I_R$? ZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE
M?V-(GN$5"1( %5/XF/E1*HL/TWP^QJR7'=SAQ>X]H,,/&VX_C%#/=H]=T\I"
M3,G(TNT:LISB%D7:]715EU^2=O<LT+3NLQS'F'>PQ5JO>ELVMU6<5.XFNJ4:
M3IP36^-::(@]ZK5\[>RL=$VL\'<?XFND]].#<*,7UQE44YM>NI093O%AY"4S
M5QST1FW)S>.L="Z[CD_ENSLJ@XY ><;6Y%J8:R5,O<CL4-F2O=*N U*L9AH^
M<3+#AI(U="/6M8:IRS1.F+W56</"WLJ4JDDMCF]T*<>CCJS<:<,=G%)8[#/:
M8T]?ZKS^TT[EBQK7=103Z(K?.<OI:<%*<OI8LZ;'&/CEK;B=I# M#ZIK$P,4
MP:G:AJF.-,HM,EO'B\^^R[('F2(G9]E*-R5)7]*DU$VTE#+;:$TI:VUCG.O=
M3W>JL^GQU[J;>&+X:<%LA2II[H4XX1BM[PXI8R;;M8TIIC*]'9!;:>R>'#1M
MXX8[.*<WMG4FUOG.6,I/<L<%A%)+/0U4V(      #T-_BV,96S6Q\IQRBR1B
MFO*G)Z=F^J(%PU59)02BG4605K=@VX3$Z$^DGHDMHDNM+(E-J2KQ'JM+Z]L)
M3G8UIT74A.G-PG*#E3J+AG3EPM<4)QV2B\8R6QIH\]S:6EY&$;NE"JJ<XU(J
M<5+AG!XPG'%/"<7MC);8O:FCWP\IZ       'L '-Q]6WEM_;$YO;3SJFL_J
MCKC!I1:FU0IIWS83V%X1+?C.7D%1'T4U<6;EA<-*-)*\J2VA7^K(7*<@= ?N
M[Y96.5W,."\NE[ZNL5@U6K*+X)>&C35.DUNXH-K>5=\YM9_MMKZ\S"A/BM;=
M^][?;BG2I-KC7@J5'.HNG":3W$:([0<K+^/H"\3/[//">MVAD-9[GL+D]/B;
M,LEOL^7-BZ\B1W(&K*E:NGSFG8;DF\9/V]+,TG]+T*J+O7Z^_:[F7/([2?%:
M9)%VT<'L=PVI74O&IJ-%_<,>DL9[N>C?V:T'#-KF'#<YLU7EBMJHI-6\?$XN
M55?=<.@KI>OIQ*_LZ\V;;9>/5GN>N^3L*7M"I6PSY<*)L!B0B%M2H0KH7<ZN
M<Y'NW>G@16:4E]*9%,'NI:__ &PY:4\EO)\5YDDE;3Q>,G0:;M9^)04J*^X-
M])&3O%Z-_9G7D\UMH<-MFR=>."V*LFE<1\;FU5?W5+H(.Q)PX"6^_AHN6_O]
M'MCAAE5GUDT+C^Y=2MRGNJE4]@^Q4;(QR'YAD1)CRUU]HQ';ZJ4<J>Z9$EM1
MBO?OHZ [*ZL.9%A#R:N%G=8+U<5*=O4>'KH*I2E)[%P4H[VB:G=7UGVEO>:%
MO)[:>-S;XOU+:C7@O%)PJ)+:^.I+H+8(@63$       H,_$3_I&[;[C&K?VF
M<+6>Z!\SM/X9<^C KJ[S/SGS^#6_H2(*1*,CX7 /A;_YI\S_ +(M%_6W*Q7K
MWX_\_IO[G>^RM2:W=)_R>>_5VGL;@M>"!I,(                    H8?$
M*<JY6[N9ZM)TMDM_ .,E*C$6HS+QKA3-E9-'CWNP+7M(R+S(Z?J?2K2HNJ'(
M+W:?1P^MJ/='T)3TSRW_ &EN887>=S[5MKRE;4W*%"'BE[9636]58X[BO#O*
M:PGG^N?R#0GC;93'L\$]CKS2G6EXUY%)]3IRPWD"0E61V))/2MX,R^>7*S&=
M<W#4YC4N&1_Y?[GMX:G&'&\,JI;;+.-0IJ33Y<R[EK9KF5)7YC32Y$I"5^ZJ
M2.-<]>9]/E7H.OG%NXO,+E]A9P>#]NDFW4:Z848)U'BL)24*;:XTSJ7*'E_/
MF'K"EEE=-65!=M=26SVJ+24$^B5634%TI.4TGP,Z0&/8]18E0TN+8Q45V/XW
MC=37T5!15$1B!54U-4Q$0:RKK8,8DMLL1V6T---(224I21$1$0IPN[NZO[JK
M?7U256M6E*=2<VY2G.;<I2E)[7*3;;;VMLL_MK:WL[>G:6D(TZ5**A"$4E&,
M8K",8I;$DDDDMR/<#SGW               .6QS/_'#Y7_G*[U_"C:B\GEQ\
MWF0_JZR_%J14CKGY;9Q\.N_=ZAK4-S-5.B#Z#_Z++C5^_-U_A]R@5#=Z;Y\\
MZ\5G^(VQ9?W>OFBRKQW7XY7)>Q'P[2     :C<^\!I]G<(^5^%WD=F1#L] ;
M2F1O/2E;<6[Q_$961XU9]JO#NAV,2+*1_I-EXE[1T#E1FMQDG,S(<RM6U*%_
M;)X=,*E6-.I'^G3G*+\#-,YC9=0S;06<6%PDXSL[AK'HG"G*<)?T9QC)>%'+
M\%WA4T !U+^'EI+O.(_%J[L%K<GW''+2%I-<<Z^8N78:SK)<E:^ORFM:C,4:
M<PZ%.UY@9[;4MD*>87L8^*-S42^@BW'1-:=QHS*+BIME.RM9/QRH4V_HLV-&
MG&SD'OK[\K9?';A#9Z^QBR7 SSDO<.ZK@.1W3:FP\";A?5/9]DR9=.K;L(V*
M1XO:2;,E)Z&GJ4G.ZCH.GJ_F;#-KV'':Y+!74L5C%U\>&VB_"I\59>&C@]YP
M+O&:PGIG0,\MM)\-QFLO>ZPWJCAQ5Y+P..%)_=<2@*+8"N0]M04-SE-[2XQC
ME;+N<AR.VKJ&BIZ]E4B?;7-O,17U=;"81XK>??<0TV@O$U*(B]H\]W=6UC:U
M;V\FJ=&C"4YSD\(QA!.4I2?0HQ3;?0D?:VMZ]W<4[2U@ZE6K*,(12Q<I2:48
MI=+;:276=)_TT^"N)<">-.,:UAQ*^5M#)8T#*MVYA'0V[)R//94,CD5C$XB[
MEUE,2U5]4V7:CRTKDFA+\J0I=,W.CFCF'-76E?.JDI1L:+E2LZ+V*G03V2<>
MBI6P52J]KQ:ABXP@E:3RKY?67+O2M+*H13NZJ52ZJ+?.LUMBG]KI8\%-;%@G
M+#BG+&0<<D.D@      87Y"Z"UKR>T[G.CMMT;=[A&>TSU7/:[6DSZJ8DR?J
M<CHI3J5^[V%=)2U,A2"2?8ZVDS)2>Y*MDTCJO.M$:BM=3Z?JNE=6LU*+V\,E
MNG3FDUQ4ZD6X3CTQ;W/!K!:ETYE6K,DN,@SFGVEO<1<7UQ>^,X/;PSA+"47T
M-+>L4<S+E?QOS;B1R#V?Q]S])N7FO,B>KXENB.N-#R?&YC:;+%LLKFEFKM8L
MJ]Z/+0CO4;9K-I9^8VLBNIT'K++-?Z2L=6Y3LI7E-2<,<72J+R:M*3]=3J*4
M&\$I8*2V-%56L-+W^C-27>F\QVU+:;2EA@JD'Y5.I'P3@XR2QV8X/:F:\#;S
M62U1\,]RIE5&=;@X>Y'9+.FRZJ7N/6D>0ZKRHF4T!1Z3/:F$E1GU785RH$XD
M$1)2FN?7],X?6"G?3T+3N,KR[F'9P]LMY>]+EI;72J<4Z$GX*=13ACO;K16Y
M$O>ZMJ^=',+W1-U+VNM'WS03Z*D,(UHKPSAP3PW+LI/>RXH*[B;8 %*+XG;\
M:;CS]P!_\(ML+*NY+\ALW^'K\7I$$.]?\KLL^!OW:H5H!-(BL6=OA@OQA^3'
MW&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I       B$]>#]%ER
M5_?FE/P^XN)!]UGY\\E\5Y^(W)Q;O"_-%FOCM?QR@<[X6\E:!LKPP_'#XH?G
M*Z*_"C5#3.8_S>9]^KKW\6JFU:&^6V3_  ZT]WIG4G%&Q;< !HUZFGZ/;F7^
M;KM'[6'QT_DI\[>G/UA;>ZQ.?\UOFUSSX%7]S9S*!=:53@ =;"O_ '!!_><;
M]I2*!ZWV:?C?HERM/[''Q+T#S!\S]@  !XTR'$L8<NOL(L>; G1GX<V'+9;D
M19<24T;$F+)8=(TK;<0I2%H41D9&9&70Q^Z=2I1J1K4I.,XM.+3P::>*::VI
MI[4S\3A"K!TZB4HR333VII[&FNE-;SE>\G-;0M-\D>0.HZPE?4S5^Z]IZ^JS
M6M3BE5F'9Q.QZO6;BO%7<S'0KN/Q/KU,7I:)SFKJ+1N4Z@K^GOK.UN)?55J$
M*DOHR945JO*Z>1ZHS+):7I+2ZN*,?J:56<(_0BC!PV<U\Z 7P]V3RK_TU<"J
MY#IN-85LO;.,04F9GY,65E*LQ4UX_P#VULZOP_SA4YWM[*G:<Y[JO!8.YMK6
MI+PM4E1Q\ZDEYA8[W;+N=SRLMZ,GBJ%>XIKP)U.U]&HR;H1F.]@
M   !2B^)V_&FX\_< ?\ PBVPLJ[DOR&S?X>OQ>D00[U_RNRSX&_=JA6@$TB*
MQ9V^&"_&'Y,?<8QS[>&A"7ON?)#)?AE3W%DK^Z=\ILU^"P]U1=&%;I.D #0[
MU0OT>',C[@.P/K.L=4Y'_.]ISX=0]FCGG-KYM,\^!UO8G,T%U!54?08E3LY%
ME>,X_(><CL7N0TM.^^R23>89L[)J$X\T2^J34E*S4GJ73J7B/)F%Q*SL*]W!
M8NE3G-)[FXQ<DGX\#TV5"-U>4K:3P52<8MK>E*26/T38WFCQ#V;PBW]EVB=F
MQC>?J'?JIB&5QXKL>GS_  :>^XG'\PI?,-1$A]+:VI+!.+.-*;?C+4I;*C/3
MN6_,').9NE+?5.22P51<-:DVG.A7BEVE&?ABVG&6"XX.,TDI(V?76B\VT%J.
MMI[-5BX>53J)81K4FWP5(^!X826+X9J4&VXFJ0WPT\GG]$?U0'.'FT$:%W+?
M+;XT[;O6"*SL9"O=-0[!G]D&)F+2W#[6JF?T:BWJ#Z):)+,XC23$A$B*W>8Y
M(+F'D?[5:<I8YUE\'Y,5MNZ$<9.B^NK3VRH/?+&5+!\<'"1'(7FR]$YM^SN>
M5,,JO9KRI/9;5G@E5\%.>R-7H7DU-G#)2OI-N-O-MO,N(=:=0EQIUM25MN-K
M3W(<;6GJ1I,C(R,CZ&0JME%Q;C)8-;&GT%AZ:DN*.U,_L?P_H %'3XFK\>+3
MOYJ6(?A>S86==RGYL<Q_6E7\4LR ?>K^7]C^KZ?XS=%<X3"(QEM+X6G]W\X/
MWGQQ_;LZ$!>_+]ATQX\P]"R)D]T?[)G_ (K+T;LMU"OTF> !6<^)1Y42L T/
MK/BOC-DJ-;[SNW\PS]$9TTNIUQK^8P[55,M!&1DW9WCD=]M1=>OU,=0HNBO&
M:?<RT+3S;55[KJ]AQ4\K@J-#%;/?%=-2DO#3HJ47]WBUM1%7O2ZOGEVGK32%
MI/">83=2MA]HHM<,7X*E5IK[DT]Y2F%E)!$R/I_5.9[SVE@&G==UIVV;;)RN
MFQ#&X1FI#!V-U,3$1)G/I)7DQ8Z5*D2WU%VM,H<<5T2@S&&U#GV6Z7R*[U%F
M\^SMK*E.K4ET\,$WA%=,I>EC'?*326UF4R3)[[4&;VV299#CN+JI&G!='%)X
M8M]$5OD]RBFWL1TT^&_%'7/"WC[@NA-;1FEPL;@IEY/DBHK4:TSK-[!I"\FS
M.Z-!J4;TQY/1EM2UE'C(8BMJ\IALBI4YBZ\SCF3JVZU5G,GQ5I84J>+<:%&+
M?9T8>""WM)<<W*HUQ29:OHC1^5Z%TW;Z=RM>326-2>&$JM5X=I5EX9/<L7PQ
M48)X11M$-'-M       ]#D>+8QF%<W49;CM%E%2U95-RU69%4P+JO;MZ"R:N
M:*T1"LFW6RD0IC#,J(^2>]IYM#C9I6E)EZK.^O<NK.XR^M.A4<9P<J<Y0EP5
M(N$XXQ:?#.$G&4=THMIIIM'GNK.TOJ2HWM*%:"E&7#.*E'BA)2A+"2:XHR2E
M%[U))K:CWP\IZ          #_]>_P *A7Q2?_P >X3__ "CD#_[YAHL&[C?^
M5U+]78>A>$+>]O\ YC(?J;ST;8J<">Q#DL>_#)?CI;K_ #7LA_"OB0ASWU_F
MVRW]9T_Q6[)/]U/Y=W_P"?XQ;'H/7R].C^SGN+^U1JFB]WTIO6_DJR^NK8W9
M7Z\W!-2Y8V4<FFB[68&0I0_8PR+YK<I,U@B::]U;5ZNZGS@_;'3O["Y]5QS/
M*Z:[*4GY5Q:1PC%X]-2WQC3GTN#IR\J7:->?O%<LOV8SO]K\GIX6&83?:1BM
ME&Y>,I+P0K;9QZ%-3CL7 G7A$O"-!*;Z2//RPX&\G:JZR*?+5HK::JW"MU5+
M?FO-0ZE4I14.P(L1KJ:I=!(><D&24*6Y#<FQVT^8^A2>&<_^5%+FIHFI;6<%
M^5+'BK6<]B;GAY=!M[HUXI1VM)5(TYMX1:?7>3/,:IR\U9"O<R?Y/N^&E=1W
MX1Q\BLEZZBVWL3;@ZD5MDL.BRB^HW:)&3MW-6O&G*E-\C($SXITJZ-</ZH)N
M4VA+\@XIQ_V<I'?V>7\_N[?$4^NUNHW3LG3DJREP=GPOCX\>'@X<.+BXO)X<
M,<=F&)9JKBW=O[[4X]EP\?'BN'@PXN+BW<.&W''##;N.=GZO//\ F<[^3=E.
MQ>QDGH74J[/#-,UJC=:CVL/WI*<CV-(C.=#3(OGV&W6NY"5MP683*T$ZVZI=
MOO=]Y3T^5FB84KZ"_*N8<-:\EL;B\/:[=/UM",FG@VG5E4DGPN*59O.GF/4Y
MA:KE4M)/\G67%2MH]$ECY=9KUU9I-;$U3C"+6*>,4H[P<?+-'P^7ISGMC8">
M;.VZ'S=;ZKNG(6EJFSC=8V8;3KE%[SF26GRZ.PL;49>ZN$DTKM#2I"R77/(5
M"KO;<X?R#E/[M-/U<+R_@G>2B]M&VENHXK=.X]4MZH8IK"M%J5?=MY8_EC,O
MV\SFGC:V<L+6,ELJ7$=]7![X4/4O<ZN&#QI21C+XEW\?;6WYJ> ?A4S89ON7
M?-5>?K2O^*V9BN]1\XEK^KZ/XQ=%>02Z(TEKOX6_^=O,[['-&?7/*A WOQ_F
M_3?W2]]C:DP^Z3_G,]^HM/97!<!%>I-4 "!'XCK]'C$^[_K3ZS7@E7W.OG>E
M\ N?9T2.W>>^;1?#*'L:I0Q%J)7@;]^EG8U]1ZAW$:SMI\.LKH6XZ!^986$I
MB%"B,I:>[GI,N2I+;:2^52E$0Y1SSHUKCE%J"C0@YSE:5$HQ3<F\5L26+;\1
MT;E'5IT>9>2U:TE",;F#;DTDEMVMO8CH^?TP:D_ZI:Z_YVQG^%"G+]GL_P#]
M#<?>:GUI9_\ EK)O]71^^P^N'],&I/\ JEKK_G;&?X4'[/9__H;C[S4^M'Y:
MR;_5T?OL/KA_3!J3_JEKK_G;&?X4'[/9_P#Z&X^\U/K1^6LF_P!71^^P^N']
M,&I/^J6NO^=L9_A0?L]G_P#H;C[S4^M'Y:R;_5T?OL/KA_3!J3_JEKK_ )VQ
MG^%!^SV?_P"AN/O-3ZT?EK)O]71^^P^N/Z;VYJAUQ#36SM>..N+2VVVWFF-K
M<<<6?:A"$)DF9F9GT(B]H_CT_GT4Y2L;A)?]FI]:?U9SD[>"NZ+;_P"[#ZXR
M&,09(   *.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D ^]7\O[']7T_P 9
MNBN<)A$8RU)\+M_67R\^P74_U_NA!7OP_F73WW>Z]SHDO.Z7^=<Z^Y6_LZI<
M8%=I-P      #"O([26-<D-#[9T5ES++E%M'!K[$WGWVO.*KGSX:CH[]A'_M
MZV<F-/C*_6NLH5\@V71VIKW1NJ;#5.7MJK8UX54D\.*,7Y=-_2U(.5.77&31
M@M3Y#:ZHT]>:>O4NSNZ4Z;;V\+:\B:\,)\,X^&*.61DV.VV(9'D&)W\54&]Q
MB[M<=NH2_%<.VI9[E;8Q5']%MYI:#_[!>=97EOF%G1O[27%2KPC4@^N$XJ47
MYJ:949=6U:RNJEG<+AJ4I2A)=4HMQDO,:9Z0>D\YT$/0!W!)VKZ<>!4EA*5,
MLM+9UGFHY#[J^Y\X4*<SG./L++KX)CUM]$B->!%Y;*2\3(S.I?O8:>AD7.*Z
MN:4>&&94*%VDMW$XNA4?CE4H3F_#)ED/=QSN><<L+>A4?%*PJUK9OIP356"_
MHPJQBO!%$U@C6=W  YI7JN_I&^87W9\A_:F1=#R&^9W3OP.GZ+*L.</SG9W\
M*G_(1\#K9S8OG?#B_H\9?W?]E_6:C%5W?%^=Z/P"V]G6+#^[#\VC^&5_8TB>
MX14)$@ <XOUG]NR-P^I'R4L#E*?J\"R>!J*DC]_>W7Q]9T[&,745H^I]"7<-
M6<E1?(MU1> N*[M^GX:=Y-9+1X<)W=.5W-^N=S.56#?BHNG%>"**P^>>=2SO
MFCFM3'&%O45M!=2H15.2\VHIR\;9%N.Y'(RTG\,EQ[A9#M/?O)FZ@H?/7&-T
M>KL'>?:)Q#5[GCKMQEME"69?L<B+7U\6)W$?4VK!U/L48@WWU]75;3(LIT5;
M2P]^5)W-9)[X4$H4HOKC*I4E+#UU&+Z"6_=2TW3N<WS'55>./O6$*%)OU];&
M522ZI1A",?J:C727*17.3A                  "*OUD^6_]D?@WLFYH[/W
M#9>VFU::UF;+WESHMOF,%YO(<CBJ;/S&U55,W83&)!)-*)914*,C=2.Z]W30
M'[P.9]E;74..RL/\9<XK&+A1DNSIOH?:UG3A*.]T^T:]*SD//#6?[&: NJ]O
M/ANKS_#4,'M4JJ?'-=*[.DIR3W*? GO1SEQ<.5BFW? _C%9\PN6.F-!0VY15
M&795'EYQ/B]Z%T^NL>0J^SJR3(3X-.E6QWVHBEF1*DN,-D?<M)'S[FGK:AR\
MT%F6JZC7:6])JC%^KN*GM=".'2NTE%SPW04I;DS=.7FDZNMM8V.G()\%:HG5
M:]31AY=66/0^"+4<=\W%;V=/&HJ:R@JJRBI8,6KIJ6OA5-360F41X5=65T9,
M.!!B,-]$H:9:0AMM"2Z$DB(O8*2KBXKW=>=U<S<ZE63G.4GBY2DVY2;Z6VVV
M^EEK]&C2MZ,+>A%0A3BHQBE@HQBL$DNA)+!(B1];OB5_:FX,9W-H:SW[9.A5
M.[HP8V&>^?,AXY <3GV.L&@C<64RD5+>:C-D9O2XT-/0S)/3OW=FU_\ L-S0
MM:5U/ALLUPLZ^+\E.I)=A4?0N"MPIR?I:<ZCZSC7/O1O[7<O[BI;PXKK+L;J
MEAO:@GVT%TOBI<345Z:<8'/!%O!6B;,<..1]_P 2>36G.0>/^\O+UWF$&?>U
MD59(=O\ #+%"J;-\=(U&2>Z=4R)D9M2^I(<6ASIU00TKF+HZTU_HK,=)7>"]
M^491A)[J=:.$Z-3K\BK&$GAO2:Z3:]$:HN=&ZKL=26V+][5$YQ7JZ4O)JP_I
MTY2BL=S:?0=07%,HH,XQ?&\TQ6SC76+Y?04^48W<PU&N);4-_7MVM/9Q5GTZ
MMOQW6W4'T]BB%(=_8W>67U;+;^#I5[>I.E4@]\)TY.,XOPQDFGX46R6=W;7]
MI2OK.:J4:T(U(26Z4)Q4HR7@:::/?CR'I     *#/Q$_Z1NV^XQJW]IG"UGN
M@?,[3^&7/HP*ZN\S\Y\_@UOZ$B"D2C(^%P#X6_\ FGS/^R+1?UMRL5Z]^/\
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M6=OA@OQA^3'W&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I
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MKM:TUA[XK7%1>)5'2_\ TWZ)-@(U'>              I1?$[?C3<>?N /\
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M5;BHWXWQKS$BPGNNVL*'+BK72VU[VM)OZFG1@EXEPOS6RP((F$CP
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M8+H2)I<CM4Y[K#0=/.M1U_?%S*M6@Y\%.GY,&E%<-*$(;.OAQ?2V2LCA!V
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M"(QEM+X6G]W\X/WGQQ_;LZ$!>_+]ATQX\P]"R)D]T?[)G_BLO1NRW4*_29X
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MGPNW]9?+S[!=3_7^Z$%>_#^9=/?=[KW.B2\[I?YUSK[E;^SJEQ@5VDW
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MD;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O_FGS/\
MLBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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ML7-?N[\H+BPJ0U_J:DX5'%^\Z,UA**DL'<3B]J;BVJ*>W!NIAMILM;B!Q,$
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M*+G57]&O4JQ?A197W>LBGDG*^RG5CPU+V52ZDO!4?#3?]*C3IR\TF)$=SMH
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M"%:$(+PUB5?=7U/3L-27NEKB6"OZ<:E+'IJT.)RBO#*E.4GX*1=7%:Y.T
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MS\1/^D;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O\
MYI\S_LBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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M'@_1O8U]US:OUT8%47>\^>2O\$M?8R+&>[1\U]+X1<>R1.6(P'?P .6QS/\
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ME"*WX';.[]JBGIGF1:QN9<-#,(RM)M[DZCC*D_-K0IQQZ%)G0W%1198
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MGG',KZ&$HPX<+:E);G&,MM62>Z=1**V-4U)*18,$2B2(
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M7R"XEPT\THX1\-:AQ3@NK;3E62ZY.*6UEZ 5?%@0
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M%)'T(\AZ0 .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#\YV=_"I_R$?
MZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE?V-(GN$5"1(
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M-*4I0X9'=WWFG^Q^=?LQG53#+;^:X92?DV]P\(QGB]BIU-D*G0GP3;2C/&^
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M_K-1BJ[OB_.]'X!;>SK%A_=A^;1_#*_L:1/<(J$B0   CA]2GTY];>H9IO\
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M:=@7=YYI_M5E'[(YW4QS"Q@NSE)[:]O'!)XO?4I;(SZ90X9^4^-JPT(BDE@
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MW-G,H%UI5. !UL*_]P0?WG&_:4B@>M]FGXWZ)<K3^QQ\2] \P?,_8
M 4@/B;?QTM*?FO8]^%?+19MW*/FVS+]9U/Q6T(#=ZSY=V'P"'XQ<E<(3&(P$
MR'H'?I0=$_8[N7\#]V(Z=ZSYD,T^Z6?XW1.X=W7YV<O^HN?Q:J="P5'%E
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ME^.ENO\ ->R'\*^)"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y
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MY<LJTY:PMJ*VOA6,IO=Q5)O&=27TTVWAL6"P1G@:L;"   '+8YG_ (X?*_\
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M3DMO"VMJ2PC3@L$NMOIE)[Y2DW*3VR;;Q,C##F3  YG_ *I_Z17F+]W/,?\
MWI(NEY%_,_IWX%1] JMYN_.;G?PNKZ)H&.KG.2V]\+-__'5__K'_ /O"$ >_
M-_\ NO\ _P!R_P#V F9W1O\ ]X/_ )'_ /;"V\( DS#_U[_  QQGVG-1;675
MN;1U7KC9+E&F8BE7GV#XQF*Z=%B;2K!%6K(HLDXY/FPR;Q-=O?Y:.[KVIZ9G
M*=1:@R%5%D=_<62JX<?85JE'CX<>'B[.4>+AXGACCAB\-[,7F.1Y+G#@\WLZ
M%TZ>/#VU*G5X>+#'AXXRPQP6.&&."QW&//[('$O\EWCK]Y/6G\6#+_O#U_\
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MO3N:5_?69V%M<U<$N.K0I5)8+<N*<6\%T+'8?)_V0.)?Y+O'7[R>M/XL'O\
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M"#]BM&_HBR^*T/P9L21$DB2DB2E)$24D1$1$1="(B+Y!I[;;Q9L^[8C_ $
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MRF79)DV3\?Y(M*-KVF''V-*%+BX<>'BX(QXN'BEACCAB\-[,BC#F3/_0O\
M
M
M
M
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M%QH/2T[O-X<&89BXU*L7OI4XI]E2?TRXI3FNB4^!^DQ<TXC:=V
M
M/__1O\
M
M
M
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M!5HW]I2E=WL=UQ<82E!]=*"2A3\$DG42V<;39*L.$G7P
M                                                       /_]*_
MP
M
M
M
M
M                                  __T[_
M
M
M
M
M
M            #__4O\
M
M
M
M
I                                                   /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>md-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-10-31T08:44:40.3837+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mednax.com/20240930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:md="http://www.mednax.com/20240930" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
        <link:definition>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical">
        <link:definition>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" id="StatementConsolidatedStatementsOfShareholdersEquityUnaudited">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>995455 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" id="DisclosureCoronavirusPandemicCovid191">
        <link:definition>995465 - Disclosure - Coronavirus Pandemic (COVID-19)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
        <link:definition>995475 - Disclosure - Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
        <link:definition>995495 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations" id="DisclosureBusinessCombinations">
        <link:definition>995505 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses" id="DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses">
        <link:definition>995515 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>995525 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" id="DisclosureLineOfCreditAndLongTermDebt">
        <link:definition>995535 - Disclosure - Line of Credit and Long Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
        <link:definition>995545 - Disclosure - Common and Common Equivalent Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
        <link:definition>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
        <link:definition>995565 - Disclosure - Common Stock Repurchase Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995575 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>995585 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
        <link:definition>995595 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995605 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
        <link:definition>995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
        <link:definition>995635 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" id="DisclosureBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995645 - Disclosure - Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" id="DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
        <link:definition>995655 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
        <link:definition>995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
        <link:definition>995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
        <link:definition>995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
        <link:definition>995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
        <link:definition>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
        <link:definition>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
        <link:definition>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" id="DisclosureBusinessCombinationsAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Business Combinations - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" id="DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
        <link:definition>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" id="DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
        <link:definition>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" id="DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Common and Common Equivalent Shares (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" id="DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails">
        <link:definition>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CoverPage" xlink:href="md-20240930.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="md-20240930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="md-20240930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:href="md-20240930.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:href="md-20240930.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="md-20240930.xsd#StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="md-20240930.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation" xlink:href="md-20240930.xsd#DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:href="md-20240930.xsd#DisclosureCoronavirusPandemicCovid191" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments" xlink:href="md-20240930.xsd#CashEquivalentsAndInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements" xlink:href="md-20240930.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:href="md-20240930.xsd#AccountsReceivableAndNetRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations" xlink:href="md-20240930.xsd#DisclosureBusinessCombinations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:href="md-20240930.xsd#DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:href="md-20240930.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:href="md-20240930.xsd#DisclosureLineOfCreditAndLongTermDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares" xlink:href="md-20240930.xsd#CommonAndCommonEquivalentShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:href="md-20240930.xsd#StockIncentivePlansAndStockPurchasePlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms" xlink:href="md-20240930.xsd#CommonStockRepurchasePrograms" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies" xlink:href="md-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:href="md-20240930.xsd#DisclosureBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:href="md-20240930.xsd#CashEquivalentsAndInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables" xlink:href="md-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:href="md-20240930.xsd#AccountsReceivableAndNetRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:href="md-20240930.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:href="md-20240930.xsd#CommonAndCommonEquivalentSharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:href="md-20240930.xsd#DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:href="md-20240930.xsd#DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:href="md-20240930.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:href="md-20240930.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:href="md-20240930.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:href="md-20240930.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="md-20240930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:href="md-20240930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:href="md-20240930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:href="md-20240930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:href="md-20240930.xsd#DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:href="md-20240930.xsd#DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:href="md-20240930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:href="md-20240930.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:href="md-20240930.xsd#DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:href="md-20240930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:href="md-20240930.xsd#DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:href="md-20240930.xsd#DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:href="md-20240930.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:href="md-20240930.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ChangeInRateOfControlPremium" xlink:label="md_ChangeInRateOfControlPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NonCashCharge" xlink:label="md_NonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ChangeInNonCashImpairmentCharges" xlink:label="md_ChangeInNonCashImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalNonCashCharge" xlink:label="md_IncrementalNonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash outflow to term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued salaries and bonuses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries and Bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net decrease in accrued salaries and bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation And New Accounting Pronouncements Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and New Accounting Pronouncements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on finance lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transformational and restructuring related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal Home Loan Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes Payable, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued salaries and incentive compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased during period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Other Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit facility, available balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US States and Political Subdivisions Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Senior Notes, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financing receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under employee stock purchase plan Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service, Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in valuation allowance deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of multi location pediatric urgent care practice acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Multi Location Pediatric Urgent Care Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other multi location pediatric urgent care practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateJointVentureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Joint Venture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Seven Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Percentage of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash Equivalents and Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInRateOfControlPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Rate of Control Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anesthesiology services medical group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anesthesiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options, maximum years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Borrowings on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings on revolving credit line</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Long-Term Debt, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under employee stock purchase plan shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number Shares issued under Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entire disclosure of common stock repurchases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Repurchases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Repurchase Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash on hand</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of financial instruments measured at carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Measured At Carrying Amount Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial Instruments Measured At Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pediatric or thopedic practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pediatric Or thopedic Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other pediatric orthopedic practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retained earnings and accumulated other comprehensive income [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings And Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retained Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition payments, net of cash acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grants and awards under Stock Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Interest Rate Risk Exposure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net patient service revenue by type payor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Patient Service Revenue By Type Of Payor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net patient service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in earnings of unconsolidated affiliate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party Payor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Third-Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plans and Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Increase Decrease In Salary And Wage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increase Decrease In Salary And Wage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease In Salary | %</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized holding gain (loss) on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding (loss) gain on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt and capital lease obligations excluding long term line of credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment and other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investment and other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withheld to satisfy minimum statutory tax withholding obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mutual funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mutual Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mutual funds fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental loss on sale, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method ownership percentage in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll taxes and benefits current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes And Benefits Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll taxes and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax (provision) benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Practice salaries and benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Salaries and Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice salaries and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition consideration paid in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured note issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coronavirus Pandemic (COVID-19)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from maturities or sales of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Supplies And Other Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice supplies and other operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand eight plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand Eight Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2008 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">non-cash charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">non-cash charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non cash charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable and net revenue disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable And Net Revenue Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1996 non-qualified employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GAAP Senior Notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares Not Included Due To Anti dilutive Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares not Included Due to Anti dilutive Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental shares not Included due to anti dilutive effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of maternal fetal medicine practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Maternal Fetal Medicine Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Common Equivalent Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5.375% Unsecured Senior Notes Due 2030 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five point three seven five percent unsecured senior notes due two thousand thirty member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, aggregate shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Other Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate, effective percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six point two five percent senior unsecured notes due two thousand twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% Senior Unsecured Notes Due 2027 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash provided by operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">North American Partners In Anesthesia [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North American Partners In Anesthesia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax adjustments, sttlements and unusual provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities - continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of refund of income tax at the prior period corporate tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of refund of income tax at the prior period corporate tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accrued periodically</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty tax year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Liabilities Arising from Contingencies, Amount Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued liabilities excluding accrued income taxes current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums, discounts and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized for repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of market value of common stock at which employees are permitted to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Self-Pay [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private-Pay Patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hospital contract administrative fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain on investments, net of tax of $571, $-, $657 and $100</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in Non Cash Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Non Cash Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ChangeInNonCashImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care, Patient Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net patient service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company's Common stock repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Remaining Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalNonCashCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Non Cash Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivables [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock; $.01 par value; 200,000,000 shares authorized; 85,865,841 and 84,018,023 shares issued and outstanding, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% Unsecured Senior Notes Due 2027 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Twenty Five Perecent Unsecured Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Twenty Five Perecent Unsecured Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of common and common equivalent shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted Managed Care</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of dilutive common share equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Allowance for contractual adjustments and uncollectibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts payable and accrued expenses, total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PaymentsToTermLoan" xlink:to="md_PaymentsToTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CovidNinenteenMember" xlink:to="md_CovidNinenteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RadiologyServicesMedicalGroupMember" xlink:to="md_RadiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyThreeMember" xlink:to="md_TwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureTwoMember" xlink:to="md_UnnamedCorporateJointVentureTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="md_ScheduleOfFinancingReceivablesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseInDeferredTaxAssets" xlink:to="md_IncreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentySevenMember" xlink:to="md_TwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ChangeInRateOfControlPremium" xlink:to="md_ChangeInRateOfControlPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AnesthesiologyServicesMedicalGroupMember" xlink:to="md_AnesthesiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredLongTermDebt" xlink:to="us-gaap_UnsecuredLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RuralAreaMember" xlink:to="md_RuralAreaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockRepurchasesTextBlock" xlink:to="md_CommonStockRepurchasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_ExtraordinaryItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricSubspecialtyPracticeMember" xlink:to="md_PediatricSubspecialtyPracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfInterestRateRiskExposure" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MaternalFetalMedicinePracticeMember" xlink:to="md_MaternalFetalMedicinePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MoneyMarketFundsFairValueDisclosure" xlink:to="md_MoneyMarketFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MutualFundsFairValueDisclosure" xlink:to="md_MutualFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSalariesAndBenefits" xlink:to="md_PracticeSalariesAndBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoZeroThreeZeroMember" xlink:to="md_TwoZeroThreeZeroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NonCashCharge" xlink:to="md_NonCashCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureOneMember" xlink:to="md_UnnamedCorporateJointVentureOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GaapSeniorNotesMember" xlink:to="md_GaapSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:to="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesInContinuingOperation" xlink:to="md_IncrementalSharesInContinuingOperation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_ExtraordinaryItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PrimaryBeneficiaryMember" xlink:to="md_PrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditAndLongTermDebtTextBlock" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PurchasePrice" xlink:to="md_PurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentMember" xlink:to="us-gaap_GovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyTaxYearMember" xlink:to="md_TwoThousandTwentyTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DebtInstrumentMaturityYear" xlink:to="md_DebtInstrumentMaturityYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsDomain" xlink:to="md_DeferredTaxAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfPayMember" xlink:to="us-gaap_SelfPayMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_HospitalsContractsMember" xlink:to="md_HospitalsContractsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ChangeInNonCashImpairmentCharges" xlink:to="md_ChangeInNonCashImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCarePatientServiceMember" xlink:to="us-gaap_HealthCarePatientServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalNonCashCharge" xlink:to="md_IncrementalNonCashCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CreditAgreementMember" xlink:to="md_CreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContractedManagedCareMember" xlink:to="md_ContractedManagedCareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSalariesAndBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_PaymentsToTermLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockRepurchasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="md_CashEquivalentsAndInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="md_ScheduleOfFinancingReceivablesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NonCashCharge" xlink:label="md_NonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalNonCashCharge" xlink:label="md_IncrementalNonCashCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ChangeInRateOfControlPremium" xlink:label="md_ChangeInRateOfControlPremium"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ChangeInNonCashImpairmentCharges" xlink:label="md_ChangeInNonCashImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_NonCashCharge" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_IncrementalNonCashCharge" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_ChangeInRateOfControlPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_ChangeInNonCashImpairmentCharges" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesInContinuingOperation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" xlink:label="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LineOfCredit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxReceivable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSalariesAndBenefits" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_PaymentsToTermLoan" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="21" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20240930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="md_NumberOfPediatricOrThopedicPracticesAcquired" name="NumberOfPediatricOrThopedicPracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_MutualFundsFairValueDisclosure" name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_TwoZeroThreeZeroMember" name="TwoZeroThreeZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockLineItems" name="CommonStockLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_DeferredTaxAssetsDomain" name="DeferredTaxAssetsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfMaternalFetalMedicinePracticesAcquired" name="NumberOfMaternalFetalMedicinePracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_GaapSeniorNotesMember" name="GaapSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_HospitalsContractsMember" name="HospitalsContractsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PrimaryBeneficiaryMember" name="PrimaryBeneficiaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_RadiologyServicesMedicalGroupMember" name="RadiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_DebtInstrumentMaturityYear" name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_MoneyMarketFundsFairValueDisclosure" name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PurchasePrice" name="PurchasePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="md_ScheduleOfFinancingReceivablesLineItems" name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccruedPayrollTaxesAndBenefitsCurrent" name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_NumberOfPediatricGastroenterologyPracticeAcquired" name="NumberOfPediatricGastroenterologyPracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsDomain" name="ExtraordinaryItemsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FairValueDisclosuresTable" name="FairValueDisclosuresTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" name="DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RepaymentsOfLongTermCapitalLeaseObligation" name="RepaymentsOfLongTermCapitalLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_PediatricSubspecialtyPracticeMember" name="PediatricSubspecialtyPracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ContributionsInAidOfReimbursementOfLostRevenue" name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureOneMember" name="UnnamedCorporateJointVentureOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CreditAgreementMember" name="CreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AnesthesiologyServicesMedicalGroupMember" name="AnesthesiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsTable" name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ChangeInRateOfControlPremium" name="ChangeInRateOfControlPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_MaternalFetalMedicinePracticeMember" name="MaternalFetalMedicinePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" name="NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PracticeSuppliesAndOtherOperatingExpenses" name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ContractedManagedCareMember" name="ContractedManagedCareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PracticeSalariesAndBenefits" name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_TwoThousandTwentyTaxYearMember" name="TwoThousandTwentyTaxYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PercentageIncreaseDecreaseInSalaryAndWage" name="PercentageIncreaseDecreaseInSalaryAndWage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" name="SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" name="PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" name="FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ChangeInNonCashImpairmentCharges" name="ChangeInNonCashImpairmentCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncrementalSharesInContinuingOperation" name="IncrementalSharesInContinuingOperation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsLineItems" name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ExtraordinaryItemsAbstract" name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FairValueDisclosuresLineItems" name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockRepurchasesTextBlock" name="CommonStockRepurchasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_IncrementalNonCashCharge" name="IncrementalNonCashCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect" name="IncrementalSharesNotIncludedDueToAntiDilutiveEffect" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_DeferredTaxAssetsAxis" name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PaymentsToTermLoan" name="PaymentsToTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_CommonStockTable" name="CommonStockTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureTwoMember" name="UnnamedCorporateJointVentureTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CovidNinenteenMember" name="CovidNinenteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" name="FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" name="GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_NonCashCharge" name="NonCashCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_OperatingAndFinanceLeaseRightOfUseAssets" name="OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" name="PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" name="NetOfTaxUnrealizedHoldingGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ExtraordinaryItemsAxis" name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RuralAreaMember" name="RuralAreaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NorthAmericanPartnersInAnesthesiaMember" name="NorthAmericanPartnersInAnesthesiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LineOfCreditAndLongTermDebtTextBlock" name="LineOfCreditAndLongTermDebtTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_AmendedAndRestatedTwoThousandEightPlanMember" name="AmendedAndRestatedTwoThousandEightPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719416400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pediatrix Medical Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,880,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719590768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,831<span></span>
</td>
<td class="nump">$ 73,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">116,621<span></span>
</td>
<td class="nump">104,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">286,897<span></span>
</td>
<td class="nump">272,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,188<span></span>
</td>
<td class="nump">13,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income taxes receivable</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,480<span></span>
</td>
<td class="nump">12,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">528,215<span></span>
</td>
<td class="nump">483,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">41,922<span></span>
</td>
<td class="nump">75,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,239,007<span></span>
</td>
<td class="nump">1,384,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">13,183<span></span>
</td>
<td class="nump">21,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_OperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease right-of-use assets</a></td>
<td class="nump">56,566<span></span>
</td>
<td class="nump">70,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">119,386<span></span>
</td>
<td class="nump">102,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">78,594<span></span>
</td>
<td class="nump">82,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,076,873<span></span>
</td>
<td class="nump">2,219,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">333,493<span></span>
</td>
<td class="nump">350,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt and finance lease liabilities, net</a></td>
<td class="nump">19,276<span></span>
</td>
<td class="nump">14,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">16,992<span></span>
</td>
<td class="nump">21,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">373,080<span></span>
</td>
<td class="nump">388,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">607,445<span></span>
</td>
<td class="nump">618,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">39,940<span></span>
</td>
<td class="nump">47,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">255,263<span></span>
</td>
<td class="nump">251,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">35,618<span></span>
</td>
<td class="nump">34,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">33,035<span></span>
</td>
<td class="nump">30,552<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,344,381<span></span>
</td>
<td class="nump">1,370,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000,000 shares authorized; 85,865,841 and 84,018,023 shares issued and outstanding, respectively</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,010,862<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(279,020)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">732,492<span></span>
</td>
<td class="nump">849,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 2,076,873<span></span>
</td>
<td class="nump">$ 2,219,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718425344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,865,841<span></span>
</td>
<td class="nump">84,018,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,865,841<span></span>
</td>
<td class="nump">84,018,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719252304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 511,158<span></span>
</td>
<td class="nump">$ 506,612<span></span>
</td>
<td class="nump">$ 1,510,555<span></span>
</td>
<td class="nump">$ 1,498,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">364,888<span></span>
</td>
<td class="nump">368,404<span></span>
</td>
<td class="nump">1,091,834<span></span>
</td>
<td class="nump">1,084,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">29,449<span></span>
</td>
<td class="nump">31,319<span></span>
</td>
<td class="nump">92,903<span></span>
</td>
<td class="nump">93,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">58,121<span></span>
</td>
<td class="nump">57,406<span></span>
</td>
<td class="nump">174,884<span></span>
</td>
<td class="nump">174,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,254<span></span>
</td>
<td class="nump">9,211<span></span>
</td>
<td class="nump">25,353<span></span>
</td>
<td class="nump">27,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">18,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,619<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">477,331<span></span>
</td>
<td class="nump">466,340<span></span>
</td>
<td class="nump">1,618,559<span></span>
</td>
<td class="nump">1,379,386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">33,827<span></span>
</td>
<td class="nump">40,272<span></span>
</td>
<td class="num">(108,004)<span></span>
</td>
<td class="nump">118,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(10,126)<span></span>
</td>
<td class="num">(10,374)<span></span>
</td>
<td class="num">(31,033)<span></span>
</td>
<td class="num">(31,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliate</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(8,592)<span></span>
</td>
<td class="num">(9,440)<span></span>
</td>
<td class="num">(26,665)<span></span>
</td>
<td class="num">(28,320)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">25,235<span></span>
</td>
<td class="nump">30,832<span></span>
</td>
<td class="num">(134,669)<span></span>
</td>
<td class="nump">90,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (provision) benefit</a></td>
<td class="num">(5,794)<span></span>
</td>
<td class="num">(9,441)<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
<td class="num">(26,612)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">19,441<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
<td class="num">(129,549)<span></span>
</td>
<td class="nump">63,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized holding gain on investments, net of tax of $571, $-, $657 and $100</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="nump">$ 21,186<span></span>
</td>
<td class="nump">$ 21,392<span></span>
</td>
<td class="num">$ (127,544)<span></span>
</td>
<td class="nump">$ 64,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">83,891<span></span>
</td>
<td class="nump">82,543<span></span>
</td>
<td class="nump">83,223<span></span>
</td>
<td class="nump">82,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">84,523<span></span>
</td>
<td class="nump">82,950<span></span>
</td>
<td class="nump">83,223<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719772208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Of Tax, Unrealized Holding Gain (Loss) on Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NetOfTaxUnrealizedHoldingGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676714103312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 983,601<span></span>
</td>
<td class="num">$ (3,735)<span></span>
</td>
<td class="num">$ (89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">14,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">983,601<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
<td class="num">(89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">63,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">967,985<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">995,847<span></span>
</td>
<td class="num">(3,517)<span></span>
</td>
<td class="num">(25,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">28,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">942,375<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">991,630<span></span>
</td>
<td class="num">(3,518)<span></span>
</td>
<td class="num">(46,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">21,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">967,985<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">995,847<span></span>
</td>
<td class="num">(3,517)<span></span>
</td>
<td class="num">(25,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (129,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 732,492<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,010,862<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="num">(279,020)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(153,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">706,461<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,006,018<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
<td class="num">(298,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">19,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on investments, net of tax</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 732,492<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,010,862<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (279,020)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724037280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (129,549)<span></span>
</td>
<td class="nump">$ 63,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">25,353<span></span>
</td>
<td class="nump">27,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">20,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">10,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,129<span></span>
</td>
<td class="nump">9,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(15,880)<span></span>
</td>
<td class="nump">10,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(2,006)<span></span>
</td>
<td class="num">(1,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">22,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,945<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">30,569<span></span>
</td>
<td class="nump">13,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(34,154)<span></span>
</td>
<td class="num">(56,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">7,527<span></span>
</td>
<td class="num">(5,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">13,239<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(22,032)<span></span>
</td>
<td class="num">(16,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities - continuing operations</a></td>
<td class="nump">82,445<span></span>
</td>
<td class="nump">73,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="num">(8,882)<span></span>
</td>
<td class="num">(5,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">73,563<span></span>
</td>
<td class="nump">68,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(8,167)<span></span>
</td>
<td class="num">(1,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(54,402)<span></span>
</td>
<td class="num">(26,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">45,324<span></span>
</td>
<td class="nump">16,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(18,582)<span></span>
</td>
<td class="num">(24,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets', window );">Other</a></td>
<td class="nump">2,359<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(33,468)<span></span>
</td>
<td class="num">(35,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">235,500<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on line of credit</a></td>
<td class="num">(235,500)<span></span>
</td>
<td class="num">(474,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PaymentsToTermLoan', window );">Payments on term loan</a></td>
<td class="num">(9,375)<span></span>
</td>
<td class="num">(9,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_RepaymentsOfLongTermCapitalLeaseObligation', window );">Payments on finance lease obligations</a></td>
<td class="num">(2,045)<span></span>
</td>
<td class="num">(2,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">52<span></span>
</td>
<td class="num">(8,445)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(9,522)<span></span>
</td>
<td class="num">(20,968)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">30,573<span></span>
</td>
<td class="nump">11,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">73,258<span></span>
</td>
<td class="nump">9,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 103,831<span></span>
</td>
<td class="nump">$ 21,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PaymentsToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PaymentsToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_RepaymentsOfLongTermCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Capital Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_RepaymentsOfLongTermCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725842432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 19,441<span></span>
</td>
<td class="num">$ (153,025)<span></span>
</td>
<td class="nump">$ 4,035<span></span>
</td>
<td class="nump">$ 21,391<span></span>
</td>
<td class="nump">$ 28,282<span></span>
</td>
<td class="nump">$ 14,206<span></span>
</td>
<td class="num">$ (129,549)<span></span>
</td>
<td class="nump">$ 63,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725619744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718483168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718343184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.833%;box-sizing:content-box;"></td>
        <td style="width:2.778%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.389%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">116,621</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676815058240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:9pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.444%;box-sizing:content-box;"></td>
        <td style="width:2.222%;box-sizing:content-box;"></td>
        <td style="width:12.222%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.889000000000003%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">116,621</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">388,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">357,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725714640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.29%;box-sizing:content-box;"></td>
        <td style="width:1.075%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.151%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.204%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,469,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,379,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,182,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,106,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">286,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Arial;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.215%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.131%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.222%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.33%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.329%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.442%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">438,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">437,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,293,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,290,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">68,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">215,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">204,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">511,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">506,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,510,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,498,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.197%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.578%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.677999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725698000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5. 	Business Combinations:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company completed the acquisition of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> maternal-fetal medicine practice for total consideration of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was paid in cash at closing and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as a contingent consideration liability. The acquisition expanded the Company&#8217;s national network of physician practices across women&#8217;s and children&#8217;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, fixed assets of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and other intangible assets consisting primarily of physician and hospital agreements of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725844176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  	</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, during the nine months ended September 30, 2024, the Company recorded fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease right-of-use asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested the second practice during the third quarter. The total loss on disposal of these two businesses was $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#8217;s market capitalization, multiplying the number of actual shares of common stock outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#8217;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This assessment resulted in a non-cash impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million that increased the Company's book value. An incremental non-cash charge was required to reduce the Company's book value to its previously determined fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the Company recorded the incremental non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million for a total non-cash charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">154.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million. A </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% change in the control premium used would have impacted the non-cash impairment charge by approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725727536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.            Accounts Payable and Accrued Expenses:	</span></p><div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:9pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.5%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:20%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:20%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">47,367</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,588</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">162,554</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">193,112</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,327</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,545</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,966</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,039</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,262</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,490</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,252</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">333,493</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">350,798</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2023 to September 30, 2024, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718483168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LineOfCreditAndLongTermDebtTextBlock', window );">Line of Credit and Long Term Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">308.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% senior unsecured notes due 2027 (the "2027 Notes"), which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">450</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">218.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line at September 30, 2024. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2024, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LineOfCreditAndLongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit And Long Term Debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LineOfCreditAndLongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725755440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.498%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.178%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.978%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.398%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">84,523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares are not included because the effect would be antidilutive.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725757888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At September 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At September 30, 2024, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2024 and 2023, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676815006464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of September 30, 2024.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718406704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718772560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.833%;box-sizing:content-box;"></td>
        <td style="width:2.778%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.389%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">116,621</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725669728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.444%;box-sizing:content-box;"></td>
        <td style="width:2.222%;box-sizing:content-box;"></td>
        <td style="width:12.222%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.889000000000003%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">116,621</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">388,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">357,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725721104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.29%;box-sizing:content-box;"></td>
        <td style="width:1.075%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.151%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.204%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,469,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,379,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,182,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,106,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">286,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.215%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.131%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.222%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.33%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.329%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.111%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.442%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">438,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">437,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,293,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,290,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">68,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">215,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">204,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">511,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">506,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,510,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,498,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.197%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.578%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.677999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718471360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.5%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:20%;box-sizing:content-box;"></td>
        <td style="width:1.25%;box-sizing:content-box;"></td>
        <td style="width:20%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">47,367</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,588</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">162,554</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">193,112</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,327</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,545</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,966</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,039</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,262</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,490</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,252</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">333,493</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">350,798</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725754944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.498%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.178%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.978%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.398%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">84,523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82,492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares are not included because the effect would be antidilutive.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676728828352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719208592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Investments Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724585152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 116,621<span></span>
</td>
<td class="nump">$ 104,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">50,602<span></span>
</td>
<td class="nump">57,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">35,105<span></span>
</td>
<td class="nump">22,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">21,508<span></span>
</td>
<td class="nump">14,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">6,673<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719102672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">$ 2,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual funds</a></td>
<td class="nump">18,708<span></span>
</td>
<td class="nump">17,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 116,621<span></span>
</td>
<td class="nump">$ 104,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725701456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - 2030 Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value</a></td>
<td class="nump">$ 388,240<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676718548848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,469,676<span></span>
</td>
<td class="nump">$ 1,379,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(1,182,779)<span></span>
</td>
<td class="num">(1,106,900)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 286,897<span></span>
</td>
<td class="nump">$ 272,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724449712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 511,158<span></span>
</td>
<td class="nump">$ 506,612<span></span>
</td>
<td class="nump">$ 1,510,555<span></span>
</td>
<td class="nump">$ 1,498,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">438,675<span></span>
</td>
<td class="nump">437,321<span></span>
</td>
<td class="nump">1,293,353<span></span>
</td>
<td class="nump">1,290,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">72,413<span></span>
</td>
<td class="nump">68,712<span></span>
</td>
<td class="nump">215,129<span></span>
</td>
<td class="nump">204,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 2,073<span></span>
</td>
<td class="nump">$ 3,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724419776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724613344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Number</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill</a></td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember', window );">Maternal Fetal Medicine Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NumberOfMaternalFetalMedicinePracticesAcquired', window );">Number of Maternal Fetal Medicine Practices Acquired | Number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition total consideration</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition consideration paid in cash</a></td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Business combination consideration identifiable as current and long term liabilities</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfMaternalFetalMedicinePracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of maternal fetal medicine practices acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfMaternalFetalMedicinePracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=md_MaternalFetalMedicinePracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724394528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed assets impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,112<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease right-of-use asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Additional Deferred Tax Assets</a></td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NonCashCharge', window );">Non cash charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncrementalNonCashCharge', window );">Incremental Non Cash Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 154,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ChangeInRateOfControlPremium', window );">Change in Rate of Control Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ChangeInNonCashImpairmentCharges', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge', window );">Good will Impairment Loss excluding Deferred Tax Assets Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ChangeInNonCashImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Non Cash Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ChangeInNonCashImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ChangeInRateOfControlPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Rate of Control Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ChangeInRateOfControlPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Good will Impairment Loss excluding Deferred Tax Assets Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncrementalNonCashCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Non Cash Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncrementalNonCashCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NonCashCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>non-cash charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NonCashCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724981360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 47,367<span></span>
</td>
<td class="nump">$ 34,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and incentive compensation</a></td>
<td class="nump">162,554<span></span>
</td>
<td class="nump">193,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">34,327<span></span>
</td>
<td class="nump">36,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">28,966<span></span>
</td>
<td class="nump">32,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">57,490<span></span>
</td>
<td class="nump">46,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 333,493<span></span>
</td>
<td class="nump">$ 350,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676710937216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 30.6<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724525024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="nump">308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit facility, available balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfInterestRateRiskExposure', window );">Interest Rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember', window );">5.375% Unsecured Senior Notes Due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_DebtInstrumentMaturityYear', window );">Debt instrument, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember', window );">6.25% Unsecured Senior Notes Due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfInterestRateRiskExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the sources of interest rate risk exposure faced by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfInterestRateRiskExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676817855808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,891,000<span></span>
</td>
<td class="nump">82,543,000<span></span>
</td>
<td class="nump">83,223,000<span></span>
</td>
<td class="nump">82,127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">632,000<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,523,000<span></span>
</td>
<td class="nump">82,950,000<span></span>
</td>
<td class="nump">83,223,000<span></span>
</td>
<td class="nump">82,492,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">888,000<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">1,201,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares are not included because the effect would be antidilutive.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676725827008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect', window );">Incremental shares not Included due to anti dilutive effect</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Shares Not Included Due To Anti dilutive Effect</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676719711264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46676724438304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="num">(23,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK3H^8U1+/FQ74ZC]OPCW#5K+>$+NT=$AFH/:,A[9!&PLU$TL ZG2YCI0DR#
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M#.#^4BGS]*%[,[=[$[OX'U!+ P04    "  (.&%9%'T3S]H"   Q"0  &
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MJ/J KCM&ENZ,6TB#)Z9KYOA- \H&X/VEE.:Y8X_-YBLI^0=02P,$%     @
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MK)-KS"W7^D7O28"*%8<Q3W3V.A #6TZQ@'&S\Q$8]V)S*DL1V)ARF"7,TH\
M$\]/!NH>ZY0<<RNYSR>ZY-VF4CO9O QX?UR_HP&P)=8XB!)SY8+!( G,_$=@
M 66>R1YQQGJ[4GWZG;9C;FW7[)G)\S1 &=L:B]I49@B,49Y8C&W8F+(D,)?\
M<P08\C@:6+&Q3MXQM[S[5E8BR^4?4.36*E\V@_XY@V((BD^>9L'Z RDA-E 7
MF]2 CYL@HA_(S1C^PB!J)\D;ZGEHO! 9%UGE$4.9H;(AS/.L^H"@Z%!M[ 0A
M>XL@7/3>@5S.E,#:[H3E>FS.E"B,FW4T16"0*5'@FZH( 8:^-[3'RCI5R$+G
M+JLU.M!-5N:4EG]VE_6JWM*K>IM?RUN_.SJ-RMP:]2&KY0+M@;U==+X@^LBX
MF74HRMQ$0U!C^C$(S93#G TJDDZ/,K<>366^U>C+OH>#Y262*,HB::-0DIBS
M:&A8=?J3)<YA]4O[(KO1F#M07<^BJ3(%5-_]6U1\C#D5[9\>8]?TEE[5V_Q:
MWOHO-3M)S-V2>'",<5N%QCPV9_<9!F.!N2F7HMZ8F<USU!ME QG(.^7+W<K7
M,<RX+31C/[#&&08#$6-J? R&\<2\^8DI[R9G1QX*43VW9TUJ&#[;4N_?7)_N
MGLZS?&I/<1CW'^CMC"+W4WH[WY]6Z=SO#\_\F%7/LJQ)+E;P**@"T-9J?QYE
M?Z'5ICUP\:2T5D7[=2VRI:@: /R^4DH?+YH'G$X%3?\'4$L#!!0    (  @X
M85G8\DOPK0(  !T'   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK55=
M;]HP%/TK5UDU4:EK0D+IUD&D%C:M#Y50&=O#M >37(A5Q\YL ]U^_:Z=D-&6
MHDKK2^*/>X[O/3<^&6R4OC,%HH7[4D@S# IKJXLP-%F!)3.GJD)).PNE2V9I
MJI>AJ32RW(-*$<91U ]+QF60#OS:1*<#M;*"2YQH,*NR9/KW%0JU&0;=8+MP
MRY>%=0MA.JC8$J=H9]5$TRQL67)>HC1<2="X& :7W8MQS\7[@&\<-V9G#*Z2
MN5)W;G*=#X/()80",^L8&+W6.$(A'!&E\:OA#-HC'7!WO&7_[&NG6N;,X$B)
M[SRWQ3!X'T"."[82]E9MOF!3SYGCRY0P_@F;)C8*(%L9J\H&3!F47-9O=M_H
ML ,@GOV N '$+P4D#2!Y#.@] ^@U "]U6)?B=1@SR]*!5AO0+IK8W,"+Z=%4
M/I>N[5.K:9<3SJ8C)8T2/&<6<YA:>E%/K0&U@&N9J1*!R1Q&JJ2/JG#=7N-V
MHS.3;)5S AY#9\(TX0JT/&/B&-[!;#J&SM$Q' &7\+50*T-$9A!:2MH='69-
M@E=U@O$S"29PHXC8P">98[X'/SJ,_W  'Y)8K6+Q5K&K^"#A%*M32*(3B*.X
MMR^?_X./7PY/#E23M/U//%_R#%_3R[;S\.-R;JRFZ_AS7Z]JLMY^,F=1%Z9B
M&0X#^EP,ZC4&Z=LWW7[T<9]0KTDV?B6R!R+V6A%[A]C3F23'%?P/7:%"B9S+
M)2S)<:$CE#''0/;&Y1J-]5?K!"2Y.=TOR^[W25P?U?='.=->IV?GW4&XWE7N
M:4S_[/QAS/AI3#>*VIBZSG#'.$K42V_ !C*UDK:^$>UJZ_&7WMH>K8_(^VNK
M_D=3_SANF%YR:4#@@BBCTW,R0EV;<3VQJO+V-%>6S,X/"_I_H78!M+]0RFXG
M[H#VCYC^!5!+ P04    "  (.&%9;EI7#B$.  #$C@  &    'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;+U=77/CMA7]*QPUTR8SZY@DP*_4]DPB$]/M-.W.
M.IL^=/K E6A+LY*HB-1ZTU]?4-8* G %$<ZQLS.Q;(/G@C@D@',N %\]-IM/
M[:RNN^#+<K%JKT>SKEO_<'G93F;ULFJ_;];U2O[FOMDLJTY^NWFX;->;NIKN
M+EHN+N,P3"^7U7PUNKG:_>S=YN:JV7:+^:I^MPG:[7)9;7[_J5XTC]>C:/3U
M!^_G#[.N_\'ES=6Z>JCOZN[#^MU&?G=Y0)G.E_6JG3>K8%/?7X]^C'X0>=9?
ML"OQZ[Q^;(\^!_VM?&R:3_TW;Z?7H["O4;VH)UT/4<DOG^MQO5CT2+(>O^U!
M1X>8_87'G[^BB]W-RYOY6+7UN%G\>S[M9M>C?!1,Z_MJN^C>-X]_J_<WE/1X
MDV;1[OX?/.[+AJ-@LFV[9KF_6-9@.5\]?:V^[!OBZ(*(G;@@WE\0&Q?$\8D+
MV/X"9ES TA,7\/T%W+B G[H@V5^0F%4Z=4&ZOR#=M?U38^U:^K;JJINK3?,8
M;/K2$JW_L*-K=[5LX/FJ?[+NNHW\[5Q>U]V,FU7;+.;3JJNGP5TGO\C'IFN#
MYCZXFU6;>M8LIO6F_4M0_K:==[\'WWY85=OI7);^+K@(/MS=!M]^\UWP33!?
M!;_,FFU;K:;MU64G:];C7T[VM?CIJ1;QB5K\TG35@KAL[+YLW"R7\NF\ZYK)
MI^ _/]?+C_7FOP3,K1OFQZF\(?F85XO@736?7LA[&5?KN:R2"[0\ SJ9;)?;
MQ:Y=_]7-ZDT@:RM?_EG_5GZN@W\T;>N"%V[X]W4GNPV)?5O?SR?S[@34I7P<
M#L]$?'@FXATV/X']4[6H5I,ZJ#J)/OD^8-&;( [CF.+U"2G=(?6]V.>;O(A2
M)LM^/N:1*!87>IE;NTR1LS2,]&*E7>R"92S12PFB5%Z$*3L4TUJ&'5J&#6F9
M-T_O1CNHA9R(_<#Q0[NN)O7U2#X<;;WY7(]N_ORG* W_2KT/3V")WHX\"\/0
M:$QDU!())D!@&G_\P!]W\O=/.52_74V:91U\V[^ WU&$<:N-(QZ'J?%$.P-Y
MMLDM$JQ$@HESC:'1D!QH2)PT?%C)2=!B_C_9??7CRWSU$#S(WBR0??E\];EN
MN]T8]"982;KD0-157RB>$JMJ:<@-EISU\&4)"58.J+T !=0X2@\<I4Z.]F-K
MNQM;YVV[E61M5W(N$-3+]:+YO:[WOUMO-Y.9G-L%:]DW!K]6BVU-L97:#U)8
M&+WVV%DE7[J&1"R1$04(3.,K._"5O01?[6X@HPASAO,=MS)[W$KM00L9LD2"
M"1"8QFQ^8#9W,OM6DKF;C\FN4*)WF_FDGU3NV*2(<Z+Y$I?;DS*#M-RB]L(H
M4B)K)$!@&A7%@8KBV52\<;Q+3E1?2@K[7<HB^V5"QBR18 ($IC$8A4KPADX.
M1;.YK^?=MI^_#WRCW(B^_.W1-&UBZ*7;?9ECDHTB);12 H6FDW+D0D1_A!37
MN^5&]B8GLKNS."9>+VC8$HHF4&@ZF<H^B-S^P<Z/N>C]OFD@M=:Z7K75SD:L
MO_2?R>GA'O*XW5D8&@/)V!W8=X(X*&8)C2E0:#HURK^(W ;&^_KK]&]'S6'&
M2%)BFPT7669.V=T!O2D9$K.$QA0H-)T294E$;D_B%"7./@^I\<>1+?(O>$%T
M>5"; HHF4&@ZB<K0B-R.QI%E^G.U.1B"C"3/EOY%6&199+Y9B6V:LM3DA #+
MTR)FYBMCE[M@$3-B"JI8QO,DHPV?2+D)D=M.()S3\PV%%.?CR/8#9',R3CSG
MR+@E%$V@T'0:E<D0N5T&G]1 1(A^*C>P+^=.#A!@9': *$>E!ZABCOQ I+1Z
MY!;KS\D0N"&]GW-;D)_($4#CEE T@4+3:50Z/W(+_4&)@LA6XBG+,VO2BA3/
MMU"T$HHF4&AZUE(I^]BM[(\ZI[MZ+=^Y\/38$ML"NTBS(C>GM[$MUG-F92X)
ML"+)>69T3D2Y"Y9$1C%!%8N3*.=TYQ0KE1V[53;1.9UO**B\CFUY+9LS)B:;
MT+@E%$V@T'0:C]+S@_/S9^=0L:UQR<EF3&3HK<DF!49--HERU&23*N:8;,9*
MY<;>:?KS#07-T\=$HIZ>;$+CEE T@4+3:53*. 9DZV-;O,:Y_&<^W]!\/12M
MA**)LPVBLZ$D;OP:2?N8TJ%Y9K(%S=M#T<I!=R!0,76RE-R.7S=['Q/)]*0P
M5UOL2QT/(I'9W9% U@ "U<PH-)T+I9GC5\[,N^-Y#U6V%(YB(CD/C5I"T00*
M36=8B?X8FZ%WPWD3:.?HK;>.2-);ZRJA^AV%IC.B]'O\,HEZ-ZPW,[9!4##B
MS8)*>BB:0*'IRVV5I&=_*%GOHM*-[+WPEM#D$9$6AD8MH6@"A:9SJ=P'YG8?
MGI,69K9?P.3H9,P[W(%]IXN#8I;0F *%IE.C' 7F=A1\TL*,4.V1:2>XXWDS
M,B!D"0TI4&@Z(4?[#)Z7IW=V>-B=!D0FGNKOL!L-L#L-7L*^8,J^8&[[XLBF
M^_MVY799F2W:"QXS:[7%OIQNT^4F)P18GW@+S3>&R/NS)#+@!%6,I\E1W?0&
M4HX"&Y0T/[;ISC<44LN/F:WE97-RZCF'>@A0-(%"TVE47@-S>PV#;#IFZ_XX
M8H4U;D!W $#12BB:.-L@.AO*;6!NMP%CTS'"%#"I0BKX6RA:>;[Z A50ITE9
M!LQM&: -.F8K_"BR?%5VWBJ@@:S9+]0L0*'I7"BS@+G- KA!YX[G/4C9+D(_
M0-E#%-1&@*()%)J^ZU/9"/S%; 0WLB^7G+(1;"JA04LHFD"AZ50J%X'C701.
M*?K4S%ZX WMOZ1T2LX3&%"@TG1KE(G"<B\ I2<^820G41A@4LX3&%"@TG1+E
M(W"\C^"&].[Q*!^!ZO*@1@(43:#0=!*/#BT8;"2<7:[%">U/K6OCE)%@KFNC
MP*AU;40Y:ET;5<RQKHTK(X%[&PGG&PIJ)'#*2"#7M4'CEE T@4+3:51& A^T
M1\!<,TW31ZSFYT68FBJ5VTL2<FYQ8H,5\C_SS(^2*-=O#C2/;:"*1;S@V0EQ
MSY6XYX.6WY]:74ZW%'2U "<6]?,PRHD'':KHH6@"A:;3J,0_=XO_8<?0V$*<
MA^9&AK$[DO<,";HC (HFSK6'SH42_]PM_C%^&2>V H0F5=!] %"T<D#]!2JB
M?F20TO")6\.C';/$EN*YQ5EB+_\W#3,*)S$W$;OOS?=50*'I3"@)GK@E.-PO
M<\?S':(26WE'(3% 0:.64#2!0M,95DH^<2OY/^"7N9&]N20D.W4: S1J"443
M*#2=2V4!)&X+X#F&66*+=A:F9C;!'=AW0!L4LX3&%"@TG1HE[!.WL/<QS!)"
M/.=6@B>Q9;VYT/.61C*UCKOJW@T-0M,;^NB\0;=!\!P;S WIW9$1NP8*8D\N
M-&H)11,H-)U$90\D@^V!X]U<G"2/L >2-"K,E8/)$'N  )-#4%QPZYVA_($H
ML8YU)/V!A+-3QVHJ?R#Q]@?.-Q74'TA(?X"<?D'] 2B:0*'I-"I_(!ETB, @
M>R<AMOM31EABI_Z))]T&(XTPHAQEA%'%7$98HE1[XE;MSS'"W)#>#SIQ#!]M
MA$'CEE T@4+3CYA5FCYU:_I!1EA*G)<7Q47"S8,6W,%\YZ-0M!**)E!H.FW*
M $C=!L!SIE.IK<I-L\4=U9L_J+R'H@D4FLZ?DO?IX ,$CO-DY/0@M0\&R%C,
M"W.#-5'.LL%N4UO.1V$4YJEYN"51\"(VC^839*FL"..0'E]2)9I3[Q,$SK<4
M-&^>$B<()'E*;,R$QBVA: *%IM.H!'8Z.'-^=AZ<VK*8E PID3FW)E($&"T9
MB(*49*"*N21#JJ1QZIT[/]]44&F<$KES6C) XY90-(%"TVD\.JT?L @_I81G
MPL+8.H<?>Q _=!D^%$T,:!*=$:7%T]=8B)_:>CHVWXNQNR;>=$&%^9 ;$*B0
M.E5*;Z>ONQ@_I=;0VW+%5N3F,> TD.F)N^_.^XUXB<7XJ5+VZ2LOQG?'\QZL
MB,7XC%CF!8U:0M$$"DW_.R5*]&=NT>][6H8;SI? C,CHF^><9=0J?7/F!JV6
M0*'IG"A%G[D5_7//RW##>G-#9.Y31FQU@88MH6@"A:8SJ;1]]F*I>S>R-YF4
M.(\)+J&I>RB:0*'I7"H7(L.G[C/;-XB*Q'1KW(%]9XR#8I;0F *%IE.CG(4,
ME[K/*/%NYF?<\;P9&1"RA(84*#2=$.5C9/@4OQO2N\,C4OQ4?P<U,:!H H6F
M<ZA,C&QPAO_X( C2@\ILX9Z%*;?RGAF1X4_,$S,(L"@,T] \"Z,D"E[(KLZT
MZZAB<9$?UTYOHJ._\N>=X3_?5-@_Y4=D^),L(<XU@\8MH6@"A:;3J!R'#+ #
M("/4?\&Y]81#MP! T4HHFCC;(#H;RG/(7F,/0$98 QDWK55W5;S9@MH,@^Y
MH&+J?PQ3V0?YZ^X#R(GU^X6YKC(_OP^ Q#%- _>]^;X/*#2="64:Y*^\#\ =
MSW>@R@DW@?JS5M"H)11-H-!TAI69D+^8F>!&]N:2W+I/< DU$Z!H H6F<ZG,
MA!QO)N2VL.=19*:?W(%]A[1!,4MH3(%"TZE19D*.,Q-R2MF;ZV?&[H#>E R)
M64)C"A2:3HFR$W*\G>"&].[R*#N!ZO*@?@(43:#0=!*5GY /]A/.KM[*;9^
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M7#0*:AB)AA=1:2#N+PGAVXET4+70_C]02P,$%     @ "#AA60!ZCZM# @
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M$RR YTMC_/:&#70?@"[_!%!+ P04    "  (.&%9F;+]H3@#  !?!P  &0
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M-2YX;6RU6-MRVS80_16,TJ8OLFYV[-2Q/6,GO:23S&22MGGH] $BEQ+&(,
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ML6,!O"^L#>T-&^@^9]W\ U!+ P04    "  (.&%9#"TPYIT#  !L"   &0
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M0!42W8_@'&R"A0 EELUG<R1L9':Y!.Z6E,P],P$W#7#XC/L'&\+@HFE)(>.
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MZK&'D"0)1,D41H,P&,$ENX*[FJZ!! 9":MU=C#==AP$$PYC:G! 6G @HI >
MH=1IC\G:/^&]P931#78F<+NE7D_/@%K8#?+Y.3K#EPJQW^N;!:J=>QW8Q*Q+
MT[30;K5[@-PT??=9O'F]?&)JQRDU!6Y)-1A>CSU0S8N@F1A9N2Z\D89ZNAOF
M](A"905H?RNI3+03:Z![EBW_ U!+ P04    "  (.&%9OH!1!<<%  "1$
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MTQ,V# L4Q#]OH.\38WP[80.+_T)<_P=02P,$%     @ "#AA6<B\_H2#!
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ME4L_2]R=R?,"?,\=#D+] P<8;^.;?P!02P,$%     @ "#AA67Y# R7U @
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M)CVU5\;;9A_G+,RR%,:S)!R/V8 E=D-"P?''GF"%"BM!@2E*PB:0Y&&69D\
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M+AT<3AC8;MHZATP3__"%(3\OT:S] X4V!/CSI3'TXH2AZ9^\X@]02P,$%
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M$X#S:R'T8\?4K.Z)2O\ 4$L#!!0    (  @X85G=KER]YP,  #X4   9
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M2@/Q?DD(/]S( >I_9DS^ U!+ P04    "  (.&%9!UIN=A$#  !,"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R55MMNVD 0_961&U6)U&)C+H$4
MD"!IVC[0HJ"T#U4?%GO JZQWG=T%4JD?WUD;'%*,V_* ]S(SY\QX+AYLE7XP
M":*%IU1(,_02:[,KWS=1@BDS#96AI)NETBFSM-4KWV0:69PKI<(/@Z#KIXQ+
M;S3(SV9Z-%!K*[C$F0:S3E.F?TY0J.W0:WK[@SN^2JP[\$>#C*UPCO8^FVG:
M^:65F*<H#5<2-"Z'WKAY-6D&3B&7^,IQ:P[6X%Q9*/7@-I_BH1<X1B@PLLX$
MH\<&KU$(9XEX/.Z,>B6F4SQ<[ZW?YLZ3,PMF\%J);SRVR=#K>1#CDJV%O5/;
MC[ASJ./L14J8_!^V.]G @VAMK$IWRL0@Y;)XLJ==( X4POX)A7"G$.:\"Z"<
MY0VS;#30:@O:29,UM\A=S;6)')?NK<RMIEM.>G8T61LZ,0:N5;K@DKE0&7@+
MXSCF;LT$<%F\?!?$\QNTC(L+.*-CF'(AG/S MT3%&?2C'>RD@ U/P/9AJJ1-
M#+R7,<8O]7URH?0CW/LQ"6L-SC%K0"MX V$0MN%^?@/G9Q?P>9TN4->8;Y5A
M:N7FVR?,?U JWI*W59X6FOU<TQ7!9M1O- ?^I@*N7<*U:^&^V 0U1=@RN>(+
M@<",05L9Y\)0LWD 'S3":OA."=^IA;_E3QC78':./ X:[6K(;@G9K86<,HO:
M9=LM)9B *<8\(A&8:5>W$<+W*;IW^:.*3ZUIU]>N3,8B''K4N SJ#7JCUZ^:
MW>!=369<EL0O:XD7*09J"7]SP< X>EQS3:']59F9A3,%7.<@N">2J5<R[-4R
M+$N<.7B3ES58Y3A&5+P\1IT7=Q697D5N=_LO?M7D^B6Y_O^3>T$+,L9CUVTB
M9I(JCOWC"N@V.M6TFL%S7PS^C5CTW!C_($8K:?F2LZ)"J5UK32? 9 Q"R150
M/J0@Z)X+<@RK^V1P%.+64?WZ!PT^1;W*QYBCMI:VZ/7E:3DJQ\6 >!8OYNR4
MZ16G%B]P2:I!XY(R31>CJ]A8E>7C8J$L#9]\F="X1^T$Z'ZIE-UO'$#Y 3'Z
M#5!+ P04    "  (.&%9VYOTB+<$  #A&   &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6RU65UOVS84_2N$5@P)T$1?_LQL XXE;RG:+4C:[6'8 RW1
M-E&)U$@JSOY]24F1+4NE[8U[B46*]USRG*M+7F:RH^PKWR(DP&N:$#ZUMD)D
M=[;-HRU*(;^E&2+RS9JR% K99!N;9PS!N#!*$]MSG(&=0DRLV:3H>V2S"<U%
M@@EZ9(#G:0K9/_<HH;NIY5IO'4]XLQ6JPYY-,KA!STA\R1Z9;-DU2HQ31#BF
M!#"TGEIS]V[I]I1!,>)WC';\X!FHI:PH_:H:#_'4<M2,4((BH2"@_'E!"Y0D
M"DG.X^\*U*I]*L/#YS?T9;%XN9@5Y&A!DS]P++93:V2!&*UAGH@GNOL%50OJ
M*[R()KSX"W;56,<"4<X%32MC.8,4D_(7OE9$'!A(G&X#KS+PC@UZWS'P*P/_
M7(->9= [=TK]RJ!_KH=!93 HN"_)*I@.H("S":,[P-1HB:8>"KD*:TDP)BJR
MG@63;[&T$[.?*8UW.$G>@X^4;&X^2IEC,.=<QO1#FD',9!0)#B")Y0#.@0R&
M /.,<I@ N@;W.9> <C@'5_,XQBI:Y)L'4L:\;%V#JP )B!-^#6[ E^< 7+V[
M!N\ )N#SEN9<(O.)+>12U(3LJ)KV?3EM[SO3]L$G2L26@Y#$*.ZP#_7V8XV]
M+2FL>?3>>+SWM(#/*+L%OO,>>([7ZYC/0F_^(2=:\^!\[WX7&_]M\LM_[;W!
MI5_'I%_@^2=BLHBZ!R(@V>!5@LJPY"K^HH3RG"'PYWS%!9/9Z:^N$"J]]+J]
MJ)1]QS,8H:DE<S)'[ 59LQ]_< ?.3UWZF00+3(*%)L&6AL :NO=JW7LZ]-D2
MO\KD TN5\3[[=&E;(@T*)+5[OLR<B?UR*)C6UZ6"G707MD=XCNMZS5%+'4Z#
MLW[-65_+V<'G<1YQ)5Q?0YS6X:7$G707MD<,!\/Q$6\ZF 9O@YJW@9:WWS+$
MY/Y$-B!!\F "F#J!W-#U3<XK)D\1J<6_-+N8! M,@H6#%O.N,W".1%P:<MF0
M<EA+.=1*>7#N"- :,2:3R&?X6FT77=(-6VOR>M[QFA9:KY=J8A(L/&O^2T,N
M&YJ,:DU&6DW>SHKQP5EQ59\5NS09M=;4/TH"BU$K>7:$8M &.LXX[1&N,_:/
M4[4.I\')N.9DK.7D5\E'!/D61%O(-MTL:!$N32HFP0*38.&XK4"_(X(-^6RH
MY3K[RL@YL;5&#*GT+\-7:;=0VBT*[3H+%BW:I=H910N,HH45VJG\8\II4[Z#
MPM;5RE=7$?M]O%,V]^1)4N_H8BU..@P[AJCOH^<?,ZR#:M+F[6GSM+3) "<;
MI,KS)RB0RML+62DSFH!'^37@/.TD48MY<>R;1 N,HH45FHKM/>>WCGNLC"&G
M31'W!;2KK=-:5<&ILZP>[F+]C-;*1M'""NWPDQD.VZGK_RB#W7T=[.H+896Z
M0)&[]G=PY?4;>HV2/%9E2\=15[<YF:R&%T;1 J-HH=LNL5W?<=H2&_):2FP?
MW,"F2(J@[LHYB&A.1'GQ5??6]_'SXA;ZJ/_>O0O<COY0W=\7-[Y[^/+R_Y/4
M'!,NZ]BU=.7<#N6^S,K[]+(A:%;<_ZZH$#0M'K<(QHBI ?+]FE+QUE .ZO]J
MS+X!4$L#!!0    (  @X85D<:0-U(0,  %\)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;*V66V_:,!3'OXJ555,K=4V(<^T J85-V\,T5-;M8=J#
M"0>PZL29;2[]]K.3-*7$=$S:"_AR_B>__XDOZ6^Y>) K (5V.2ODP%DI55Z[
MKLQ6D!-YQ4LH],R"BYPHW15+5Y8"R+P2Y<SU/2]R<T(+9]BOQB9BV.=KQ6@!
M$X'D.L^)>+P%QK<#I^<\#=S1Y4J9 7?8+\D2IJ#NRXG0/;?-,J<Y%)+R @E8
M#)R;WO4H-?%5P'<*6[G71L;)C/,'T_D\'SB> 0(&F3(9B/[;P @8,XDTQN\F
MI],^T@CWVT_9/U;>M9<9D3#B[ >=J]7 21PTAP59,W7'MY^@\1.:?!EGLOI%
MVR;6<U"VEHKGC5@3Y+2H_\FNJ<.>H!<<$?B-P#]5@!L!KHS69)6M,5%DV!=\
MBX2)UME,HZI-I=9N:&'>XE0)/4NU3@UOLHRO"R71A#R2&0-$BCG2@V(-<_1A
MIQ>+!(G>H:E>/O.UGN<+=)KF? R*4':AQ??3,3H_NT!GB!;HVXJOI5;(OJNT
M 8/A9@WL;0WK'X&=0GF%L'>)?,\/+/+1Z_(Q9%K>J^3XI=S596MKY[>U\ZM\
M^$B^QKY\]D^81#]O9E()O3Q_V0S6&0-[1K-EKV5),A@X>D]*$!MPAF_?]"+O
MO<WN?TKVPCQNS>/7LC\OG+*N@LULG2&J,ICC9#,,8AS%?7>S[Z(;A8,P2=JH
M%WA!BQ?\#:]:CI(P(FCSCFB106&.#93QW"Q38HX2&WF=/-QCZD5^& 8'Z):P
M%/=ZOIT];-G#D]AU905G#"FR:PS,H( %5=:M$W98<(#]PV);HJ(P".W 40L<
MG08L^ *D.> )0XR2&654Z>+;<*,.B)^D472 VXW"OH=3.V[<XL8GX=)"@=X8
MRH87=_'B)#V@ZP8E?G3DY2<M7/(JW%>U J%OMQH1FM/4AIATGA[&0>H=,':C
M KV2CT"F+63Z3YN_6IR'S)=(<468#3WM;GF,@Q0?L%O"0B].#X\&=^_Z,Y\>
M7XA8TD(B!@LM]*YB[5[4UWG=4;RL;L095_I^K9HK_04$P@3H^07GZJEC+MGV
MFVKX!U!+ P04    "  (.&%97I,V91H"   Z!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q]5-]OVC 0_E=.41]::<-I:+NU"I&@=%H?F%!1MV<3
M'\2J8V>V _2_W]D)&9-&7XCO?-_G[WZ1[XU]<Q6BAT.MM)LDE??- V.NK+#F
M;F0:U'2S,;;FGDR[9:ZQR$4$U8IE:7K':BYU4N31M[1%;EJOI,:E!=?6-;?O
M,U1F/TFNDZ/C16XK'QRLR!N^Q17ZUV9IR6(#BY U:B>-!HN;23*]?IB-0WP,
M^"EQ[T[.$#)9&_,6C&<Q2=(@"!66/C!P^NSP$94*1"3C=\^9#$\&X.GYR/XM
MYDZYK+G#1Z-^2>&K2?(U 8$;WBK_8O;?L<_G-O"51KGX"_L^-DV@;)TW=0\F
M!;74W9<?^CJ< ++L#"#K 5G4W3T45<ZYYT5NS1YLB":V<(BI1C2)DSHT9>4M
MW4K"^6):EJ;5WL&2O_.U0N!: #EMBP*>#M1[APX^PU0(&<K(%3SK;A9"42_G
MZ+E45W !4L-"*D5>ES-/TL(#K.QES#H9V1D9][ PVE<.GK1 \2^>44I#7MDQ
MKUGV(>$*FQ&,TT^0I=D-O*[F<'EQ]0'O>*C7./+>G.']07LBL*3Y=QA2YGVI
M'%?<2BI5J-_:Z);*]K\R=.SWD3TLS*X8IZ.[G.U.-;&3?M9HMW%J'<1.=:T=
MO,-B3+MY^!O>;=6"VZW4#A1N")J.OMPF8+M)[0QOFC@=:^-IUN*QHN5&&P+H
M?F.,/QKA@>'OHO@#4$L#!!0    (  @X85D^RNJ3#@H  &PZ   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;,5;;6_;.!+^*X1O>^< CJT7.R^])$ 2
M;7 %MMT@V>Y]6-P'6J)M;B52):FD >['[Y!4)"N6F>C*XKXDU@N?F7E(#F<X
MU-DC%U_DAA"%OA4YD^>CC5+E^]E,IAM28#GE)6'P9,5%@15<BO5,EH+@S#0J
M\ED4!$>S E,VNC@S]V[%Q1FO5$X9N15(5D6!Q=,5R?GC^2@</=^XH^N-TC=F
M%V<E7I-[HCZ7MP*N9@U*1@O").4,";(Z'UV&[Y-YH!N8-WZGY%%N_4;:E"7G
M7_3%A^Q\%&B-2$Y2I2$P_'L@UR3/-1+H\;4&'34R=</MW\_H-\9X,&:));GF
M^;]IIC;GHY,1RL@*5[FZXX__(K5!"XV7\ER:O^BQ?C<8H;22BA=U8]"@H,S^
MQ]]J(K8:A/,]#:*Z0?2BP5X)<=T@?JN$>=U@;IBQIA@>$JSPQ9G@CTCHMP%-
M_S!DFM9@/F6ZW^^5@*<4VJF+7^ :\16Z%B2C"F&6H5\X6Z/?B"A00I8*C2\S
M> )]A'/T@=F1!E<':)P0A6DN#] A^GR?H/%/!^@G1!GZ;<,K"4CR;*9 12UH
MEM;J7%MUHCWJG**/G*F-1#^SC&3=]C,PK;$O>K;O*G("WI#E%(7A!$5!%/7I
MXVY^3\HIB@/3?-[3/'E[\]AA3=ST5FSPXCUXID,^,*E$!7-/H3],]WU0I)#_
MZ='NRJ+-^]&T2WDO2YR2\Q'X#$G$ QE=_/UOX5'PSSZF?((EGL Z+,X;%N<N
M=,LB;5FD3!&0HI# BO31Z(0;2J,%"^V0T6[YX2*8!HOX>'$V>]BFR)/4#D6+
MAJ+%ZQ2U VV";@3Y6A&6/FEG<4L$Y1E-T2U^TH_[.'/B#^7,K6R)G_ R)TB2
M@AYBQBJ<YT_:$6$!2Z&0"-87\ .B@H4-A0OCY"ZK-3A7N)J@)5E3QB@X/7AO
MZ_X>CY%XLJS3+T=-OQP-ZY>$R%304GODOEYPH@WM!;=JG[@B$B@G: U$8YA3
M)-.,8H8J)DE:P0H#7<0H-RLUE6CYA-0&N@T7\*=:2II1+*@&@0["JQ7-*4S(
M#)6"KXB4=@E*87T0$"UPZ%>UP:J59L N@198.9[7L\NU(,1,\C&6.AX I3/H
M<0AW#J:P4!$8)AD\!N5 RXP(]+BAZ<9 14$<H-8J*F5%L@G"A5X?.;PAX#48
M-G*"<EI0)4VK:UZ4F#W] QHMP0 %-G(T#@] $%  ;T+,9 P<1P>(:,^C_0\'
M%F $Z_LY@3#F<(G3+P@,91*;  F$&%9RR5^55A"QAD5=H(S*DDNSOL.4T'<T
MS0K8HF:*F)LKI,&PE$2!$#UKX&X*.L 5O/XG!&@:%"-6%4O0%AK8N$3/)O(M
M)6;P]:WUB:?1UYDIQ\U,.78.Q]M*I!NP D8/37N]NK/]T+EAP<)@RZN'TR!\
MX=(]B>P0<M(0<N(DY(H+:*''*S(A^P//'[332^U,T:_WL>0$'<J2!3O:(BF*
M%XL@>$'3[FOSXR#8>JU#P&E#P*F3 !W7'C9Q;9^MSO9#;?4)EG@"Z_ 6!FV.
M$'@-.VLX3T1Z14M\H76IW$JW0K=;$CR%A5&BE>"%65,P2XV';A?);,_PK*$[
MTV?1F1<U84X5!A/F":U+6-02%CD)N\9RHQW6!I:_7E)L\\46*7%PTD.*4\Q@
M4CRA=4EIT\#0F1]=[$0W?WPD>G'NGXU>LT"O:(DOM"Z/;2(8SOTZ-J^9H%>T
MQ!=:E\HV80S=2=B+C:053DT\"F'K Z:YR<^6.-?.KI=8K^EBC;;M$^8]CC+Q
M);5+69O+A>Z,R6RT*1V0[/7X7O.W&FV;EB@\.=FEY4?$[6$;N(?NR/VN"4WK
ML713CR6WE_,:SGM%2WRA=0EM __PQ*^7\QKS>T5+?*%UJ6Q3B-"=0WQ7^':Z
M,_W"H"]\\YHY^$+K[KZWJ4/DC*?_UZS3C3IT"-9HG1CQ>#?M]"6T2U6;&D3N
MU.!UOX?^BUY/8MU2!E/G-9?PA=9EN,TEHLBK(XQ\Y@S77M$27VA=*ML,)')G
M(-_C"-W0@VF-=Z.:OF#/E]0N86VJ$;F+3F^:W8/R.K? P31Z349\H77);I.1
M:.%WHGM-/[RB);[0NE2V24KD3E(^-].9<?5<!>GET&NN4J-U]H![9_6/R%6B
M-E>)W+G*A^?2\1U69 (>SUF-<X,-ILBMVI@>V(I8#BHR4 ]=Z7*(5A2-GRMA
MV):1-G2]T5: ^QYCVZP4M""F(JY?PHSQ"AQ\IHMV5YA]T:]>%D30%$_0I^GE
M=(+&2]ORAF1$X!S=5 S6!R.OS"N)@NDB>&=+7^F!/6!R7P^M7Q] 17U"!]U0
M!@N)=I-6T=']KS=WHP.TXD)7$IM2?6E*T%H+#C.[T(=&K)1P&H"41PK7N+Y8
MY9R+ _L8,'!9YJ"VWI$HL%A39JT$**NA%J7M6%$!@M0CAU\R!8.^5EB > !9
M*6+?R>J6IA;WTGF;6J0MTVJK=<60V*98.101F*TU 69E#:9AM'BG"W#!]%AK
MIP\YF;IJM_R7<B9Y3C-3,&4$(FL"G.*UZ4+*=>UO3.DS[<"IE34&N](J-ZWJ
ML?!JGY35,J=RTVJQ9<<=J0Q#, T(84@?':MY1_9<&L+9GY54AA_#>!B\F^A_
M8"3H&$RUM1DI@;FZ(D]7VZ8B>V1, T+''YJ.G\ +(,Y>F"HG_59?O!@O$\A
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ML7NW9_ AQ!KO]8.#UV[)@WGZ$7LV<;MG$[OKOR]XFL!"IRJA\^8G@D4O46Y
M[11[C[=ZW9[QA=9E;>N<L'M[ILE+<)J*2I^AJX]LZG-?O:3Y/2H<[YY4"'<W
M7'T)[9+4;LG$[BV9U^MO;H#!K,S?Y.<27U*[M+2;)[&[DGMD8G!G6!$=.\,*
MMX#!M'G=3O&%UB6WW4Z)C[R&%;'7716O:(DOM"Z5[=Y+[-[@&+Z"6KR3[@)Z
M%.VLGUZ+O[[0NBRU64+LSA+,9/VT-_3RF@!X14M\H76):Q. V&\"$'M- +RB
M);[0NI_;M G W)T O+[0SG=3 %L;?YD#N"4-Y<47FN5EMO49GCF#KS]GU!LK
M%5/VB[7F;O/)Y*7Y4/#%_>OP?6(_?&QA['>8'\TNCT0Y60&DWA(<(6$_;;07
MBI?F8[\E5XH7YN>&X(P(_0(\7W%P!?6%%M!\8'KQ%U!+ P04    "  (.&%9
M3=YBO@L$  !I#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RM5VV/
MVC@0_BM63JI:J;=YY^T :1=8M1]Z6G75]D-U'TPR0+2.36T'>O_^QD[( C'<
MJMTO8#LSSXR?&7O&X[V03VH#H,G/DG$U\39:;T>^K[(-E%3=B"UP_+(2LJ0:
MIW+MJZT$FENEDOE1$/3\DA;<FX[MVH.<CD6E6<'A01)5E265_]X!$_N)%WJ'
MA<_%>J/-@C\=;^D:'D%_V3Y(G/DM2EZ4P%4A.)&PFGBWX>A^:.2MP-<"]NIH
M3,Q.ED(\F<G'?.(%QB%@D&F#0/%O!S-@S "A&S\:3*\U:12/QP?T>[MWW,N2
M*I@)]JW(]6;B#3R2PXI63'\6^P_0["<U>)E@ROZ2?2,;>"2KE!9EHXP>E 6O
M_^G/AH<CA3"^H! U"M&Y0GI!(6X4XG.%Y()"TB@D+[60-@KI2RWT&H6>Y;XF
MRS(]IYI.QU+LB332B&8&-EQ6&PDNN$FL1RWQ:X%Z>CH396D"S'/2#!<_JF)'
M&7!-'C=4@B)_DD?,Y[QB0,2*S"C+*D9M7N"TD?FB("<%)W=4%9F%FQ>LTKCX
M-YZ.CSP3)9 'D+4\>3L'30OV#K&5!1C[&G=C?/*SQO-9[7ETP?.8?!)<;Q19
M\!QRA_[BNO[PBKZ/++941@<J9]%5P$?8WI X>$^B($H<_LQ?KAZ[MO-[UN]_
MV?H)&7&;5['%BR_@+:CD!5^KHYA_OUTJ+?$J^<<5[!HN<<.9ZW6DMC2#B8?W
MIP*Y V_ZYH^P%_SE8OHUP1:O"7;_2F G,4G:F"37T*??[#6+1Y+N0&+5(+PJ
MEQ@>/,59??;KLTBP "F-9Q@#Z I5;26U5DSAVDT'\6 8!D$P]G?'87 (1FD2
M=P07+L0HZ@K>NQ##J'\L>$)-VE*3_BHUN;G'L/J=<$2@O25=5]?==6O?0^<1
M2#N;Z\51E]6N6!+TNYQVQ<[)[$K$O?0BE;V6RMYO9IFI#LWPF<87YEZOFP!)
MZLB4N4,P&IK=G?/D$'3GG@LQ&487">NWA/6O$G;+==$FF8*LDH4ND(FW2(>6
M16:XQ#X@>[+$U2.Q-?57O2-<:"R[&:ORNO[J#=09BU,.]INIO%L,P$G^9L]5
MW$5SO[-71R)VA0:#09?@KAC>%EUZNV)A%(07V1UX9PO#EN[A_QT^,J^ :$$H
M84(I@NVYY0T+%I"R;@K - 4$JZ(&F[V'RDK>D^ FP4Z,,=, (;T2L,_6E!T2
MV+![$I4E9+128$W :H4M-7;;%3,?,*+/L;]Q7?'^46M7@ES;)EQA+"NNZ^NM
M76W[_#O;WIZMS\+1/'2L+_!=X%J_'8P6 ]?Z<+2P[PC_V9WZ$?*)RG7!%6&P
M0M>"FS[&4M:-?3W18FL;T:70V-;:X0;?0B"- 'Y?":$/$V.@?5U-_P-02P,$
M%     @ "#AA64A;N@V  @  0P4  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL?53?;],P$/Y73D%"FP1-FG8#1AMI[8;8PU"U:O" >'"32V/-L8-]
M:<=_S]E)0Y&VOB0^^^[S]]T/S_;&/KD*D>"Y5MK-HXJHN8ICEU=8"S<R#6H^
M*8VM!;%IM[%K+(HB!-4J3I/D,JZ%U%$V"WLKF\U,2TIJ7%EP;5T+^V>!RNSG
MT3@Z;#S(;45^(\YFC=CB&NFQ65FVX@&ED#5J)XT&B^4\NAY?+:;>/SA\E[AW
M1VOP2C;&/'GCKIA'B2>$"G/R"()_.URB4AZ(:?SN,:/A2A]XO#Z@?PG:6<M&
M.%P:]4,65,VCCQ$46(I6T8/9?\5>SX7'RXURX0O[WC>)(&\=F;H/9@:UU-U?
M//=Y. I(QZ\$I'U &GAW%P66-X)$-K-F#]9[,YI?!*DAFLE)[8NR)LNGDN,H
M6YJZ]LG1!?3+V]^MW F%FF!="8L.WL.:>Z%H%8(I82E4WBH1<LIF[_/HL "I
M82&<S /<C50M\>8W[JP[G9L:886V\X>S%7\U54@R%^H<SFZ0A%3N'%R'QU#W
M4BF^Q,UB8J&>;ISWHA:=J/0549_@WC"X@UM=8/%_?,P)&K*4'K*T2$\"KK$9
MP21Y!VF23GN*)V G0_(G 7;R"NRML%KJK3M*S,_KC2/+O?KK)=D=W/1E.#^_
M5ZX1.<XC'E"'=H=1]O;-^#+Y?(+L=" [/86><0TM\CB24(<B:1-*JUK.,A0M
M ADN/4DH?.UYV@#+DL?O)2G=9>.N+_W3L<N2T706[XXIQD>-7:/=AO%UD)M6
M4]?CP^[P0EQW@_'/O7M>[H7=2NU 8<FAR>C#102V&]G.(-.$,=D8XJ$+RXI?
M.;3>@<]+8^A@^ N&=S/["U!+ P04    "  (.&%930V%_*@&  #X-   &0
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M5Y3(NDXUD/<7:2I>3I2#ZF.GR3]02P,$%     @ "#AA6;JIA,TE!0  RBX
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M!+N*:<.>8!Q)$@R!7O3W:!PCU8GAX]\?["F)HB3Q(X#Y%401AL#3B".8 M"
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M*B2G030I\Q2)S4,*<AA-RD%%8@>1R7V(23FH2%[@$%ESB$DYJ$CLH <7ONR
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M=V]R:V)O;VLN>&UL+G)E;'/-V;MNPD 0A>%707X EIE9;A%0I:&-> $+EHL
MV_)N%'C[6%# 02G2H#V5M6MY_!?6)\N>?853F0YU%?>')O8NYU,5Y\4^I>;#
MN;C>AW,9^W43JN[,MF[/9>J6[<XUY?I8[H+3P6#DVN<9Q6+V/+.WNC;A/Q/K
M[?:P#I_U^OL<JO3'8/=3M\>X#R$5O579[D*:%^YR>FQ'=SM(OYM<]):;>=$N
M-U*XW$$*09H_R"#(\@=Y"/+Y@X80-,P?-(*@4?Z@,02-\P=-(&B2/V@*0=/\
M03) &0<$22]8$V@MR+40>"T(MA"(+4BV$)@MB+80J"W(MA"X+0BW$,@M2+<0
MV"V(MQ#HK:BW$NBMJ+<2Z*TO+]L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM
M!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZV\O'$@*]#?4V KT-]38"O0WU
M-@*]#?4V KT-]38"O0WU-@*]/>KM"?3VJ+<GT-NCWIY ;X]Z^W?J'=/U%.*C
MY[[&^[^3ZM1=&QZWORWOFR^/R@UG!S]^%K]02P,$%     @ "#AA6:C*A]FK
M 0  01H  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;L(P$(1?!>6*B+&=
MTA\!E[;7ED-?P$TV)"*)+=M0>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV
M==6X651X;QX8<VE!M7*Q-M2$G5S;6OGP:I?,J'2EEL3$>#QAJ6X\-7[D6XUH
M/GVB7*TK/WC>AL^NU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-
M*TKCAJ$@8F<=VIV?#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE
M.EW7H25VQI+*7$'DZRK>BP[[G7VX8=H_^=7^G4R?8:A<6&U<F)BER^V.(VF[
M1R8(D?5E_Q%/CD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."
MY$A <MR Y)B Y+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I'
M 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$
M(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"EF3_R3KN]:KO_ZIT:YQK<KF
MZ,^Z/T?S3U!+ 0(4 Q0    (  @X85D'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "#AA68&#]G;M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ "#AA69E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (.&%935?:!LH%  #0'@
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ "#AA6?I7R.#F!@  E1T  !@              ("!# X  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  @X85D4?1//V@(
M #$)   8              " @2@5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  (.&%9)H/;O[$'   A)   &               @($X
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "#AA6=CR
M2_"M @  '0<  !@              ("!'R   'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    (  @X85EN6E<.(0X  ,2.   8
M  " @0(C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  (
M.&%9)\Q[4-\'   $(P  &               @(%9,0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ "#AA66[DO,'K @  3@L  !@
M         ("!;CD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   (  @X85D >H^K0P(  (H&   8              " @8\\  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  (.&%9=+TX)VT%   B#0
M&0              @($(/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    (  @X85F5^,4B/0,  "\'   9              " @:Q$  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "#AA62O9DL<B
M!0  L0P  !D              ("!($@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  (.&%9FYJ^N$<'   ,$@  &0
M@(%Y30  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  @X
M85F9LOVA. ,  %\'   9              " @?=4  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ "#AA63UDE[5M!P  VA(  !D
M         ("!9E@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  (.&%9#"TPYIT#  !L"   &0              @($*8   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  @X85FIUO,&*PH  )T<
M   9              " @=YC  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ "#AA68+W$<*Q P  H@D  !D              ("!0&X
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  (.&%9OH!1
M!<<%  "1$   &0              @($H<@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    (  @X85G(O/Z$@P0  +T+   9
M  " @29X  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M"#AA6:VU_Q[(!0  F0\  !D              ("!X'P  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  (.&%9?D,#)?4"  !:!@  &0
M            @('?@@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    (  @X85D L='O: ,  &\(   9              " @0N&  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "#AA65PP@FX0!
MF@D  !D              ("!JHD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  (.&%9&';48N<"  !5!@  &0              @('Q
MC0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  @X85G\
M&2OV:P,  .@'   9              " @0^1  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ "#AA6=)?KY$] @  _@0  !D
M     ("!L90  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  @X85D@XZKEI (  *X&   9              "
M@5&C  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "#AA
M6=VN7+WG P  /A0  !D              ("!+*8  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  (.&%98*K#)!P$  #8&   &0
M        @(%*J@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   (  @X85D'6FYV$0,  $P(   9              " @9VN  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "#AA6=N;](BW!   X1@
M !D              ("!Y;$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  (.&%9'&D#=2$#  !?"0  &0              @('3M@
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  @X85E>DS9E
M&@(  #H$   9              " @2NZ  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ "#AA63[*ZI,."@  ;#H  !D
M ("!?+P  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  (
M.&%93=YBO@L$  !I#0  &0              @('!Q@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  @X85E(6[H-@ (  $,%   9
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M  !X;"]S='EL97,N>&UL4$L! A0#%     @ "#AA69>*NQS     $P(   L
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64$L%!@     S #, W T  "#F      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>221</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses</Role>
      <ShortName>Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Line of Credit and Long Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</Role>
      <ShortName>Line of Credit and Long Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Business Combinations - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail</Role>
      <ShortName>Business Combinations - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails</Role>
      <ShortName>Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Line of Credit and Long Term Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="md-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="md-20240930.htm">md-20240930.htm</File>
    <File>md-20240930.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img260272796_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="514">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "md-20240930.htm": {
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "md-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "md-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 195,
   "keyCustom": 26,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 14,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 148,
   "entityCount": 1,
   "segmentCount": 36,
   "elementCount": 505,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 514,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited",
     "longName": "100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "md:PracticeSalariesAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical",
     "longName": "100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_03faae58-4912-4ec2-812d-9cda8660c060",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5dd0ed8f-b21b-4d66-9790-efa9a58934b9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation",
     "longName": "995455 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments",
     "longName": "995475 - Disclosure - Cash Equivalents and Investments",
     "shortName": "Cash Equivalents and Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue",
     "longName": "995495 - Disclosure - Accounts Receivable and Net Revenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations",
     "longName": "995505 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses",
     "longName": "995515 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses",
     "shortName": "Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses",
     "longName": "995525 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt",
     "longName": "995535 - Disclosure - Line of Credit and Long Term Debt",
     "shortName": "Line of Credit and Long Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares",
     "longName": "995545 - Disclosure - Common and Common Equivalent Shares",
     "shortName": "Common and Common Equivalent Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans",
     "longName": "995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms",
     "longName": "995565 - Disclosure - Common Stock Repurchase Programs",
     "shortName": "Common Stock Repurchase Programs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995575 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables",
     "longName": "995595 - Disclosure - Cash Equivalents and Investments (Tables)",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995605 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables",
     "longName": "995615 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "995625 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables",
     "longName": "995635 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail",
     "longName": "995645 - Disclosure - Basis of Presentation - Additional Information (Detail)",
     "shortName": "Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_a75a21da-6809-46e5-af03-95d29f9164a1",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a75a21da-6809-46e5-af03-95d29f9164a1",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "longName": "995665 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_34b50bdd-0dce-4d36-b6db-803f912a1615",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_34b50bdd-0dce-4d36-b6db-803f912a1615",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "longName": "995675 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "longName": "995685 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "longName": "995695 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_345a8683-3a40-4392-9de5-24333799ced8",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_345a8683-3a40-4392-9de5-24333799ced8",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "longName": "995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "longName": "995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e677cfe7-2e92-47c1-bdb2-9ea23c33d51c",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "longName": "995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Business Combinations - Additional information (Detail)",
     "shortName": "Business Combinations - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)",
     "shortName": "Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "longName": "995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)",
     "shortName": "Line of Credit and Long Term Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "longName": "995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails",
     "longName": "995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f361e6-00e7-4dbe-9266-268c420fcb04",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_2174c181-c272-4b4a-a55a-328ca7305cbd",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1eb0559c-65bc-419b-9342-1cc866cf8e35",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20240930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued expenses, total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r70",
      "r935"
     ]
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r719"
     ]
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable and net revenue disclosure.",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable and Net Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Gross accounts receivable",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r250",
      "r670"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r115"
     ]
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll taxes and benefits current.",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "terseLabel": "Accrued payroll taxes and benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued salaries and incentive compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r672"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r82",
      "r180",
      "r532",
      "r561",
      "r562"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r15",
      "r438",
      "r441",
      "r480",
      "r557",
      "r558",
      "r841",
      "r842",
      "r843",
      "r852",
      "r853",
      "r854",
      "r856"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r852",
      "r853",
      "r854",
      "r856",
      "r943",
      "r1002"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r374"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r794",
      "r802",
      "r806",
      "r814"
     ]
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate securities",
        "label": "Other Corporate Bonds [Member]",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r408"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r251",
      "r293"
     ]
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated two thousand eight plan.",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "terseLabel": "Amended and Restated 2008 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of premiums, discounts and issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r686",
      "r687",
      "r847",
      "r954"
     ]
    },
    "md_AnesthesiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "AnesthesiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anesthesiology services medical group.",
        "label": "Anesthesiology Services Medical Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r175",
      "r199",
      "r232",
      "r236",
      "r244",
      "r245",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r430",
      "r435",
      "r466",
      "r525",
      "r613",
      "r677",
      "r678",
      "r719",
      "r737",
      "r902",
      "r903",
      "r959"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r184",
      "r199",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r430",
      "r435",
      "r466",
      "r719",
      "r902",
      "r903",
      "r959"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale Securities",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r299",
      "r448",
      "r519",
      "r707",
      "r711",
      "r866",
      "r947",
      "r948",
      "r949"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Short-term investments",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r299"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation And New Accounting Pronouncements Table",
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "md_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation Line Items",
        "label": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r424",
      "r699",
      "r700"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r424",
      "r699",
      "r700"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition total consideration",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r9"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r425"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized",
        "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Other intangible assets",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Fixed assets",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash on hand",
        "label": "Cash",
        "periodEndLabel": "Cash, Ending Balance",
        "periodStartLabel": "Cash, Beginning Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r529",
      "r583",
      "r608",
      "r719",
      "r737",
      "r839"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r172",
      "r669"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r96",
      "r198"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r96"
     ]
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Investments Line Items",
        "label": "Cash Equivalents And Investments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CashEquivalentsAndInvestmentsTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Investments Table",
        "label": "Cash Equivalents and Investments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total",
        "verboseLabel": "Net cash provided by operating activities - discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r96"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "verboseLabel": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "md_ChangeInNonCashImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ChangeInNonCashImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Non Cash Impairment Charges",
        "label": "Change in Non Cash Impairment Charges",
        "terseLabel": "Intangible asset impairments"
       }
      }
     },
     "auth_ref": []
    },
    "md_ChangeInRateOfControlPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ChangeInRateOfControlPremium",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Rate of Control Premium",
        "label": "Change in Rate of Control Premium",
        "terseLabel": "Change in Rate of Control Premium"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r176",
      "r177",
      "r178",
      "r199",
      "r219",
      "r223",
      "r225",
      "r227",
      "r234",
      "r235",
      "r290",
      "r325",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r466",
      "r565",
      "r566",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r600",
      "r622",
      "r639",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r824",
      "r848",
      "r857"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r117",
      "r528",
      "r599"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r318",
      "r319",
      "r665",
      "r890",
      "r896"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "md_CommonStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CommonStockLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "terseLabel": "Common Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r728",
      "r729",
      "r731",
      "r732",
      "r733",
      "r734",
      "r852",
      "r853",
      "r856",
      "r943",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "md_CommonStockRepurchasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CommonStockRepurchasesTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchasePrograms"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of common stock repurchases.",
        "label": "Common Stock Repurchases [Text Block]",
        "terseLabel": "Common Stock Repurchase Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r600"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r600",
      "r619",
      "r1002",
      "r1003"
     ]
    },
    "md_CommonStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CommonStockTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "terseLabel": "Common Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock; $.01 par value; 200,000,000 shares authorized; 85,865,841 and 84,018,023 shares issued and outstanding, respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r531",
      "r719"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r188",
      "r190",
      "r194",
      "r520",
      "r544",
      "r545"
     ]
    },
    "md_ContractedManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ContractedManagedCareMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "terseLabel": "Contracted Managed Care"
       }
      }
     },
     "auth_ref": []
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Reimbursement of Lost Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coronavirus Pandemic (COVID-19)",
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateJointVentureMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Joint Venture [Member]",
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "md_CovidNinenteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CovidNinenteenMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covid Ninenteen [Member]",
        "label": "Covid Ninenteen [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Credit Agreement [Member]",
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "verboseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r900"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r900",
      "r901"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r114",
      "r116",
      "r200",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r718",
      "r849",
      "r891",
      "r892",
      "r893",
      "r953",
      "r955"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description",
        "terseLabel": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r52",
      "r64",
      "r114",
      "r116",
      "r473"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument maturity date description",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "verboseLabel": "Debt Instrument, Frequency of Periodic Payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r352",
      "r473",
      "r474",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r335"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r718",
      "r849",
      "r953",
      "r955"
     ]
    },
    "md_DebtInstrumentMaturityYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "DebtInstrumentMaturityYear",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maturity year.",
        "label": "Debt Instrument Maturity Year",
        "terseLabel": "Debt instrument, maturity year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r200",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r718",
      "r849",
      "r891",
      "r892",
      "r893",
      "r953",
      "r955"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued periodically",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r30",
      "r51",
      "r105",
      "r106",
      "r200",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r718",
      "r849",
      "r953",
      "r955"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "verboseLabel": "Schedule of Investments",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Assets, Net, Total",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r129",
      "r851"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r526"
     ]
    },
    "md_DeferredTaxAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "DeferredTaxAssetsAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Axis",
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "md_DeferredTaxAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "DeferredTaxAssetsDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Domain",
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Additional Deferred Tax Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r232",
      "r240",
      "r245",
      "r677",
      "r678"
     ]
    },
    "us-gaap_DescriptionOfInterestRateRiskExposure": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfInterestRateRiskExposure",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate, description",
        "label": "Description of Interest Rate Risk Exposure",
        "documentation": "Description of the sources of interest rate risk exposure faced by the entity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r377",
      "r405",
      "r406",
      "r407",
      "r702"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dissolution of and net loss attributable to noncontrolling interest",
        "label": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss):",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r231",
      "r422",
      "r428",
      "r445",
      "r446",
      "r521",
      "r546",
      "r674"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "terseLabel": "Weighted average common shares:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r219",
      "r225",
      "r226",
      "r227",
      "r231",
      "r422",
      "r428",
      "r445",
      "r446",
      "r521",
      "r546",
      "r674"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Common and Common Equivalent Shares",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r228",
      "r229",
      "r230"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r166",
      "r191",
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r214",
      "r233",
      "r291",
      "r292",
      "r315",
      "r359",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r423",
      "r427",
      "r428",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r477",
      "r480",
      "r542",
      "r557",
      "r558",
      "r559",
      "r572",
      "r639"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r418",
      "r826",
      "r827",
      "r828",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage in joint venture",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]",
        "documentation": "Person with designation of executive officer."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "md_ExtraordinaryItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ExtraordinaryItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Abstract]",
        "label": "Extraordinary Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ExtraordinaryItemsAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ExtraordinaryItemsDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r456",
      "r457",
      "r458",
      "r486",
      "r487",
      "r488",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698",
      "r707",
      "r711"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r707",
      "r948",
      "r951"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "FairValueDisclosuresLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value disclosures.",
        "label": "Fair Value Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "FairValueDisclosuresTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value disclosures.",
        "label": "Fair Value Disclosures [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r517",
      "r707",
      "r712"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r363",
      "r368",
      "r449",
      "r457",
      "r486",
      "r696",
      "r697",
      "r698",
      "r707"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r363",
      "r368",
      "r449",
      "r450",
      "r457",
      "r487",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698",
      "r707"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r707",
      "r948",
      "r951"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r456",
      "r457",
      "r458",
      "r486",
      "r487",
      "r488",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698",
      "r707",
      "r711"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r951"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r350",
      "r357",
      "r443",
      "r463",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r543",
      "r681",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r878",
      "r879",
      "r880",
      "r881",
      "r944",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount.",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "verboseLabel": "Financial Instruments Measured At Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r887"
     ]
    },
    "md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.375% Unsecured Senior Notes Due 2030 [Member]",
        "label": "Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member",
        "documentation": "Five point three seven five percent unsecured senior notes due two thousand thirty member."
       }
      }
     },
     "auth_ref": []
    },
    "md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "label": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "terseLabel": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "md_GaapSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "GaapSeniorNotesMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GAAP Senior Notes [Member].",
        "label": "GAAP Senior Notes [Member]",
        "terseLabel": "GAAP Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Loss on disposal of businesses",
        "negatedLabel": "Loss on disposal of businesses",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r847"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r624"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r522",
      "r523",
      "r680"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r522",
      "r523"
     ]
    },
    "md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Good will Impairment Loss excluding Deferred Tax Assets Charge",
        "label": "Good will Impairment Loss excluding Deferred Tax Assets Charge",
        "terseLabel": "Good will Impairment Loss excluding Deferred Tax Assets Charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "totalLabel": "Goodwill, Total",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r305",
      "r518",
      "r678",
      "r682",
      "r709",
      "r719",
      "r884",
      "r885"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinesses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r886"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "verboseLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r306",
      "r307",
      "r308",
      "r682",
      "r709"
     ]
    },
    "us-gaap_GovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government [Member]",
        "terseLabel": "Government",
        "documentation": "Organization that is the governing authority of a community."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCarePatientServiceMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenue",
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "md_HospitalsContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "HospitalsContractsMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospitals Contracts [Member]",
        "label": "Hospitals Contracts [Member]",
        "terseLabel": "Hospital contract administrative fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Intangible assets impairments",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r847",
      "r888",
      "r889"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Fixed assets impairments",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r103",
      "r708"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "(Loss) income from continuing operations before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r120",
      "r125",
      "r523",
      "r538",
      "r676",
      "r677",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Incremental loss on sale, net",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r61",
      "r110"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) from Equity Method Investments, Total",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity in earnings of unconsolidated affiliate",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r84",
      "r119",
      "r232",
      "r241",
      "r245",
      "r286",
      "r537"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax (provision) benefit",
        "negatedLabel": "Income tax provision",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r213",
      "r214",
      "r232",
      "r242",
      "r245",
      "r412",
      "r413",
      "r417",
      "r547",
      "r704"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued salaries and bonuses.",
        "label": "Increase (Decrease) in Accrued Salaries and Bonuses",
        "verboseLabel": "Net decrease in accrued salaries and bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "terseLabel": "Income taxes receivable",
        "negatedLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "terseLabel": "Long-term professional liabilities",
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "md_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in deferred tax Assets.",
        "label": "Increase In Deferred Tax assets",
        "terseLabel": "Increase in deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average number of dilutive common share equivalents",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r227",
      "r376"
     ]
    },
    "md_IncrementalNonCashCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "IncrementalNonCashCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Non Cash Charge",
        "label": "Incremental Non Cash Charge",
        "terseLabel": "Incremental Non Cash Charge"
       }
      }
     },
     "auth_ref": []
    },
    "md_IncrementalSharesInContinuingOperation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "IncrementalSharesInContinuingOperation",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Shares In Continuing operation",
        "label": "Incremental Shares In Continuing operation"
       }
      }
     },
     "auth_ref": []
    },
    "md_IncrementalSharesNotIncludedDueToAntiDilutiveEffect": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "IncrementalSharesNotIncludedDueToAntiDilutiveEffect",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Shares Not Included Due To Anti dilutive Effect",
        "label": "Incremental Shares not Included Due to Anti dilutive Effect",
        "terseLabel": "Incremental shares not Included due to anti dilutive effect"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r794",
      "r802",
      "r806",
      "r814"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r818"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r818"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r818"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r844"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment and other income",
        "totalLabel": "Investment Income, Net, Total",
        "label": "Investment Income, Net",
        "verboseLabel": "Investment and other income (expense)",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r90"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r643",
      "r645",
      "r647",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r729"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r643",
      "r645",
      "r647",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r729"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r950"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Cash Equivalents and Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r144",
      "r252",
      "r254",
      "r464",
      "r465",
      "r967"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r66",
      "r69",
      "r70",
      "r71",
      "r72",
      "r199",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r431",
      "r435",
      "r436",
      "r466",
      "r598",
      "r675",
      "r737",
      "r902",
      "r959",
      "r960"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r118",
      "r534",
      "r719",
      "r850",
      "r882",
      "r952"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r171",
      "r199",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r431",
      "r435",
      "r436",
      "r466",
      "r719",
      "r902",
      "r959",
      "r960"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "totalLabel": "Long-term Line of Credit, Total",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r969"
     ]
    },
    "md_LineOfCreditAndLongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "LineOfCreditAndLongTermDebtTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit and Long Term Debt",
        "label": "Line Of Credit And Long Term Debt [Text Block]",
        "documentation": "Line Of Credit And Long Term Debt [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit facility, available balance",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r324"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term debt",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term Debt, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r341",
      "r351",
      "r684",
      "r685",
      "r718",
      "r969"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt and Lease Obligation, Current, Total",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of debt and finance lease liabilities, net",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit.",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "verboseLabel": "Long-term debt and finance lease liabilities, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term A loan",
        "label": "Long-Term Debt [Member]",
        "verboseLabel": "Long-Term Debt",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r891",
      "r892",
      "r893"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r891",
      "r892",
      "r893"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "terseLabel": "Accrued professional liabilities",
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "terseLabel": "Long-term professional liabilities",
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "md_MaternalFetalMedicinePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "MaternalFetalMedicinePracticeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maternal Fetal Medicine Practice [Member]",
        "label": "Maternal Fetal Medicine Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r320",
      "r321",
      "r322",
      "r323",
      "r370",
      "r409",
      "r452",
      "r514",
      "r555",
      "r556",
      "r563",
      "r590",
      "r591",
      "r644",
      "r646",
      "r648",
      "r649",
      "r653",
      "r666",
      "r667",
      "r679",
      "r688",
      "r701",
      "r711",
      "r712",
      "r716",
      "r717",
      "r722",
      "r904",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r320",
      "r321",
      "r322",
      "r323",
      "r370",
      "r409",
      "r452",
      "r514",
      "r555",
      "r556",
      "r563",
      "r590",
      "r591",
      "r644",
      "r646",
      "r648",
      "r649",
      "r653",
      "r666",
      "r667",
      "r679",
      "r688",
      "r701",
      "r711",
      "r712",
      "r716",
      "r722",
      "r904",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, at Carrying Value",
        "verboseLabel": "Cash equivalents",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds Fair Value Disclosure",
        "documentation": "Fair value of money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "md_MutualFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "MutualFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "label": "Mutual Funds Fair Value Disclosure",
        "documentation": "Mutual funds fair value disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net (loss) income",
        "totalLabel": "Net Income (loss) attributable to Pediatrix Medical Group, Inc.",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r98",
      "r121",
      "r169",
      "r187",
      "r189",
      "r193",
      "r199",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r224",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r422",
      "r428",
      "r446",
      "r466",
      "r541",
      "r621",
      "r637",
      "r638",
      "r735",
      "r902"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dissolution of and net loss attributable to noncontrolling interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r111",
      "r187",
      "r189",
      "r210",
      "r213",
      "r214",
      "r540",
      "r843"
     ]
    },
    "md_NetOfTaxUnrealizedHoldingGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NetOfTaxUnrealizedHoldingGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized holding gain (loss) on investments, net of tax",
        "documentation": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "label": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "terseLabel": "Unrealized holding (loss) gain on investments, net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1996 non-qualified employee stock purchase plan.",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_NonCashCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NonCashCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "non-cash charge",
        "label": "non-cash charge",
        "terseLabel": "Non cash charges"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r794",
      "r802"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expenses",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North American Partners In Anesthesia [member].",
        "label": "North American Partners In Anesthesia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Notes Payable, Total",
        "label": "Notes Payable",
        "terseLabel": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r969",
      "r970"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Payable, Fair Value",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r65",
      "r946",
      "r950"
     ]
    },
    "md_NumberOfMaternalFetalMedicinePracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NumberOfMaternalFetalMedicinePracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of maternal fetal medicine practices acquired.",
        "label": "Number of Maternal Fetal Medicine Practices Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NumberOfMultiLocationPediatricUrgentCarePracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of multi location pediatric urgent care practice acquired.",
        "label": "Number Of Multi Location Pediatric Urgent Care Practice Acquired",
        "terseLabel": "Number of other multi location pediatric urgent care practice acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricGastroenterologyPracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NumberOfPediatricGastroenterologyPracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Pediatric Gastroenterology Practice Acquired",
        "label": "Number of Pediatric Gastroenterology Practice Acquired",
        "terseLabel": "Number of Pediatric Gastroenterology Practice Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricOrThopedicPracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "NumberOfPediatricOrThopedicPracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pediatric or thopedic practices acquired.",
        "label": "Number Of Pediatric Or thopedic Practices Acquired",
        "terseLabel": "Number of other pediatric orthopedic practice acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_OperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease right-of-use assets.",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "terseLabel": "Operating and finance lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r676",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureGoodwillLonglivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating lease right-of-use asset impairments",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r109"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r719"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding gain on investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r285"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Noncash Income (Expense), Total",
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other",
        "negatedLabel": "Other",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations",
        "verboseLabel": "Payments for repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition consideration paid in cash",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r426"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition payments, net of cash acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Investments, Total",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "md_PaymentsToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PaymentsToTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow to term loan.",
        "label": "Payments to Term Loan",
        "negatedLabel": "Payments on term loan"
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]",
        "label": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PediatricSubspecialtyPracticeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pediatric Subspecialty Practice [Member]",
        "label": "Pediatric Subspecialty Practice [Member]",
        "documentation": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase Decrease In Salary And Wage.",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "terseLabel": "Decrease In Salary | %"
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net patient service revenue by type payor.",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "terseLabel": "Percentage of net patient service revenue"
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of refund of income tax at the prior period corporate tax rate.",
        "label": "Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate",
        "verboseLabel": "Percentage of refund of income tax at the prior period corporate tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "md_PracticeSalariesAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PracticeSalariesAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Practice salaries and benefits.",
        "label": "Practice Salaries and Benefits",
        "terseLabel": "Practice salaries and benefits"
       }
      }
     },
     "auth_ref": []
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.",
        "label": "Practice Supplies And Other Operating Expenses",
        "terseLabel": "Practice supplies and other operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r353"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r600"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r353"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r530",
      "r719"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Current, Total",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r303",
      "r304",
      "r671"
     ]
    },
    "md_PrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PrimaryBeneficiaryMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary beneficiary [Member]",
        "documentation": "Primary beneficiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings on line of credit",
        "terseLabel": "Borrowings on revolving credit line",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r849"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r845"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Proceeds from maturities or sales of investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfOtherProductiveAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from Sale of Other Productive Assets",
        "documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Other revenue",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r246",
      "r515",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r668",
      "r689",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r838",
      "r898",
      "r899",
      "r906",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r999",
      "r1000"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r246",
      "r515",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r668",
      "r689",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r838",
      "r898",
      "r899",
      "r906",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r187",
      "r189",
      "r196",
      "r199",
      "r204",
      "r210",
      "r213",
      "r214",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r422",
      "r428",
      "r429",
      "r432",
      "r433",
      "r446",
      "r466",
      "r523",
      "r539",
      "r571",
      "r621",
      "r637",
      "r638",
      "r705",
      "r706",
      "r736",
      "r843",
      "r902"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r479",
      "r524",
      "r536",
      "r719"
     ]
    },
    "md_PurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "PurchasePrice",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Purchase price",
        "documentation": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "RadiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Radiology Services Medical Group [Member]",
        "documentation": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r320",
      "r321",
      "r322",
      "r323",
      "r362",
      "r370",
      "r400",
      "r401",
      "r402",
      "r409",
      "r452",
      "r489",
      "r498",
      "r514",
      "r555",
      "r556",
      "r563",
      "r590",
      "r591",
      "r644",
      "r646",
      "r648",
      "r649",
      "r653",
      "r666",
      "r667",
      "r679",
      "r688",
      "r701",
      "r711",
      "r712",
      "r716",
      "r717",
      "r722",
      "r729",
      "r894",
      "r904",
      "r948",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r320",
      "r321",
      "r322",
      "r323",
      "r362",
      "r370",
      "r400",
      "r401",
      "r402",
      "r409",
      "r452",
      "r489",
      "r498",
      "r514",
      "r555",
      "r556",
      "r563",
      "r590",
      "r591",
      "r644",
      "r646",
      "r648",
      "r649",
      "r653",
      "r666",
      "r667",
      "r679",
      "r688",
      "r701",
      "r711",
      "r712",
      "r716",
      "r717",
      "r722",
      "r729",
      "r894",
      "r904",
      "r948",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r369",
      "r481",
      "r482",
      "r527",
      "r535",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r618",
      "r620",
      "r642"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r369",
      "r481",
      "r482",
      "r527",
      "r535",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r618",
      "r620",
      "r642",
      "r958"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r849"
     ]
    },
    "md_RepaymentsOfLongTermCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "RepaymentsOfLongTermCapitalLeaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease obligations",
        "label": "Repayments Of Long Term Capital Lease Obligation",
        "documentation": "Repayments Of Long Term Capital Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r754",
      "r764",
      "r796"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring Charges, Total",
        "label": "Restructuring Charges",
        "verboseLabel": "Transformational and restructuring related expenses",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r316",
      "r317",
      "r895"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r107",
      "r533",
      "r560",
      "r562",
      "r569",
      "r601",
      "r719"
     ]
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained earnings and accumulated other comprehensive income [Member].",
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "verboseLabel": "Retained Deficit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r232",
      "r237",
      "r238",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r360",
      "r361",
      "r515"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "md_RuralAreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "RuralAreaMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "terseLabel": "Rural Area [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r215",
      "r371",
      "r825",
      "r855"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r81",
      "r250",
      "r865"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "verboseLabel": "Available-for-sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r418",
      "r826",
      "r827",
      "r828",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946"
     ]
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of financing receivables.",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "terseLabel": "Schedule Of Financing Receivables [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Net Revenue",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r26",
      "r50",
      "r112"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_SelfPayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SelfPayMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Self-Pay [Member]",
        "terseLabel": "Private-Pay Patients",
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes",
        "label": "Senior Notes",
        "totalLabel": "Senior Notes, Total",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r969"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Vesting period of options, maximum years",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "md_SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.25% Unsecured Senior Notes Due 2027 [Member]",
        "label": "Six Point Twenty Five Perecent Unsecured Senior Notes Due Two Thousand Twenty Seven [Member]",
        "documentation": "Six Point Twenty Five Perecent Unsecured Senior Notes Due Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point two five percent senior unsecured notes due two thousand twenty seven.",
        "label": "Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "6.25% Senior Unsecured Notes Due 2027 [Member]",
        "verboseLabel": "2027 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "label": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "documentation": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r176",
      "r177",
      "r178",
      "r199",
      "r219",
      "r223",
      "r225",
      "r227",
      "r234",
      "r235",
      "r290",
      "r325",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r466",
      "r565",
      "r566",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r600",
      "r622",
      "r639",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r824",
      "r848",
      "r857"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r74",
      "r78",
      "r79",
      "r166",
      "r191",
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r214",
      "r233",
      "r291",
      "r292",
      "r315",
      "r359",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r423",
      "r427",
      "r428",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r477",
      "r480",
      "r542",
      "r557",
      "r558",
      "r559",
      "r572",
      "r639"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r233",
      "r477",
      "r515",
      "r564",
      "r584",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r639",
      "r730"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r215",
      "r371",
      "r825",
      "r829",
      "r855"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r233",
      "r249",
      "r477",
      "r515",
      "r564",
      "r584",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r639",
      "r730"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited",
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued under employee stock purchase plan shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeitures of restricted stock, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Forfeitures of restricted stock, shares",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of restricted stock, shares",
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan Value",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r73",
      "r74",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of restricted stock",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program, Authorized, Amount",
        "terseLabel": "Common stock authorized for repurchase",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Common stock repurchased",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased during period, shares",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchased common stock, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107",
      "r568",
      "r639",
      "r662"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchased common stock",
        "terseLabel": "Repurchased common stock",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74",
      "r107",
      "r572",
      "r639",
      "r662",
      "r736"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r78",
      "r79",
      "r102",
      "r602",
      "r619",
      "r640",
      "r641",
      "r719",
      "r737",
      "r850",
      "r882",
      "r952",
      "r1002"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r166",
      "r167",
      "r192",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r212",
      "r291",
      "r292",
      "r315",
      "r359",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r423",
      "r427",
      "r428",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r467",
      "r468",
      "r472",
      "r476",
      "r480",
      "r558",
      "r559",
      "r570",
      "r602",
      "r619",
      "r640",
      "r641",
      "r664",
      "r736",
      "r850",
      "r882",
      "r952",
      "r1002"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "terseLabel": "Tax adjustments, sttlements and unusual provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Other Third-Parties",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r957"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r350",
      "r357",
      "r443",
      "r463",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r543",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r878",
      "r879",
      "r880",
      "r881",
      "r944",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Seven Member",
        "label": "Two Thousand Twenty Seven [Member]",
        "terseLabel": "2027 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "TwoThousandTwentyTaxYearMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty tax year.",
        "label": "Two Thousand Twenty Tax Year [Member]",
        "verboseLabel": "2020 Tax Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "TwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Member",
        "label": "Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoZeroThreeZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "TwoZeroThreeZeroMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 Notes [Member]",
        "label": "Two Zero Three Zero [Member]",
        "documentation": "Two Zero Three Zero [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "verboseLabel": "Federal Home Loan Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r968"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "verboseLabel": "Municipal Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r720",
      "r725",
      "r998"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r696",
      "r698",
      "r707",
      "r968"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "UnnamedCorporateJointVentureOneMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture [Member]",
        "label": "Unnamed Corporate Joint Venture One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20240930",
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture Two Member",
        "verboseLabel": "Unnamed Corporate Joint Venture Two [Member]",
        "label": "Unnamed Corporate Joint Venture Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding gain on investments, net of tax of $571, $-, $657 and $100",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured note issued",
        "label": "Unsecured Debt",
        "totalLabel": "Unsecured Debt, Total",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r969"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnsecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "label": "Unsecured Long-Term Debt, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.mednax.com/20240930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20240930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of common shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r227"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0000950170-24-119796-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-119796-xbrl.zip
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M-AWB@TP$W=)(:"]-N()GK8T!B@:,1X]BMIL61X+ZCXJW[:(_*J-FQ5-8V,?
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M:"J>_RRG G,R,84@-#B-/!' +Z#BZ<3^=W0CN"?BA'[%W_,B[,4/,HDO&(2
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M>6<HS,L!ZR\W+P<7L(B[-]B%@_UG,\B?;&=B:\86(_$K75M5]0H,ZNSFB67
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MQ(!F9&=49_1@?,18Q3C)A,\DP&3(Y,>4QM3*M,I,PZS #&*^QUS&/,:"RR+
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MNSLFM&9^5?%7W);</!:LQL<M.QW)O6S!UY"ZZ0X.TCK1X^?%^^GFBJLSL4O
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MV'WQ0'M?;_B^L.A-X0@!GM@$BH5<6%_?._>Y_\7+>X6UF37=@G2W$[8Q;6S
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M;+@]():K8J39)6^8Q CU>IQ%R^M<6R^U"FJ2JWCPPL3:'XADZ)?G3-,J?VE
M*0Y?#Y1QDU[@0-D*ZV*T[I;G&Y*%Y<SN_S5MB1XRN)41D;'B*]6]ZX%IJC=)
M'L0]3;&,)YBF)OR7WD!8$YQEA+6R7'M[DKWB]V^EA<:_J-)1-U;IE;IR#UF^
MN"V:9/*]C1$SZUA]?W%;PYO03N:DEOH#C!(]XKK!LL2BB".>?:G3"BK9WU-_
M\$.;M^,3+>]JV<0!)V?]):5T4O^65Y^>045MC\@@-9O1VK3NU5!NS3M]B'E]
M:/FJ6_WI YT.AM[22G530B!L/-DQ]^66O=>LEA7;@S/9<J,TLQ?R(O,\JD^N
MWK^G?AEK :>2);*QR\,>&\\2,%#WS4#I_2[SSN\6UW\IN666UEN^524_7^J^
M5#=#Z7](>*(<#V:OR*D+1!1Z.P^TR[^1VE5X3=>AG&&^7)OM^.T\^\:?QSIB
M_0>@'J<XI=/X.SC'W_!6$WU_85&MF+GWR09L7JB$T04:DWUG,-HM8<*DH<;/
MF, *\$O4W*OK]*)^*4#J6<>MB0DF(=6TC$M+N]]"BTQA4NXA[H8?4.Y0DBBW
MON*B4I<4S%+YP7Z#YCS-<;#J ;8Q&6AL!RUHP3GD&O;TQ%P_3Z5]$BSE8_M!
M1S-(JLRAJ+7IQ<4-*LM/,AFI*/:ZRA1T%3IZ7>;'/J[AY1R(W--Z35.9'>T_
ME.G5MU^E38Y-)-0/0TXNS@N-B%'NF=KJ>D\#_,XC9;&OT^D[B4KV "!M0>J3
MFNJ]IZ"N\%7QR;:;#M ,+6!)XK/''AI_N0$AQC_HEKDL9?^I5\LRZ?6MC?0:
ME-Z\WQ@E:*MZY_Q5LS1H@Y::[EW/(2?D;BFP%'Q84*F=2BXN$2+KV'G;>G E
MQ(MG2-B^[C$>/,>7+F0G6NNIDP.*OOZ)2?^K ZXJ; MK_8XTML'$;CS;'Z2*
M^YM<!)L9^#:?"*%_>81=[3NW36JIX(KM_*:!DVTC9%61'<<DK5U#3=;^OF[6
MZ,BG 6:_QN^9YE[1L[$P1 ?F>'47I#UH$[Z.TV73!<<T/&B06]N &%R&21Z_
M'<E4[RNWXJOAPP=Y2GMM#)&?*4,@UO!<VI'_QY6@_V?.J(/ZU1L!T'*KE2H<
M:&ISA:>?E_A'CM?)::YQA_0/.J'#OIW1]"Z<'1='W)'%IYIAI9M1[G7UE5FC
MU\K#\Y]B(U\=P:<G T%;^J.C7;:]9Q%])9YF?>H19P21HH@O7Q@SECD:?-T,
MSO>O/?^NH&+<0IU.S"^%/\TSYN5WN\-&^&7]Y=4\"(E0@?P-:BM8/"T@)TNQ
MOF&)"^'[6/@JTCTQ@K@F(P)/=63["&K:B/8Y]?&VT[ 7"+QSP?8;76X[18=A
M\BML/GHFQ$3@6=&<IZC+BDY8OP.'\]N2ZU/L*).A-47N+2[0-#)>>L?=&(8"
M()1?O8JQ0@CBE]U$JQ/DMB%@S@-"C40[%^B20VS;<?/TSFK!67QW\C_<S]!T
ML?=HVDY?.K[-^^!T:6IXB@JI1,Z.<+UDIN5,;T@SM^L(_O.4K'Q'RDOY)Z>L
MN>N;9^V"$HLC!>^#%%)7WR<'K/(I;!57]@P[.!EQ(IHH * 7*GP@O#^_Q6_%
M2;?T<MOI<<+CG;%'>]"8NT$![HFA5".#RQ"/+&7>E.'C/IC!AW;C(6_"AR:I
M^LS&>X1OV[S""@R5F'P3\H<FOI$8U]]?_TO8Q_@OZKBX#<9T HO,W>5K3: &
MIU9108X8PU>H2M5JP0]O;HWJ)-"ZA@YKQ,V&PR4$QZDY5?'J80Z!O E*D+K^
MM&,MC!AOZY72XI/ !TH2]XW4&Q:;$_9'IM?(!47P_<GU6F<+^9+8^AV_/)A
MI0MQ%U^"7E0V1+J.Z#5R=X_0,;Y 8Q?]NAC\;\YX ^/=YX0.;'?2E^#B_GK
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M-USU*C*$VRQ[^DGXI1[+T4"#]I:V0\W)V=$,1Z2^[$(-+S/S*M^7O-$BFX5
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MZL8>3_<"A]D>N2H-A.IU6J$N 0<HG8D5W"+S?F?S&AQ^&AZ[RO;L2P\'R2D
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MDH4!U;P!;9I2$8THLYV?WN@RF-US__-MQZ"]7O0S!Z7[X BQL)Q6'-OH7+2
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M)RX0RXHKY#&EV:X.%E0<7)(#](-.DGJ%O8#)%+4O=GB%]\1FXI7]GK0ZG>T
M/\/0AVJT3$?PV!A9'RL?* ?4"GS$F[!T1O6TG:W6HL#RTZG12L.):3<F^ ,:
MOIX.5[[ECM#;W[_\F70 Q*5_[9&\E$.QTX 2BX-.U1[QZPN!R #6XOZB/Q;.
M5OW[P$NH(?^:VKPZO0KVD9)]J"'4=NX!$7MP#Y]<:FR!I'X\-MDP)JPV=HY<
M-]8F?6H6Z1&1MT3+SKSW:[F<'8):IC"$)NC'?#Q_$RB<76A/:^AUU1RZSOBZ
MXO\IT-7&,#X&EK#"^L2K3_XHZ])F#F+NMY#QQYQ++6D340*I;RC+CGUIC8CV
MN\J_Q_48OY=,O=VTG%:%Y<R0*A%"2DM(2<JVMD8:!A?RB6OK/!X96I(!!5S_
M-9I_NM U%!B61N8?:/6_<\YR<&VL85!C^GJ,NHI=7*C UK$/:$1)A/:KPRLX
M=:0DS_H?DDMJQ12\H9-QMJ\0/N(O)#OZEWF>'YT+:)2C]QVE$[]'JYB*K+MQ
M"ZZJ^ 4('A1Y%;1*P/O6.Z_DRK/73!/_>EW0/8]?0;UPTPA#7:LXZ95KOXU0
M7M5H13DD&MPH[AZ6X8F+_4%7CO]P953N.'.LY/YN6$:T09+JEBN9:2K2-N('
M[ONXSWY\ZFWMJ:5D/CMA!L[LJE#28/)RY%)_-1!-7"-NF.7#<-+![+LRB+P6
M@D"WJ8-B>HN'$6^KS6:,?;QUM<SYC?R6Y,L0YS&B84=MEX>].A8^V)>),CI/
MR?=&#>X/DV[J].7U!:<<\.+]E3U).'T::WYEFO+X]TQZY89Q7C?YL8F=BEHT
M^_BXMNT?#NX=O>?WI]BK6UW'><S@*2-F!<7G 5R?^EQH.H[=,N_)RE2S:K41
MD1H);Y <MRECJY"2UMFJ>$.W)T=^;47/]@;,!#9ORD3D7\0,!O]^)/D:W2G^
M\E,D)YHS< 4Q,/>U4ZTS^F$Z22%'XN\4N##/_HZ[7CFN)OH>GF-BT(K8J2&\
MH4PSR7]#V8:7;T[KN1E&'17'B)231;EO#+;V&89<G;%D-/3OH)^:--\Y#X@=
M; P6S2!%3I[2> C\5Z]*-[FF7Y>_^PL?[/Q<HE[W^"QD-]F>+T+=CA]H@!W@
M%ZN<U,;ZARW&0%?EJOL+_"OQ*JD'1?:.^N9?2W/G[+10(#V7;>3K.69XH6 K
M_TW]%.B83Z?T_0;NRJV"1<SDP8:&@7I:498B(82E]8,;F[W@1CN?S.]T=&@0
MFFP5U!@%@O>/]<=D&;L59YUU[O #$B<MV#GA@<J*0Q$0%ELYH+0,]WY59::O
MMNFII FWW$=, J#HKG/<=5.W;!DI<05J9Q-JTJSLS4.D%_L.DM93(\D-#R(1
M"K]8;T=.UXF93#Z2LQ!TEY^ZD2TDWU*48XV8D9&M'5O)EQY&:.!SAU<]!L>8
M1RP?%%H1DAS6A_\J\2#6>XU9KJ>R'F=1Z_DQ6-Z5=M\+BMK=FB@M;5\6J383
ML9.^"IIO]7.:HR4FP+V-HC@/\/EB(JPCR2]L&1?"#[8<_L]F!P( I!X!@M@(
M. 4U<0QC@$KJ3[9=)GOAC>DVVTLZP;\LCO:4_"D&@()3 FY+W0^"L"[@VCK*
M^,T:W=75A5]^Y#G3#N@&;W TWT8Z&Q&KJ_:TOA/4GUP]*H0'/3],L="6D[U.
MJ2?K!R400/J3F)+U:&2B=KP-L[SK*.<:NE?U"X-*T$GV6"<$0C3O+(M(\+3D
M/7=@DL1O.CTN/7^V!_Q!]\IE]+)DN")!SEI8PT1^[H27_TA_,^[TP6J,,[-J
MFT60=<RQS89QW)X=4GM![ >= 2-]QOH5G4_\^O,ECO"_15@"55N&YJN9%PR#
M)=ZL=!;*!>, ;(CWQ'KD5!&@O94>/."N+)9XZ;/1%1%D-$S%9A@XHRR+4I>5
M%<\ZSDTNU<\>RFO/ >#0TUC3L3RB_$1PRL#P$D*#*W'%+RCO(F@=:5=ZKGC5
M>?UK9_>ULHPXAST9H.2M6@/WO[X,^G._,NB/VC@EB3.%!F]<?E21G?5BM;XZ
M:&]O%_ISV?JUIM0*N0O3&ABVDUJ?+QV;V6(G\8-NL0%F;'#@E%5"&9D<*-+I
M_[:]=RY0[90>J;K0"@N<M-1#E42D+X+]G/[^]' U+@.7XUP \3O:WY;A/;M'
MPJCUBWFKW9A1'*(<,S.=(&[+]JM@/#<!&(*]9K?,_!JU%@/;%ZFR/&O#N%P+
M>-CKRE^FI67+V_##GM)FZU(B)[K:OBQ_+\HU,O^T&9OIE^$2O[=_PF!S\5M?
MZ?#,-@7D;D-JK?I!9V'/E?5.S:3S&OXVO*LPOT/"95TGT,(P-<]E;GL/DKUJ
MX#-DH_W;RFKO"K3/03%!3[O'QQ%$S:1^O$GBVJC/Z_A W4R360MDJ.RM9'*P
MN14GE3;$JM]O:&EFZX*QC0QZ<8A-GD37("QKP.D!,"7B!UNL$*RW\@.TZ&D9
M16)ML$AAY:$ 7^-U^!]T=#/7@I/ H$]2!"/>Z8WM#0J[F>W$ [TMP3?JVAF'
M0+G>(_7Z(8X,/,MV4]^V6,3PQR!U5N8C/E/&R\\.QKA"W/#PMRH[E2G+N/4V
MQ"SER?=BXKO.PV]$TLG$@NKDM(20=4S/U^[/"<MV,DY,.\4GSSP+HAC\G:6L
MG\@FI^23_8/6]D]]+LH*\X%(91ALA3W(B%H4C;9)4J ^8T?M;,X'@<]-OX?7
M=3P[#FB.QZT[^)/3D<2I)M/2!#E4/-K964F#EU%W#7@BXS<_H:]/<A,#T.0^
M<7M?:?<,5T,YBI@K#9PSV+2'SU-8ID#+@[:C*@-KQN8[!BEL1W'AT2(&GDC-
MD=\.IOO:%<JC=VR-H$1QROI1&S@@;MV@O3K7JC!L#&^6S.X30QH8>U=;3BE[
MLI6FE)-*,OEX0!H)$XED GX;3I#".AS\?9KRQ[] /G_Z=\9B5(&'WT:>I\#A
M\OPHE M09LO%N=.)X\FO=J4>_+TIXL\)5#R\G.2J6,$$B9,3Z@CO"01 R#8%
M;PVC4E>&[9_D+@,4/@#%*)4E_!5UX9=0DGZTTC]E^Q,M!8!\'% 4AMKZYV-=
MQ..\X_?'%56S<=)!TONL/"DZ.3!HEU@457@FX.;L'(],K/HGEKCT,;M%X;/>
M^@.T39D!-"/QQO!TK=#.V4S6'+@IK&*%@=E,QD]_=A0(8DF3(IF@C*O7(Z?8
M&5TGJY3?@=.LSBAY_&:@MS6%:1_:F MY(W']+T(5ZF65GTX(DYVZ_$BC6+V?
M13*ZR_C,-,N3FIU64288!=JKB*I3*9.7BY_&UM #P8E_C1X[W^O8:#*X#3!N
M;EJ$R#3W12D7\0LI3W=UIS_)$SX(NB^VD?.#KF#AC5%7YP$=%_F^&O^*O;;C
M!!.?\M3#Q>+)&?_3- OY(='R"78L0:@3 'K5TW/^ZS7(*,1J90^,='L#]"J[
M>-+E8?@!5?D!C$3M +WCT];7UXHZKUWL*I2Z)/:MM7)9_9'/?& )561,",7<
M/2]AKV3ZYTQXW&58LBO/C C 9-M;1M-&X:GEO?35NB4O"3&QS7%A;QG1+D@K
M)#L$OO>N\#9D =@FM> )+HNV\*K*&5*J5$)7>:JHC([*G\?,^G.6NY"@H(/4
M>=N[%4AU1<L*]G0K9B6MD2WH8DBV -YU8!IQ1/]-/QS!D.X=97V@(A.CI[S=
M-ID*:K7$9AP38(5Y@9,51F-#5WH-(\RLL5MU][50\-E:?$TN)!,W%J;GL@]B
M*3D9K5'\ASH81P1L6$>>&TL1:FL\-@V$1GJ$^F4+ZTR:3VA!"1A%NT\?B(A+
MO@Z[[_IL16\S%\8?\&)>?V\-0/]FGQ1XTU1.ZR8GO5KQ!L#RC8K6U_ :[M*3
M.YM)*_X);MXB6Y,+E!'_<P0N'Y2SO)@ZG7,YZG,A<H^#.BN?[,WN<Y1=\WC^
MR7._[,=QAP^/%IL"_H]D^EFN#E1MT*[V$\FZO?+63W^ZW>^7#)4X8R <@H1U
MLPI[M768_06,?IY/OA,!:>H8K*25^F@.NNB<M6QBWLBHO['Q.+W?+%!+1@7R
M;UN'6@RF]YL C+$.?V5\ZD*S@HUJ:9]4O!0 7I7V&5-&O9XJ'=VSR8&OFA"!
MG!7>_.)]LXSV"1PF?&G*:.CR71D7!M^PU='12L$7MI\Z2XJ+BV-_N6,G:[ZM
MI >90>1F<VC(\_F)4E["X0E?%\+KT6W9D'[<BM7V6$"L?()G02$AQ32=OJ\\
MXVTF%UC_D7E>D^*6OO3L[,F$B;(;+;VHLU"@3 0,J[7$"1J7$O4L:Q"H^CX,
M2?!.D]C6-L DXZ[1XKH<67"0S9J[ZDK!U>A&[,J5@:/+-+\:#"6P+1V-L$RH
M2.9^R!EH39(K^&S36RDX.O',=81?O8E\S"P9(^%,2%"5;J4QM0+/!_77^GS?
MJCD*64*J3G'3>Z#0OL?3.=]-'V^\68=ZQ#<]-#9Q#%.+DQR,RP&\LH3B"-HX
M_I=P"#1^+8<DN*"ML\U=F>9W_3O=[=(H,P$P/*X,\?BF(BHM9)F4E ;SSEUZ
MI$:OKTZEK8PN2J6X#SX_]?':?UH8M3Q;L<)\6#QPY@V;T"(HM0H-$"-1/A6Y
MBZ!T@#JS$E%4,M+-;KY'1K5!F##EQ)P-DO"10$[&ST>V09J98^_ZB179+65.
M^@FC4.T!RR>]A+P5L37FM!9<UHN;[$Q#@.%3'['$+EUO/R^8QF_X<]9J3IK]
MTSY[IQB/V>V"]TF47O?ID8\>$Y%8.\TG:B7Y?9[)A_R"C?%?V]<WSJKF[Z@&
MX.,S8FY^46.ZTO-R(G:+E)L)[%DC8RP=?,*CBOQ?[DAH,?(7E::N*[ R3?H;
M1Z,;G[LW\S77&'<*<!AA#XW!4*H4Q_J.-]%#!+"Q8["\@5UK[5KH=3<A*1(P
M9%A?=IJ% 3KMF6![?1SD0)!V&C0Z>5MOU;BD_X#\%$:NB3'LR41IIYE W%CU
MZ[1N+.IUGCV*PKR>2RAV=:\Y^-_L?/W5,3?]?K'7_F3L_]7'@9]L?M-X>'HN
MT%!<GLY[' !7)$I?0KCG+7QI1:TR?#8+J\P3R.??"3*7)]=:W%K#877)<#V-
ME#<[VYEM5U9F-R[?&S4VK+^AW68=4YNM5NK14L;'\E2>MNRW+<RJGU0M'/=1
M'O29L*^9H%\=MU)"A#VXOJ(%\UYV7TMNC1Z$61YR.?\TT<Z2_=NV3M\+.0N*
M\:L_^9>Y7F8^XM;4?%63_SPYQ@U_4+,24K?_>6S1W2\/V@AV&@D9G'=K?U)$
M?T?ISVE6E<[-(-CR [?=B($XDO[D:1C.KXLQ4@TWHIAOG YXEX_-T[*+RNO2
MV9IQPR)HW3S-!_B($8^UHIV\"(_/H27\&_#V!P:UO3$(NY'?+H"#\%8?H0N3
M@9<.RE<ST=LA(R(;$ * GR\'WZK6ZP54#TLQR$PX2X='ZQ&0@V4C2H'OZ^L0
MAI0[9D0A]Z&\DF@0JI"]G+"!,/8@BNW':VL\,[Y#]U2O%3 8G^@P@DI&IZ8Z
M%"SE]'1<;G2_W5O(:]@"%#[\03>I="H-5UJ2Q!\S9\U%-"$'WGX(/GB8"*U=
MPN&6Y6+K9)#PSF--GS%L/695=S:SJ>NU?$H$K6[JO?IX@;/R:,^2B;Z5^5DA
MO<-%>]3*T98BXE3DU?;Q04XYR**I&*[NY4VRKML66['N6V+_)#DT%KG19=XZ
MWWY[W:D&OX;, B/VY3,LEF\K><?R'XMZ;DN814;K,'O#Y2_NY<//+0CKSARV
MCI8B,2EN]^T 3;[0A7[ L;.X7 A#8D%![$J*H0<-TMAF_&5>Z39N10WLSYRM
MX1:YT*ECFJ-P.*6>4YX%7++8COFKQ(P*V0,Q#FG:4,%?T?C)J,YE!?GR1,4C
M@IH1 ;'3Q,IRB*164,+$<>9%ZH]LM%Z=&:$')[B3E?^[ =+_C^WVOS*5^(/N
M<0Y!X+^ZC1!L-@\(HC7<TW,5\GN\VXVGS4B TJ;SQH4@&K9DI;,HH)];'L@Q
MACBI;\E.@%\GB?_5,"7X)#.#X]I'ZN'P2<T!\Y33 3H.\2%L1+Q;I?P4'990
MF=W#@'K!T9</J:C$_Z #T(OA!%E_T+7TJD5L9[)^;"(C4A^L]BL3\Y F WA(
M(5N@0K.[)>-E3_R4/D.P.VL=!>= 15OJ>Q,?_1Y%]].2<IRJL[R,>&[DW6.^
MZS_3':'I#>?W.^ UD_I*WC?J3+P:CO(;EE1B?2=!N778N;P*"O\5POV(SZZD
M#UCCZ,((<; H45 +OEIJ'UMALP([Z@O;)JS&Y9@\W]',81.IBFZV9!=O?[3B
M'R$P0EX]+Q/M>+,^'$@)BG1'OW_@AOBPOS +R*LHC[>>4\GS-*9IG9-SMZ\6
MXXTS;KX?7)&.+I<\VLM*>%1;F'@*?9\$;#0C:\I@>IM;]G3M[SI,917Q@2Q9
MIDZ&&)@*^>4KV$B53B?$DEO6)&-=;NK()(Z=(1#ZWEAYA(V*%B@D-H.S4J4,
M;=23->ZG-&??+*X3U_157EKE%AKHD4Z1PSM_!L?*TC (,^-F>A5+--RBF97_
M6:O/)=,WLKN%*'@X0'2L\M[0E#%0$RA<V7&2]K']&AV]A1;.,OI!=_[0T';I
M(6_2H<=(Q1@EFO\''9'UD@ Y/:G!M?O3-K#IPJ'WZ^_]G19]-SU:^W+0I"WR
MQ;O_,U9DLU-IPXU^L'R;;G&0V$E3QY!XI<5K'=[N+U^LI0?\1^75C<XP([_O
MHB8.[F5>+DE.G/7+RU&,2"BOF8]%QO2CZ<)IZLGJE2-/=N/W^2NR0P]WTRUN
M\QYARJ)FGV*Z5B-9Y).^;9J 75;#QK\2(G$6W^WU)6+< ?S4D]%@&O4!L%S>
MYX6$0$]I<E>RH[W0A27\AO47$>0;WA/%KPM4H).H4_CG(3@(8GU'^WVS9&VO
M^&I@H((R[IE8PU]Q:T 7H,NKK&C[ F^6NF%?RR(3JZZ-DQTKX]1*_AK)$%_-
M5-X0>).BMA20S]Y]4>XSW??4!EM[BQ1]\3XV*?C$9.^P^*CHYQQJ&!X@[B7;
M@0*@[O"IXWRR\RV-M;,-IZ4YD2E+248>IZTWKZ:GQNOC8%;O[[F84=KA$T>,
MJMYAX=]**1I=2N_?68?"U86T^.(R8?3Z<4#^)W+*1N;S0."^F%&WG+915#</
M^";2<+/[);HJ1[<97FK!Q.SA1J;2GY"$+3,\.R72Q@\Z*_)J=V+KKFIK" GK
M>!/Q(N'Z)U.:#TRF]C05J\73A18?5U9\;'KWML]QG=,S$70A6&V(XX]&R*7"
M1[)*P&RMU%0IY-W/6-+"L!]V*/+[<*VUQ:3[X AMZ40TIP,>#,D6$V?O2/J3
M&P"-YQ'H&0'<&(N*SE<A;7MM>6+K>BGKVNF^O9%I.2<@I4#Z^3M;,''7W_93
MYJ)5_(5RX[=74CZT.-.:&VM=0NU_T 4@QS7!K<M0:S$?=$Y )Y,#V+,/>UA4
MI5<^:+HQ7/9"5%ZWN$OY2OBI)B3DMQHFR,LX'AZ>1T7"7=(%D4WI)G%3D')J
M5G&HL&2TLKO>PG>[&UDEJ,HR)*JN8/F458'5.ZUU>!GB,0=0$-@;I];5LK0.
M4WGWV!Y]HV/I.U(^#@H2306'3.=T,8Q+/V!1:N\E!$N<O&+,>%5A&2]>%E>4
MVIPAAPFPS]^8O$".9J.,Z),89WUKIYWOQ3BN(9X [2'7D_BC[O>%ZUH!A(KI
MYRY(]DZ!?'?=F-\/\PUQG+?)2'O6$-$=@5.U@4J2X-=3H_CIO9P3Q7=35683
MLO\37I6&/*[#JNOU/7S9$^_R35;5_J!S'\V_T;$-"J=NGJA%B3*-!PK$R[+3
MOS)S@^9% -<<M"'Y_6+=AW5RSB]DL]F_XNX:T(OU#L6,U^VC V4M@QY=":]M
M,V=7DSK4Q'#(GIHP9Z1[O"..0T2'E;ZO*48. -4SR3:CE\T?2!764@A)X/-T
MM@K2C-@4?=@W$JB\7SVHG'.19@8AE6.+?@;I<;(EE,GP46SV$+*R2BQYR]8C
M>-Q.FFN=7)27[01/_9>=O,JM";5.]SJ"M^?NM<;QK:10E$%GQ'!O@7VKTO*(
MI._PFP2)V4.0%"WRH)C8? ];Q7W36P$@9H5C@K))-*6QOU3Z8@UCR@(Y=AS8
MJP_6<CJ>/..!L,3S\O._U-;Y9O\9])]MR'CXMZ'Q(=B0-0-SG4THVG*(6AU"
M&B8*LC4!VXRP-DR8K#WW.'@N7D_NHSPXLM#'Y5[+#[KM8O*M'W1'MJ-U_YP,
M$K9:8%VS0$CN#[ICG@9L>.!W(>U*7]W9G,K!(GO^15^LW9I>R@[OO-;KGTI5
MS9>?]2SHC^9/LL_Z!CLG_B+2ZJ2Z(>3I G=[%"\DCG<KTJ]3602"]#IVF:QU
M;")!94HL_FCB[F*@TR53U%%9K*[M@=KZMH[^LH2\G(&@MS>G6:ZP?=BO597Q
M"-S(K7V<,,E_#Z\/70U9K";ZB<L?R%AY)!HO7KA9C%_TZI6JC<ZF@R9%"L"\
MF$%F9-32PQ29@V5MN9R.[A75P91 @E@BS#)G5B_58I7Z:X]HNE1"6_IWH!N&
M)M*'O$65M64554K,]2_+$:N(22"W:I?.D_3-?:C'68EPS7(S0NI36["BXO#'
M=ZFP?EYAKU__?^</&O_*0#6YO<@W_\5D&WXLA/T>#S0P% >E1I\E#75MQX<N
ML!IVKLA5..0R5M>JA/?Q3^G<Z5C\V_T^L;HS$@IOG#'^,M"W S]4,!EH&PSY
M0??W '["LN#9@P7@+E$;F \>&=$WN*D':*G?5YU*,-8,N*UOTK12'MPZ'#4%
M2DT0#K&<4?[B-QR4FV(TN?(=CA5]]_$U'9V_B/2U[DKGE<>:R-</9]"BY310
MS</WQ*^8?[B(N(7W[4TD\0<=P208,%U;/P(]WLJZLJ:\+=J$)&:R.$3#LP>X
M9B0.D^IVCW23_)K7KZ(_2N_8^?_B?-0M<3/UT1[P)$O'^- >ZS!BN0_Q[/X?
MO+UE5%M;V#7*.:<&E+90I$"!4C3!BCL<*-(D!$IP+UXD4"2X]%"D14L(%JQ(
M""&X!(>#NWNPXNY6I/32[_WN=^^X_\_=8^1/QAYC+WGFG,^SUUYSE0$L^48*
M")@)W&ECM.Q\51;D)[VGZB^2F+I^:_!,\O/3;-@H,(,"HH:K@577Q^3J.#.X
MX.!PCK"[SZIG]: #L$SHZZKI' P _ 3)GEG!6L'*KH02(X(H,DD%_F2/I:2D
M^X?NXXI6ZA9T+&\6PQ4!7YKQG7'VY1\$]KC61_!EQEDEC!7L\F4RN+]_BV70
MQFF%M[S"JI.]"GY)X&YG3U@)?'U@1=YR*=@#8$XC0K.$A#_!*Y?R(K#:Z+/^
MV?GPS:,3KYC.7R3]0RH!%IT4)JZ7XURW8W/W.NSB8']1>61?/H_S%TD]-A$R
MT%MH_HLD&)69\^3Z?Z;]U<WE_#.6YZ?J)E5GLC'5R_II/CG//:+*R^HKO:[1
MD1Y(Z5"DA]5D_\-7GX1 ]"G1  I6!W5IT;Y=5U^RY)#E%NK)%*YAFHF5,P'9
M'2C:[%7E6L9J>FS]A ^ZV-;!]N$'?9?QO#.M;)",1+Y..F7X;.E27"0; ,CK
M&HCTO1^?$L@VDT*FB:H3E^UE[ISR[[3_,*O+@]>1$U2+1_J(M.ABI/8MM*^V
M/5Z'K$EETI77K^W+]7$EF<J633\[4>1QU_O'O3$QPM= 069B+2![;:^\9L(0
M&6"BUZH2#A\E9-)>25$?MG8'P7OTN6#9:2!^0+EIZ(OUVV[#!:@E0JHN/I6D
MM(A&:8H:_*&98V/0CW>N"E_4T:BV4ZLS@+/W=S]"ZK[]+CR^20:N _&)'1?:
M"C'))MDS-OD:J':;ICN/-".J)BY?$IJHX(CHMT<.!L<9F@41X.&6>#DZ-X2F
MJ+,#M D* \%32_S3N)>EHF2H@FTE9F9B&E-3S89JP\^UB\V&',?641F:'NG0
MDKQMIQV/.[90@3?%B52&S^V9[)D5F2),&+,88(P(B =873%G(KPW\)T3P$;*
MM6###&8/7J/Z4)#3X)A-$-Q8-&*8YN<U\E3M*=J[KEI53\9]73W[T%CHJ1%T
MM+5&F6:4UM^^A,8H@[C(7AU9!EMS27T90WPXU3\1[O::[U#MXN=HJ1T0$3'S
MJ>Y#E$T"MR7&7D'P1P5X4SV_B$@/280XBYG[%!\EOV:W^6,UIQ%OROF 7@-P
M-')R)*3(@9=59=F*>Z[7-3*A:[@Z44F7>JO72H)]&=HY\,$SL';D$(\3<;1V
M2>2UU@V=UB$8S6:=U:(L1\X&T#-RW#BHWD,UBU<D)'_<8,"*R K &T-J,!AI
M$\\!DL/!M$W9?UO64'"6V)Z*I7,W>&8VY?.D%DYN+JL?=,DNQTH5?7ED.4U1
M@-3>;2["PY*Z*GQ>8V=_[BI""7#IVCJ.3_:>>L;GJY5ZLNLUS!7,\"N[7.[%
MN 6-&4"[MU@B5?M!3@,?69V)@!:I"^Q(SPKSKO[CVN@$O?-.4:#6\X$!9J65
ML]GAZ '.^<N*,V":<#2-6.,P_MYG).C%_^9-R?EC6DWUU4' 6DXW*+EK=P$
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M#P1*KVK79:8\$&(NHT!J K65BE(.=RU&"0PZ!7]&J2AS%NYQSPV%]%>@-L?
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MAV6$Z/?O+MD3:>X3RXV>'L,NXU)[]/&S$H6N.44<X5/;EB'U+">C^$5MM._
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MXGU%P@Z;+I.U>%@E"#&0D[IV/0TJ6^#E+3SJ99!$Y'C9&8V&2/#G*0(%32U
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MM?BPXWKJGDEG6U:Q%L\Q:FV*C-?'M,,]Y1<P#F4?ZQB7H!'B8\V*YMFKJ9=
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MM[?%?_:XK3G/_?L0Y4=2+@1HIO0(=?&[V#U;/C^)M=43>^OG$D1O@PH"=7$
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M\SBU?>1H6P+++?<]OV/'.:2DR8V!*-(,[?XD$J=/&VL?3"-208LA98 ?H0N
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M?4:09 Y!#SAR\Q[D>H>+O?C .,Z*8A0SXTYGRY:%$O$5UB4@[MHZWG>1:9Y
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M*7&X'5P)<DUY-(P/8#M<,CH5)UX":S7/<O\1T#]HODQJN/CSB@0A\FDIBGK
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M[N@[00 $4PETS1N.DD,6VA-Z ]H']'I@T_HIJ3@'!T<NF6V]@B/H7$NUP%'
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MYW%3BQ[QY XS2;/AJ!*[6W/*APB#=VD0=1Z.4*C:BM5Q3MDZZ<:,K$$2;I*
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MO7P45PN?@FB!JLHM91Y+1.:ZQ]8+-Y6?:C_\=WA0F2ULZQ*4E:S]=*YH)-4
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MFYX(#J07DCQ5 V96/8[O,O-[R;<W+(TJ\*[/(KMET<@>2 GY#D=56CJF^6N
M-;P$^502C=1W-8VM1FGI[C5L,6#<I3;UB $TJV_.)=(O)24'_SG31F89:0TF
M=YM_=0S<_J@N;>XIGXD+WCR0IRMVS?3R(RS)NX;6ZTCB(N*X]_]R@8#1]DC
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M\-*W)KG,J7TFV;=.T6K7<%#.0?EAWP^&+*B^H%!,P>+++C&QU_OJ,>_7Q18
MR<)394)1218&C]HTJ[3U/Y8 3=WWA4$9L97($ZV# F97F#F0/%.4!'/+>"IU
M>[BRNI,9GR11S2LF564,+N(8RKTV]9RZI]:\&U&?1'25-*O7<RH"2J>-6Q!U
M6Z_E1H]HICF)SI\+VX%<V6E<=?(^_#EB_>'?UAGU;Z9L"@J+J*W.*)XNW(V
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MB_\Z*3$W5KE,I$ME<$A)+'&PZ]3K&&D!2H/\GMH#).:J%E8@LLJ;T3;.7_Z
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MCH]NW W\<SU,L\"<JM"GM'T EXNN?M20U5MT#BS&8TXYJ*$R]* =(0;L,^M
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MYV5,K7,?KZ^OZW'F%V:*61R\OC[TKX<6]>$.\?R[NUP-"#O#F1DP-%;^<A
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M#SG^_A[.?J-@Z%&13V5[  9-W:Y "HD8[?/00S7SW\V?I:\$:W28G:7(TCO
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M@;B>1Y+[.E.D^,T0N@E&:T!\UG.H<]6*[EQT\8?17&%AMF?N58Z0FCSR2!_
M6$%B'G?5*G>/)?H'F&J(3G9&E!2!,/<J\HP%'@?_!;,4HJ<_L+:.83DVY^BO
MK=X-/58@39T:;M#2Z<497<94+'V.S3]Z'[ O<..)S,QGL\8><XXT\81PMS45
M3Z4(]LH')AUIQUML73Y-YM<+B,[U1K1D*0+EPOVI :?R*/!K?ITY,PN &U^!
M Z?+V#T]P>[$-.>HK/N+IR733KCZ4>=/64F,K$VT\C>KW1W(I.A0IC4DHTX[
M^7;">9WN^<O5B['J:\^""0GTZ5)]4=(DIU_5EJDH%QV7D7RL_JHS,FY%_9*Y
M\HC:7L$U:JNXNBZ(,\CV,*D_6EF-_/*K!>PN?Q6_;5-?\ )D&:[I;_^F_'2F
MXU^+!_,C5_5I<N1(W<[!0>_Y7D$;QP_?R;PJ_;GE8G,F.I9WWR;@7Z>M&?VE
M#XJHE7!Z3_,7U4T4.6*ZE K/^OG(MZ+;PTP1V0\ZEAEDXFV-R/%!1:'F3 ,=
M*1"=DB>N,QSR1Z_ULTL]FM3Z!O@]"H]F+%06Y=4?FW@4-B9^'M/TWU*S_!S1
MB6@52H#*QXSZE!#'Q2^\N&+$')MY-.09W:>P1?(%+?#MA%:A3@CPN'1E@Y&
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M)P8:+U!&IU5!W%6#'?M[;!&<+4<%J!NQZ2(..L\O:?K9$*8!1Y]TA)/DN()
M%Q%MD94I*;?.>!))H2"(W[B#HB!%S1M5?E6,& NRX2PLKQ('TW%F<CVT33X#
M.]+KFM&#U%K?Y%2E_S,NFQ481IIYT-QW8'+TJ#(PA;>U0EJ]DJ$FHF1&S.B6
MC/5$HUR4AW^DK1)_3?;$LY7^BDO9.<'2)-N'>MPF8YD\/V@P&&W"1??)%<Y2
M]&0.13R-L;*1 !/N=F*D^ ]0[!@&P7M(]:V7'=\V57M*9#<7SF)R\GE/DV\J
M)3;^E"([/F8*^J"^EGJ8N1705U+NK'N;$G=UJK=B&4-H2JD;,:X7&DU)K9V>
MRN3@JHRYNPK.9]8#U QXLT?"1XW?+^EM%C$KPRLDW"VT2Z&<92C9M^F)K&&<
MWHRXLE]OM^Y21$9N4;AD[9K,P@PL&5<INX_\DUT&Q,K5HG3K72V=GMDBH?EC
M/&H:\2?& ]R"CY\E=A_Z[2JA9JV-K+WW!'EU\C0\!M'C;+&0CMT <EJK(Z?!
M,8[>/9'(\[?#!*QT98 VE@Y@,?D%2J?6PE0GQ=QPN*?N L<UN:7H%J?8VXK/
MO"I81*R):-Y2:]*@E;HY=2?1U>&3!&.=H*L'I]%+U@\-<LR8PV\TF&+W$OW&
M_,XH %?8 X0:PSCR9(*3!#'7X-0M*1BGJRO26G3@:[F$+QCI.C+IZLS<$<1@
M;]*K;EI&<8OK_/R7#9\(=30]13Q.,[H0FV(]V<VR<FA1#;S>5$F?5Z+ QRT3
M,YR:N=/F:!\KB-G.4E<&'"G&,Z1D?I[9--Y(-59-D5(;%+.9A^,:]"1]'0CH
M%#0&Z*/C5PY[VT6]P=T%(\#X:7 >G3;G(AISH(;)!XCCJDWEB\(DU@2:YINQ
MU&4.CQ*FH2X?FA]0,HM52?<G)#.8YE\/?*10X"7OXIRSD$ZNT%0TSO.9Z(OU
M<R'Q-3F%V[3:C)^HE=T/^67]MG^ !6H\,_E]#E/^G(->H0I-";KN"S+IGB'^
M0+N(N[&\4'V ;B%8W>9MZ&0YGJ^SZ0ST0!>_<E$>J>?PYIM.DB2A?(PK6^=@
M^Y5]1.>6:%/F9#KQ'H,:N0IYZ.K7^8\PD)]&'\.$D_@5EF;7=5. WU&!AKN_
MOUU_Z,03-R&6V8GN=W9!+\HO&6->->4+)T090"* [NRO_3,T8+MR0.WN8GMC
MU?MRA8E/ER8DT6L7\QDNF+0/COE.9/(*PE.IMSJ+]01:6\JN]C*MT258X4X8
M(J(#8S,"TR4GLMIW7T-$O:-BH!GK,W(N_B0Z/;R#H($*>E/M8CC1?$368,;9
M-&UT1X37U^OA"<&",?XH/_UY7]QB6%/6DSV^S8=BC%7.>MR94 :5J+)KY4J&
MB4>XJJP'1XCR-L?F'#S_.'$96ZBU)1V?XC8JMU';B.&ZH]>OP*,50S_:&.LT
M>UGA6M-%,3#AR%S"MV:<$L=4-:Z5B)L)U"P^TZT*0)J?:X!BZ/=;TP/NYI;*
M'AP+DB@?\I80!<BVI!ZC'8SCY8< ;9MK_QI\<='I6[?3/V2>4)'%75P] 9Z>
M?)W8^S"TD3N7+>=N<^_@,2-KJAYN[;SB*C9MW$$(8^R@RPO< 47[/Z_)6 "C
M83W$O-O:\2*I 4L$YPB,CDA?-DGFCB4)@C(N O/FXYFLOT*6I)U=@5*:[QY&
ML?>T_.7//ULV4OKX_J#X/LUA6@LSEUEE:\*?-N<WL8OBGY1J:E'*)<)>0)77
MH&43_H(2^66D<;BX952[U[Y4W^?M+".3!>.VB$ONE?K?1@]1SU@/J%/ CW-1
MB?HSNE@-YOHXXU%C57.MZIILBGR[4(+N8@= P1XW$>4@1KO8W>IFI_1,VR;I
M1^K^6O/CDT3G'6>P!9-U;AGD(%!^]?Z"C5":>T^:C(SU2TM2.Q!>*5J[1ZVL
MKSU9BIHE]:F^.C'P2/<2'S[H.=:8)-:%T1SYEE!G0/4(#1B*3-Z89L?VY!X>
M]\5YVH=LC;1XGZRBZM'DP]-B8GK2JZPNLSK(W%2+6F7+/MC-U,8EI/OY_T3H
M8N_]OH /Y8:^ZCA!B3]F7N,WUN0/>XB&%LG=XP2\"A $^9'9OE(>#[23U G&
M:1=T HAS+>S5Q NJ3;LMH<2UG!MS+C>2)^?FD=N<JI'7(?,G:_[2.S$;Y+C5
M:\HW86M" ?4<X*[]?"4CKR=)LZ=ULD6Y1N@>C0#MCW>Q=[J'#U(^Q*0O-7+Q
M5,&!,W,F0^)U88#6 17TXPO'CR#1M]L[)(A:/I?+J.F2U,?"9T\*C]F2Y_H<
M,L?>9IBKJ?#H^9NXYF>_^I@\V4Q^G?:.4;J:DMO3TT (",((X=]>&9AWPNR&
M)]M]C!0K;"2!!T#I?.V%XT7CP$15V>VFO;PB\:I35;BBW(-U@O'N5V,T'GE@
M^64A<M&+J;3.615\=\.'X#NZJ0L8RVT CN\>''PJWX)&ASDNEW[ZQ>DQ;[^/
M^&4(DBUQK_UWX FKTGEGLI"HV%1[8W2\-UUX=4F.P'G#M-N*_KF#*6BQB55E
MLSG7J:AN28#:V]1O_>+20?(;N7O3NW#QVVT4G7/<I<GXM<"]-CL C^3>1A*]
M0-?[L3!SB2:.&^JF$T]CU\[>RV>7B!P\8=%9<C$:2;^J33 R:<-H9?KY*(BC
M]R!!(T?W66P6%-3T@J_BTTVU4E3AC'I3F7>&O8->?WB@>:4@NSI<YH0P=:-D
M7"MA_NE!MZMO2T_<Z0UO]?BT1E[H(@<5NV3I@^EQY(ZI?+/:<%2OHGW,J7_9
MA)Z%#0J4K^8J2_<5Q7QK2;$F3"AB.\E^)#9DI:ZR/K!YK(KDD:S"@+^S\BV/
MQHAC]+/F7> W?H!>X,^43MM\.">[L?FI01RQ*.5YTV#)(/L'6K&Q%6DGM5#Y
M^^B<23,8#,($;T<B_\RHN+@-\MQ4Z&C'HD%N(.U$XT0;VG)(5#(@G_@C?W*6
MI#'6L]=+NG?P%O4$$I4 B80RPG8UY*+E"OZM)/9_/+@,8=WWG2PS376&9FF*
M2_FKS7>R->Z 098.ZE6_:T3U1-^,R$9XV>'_H.ZMH]K.MH9A9CI3@986"L5A
MD.#N4F!*BR1!&MP9K#2$0(,4 @1FBA4O$ ($*TYP=YGB3DD@.!1W=W]GIKUS
M[_<\WQ_/<]=ZOW6__5\69QVVG+W/V?NWY:_=G\2?FOL6-AE=#53F3$I\\),_
M512V8;E;>R)K4[N=<+8B<Q'^T$YT\5T=L(F$Y <7SZ+]X!F.-Q9N#EBO'PWL
MC!XH2;PM1\4U!!>LR-TCUWE16>2"<_7)HVDVDS271_7UIEW<L5R4#(IH7@XT
MB3%]'D$,NSIPQK;+2IYJ=%B ];VI+*;)K0>8C _MA'8.0)1S-?G,+7Y:M_.(
M';R074(DD][1'8G!U[5EA3__@Q62K6&F3$NJ(H(T!IW]<C'+NU8@=;!W+;PS
M[?=<)E% 87W2S!4BWQ@ID(J%D"IE%G+XZ BR*,F3F;C(*>UO3QN,U(;S&0&M
M20UK1W/KYE2PL2JEXYTM'U.SHZ68N#Y*^%07CZW5T\=1:-W3'2<5]M70=Q36
M>M#P5!/N&,JU /(63B0=X  S*^U;T[2Q&#]:3#+0F9>4R5_4I$&4+%N@%34)
M@A\;:)9&U)[EXP#V0,I8*C<A5%]Z !""EQ$P"1C27R]X7<QB"Y)(U,J@+_%P
M FYJB[%NIR;H^=NOFQ*3:0B:,TEYS310" %8E,33[:80XRUR0Q(8Y$>]]]E@
M4BX&236#YTK6M"Q<^X(-G<AF;6M_LBY[]6.WX5(<ZK VS=AIIDH&3GLHV#'O
M?&!2!SR+4GU>M5W<>PZY(:%P1^F;*8PK\?6!IBN7NU,'GN]^?F/?(=KC]]H9
MQI@\8=.;WWO4V/<]Y(*:C:I K]J L,JF_3VA*4YLM=]KNU.@D#EVW%3)W":6
M .X/58R3'ZGUU5><*]K!@3,FN8%(W&3V93?[S^ZIK=05.-:^BH5J=@3_6<?G
MA3XK$S!MZJ]CA0^B<M-?]+QFJ0EE/;IXY-02.(HX-/Z<DL=D#3Z9Z-JV5PDL
MZ5Z?X"H=J<+1[^W5Z5'3J?#E!+H! A=G6I/6R=?I&N^"JA+Z>:8J*W5JLE=[
MV_*>#8<Z9=!^<JML*(YD]XCK:@+80EN1]W#[R4Y0@%:L^J1:OWJ'L^0"=_ :
M;9.9=BTU1DU5]RR(W"1P5IOK'JG".Y/76ZB,HZ.@)29V7]!^TIN%,!,]GNI:
MO2P)>O3DZD)(9P:5RK16AIM">,-)1%8Y#B8521;=\;C5*T=;@(#=F(MIS;EE
MIO(%]K=O^__/#BO_!-' #]=U;@^GGY-<P-X+>R8NSECNVE\OB0E\\$&5732R
MN :/E+P\>_/S=^_/OKMZ[CA;R]QUH8&5?,"UG\-_:M9<_W.KO6+,Z W)G>)M
M;1FMT"G>;_L*TNS6^@J?A1^;92N4VU@UU._YN!*:G1N.WRZ.;\>>-3^]R"HN
M+3)N>_:]Q=^TOIR<OS/WV]X.YNZL=+A!W8:@5BQ&AWW::#,(6,WWH&Q,KW>_
MJYM%]W+UI!#73E%WF("#RT<-9N6<@)=5M]Z^\S00QK5[1;_!&S:65V 43N*"
MREMTZ<TQPIF3';9(]P^?9\N-.X]#>FB-7TWI,9/9.%H'P5GN0,/L"]Q[W(3'
M*6_]4,C^\5O$ EZS(,A*Q%0E0Z&('!/M#PN.K&9=QD]2 E547MC8H-0Z][(X
M%@ A7D-7&NWS5>*NQ8<U2^7> W-O<R:(DG>32W@V!DWAF5A\+?<XK>[;CY-C
MO2#O1_FO>X,\_&G>F6#]+[1M=#\-,I&<(?I"+P/#I.&\X-DGC>8G!5-IU$0<
M4#,4)9B( F3OQQ@)N*0Y'(24S=>^VQ24O? $\@"O\$\EM%?U*"5,B-7# 4U4
MKXM71XVFTR* CN?YI%/R74X<*QM)/*_R+OU>-?FSN&C?O?@R1'_AE8V,?KS,
M>:L_WVM[I+NZKU#G#":;%:&! 8GFA^P[\GG:O^U-ZW3=F(N@VO7[-!*&21OT
M>2UP)Z<98*LGW"\TOZ!UIRI<""R[@]L)$*S]@_8<CK/+NHU(Z85!Z6IS-YC;
MJ)EQ$F*4T<!S"@%;M]<.Z^OK.T\(M0FSILUM_P73AED,F8-WUP+GQR\?KGW]
M+/^T[OSLF#"GIZ<49VMG)RB!<G.].ZB>;*E@W1U.3L4=U:TI>_!GL=P$Y1_;
M14>+B;(>Y.O'-O(8% /N/I,!:4-51, T?S;NJ*HZ!E2FUKFNZ^/HQ:U69"HR
MJ!+AU>^  H75I8#*\C35C)SL1?*[J_Z+"4LVJDBN&MA&897- :=-8X".*P\:
M6Y1G)1>M]LZ>JS#)5B7A<;CRS %%.H\$RPQ74B4R*P^U$JM1D"B(3H,SX?13
MUJ:!;H-N',<M& 9VGF'-'AGVGG7O1L+,>=\O*5#/#-X=:]>,IB=[*,@LI# :
M%S&N\LC>ZH6[W'^IH/CNSS&I_TY,[,G/AQZ'QH*:+5F+.SP;!?GB+(U> PW$
MQ<6\?%07@EE<<'_=^O;4>P^\*;!J]$.F6@F$1Z.F3S>K^^5"@R*292PD5EPS
M(,D..Q?0WM&M1*!>^RE%)+GC(4U;$G?!8^U$>TJ_:-.0JX( >8/\#&[;L065
MP+&>E3MKBT1R<9&QDA8]9FGI3UQRA?,>$7R_6;O6.%*$#\W38F2^P];=MZ//
M"P ^!YO0UAOZ&>B9!HY99EZ^A_]@3CB.+X1=MEQ(-.+BE]UR$ AC33U>772.
M3/<..HMSB?-\D@N5')MB!ONS-R$W)!-MJ4D!\;>JYN[@X6BXQZ+TU.[/@3&W
M:!P%>'!GMWZ;W& B_&IMPOYC@P-!D;E[8S*1Z>%C>W@B_?B/$Y<\!2<\D)SG
M;KC[^2L5ZU0OK&5RW 1],\N-D3.)]3@[-S!^.(>?F4DD^K#<K[7'?S@-4 9Y
MW;:")-?"B:XM&6U5"!:N.P6HS9>NHLU/NST3VG'*6Z'J&9WY#S.8C5H"QIP>
MT"X1?U^@&E_C>Z'.GAJWAM-9?/SRBZU6)]!K2:Q(@+^EE@.@9I0N/AR3W1?\
MUJ7+?.^8L><E@3Y-B2 7YIWT%&L0PD?#"VQF*P/6#K5GER9+M;:3OGF<9!K6
M\-G1Z#K5N;;'YK+@[7 5?%./_G XT4.EB.R.OSU\#OW% >3\]!_'QUTK, Y5
MF[AG;;\J!^R)LDT_!KN[BDR]N2&9VH674F\8EBR(%]M#W"V\6-NY?H\ J76%
M=8T8-1Z*9SKWNUGFK:K>?86Y?(QRVS(.A9^^'DZCCBSPL3G>+LU-OHYJ(%3:
MANV?7[XQTRUZ' UNUZ>VN<8AJ]0>#:-__LY"Z/UHU,!Z"IWUA";6.7W1.WH@
M@S  S]'(B2TZFLA80EI-(.[,7@!"5MEDH\_R;4\^9*R^B@4[KF!E94Y$-NQ-
MXO<@W;DRG=0A)^V=U+R&AP[9^?WRZR]#3=[F3LZXZSY-?:[=]1I,6INE1_/Y
M@EY:%S<WJ= A5"0:C=(,^7XHY.PK ^YQ'1(.I\=]TNK=/*Y,",)7$@'RMU]-
M3BBL:DF!;X/"$:5AT.K>GECD+_[\Z15%A27C@N#%UTKT7F$'&4D)0MP5Y_5%
ML1W6SIF% J6M$6 4*!X>3@\OXJSJG[L+=X2LFQ8L^<#Z&C9FADW2K)_]<68#
MG_)LY]Q_"RK8]>9SU1?#M*'K*!"3X1-V(=BFR)>O^WBK25MY'H%-() 5$POC
M&KQ)8M22E.!1E*4U5RGG(8Y,NX[2Y!DK9A).S9Y_A,D812Z9/<\3M'5Q,<C:
M#)">W\T!D77G:$IOAFD;SL^(PNLY";(6[$-G&D_CM#Z'DU*=5_4XKR4#Y<N3
MZFR%OC=4YBB/_ZO-V5]1\A>VGR_5+N]'CMF0Y"H6&60J*+['+R:-SF\+,$>G
MW(HPWKDRB6P%2^@-938258AMO!D4G&(/:HJJ/\<#Q2>T9B>?OW[13G9G^],,
MZ8YP;4:O!L)L! =HM72#+/"(5QF/Q!SBH5XO%D\3C[,G78?(9&Y(NKU@O-1N
MR]'IN!8%O:6&)Q0A3O!VZ6)0S(6X?EMC*0>Z)SEX_?E?E^FM(\N3^::^^$$Y
M9G5W$Y^G@8PF6B478"YZ9)R)J+9^+ 4/+S J*DZ;)4%%+-0?#RV@]]+1\H1E
MB1W1@2AU_#X5X@K#)? 1J5/W%^F<4X,:?&8&N^PUB$[%O*%"B!2\0_D4W-$J
M8=U$R2>*1?^G?DF\[? '*%5HOP;@@JSOZ21869I061-G&SG!:ZD?%'XL%BA4
M3#EVAL0IPBHT37)M]G (%?EL%L= \0W?]19##V')19<#%WF-HR5]$56W:/,^
M^[H89EQI0TV)=U^"GY[. Y=-SJ>VY\0$.,Q@_=&A\<1H8UV.+8Q&MC*'5HG/
M.TLR@ZI!H"(RO+V= >P99T YEP,234J<RJ":2MSC&.\Y^##Y;N4#PZ23X^21
MXI$6=-.T6LHMF.R QH+^>FUM9.1! EV4!*EHPON>N^> *GST+AM-5J;K454,
M?MPGH:+U7<=,+-5HGNN7#)[3%8[E63 \]C'.I>X\YN7,RJCTWC019W#G<P[G
M @N5M;^!-I#VC8/*MV(?,5\FCXVJ,YVJ4A1/YAZ43M\%W041[=';'G&MA/3%
M0J,7JT+8':D=. ?[8@"#=OWPBIJ#</%&.T/8 \4T4=+S..U178'7 L7>.5QK
M4$+$V7#B.&TQ&5P9!%;,=AUPR3_ RI _5R;6%!P+#(499"<MU0F'3/(H?@_L
MSMRI7QM9N]49<0]/6,+H528Z1>6'$$9-7%@+X,<BM0.5>&7'PFPL6$/]U3FN
MV9=-9O\NT;$A4#^^4$]56J[%_AIJ.ER2(6-[)@M7PB>5N+&E=)OV_[+>O>G-
M8A4X0%O+)6.8RE_+EUV+4J*)M6:8(MRW14C/?]R=9/!H\)(NG/*UP4S9I ^S
M"][ZE>EK\FGP#8FV$+"0>C!,G\ :;J%7*,-B9MJ\&#&;_RN&?/F%OMPO"_6R
M'!S1A3"#"4P4 *C;I3R$P&1WCQ6?%&D<'.CN9Y\_B4DJ=H;V3L(!_!Z/??3
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M=KY0.[KEZCS=S;6GS)2MO<725T4AT+GUY;D'>'3&J(Q\KUR$];J>2AW:><.
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M[Q<W3^8!4G(;]K9G(IK:]X3J0^<>8NHRB\6.$QT&BVI0Y8H8I6O-=P5><^O
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M_!>3:X+\!A.'*ST@,_L44V F;.PA0.7%<#X[A^A1OCJF_Y795.OPGTFW175
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MP:29FPC]A'O1'<?'7[\;E>_X_O!12E$N.:^CA"V/<$*061&^Y%%YA<^#O3K
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M'\NQPC0LK0K^?BS_+ZA82'3L0;LVR7?/'!?3,RSRF+L*)89K_#HT#@^/6WG
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M] Z83 J;&G(U!BB..!#U'9YN5;R*,,>MCB+'W+/!O[;PV%=VR+U,A/&77XZ
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MQQJ_K&GZ=KC!QY]="V4U!I.]NAH9-6VN;\,Z^TL>C4GFY(O36JW6#1A-^^M
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M[P*+2_DHG]"\85?/$T<WME]52_<>60_^Z&OO$.'\&%/;GTB6N\PDLR/R4N5
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MYJ?,%P =-)'E]B\1E3*'*LU$B!L%+S=O.#Z8W+JBJ 8ME"J.35; <QU2#9>
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M7ESC631<,-]MD!$K]-:RIQO'';ZC#7E(T-;:$RXI,FN[!)VN<U!B]H9-NJ<
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M*'_=>?^F-VH-PG%PE^&GNL'""NS^^ZO[X0L[/\TV=UOP4V8>Y#="V6J]'I3
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M4&9Y-P]0?+7WG"W+P\V"WVY-O6HPTPQ$ B4IPD5GHIKJ)!A^J,D'Z?LZ$G@
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M T3'283S3PYH1YF!+POM2^V[!Y*LZ*M,L*&V=<42._:RG[IMHU8R/#W'F1U
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M/?5O='/]%1;7$_XHME:!2R;5LP<%&G^-)B#G7B454#)+/PLD)3KVXD&=I1Q
MEX=C#(-J51->K0<7V>HZ6DM1V ]VYGW^/ZC.%[N+WV:E$J8U-WP)*Y(5J_DV
MVQ*CE(C\<90+E&'ZJ\[XP+T526([AJ90,X#RD3.,M7Y5,7EEU:Q,?'-N6N*2
M_]<6_4+"EF5X"]\>9N8-R?++D&OKJE-IEK@,4&R<[4]G&6;D2*7!)16:Q10E
M+&QI:U:U_K['W0?QMNN,)A["8E/^Z16,=F+;0ZN^O^,</>N3S,24(=<P%MY?
M]>#;+#R%1TWLEHS@,(-OLPP$XY 28Z(8CU]M3<[>C\L278@]A0V%78N)<EX
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MP!%*#9GGP29JC3R5FJX;/6-Z@8?9(G>, $1A741C&-._JGZX6X]EZBU9-)O
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MFE5(NN[-I\.Y>6-K8E53+U)Y+A@0N:F'L7A06@O65A-HF5+/&1O:O5F43)+
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M>\A973WW'3TVV*[R%?M0)Y]H03.-7(B%P9#;8,$BS*J_P<T?#G6KW8AP.U7
MYZ'+5D@.1_8&3:Y!)'=&'>=HT]\I%/Y2ZLWN\6 Q*'5U)CNG%14N6-"3LDM6
M"^92HDBHJ?OH7708">M)8=9J8WBO,?8>TFEAI_,,7!0+UI4 @:)-$WWRW?/
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MBC63W@5Y.UK%*XPJT_)!/1AA$=JAD>_<*.)4U"<@XZCPRXN"(N_4Q/H=34\
M%.J JF0.KJ(=PHVT%SI-D" ]V0DY*9/!X;9IQIO&OY@7B=^41RJ5XDR\5!KU
MQJ42>4*DM3G:(&]4:2MGR@8@"V1D%+^LI><DT%P,RXLT5GQ4S)WX$N2\(2%$
MUR<E$_/N"'DJKU9@/:WE43I]ZJ]1;2</ .=-<AN+NLM8H&<VQC$E^/ NH535
MU\XX&X.ZZ7Z+F@?+D8#F:JA3G)>SLS)#DW/QA5[6Q0='+LQTGK%9D!"<B_S
MGZ'W,9^B3T^8YGQ;ZVD^O\\''YN]'V0:#8O),X=4UH8E'&4!W TSM2L/'W2X
M6*AH7XF?4='DZFFZJ,44374+\29,+2W) -#$34,>0!TA^Z(*+36IW;CCKP28
M,2#&[@".02W;.K;+9=IA^N:H=X0X3?Z]))8"HE]-'ZU ATQCJ@%0:>WAJ;N4
MMF4UWMUI:K.[P<F!&J-EE23SNPQ77*<=>93AH1@3YUYA>=[\F)<B$7H6"0J#
MM8OSS8VP?"0-J-H\LT[X/9.'?ZEPN:!<]3#9CO8L97UK],Q=_%YTT0^RJ3S5
M1\E#OD*DELMW54US\>A.?)5B1UF0&4"E^.VAXZGU%%.OUL@/LEU@5B0Y%(;$
M=?O >?"-"J=%QPOG)M3Q(^4,(2L9_P;B?]4N_$]M'IUK@]L*IQ,W5RCH*D%/
M/9ZD#WO4YS*U<Y1K2*?2221#A^?,OW9S(@#%XY/@&*.0KOY-@2KF#.^;C76C
MUC5N@]Z2;@F#,:K*/D<+&VB!%]\S+!,A6&_X[WRM"#N)33. !G'AS)\V4_BD
M>97?KX#1:-)0A40STEFU4*#R- ?OA>'AN=,HOI1%*C-TR\:10[7C_EMB"*L0
MT"8<'ZH( 8:)HTLG!K&M%:^SC*W.F_R#C <Z*EB$;G-YVP_)._U2R!$D4%=Y
M?OGGQ9@8P804N:YX)65"YN>NOM!PT=Y"UXBF)IVDD4B$;[(K5A>#%DD%M7=H
M!MQ+,?97SF^]W!-HS$J<T'8K&,+8:6$\) <H5$1-:$9L5$S599%+UX?+="]J
M$>H4'NXF\4NP0.K/ZU&"9?GFU07:G69V4,*O+8\<>LI4H,VS<ZJJ!DV]WY,M
MUND%]NKTBHK%=QP 4X/32+[F/>3:_!-ASV>O4J52&FKKN-IXE^%&I>/5F+81
M-S&\OM*2[+@K)-#3$.#\9\T^!"CI>&@9YZ>)9EX"F0WU,YY0K17SM#P1M89E
MKL_8N]X?\BK.^6XE!7]=;PEK=]I\@1^A06%XX<AI9B 6+!K6AI-K6*U$N=V^
M/QS[N5/SF9J&3#O+S?HB1[6;VAWOU4[YZK$<:&_F1B=(5M=J)Z]?]XU[^#6.
MH(ZFSE7J3^M]'*]Z#C6"W?<[[__L[.?*]*?@(^V!HX@*Z[4DD^\#>SR6=3F.
M7V%6(/6WEHN@5W.GAW;; NM=XC&<D9U&T"\/P%Q<PP 5J(*BZZ2)GEFL5:5H
M1'Z\[;0A(9A/>WG3[(&BDH@)9TUCB2\299-H39]4=&(_*))'&J_]N0A@:GI<
MD=W-S/[,=*NE%UTQ7!HHICL/1K@'4EXD?EW\;M4MBNV)711C%;?=CD4O1PDJ
M!+VX8YTERLXAQMJ# HSD\E599C'D3#O>B9V:=C0'(Y&[KTN#2!"M' R6.Q9L
M/NU+_?->8]?,K:/3..\B*R3+?<R?BS Q><8J(M-9"J!=968(4$Y89^12U4<\
M$3>5<3\Y<3),;EK-7O,=C*\26TU<9RE? T:+"52H+?.%G:7FF.F.!)TN&Z;R
MO3IT3Y-&J:"X%THU*A:65(R43DHJ9>8^UO<>]K7_( NK*\]U-92AR846>9VJ
M%K72+&";>Y=;:A?@?VPJA1CN+3K>>AQ);[LJ^;OV!%'L=5XT0VY&SB:FXBCQ
M&A=]9R1!&52+$Y5)]BC9 ZKSJ&;E"(WZV\K+?B\N4]>2U$V_7]<GASEJO/=2
M%/=[6#MP\E1V7%[4E)N*ETKGOF<VG<UV7B[J?M<#).$/Q&/-$6^9H]18/SZV
M'K<JF@9#K__R2?M/E+F&<8L>M^47WJ>/<+?-LP_XYT./A-*N&L?KAKG6W9H'
MZL9GBFY2H<N_UH-K__5P+>:EA\<3.:,2D"-/\'+?J)G!G-RH^EF'G3DV><95
MIM[M-MM>4M,BP8+*D74WTEHA/N,5=V^C[NK';CKI66',..BD8C4-6T@RFB*X
MEN$D(O+??SS<F?:UXGO4D]N(Y].<R"O\<]S[B>Y0]U:1[]>1]QG.0&:\L[X2
M+783P5G-.QH @73K+/H:*P>;WIEG-TNN76T4>R*V!X$U.4F,C6D4BI$W)'.Z
M^#M/UGQXUA;M&SG@7@ZD@;U[ BY&*QA#$F;8#T2*$,^$$Q#&POY85YW(1R31
MG#F&6G"A&91_')J7!66#T-A4=GQK',%_)&A:#9)7HS@T!9R@JI8+M^ALE@QA
M;)Q4U!;R0R0RTO,C\K&HS>AC90NS\SGGB'Y1%1V^4+Y<ZT/<^N]QHBK]H<-S
M4;E3Q=D!G+Q;H!Y'%Y:Y+8Z^K!9G&T,L4PPI%5 +]JK-W/?GAR.]3:P0&"OT
M155$;=ZL5K"A8S$M>R[].O#+:1:3[]^_)>OE[VTRK]'/IK^XP<6XO0ZY2"4T
M_Y:[45X(:CM*3;WF"^Q2_GO+YI5PZO[2;31CH.=-PDERA(ZGGVGJQO6OTY-C
M F_J*?NSSJT"+=ZE+=(^I":CU3I/O-#D"Z<D^,EV%"8\FUELWY7YUD;)[/ F
MXOV@1[0QH4=.K;MK9(>I'+-$ISAUXJ:38!KK<28P5+E;P=*9Z%G:;ECB WM5
MHX/1WN7&8YG4,4]ARX:VGV5(57X[VX5ND,)]3[8E1/89X9-3%OTXH[96B@D^
MGE']P&R%2TR/Y5@)V=V_7.@F5!^EL5HOS?<IZ@_OCK$5PT0$EUICU_;[R=C&
MD>+?H(763++.HFTAL4 WCK&J$%RON'IBXZA!6^M<3WP^6##*T0W0F155. -O
M>X:!ZF^+35EHF)(:;@GJJ^%,X^XT3S?"YD&]F_ 6%9=+_8J<3H;SU:+:U.R7
M@I3YB*>_T;3@ID)P4>(]@J*PSO#!IM[R^TGL/#:3*A)<8-.1;"*D,EYTVA8"
M0" M,%NS&I[Y%9L'X_@4+_-S>(M],!]\-UARD:%H[PG @GNZ*A*0(]KX["L,
MOIW&(HY<#I&6S)6H=N<>NQC0[]%PZ;P;!%65H=">^!?;HI0/#+=@A '+#C$N
MX9SFR8>Y/+G6EYEWVW0,N.YDIBI^U:WY<SKH^X9&=MH7P4S5(H$O$!S? 6N!
MZM;T0W4/8*XB,6BSO]7E$THJ/,1MM76<AN=9;'B'*(S)]FAFRM!$B:H>2YZ/
M68;R.4,7,:PO,<X:#]MW(M 3C;BL>4K QK^F,>O?]R78=.=@@?;JCLC7I.1!
M4E1M"Y8N9Y0</O_JZ80)E>#Y@,E;339%H+/U:G";BGAL TXPPY34993[W.W^
M[AY:%V3<)RDLE-!47*8/-"P/7T@(B02JQ\%JOTW-Z<R#JM)WJIL:^G@UPL9F
MK^;F'0 CV5/+)N0H%I(0ACMN1NGSSGU^X>6-1]\'MX]:?68SOH[YIK6N')^G
MB'8[5JSVAY>P*[O<*\09XOW64D-64CHTID?Z1@)5A_+#&P.:;HK7C ZEP0>&
MEC$>PRW;GA0X8]6.G"S%FS;6V [?NHWYR:+[CZ?66"1 %3JK85-YV:,-?NI"
M.GJS3AO\V*W-[R7;6_TIR(1H7=^T^I5M@*\<UEYLM?5+*</7SS!H!OF&\4"Q
M:\SN[.:"HG5\PD@23<LNMN0'F3T(KL'5D$Z[!N9"OC81=6-R& O@NLO'OTMQ
M'!/78!)YDS0>UX_,:$.F\)A("H:5PXV4.]9&]<ZT\0^DJ9T6N)INF81@5S>L
M$XLA.C9CD$?1N\8J,[EXG/8I99EFN4A7@%D,M46OL7\6U30)RX+;3:*&:8:=
M[65]D^8O>&*I+]]=$)PZ]FBT7<7CA)453XX%@+>-:+(:,^T\]<;\L8UKP0UI
M4UXSTTLWJG; A0:H4U[LU#E)]5OU@P^6W__MI"1V\/0VIMZQMJ/H)L>I*FV#
M3:SREM%UX^_BXJ,WH*-S8',&.[E"%L>B$V5P\T5NWP^R<D'ZDQI^VJWYZ.O;
ME*O4O?(J[AJW]$/OO=$I7^:/XQ_OQ3WXO[*7&:'? 3UUL/HDTHA;M6H@V3(7
MGPA=ENA!,4T_*DXYVK=4T/==5T/7YF6Z2F4>/J-+V"-=F;(H[TQY*/YX4/ '
M&=S!+'C.4W:TN@&+A/30O%A*J-:%..I81"TU2/<@'JY?KA]2/%Q&QG=6M,A$
M-8RDPKW&8\ G4BYMWK_*Z<1,Q&JHS#WN74_@%TEU=2*N 848V2X"ZW86<1TL
MCH_ST=,"R^]SL@FK??7H:D025&]-?&1%14YO-__=LM')FK^LSH;417M]>)^0
MJ9G-_4^GF]RS2G@SI8=$KT(N+G)DL?@ MH?5=##1IQ5M8 RT>NLQ#H7)Y MR
MW;GDTH6\=<M>%4__3>H/BXD3.BYYU7 +6MJ)6XE(XOCP>TUM!?.[.D"@FL+;
MPH*B3PRQTP+*5I7BA'=@+@"8BHJ*W*F^'M^,+_#WA^H@=.-SH:X.4,S:S,]7
MO.,2AZP^K>Y]4UU=4U&3"X<_(&!5^'X/@FI&F)=&F*._QX(Y:SAF*$%G_^TE
M/(&Q#%X[79A>].R9MD;F-:09^<U9OBDH;*;+UHZJNT!B_*3V9DE,1 DQ':GG
MEY2WX4+ @.O9P-"9;]H2/H[IK[?:;<XCRZQNYIILRTN>C2^CNGVI]G?^$=0R
M10XVW$NW<8I&G1NO>%C*5PPQJU@ZR@!@S@X'UTJZRI$&IP5M^&<1[\IC;N.L
MEDR&AT":R3.6F+XN5WY=8D:@?=JSESA=<9+RI=LZ;_-OX@,65D0QY%V,OA'G
MLK1T2-D&!M#CE'!LP]#MI=F[;[RH]<<OQ.90=.R>9'1[0?W=HNXS%I<1NC@C
MUY+$.@^F@7(C5$E)#\(PHIW)]4FPM,F?-M7$:KDT,U^&\RQ73>%OX<[#P%SG
M+-'PL!0K:7Z#-RQY6HX;%19*&/L5ULNKPVK39[7R-B5EX5Q_#X*$G78+_EKQ
MA.!*][D7_;4F3]62W$C3I9%ARN%3X HNGHQ<''B )/4DK63-7@PQX3RU4JH'
M;;>@-V5EMFTF3Z>U6LSZ-.<D=)#<ZF/SQZ!@93I%!T+8MU B7])9+W9?<A%\
M,T[]5^8$^8I,U5V* 2U?U0@+5/FN"TO4%#XD+*T1]2X=Z>HH0GOB7IJH'#;G
M?_8[P5;X*?1S^-3K,T_=L5=5CH[<N.&LA^JN<:TB_U39X1G*HIGV?\B&0/B<
M>=+L"/Y)^E>!'55Z !C+@!V9AG.-N:4?$Q:*N?Y.$U]F&F-1N8#)<T7^QC=;
M%^3V:AL3+8-Z'*5H\?1S?8*!FJJ.OY;55+0@?ZRMZF$VP*U_(,IVC65T#'64
M'QMO;UL'K<@\Y7-[.LG#&H8JU>%K+*'+"(]XCLH^+$D8,ZH?J2S/4Y3^B63X
MO)J!"IAY^M2F10O$7I]'0#)7P)+%13[[7^L>@^E7_"/#0U_U=2EIY'"-;Y!-
MY:#.(*(J>S _,8Z'Y"(%4,<&[)D9<PFJ!3^/]8^JCA.%^L86Q;TC-6PIV/$;
M:^22\'JZ%=#PZ38NO-M:G)$V2;%674;$T;6ED Y+2-(M[!82?;R6#G=TIJ<?
MIV\2^S3=)JGZ4/%8O*90LZ\7=>W87QO3)9/>.7/#O;K6T)56\L7A\U8D)4_'
MVJL4 9A ,=RZ>$R@8"Y:\,&>9C7B%3K  L&.3[U?6-X?F%WH[J!5CEH%\CQV
M=LL7YBX"O#%6SXQG;@'\F5TMKJ-;.G)V*08UWFSH1*K"*[$AY-EL*/5LOZ>?
M(F([K25E<,G[KXX,!#7W!UUR=)3<:R5]8R8%-LM)V%T9.*M\_F&FE?A=UC@9
M7!"*\<0XV.6;.B<5-31Y??QX@$T?,*\A1ZCM.=PUFVR;%ES=4T6CQU5R:3;
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MBKH)"MS9LN$6/^^Y011FF#Z?=//(:1S&Y[1IK^[D5P,7=3CWER),$R W@N]
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MKE.$8"!_K[MV*&24:R$L:)N\NR-E8 ALZ#N]$%'5$9_MCM)VI.&'[ ^FZ-\
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M;5JNW$CF-@_L42,I":J#_:\EBXF?WMK[1!1=M+XP%=O>E1BX!'@;_^:4L,4
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MRHYZMDO %_C-"V;*V>)8EF\VYQ?;EP!G>?^ST7-!^9IQ_VL!?AYY-Q>A,9>
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MW?PF5HP5A+B.=7-P/TZXO&!X%#B_:C'4TY_&+4K;7:G"0=\4#1N^:ZNJGQV
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M%.)(3?^H+04#Q-!\"51H),E?DKP4GU_4R,\8D;@TGQ#WR9YOV34ZPZ_ZKZ9
M,0*! ?$R3.5)B=15@"N1_,U+3!I/VB/,:]M<H .20+,5E79Y>^:@6#Y<1D!$
MPX24KU5! [80D^# )"-@+43_(]71Q:!4_L?\:4L41FZ9$&6ZR,NL[?-=\89"
M=87D5>V?XM-EJE7+;#TU'NRS.R@ZB'!%[W\^>9>1)[RQZS'&']6\D5MF]^L
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M7R8*;Y:(O&TMPCMN_MZOPPX[-M=)1Q8^UOFGOX&;^RGL4'BD(8\Z'=Z%44P
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MT)=X5C>+$76LY!LU,8KL444I864?"4YP:68Y*(D>?XV2> U6$H0(AALG6):
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MD!NXI<N5FEB&WFG=KQ>F*8Q1C;04$3EM VE0<KS#B(C0; _KZ+6^/%J;I)Y
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MNE7HW& WK.HD4Y:N.4'1?78D=P<=2:B_#7(QX';W?KN"D*SS[UU=FVK.]W<
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M5"IT\]CEE-5\0J4?" <W%L#__])03T04 /[_ET>T[Z^,:-_?! !02P,$%
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M]\R"F1+ GS93M$<!\'5B@1>'U[8:@;7,AK,3@KX'#+.&#[4A:,.2!K^*!TN
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MHL-)A^MQ9^Y4=F7)PEP;H_,Z$I4QQC-A<PC ("NC1,90'0!RG J=K1'1AC=
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MO4\8^5RMEYO(D;4A &'!4F',0ES^1IZ'"O.:\E@7*.;[XRS@3NEA>Z(#!NF
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MF<Q@G#+YSU$' 1X:U1*%P+1,CF%@(5V5Z(;8O#;UCW,J/<W+QM8"F\=9]:1
M*DABA$PA\LY*JZN!OO5$VPF8-QH8SLFU!%@_R%23J!$!"A.3(SIU;X?P0BYY
ME?&*JN?@0?^_6(V;$KKYATUQP(@624I.4<3Y/*ZD(T!@L,A[ \S2<+C<6:/6
M-=K1 19)O,JG1VMD<OT1[L"I!D=:(24HHT[0H'%G(QZWQASWAL.Y#9L?[/KG
M\2AL3+$1$AT6.0D*N'S>8&!<WK (/J'W6DH/FL>63O#OU7FB$=9MP4R,@.J
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M:2TG[5)H3Z@'+DRMS"FSH&R&,! 89T8G900SG4V9[5X@?4U:9C#X,(0ADDA
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M3G<7W[\BAC-[G91_/$]1YIV<<93GUWR'K.8K?$?JU;QI1ZSF/71'TR6\Z88
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M-N+#RX<L3 =:;/G&A#XXO*+@<%.8K6>[?;&AOMC0XY*%C7.> _N5(1\&A1/
M4!("8289YIK)1$3+!=G>C4>^U=W52@_$,H,N3Z7>4 ^*/2CVH'@'4!0A)&E2
M0C@IGZM4,F0\C2C:$$UR."9W*=/LD1786@=%30=DF662GPHH]J645\/89T78
M>L;>HM+1'9JU+HRG.45\?>;IXJRX;BC^?6EVZNIQV I+Y:W2QB6+M)8& 8]/
MR,:@D-',"2X<-JR5NA:M+I+2 59RH-42TY]OG" ;99]Z7.QQL<?%^^(B\&UJ
M12)(:A(0IRX@:RU'B6,2A([)NDM)<0\O%M<:+E)B!IJLK+[\)N-BNY'V*Z?<
M93)_ZSK5HF]+'+YO2GM/9MZ\[^MLB-QX&*Y5J5_?[OWY[:]O/[U]O5_LO7M5
M[/]U[^/KO[[_]=7KC_M_*E[_[?>WG_Y^VXQ\BE8)QCA?^?D9??:4N]EW;1.[
MUD_.#>Y:NT&H1QFS==/D>XWHO$IO,2RM*X?EI(SU[I9-G5[Y^ZYUNVO]Y-S@
MKO4)3:NQ9'O>PRA.ZN+8GMJFXLLH%-;[:AI#$4^.XZB._;K)YJ0.KC[VMQ5Q
M/9NT]=(:I 5)B"=/D?:8(R99#$0XKNBETXOON=EUH8D?9HJX-PI[,S7\]1O)
M?'WBA].0=Y7-+ITEU<:6#XY@C VXZ>O$]!#7/4'V$+>DI0OBO),*$2(IXI1*
MI(./B!B,A;,LNL<5C.D<Q D\4&:)QT5N L3U>V97&S Z'E>-RHT33%4WN:+$
MS+F04E]V\:FK7V^/;K!'P2FGHD!2TKQ#P$GD?! HI9!,\C8:ULJ>VE_'HX-/
ML3IZ!?H(%NFE/2XG=M@4:WCOH/<VMZGMDXK-@*I^EVT/8ELLR*T ,4*U<8Q$
MI(3(M6,U0XXJCI+6QJC@C:>7MCD])!]H+2#&!X9L>8B@#U.OC3^/S^HT7B+.
MO;EYPBK7FYOKS8TBQ&-. F(N8L1YP,@XHA&1GD6;)$GJ4F&S!^VJ7>A>8V$6
MT9O3ENV+'!BSY74=>M3:;D%N!6HEG)?7#$8AY5H UD1DA:/(@YL?7!!)ZE9.
M6%\):E&2=QEM-VKU4>75L.*W9P48XUD"1V]%^@(,]Q=U7X"AL40!># GEJ $
M=B2?#\>1CC8BF1@S)G++XZ/2/,ZV;RU[;7/ R!*//7XJ-1AZ7.QQL<?%NQ2F
MX51)HCG"*GC$ ]/(2&F0IS%2DIBDF+>RK77)N$@'1/2XV*FH=E^;QE_>3-0;
MJR?L'?>AH.L-3:36XZ@4,EB"H8'?D ,[@DQ2W.AH2."MG+5Y+N&P9>:MV #K
M+3^JKH>J[1;D=D"5P$PKC)'5!B/.HD8V8X\0*2JO(HX,MY+:L32HTGI@>!^J
M[D/5*Z"Z.4$) 1(<]7G/O5WI[<I-L1:K5? B@%$(0&<)<%JG/!@*@J4C/+K
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M$2&IU,3*2U5+'VDE'Q$^N<)(;OD^EQZDMEN06P%2B3+EL/4Y=.(0#\8AJYD
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MQN!##*6=5.5)\1O\!%:V^$LUGAX/BK<C_SW2K&)0&CY4GX'=Y[))A.[&6%V
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MRS,,V_]VXEBBMH3INMOO;!O?<NS^C*HD)E9M=&0#9*HK.EH!,B8/:',%7[4
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M(2BDK/O02=C;,QP2SWZV7K7+Z<]RA^J5=:]AE!LKA#<(#$8&XZC!J%%@+D:
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MO/%D4;/.3D*0K+.3$37K[$@$R3H[&5&SSHY$D-.(G2 569,$3]D""A007"A
MV6"55$J@O6[ WL3VLD6(H1]OE(N#8(0'DQ,IZY/,Z&_&3IYN7]&ZGT"TIE>T
MW'1OZ"J4\NLV]F]7N]B?VB:VCZ\\7?Y,^7+=;3O:/%IWF_;2QUVHGM#V:7T1
MWPY6C.K03#L*P[B;MB#919F,J%EG1R+(2;@H/E.I,FN0T0A [1&\;#Y'RI1%
M$)05[77'..1XAUV44]<2KLHY0*F^_VARXJS;]>-K"[+0>D:O+Q:K=T37K[WO
M]CJ[6,0E6YL1ZQ%;F]NMC2C*1E%",Q4R 1KO(:'I^X&@%=8EDS/NC<=Q5B0J
M&LA%;!9*)P@%->C^][8H%%%]LN;SJCWF_O#"'ZXU<_>F9]=Z^:RIY8!C#26&
M:5L3QMFT!3D)G 6LI0B3P#I'@+9!*F!6/:1$:O^S&>L1<;9K%G\KS8;RC)EC
MS+'I"G(:'+.8/04-1N72-O2R0J@Q@W15QU1+,&&O;;GTIEJ+"DA8ZI/7";PJ
M$7(.+E/ ]O*GIQ8^$,=\L$PR)MET!<E'$),1->OL2 3).CL94;/.CD20T]@Q
M-#??5N- 9=MV#)@">.<<5"EJ/SHDZEB&.#9\V!V#F_:.@4O'#M"7'U?K2MWV
M<MV^?U5G?>_(=9>W5*X. MEBC%AASMIBG'4;;1'(2Y()7)46T%F$( KVEJD*
M6VV#^M[LUL$/%I]_T/7=VQ[]*Z[+-0[^X)B^.\XD&-6L/FZ<S0#E;3*+FG5V
M$H)DG9V,J%EG1R)(UMG)B)IU=B2"9)V=C*A99T<B2-;9\Q,UET\=L%!V<5)(
M<4-EEE>O+VBYB;NH+KWM?^911V/6&(8CBYIU=A*"9)V=C*A99T<BR-/(2CAR
MWD"A6)S1%9RG"FB=!E_ZYENB5.F5]2C"$)4OC\H_+Z^[1K]8/2JEZZ\A+I[%
MKCQ>?A\ONFU<[)((=K[P]Q^YPL_IE\MNTV[T9UJ_Z3)=)1P\I[QZN=Q]RBX7
M;J"4-YQ+*<:45,#88^RQJ\*B/I%;8YUEG66=99UE04YC>U&UL<F@!"F]!_0J
M0/29P.F@I+;%9+>WO3BD3(:W%^>B+5Q3<X!R/:?W[?-VQT0?.NZQ73E04U);
M/+3^<*E?FXOM;+-:=&7V7C[GH$L'BOKW;_XT;--9%^1(89N=J@%"L;)9,6ST
M$@E!&"&#-KF2'*X@YR,^[%?E#-?43QVQWN8SB_(J44#H!V<VU^0PAT^2PU/9
MUY\F)'COSVPX73:PCW:[CZ94K7'7M#1Z0-M[:Y8R!!F5$KD$'>1@;?]N\=&&
M#"](J]A!8P>-(7QR$&8'C1TT9L.81,UL8#8P&Y@-O'E[H,U;=#&JH"P4Y1.@
M:]NXB%I#U3ZAC,+Y/%P'1MZ\G=CFC:L-#U"D[^(B+C/-XG;V,UULZ76B]4R+
M^4P)A6SJ!M$M];7JE:NL+M."IF?L/GW[IV'NCEU*X6Q-:$TS0RX"2EO!1Q(@
M;"X:2_0NNYL&*63CG0D"DBH>4)$&3Z%9)5<#DI'%&+MGD'9'N%<]&(<[V_5F
M[NT1)X1\=IFP_\]0/!V'XT],QR,TJ+5HBZ,$3D<+B"9"\,& D-FX9")6J0>A
M8^^NOUHMVE/?_/#+9;=]]WB9%Y?]9.5GJW5_08^VVW67+K>QR>#%ZLEJV7_I
M>K58M+<\[A\_;;9#=5 W1YR"R41EHC)1ITO44@3E4A2$:#1@,M0\3]4\3VR.
MG,=0;=H;6B<2JA Q@,#FF6*L J)& E.="F1-\M:<-%'E7$C1/-5[BY4P5YFK
MS-63XNI9AZU#=J[YO IJ<8W:.GE((D>HVO@L3%!)[/G!4@FEA:B00FY^<# )
MO/(62M'>UJ0%]7E*#TOMNTUL4&*"#C'G*#'!F>"C(7A4T4F,_:RWW!\\Z@A1
M"NR'[@0OLD^NXDV":UT""5<@AF#[.MCFJ_?AC$A*R9HB%?7IK-'3([@+<Z&.
M6,3*%&>*,\7/@>)'YJPQ.A49(P3T E!H ]Z6?KA9I>8,6V/S7GPC:I$QQP!%
M-/\8:RG@99;@7-+1Q(#-U7YHSGX6KTZK.0:.;MR!,L-V$OCD@MW/"SF7%)#=
MM_WKZFFDMK:O/K(ML]5ZU_;BF_9<:-T6,-VJE?VF\_>6W1@-5WNZ_2O_^ROU
MU>=O\R02?(]@LOEN>0F/4JC3NEM>PB,4ZK3NEI?P"(4ZK;OE)3Q"H4[K;GD)
MCU"H8[I;+@;ZLF*@_XS+R[A^-Y.[2J#?#?KP$<;)W"UW*Q[RQ,$GI;$* 2EI
M!ZB%AVA5 )55C+'::JJX>>*@T'F9@X&<,0!6'< ';T"6;$J-%)UU]U3!H^8!
MW;2["S.F3E*0]W^*.@U>"6$3H86"N@)FF2%E3Y"E5!1,)1OVNJL?Q*M3.B'U
MZH@IA,PX9APS[I08YTPU4C546:T0,/99T)3ZEATIU>H-VNKWLD!*;J^X +K8
M!)A"[>L&VT<@NN2"TH'R23,N>#VW0C+GF',G)\BI<N[,<Y8I::T)M)<"T(H(
M7I0$I<A@78EH:<]3%!&5,NWMNF"?W9P;1=L.&=!789R)4J)^:(K>+6=9SYTV
M8X(IYR(S59FJ#TY56:7QV5<@73.@S@5"%6T3;HPV25=9:,\W3:+ML$,R4$O;
M=6,T$KRN%9RM&E6VJ 6=!U5]F M[Q(DPIZJ$C-6Q271\6#TV^"SEK(N"Y"(!
M&HR0)$DH51F?=+15[ U.$+K&2*:O7Y;-B:2LP$O5B)E+]-:*+*QX:/#]#N_D
MW.HCEF:<PZ:<QS<>H$1/:#OKVLI\36PZ1JP;/+R;1<TZ.PE!LLY.1M2LLR,1
M).OL9$3-.CL20;+.3D;4K+,C$>0D(J J5*&"=)"M=8!6"O R!B"14S EV8CJ
M9@34]!U[BZ^0E$R Q5H(+@B@&D,T/FA,X68$] EM'^\B1W]?;39#]=#%N1)'
M'/4PXK7-D!J)(*<!*2\]-K9 DA&A'T$#P0@!FER@$),G;6Y"JHIH4TX>R,H,
M*(V&E*,!6ZJ2C6XQR[V9"PRI$SELX;K&K_[RCV6[Y46[P#+K3PZ[Y<O9R]@M
M9[U6+-_09ONZO6\SGRUI.UO5V3:^9?LP8AWBC2>+FG5V$H)DG9V,J%EG1R)(
MUMG)B)IU=B2"G$3L)"@,7D8+LIH,J)SK [P*;)7!VN@M^;W<_I*-#3D[L)$2
MH$FJ'TE?P(A04OL$3?NQDZ?;5[3^?O6Z7>8K6FZZ-W052OEU&_NWJUWL3VT3
MV\=7GBY_IGRY[K8=;1ZMNTU[Z>.1]$]H^[2^B&\'"L-8@=..P3#LIBU(=E F
M(VK6V9$(<A(.BK?19)7ZD=C1-V?#5D@Q)8C6:9TDJ=UI\I<?[K"#<MHZPA4Y
M!ZA46\^O5_T'K?)_S[I=([[9;B+*C%Y?+%;OB*Y?6UWT*VK^'VG]YVL9?/SO
MC3=?7*[SJ[BAV<6B765<ED_]G@W6B)61#=;M!JNX6 N&#%+TTQ(+-EME@@/A
M?:Y)%1_S7C:"))*^6@*O^\XC1BM(M6W*1?L3CQ(3E4]7RU\UU_S8[EPUW?SA
M6F-W;WIVK9?/FEIN!FS$.?&T!:;9M 7)6^;)B)IU=B2"G(0'XHRNSF8"2ZD
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M=99UEG66!3F-[840-L=$!I3- ="3@]A<? BH; G!$U8:HD4B;R_.15NX\.L
MY7I.[^>$[8Z)/LPG8[MRH*:DMGAH_>%2OS87V]EFM>C*[+U\SD&7#A3U[]_\
M:=BFLZYY<%$;4X6#$D3MK5B 4(,")8L/"9/ O#<D_.":AX_XL%\Z-EQ71SRB
M[?K,HKQ*%!#ZP9G-E0_,X9/D\%3V]:<)"=[[,QM.EPWLH]WJHX6H/"ECH#EF
M&3";!,%:#56Z*I/1M0[8E_$6'VW(\()S1QS5<)KL90>-(7P&$&8'C1TT9L.8
M1,UL8#8P&Y@-O'E[H,V;BE;HHA5$4@C8]G(0LA30=G%5J^AD2<--W^/-VXEM
MWKC:\ !%^BXN=C/YXG;V7[$MYYF6\YD22K.9&W'&!><G?>:4-ADJ7@:H3B;
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MHF8UYNSQ0X.B)@E1$F6002&@U J2"@*J]LHJ&0O5O6Q,ZT2,)4DHHL_@3-E
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M]^<E_G"ML;LW/;O6RV=-+8><I"BXMQ/C;,*"G 3.G) ^:)W;Y7H/6+4$7Y.
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M,W:?OOW3,'='-DB>'.9^F)*R40/Z(B'$?C1["N2T<D*FO=:-45B,1GIPVA;
M+'1?I$&0-$81M48I]V:Q7QWT7O5N'.ZXU^MY4.&^+-"-9<+^/T/Q=!R./S$=
MCY B0Y0PH0.MO0'$C)":VPU.D"546EKT@]"Q=]=?K1;MJ6]^^.6RV[Y[O,R+
MRW[2\[/5NK^@1]OMNDN7V]AD\&+U9+7LOW2]6BS:6Q[WCY\VVX%\>J^9J$Q4
M)BH3]0A$U=4ZK06"<[[1L50'20H/#9H"T:CHZEZZO9'66*D#F! )4*E^;EX-
M$+T-)4F41M-)$S4$,_=XQ'D63%6F*E/UA*EZUD%KX[)0S:5MZ'4)4&H%*00"
M@T+8X(06MMQDMG5)EY0JD!&NG]F<(4AEH2)9[W1/<GQH9M]MSH.>&SE!='/:
M$C.<&3X:AA<;-?53XF+8)84*"8F*[(\@"U:JQ87]V=/9QERQ^>H^^@9_KR D
M[T!+5*6T%WS^=+'/R3%<F;GT1RQK98@SQ!GBYP#Q(V,VN!BTU0:$:0XR!IO!
M6^FA:$NN!)70[H4WJB-#%3.XBJ[/\6^8S1&;TZQ*]D;[QNZ'QNSGPQO6S8,W
MT\/KX;T%VG][P>Q^/*8.W!F8-[[[LU]WU[L^P9OSYW)OOR+R8!<T_,Z]7KVS
M_^!O^N8C7;[U[E^\HEG,?4/PN'S7^#%;KK;MH^*Z_;J1K[WMY3HN9A=QO>VG
MKFY?T89FWZ^6NV2MV$]?_;%;QF7NVIM^WK9?[-J@?'WC<9;NS2POXJ8AYR*^
M)%BN"KV_B/8<^I>O'\/_0+<L]/8;T-_6!;V%TJUIAYQOV@.Z?+W\MG2;BT5\
M]TW_ZK<7L?1<_"B/K+L2]'7JE?A:MU_TW5FZ^N[]%^[^%&A9OKU8;79=5KY9
MTR)NNS?4</2V?\+M,[_Y0*:WQ[9F][ @;A._^0W)FARN_^V%]NI#(MOUM7?+
M9F':16S;8O@F7FY7W_[_[+UK<QM'DC;Z>?]%AW>][TP$BE/WB[2[$;)LS_H]
MMJ4S]IS].%%7LG= - 8-2.+\^I/5#8 @04H4"("XE,*62* O59693UXJ*_/N
M%["D_<<=C?MT-IM@:J_L\*.]:5]_\Z<E-\R?O"!@MWX=]5888(V0!T*O%T7>
M6_H<+DM^[(GFP(C9 H^^CZ&V8/%\JGZ!G\""J/X\:6;C005VT7V@V<>:=/9@
MN\2ZOWG;7OTM#9N/[4$LUQUP_NVA>,3+C&MZ.$-9D"YKM+= O>K'3+VC,0&V
MNQA_J$>@UIM9:T>A_>.Y+L)?1Q9<+!"9?:[ 2UNYG:-R3\GG,?5:?*Y0\U"R
M?H61Y\L1&%_-#(RH^E,,K_M7$8PO\+>+&X""0SMNXZLV@MD(LK98@LYK[Y_]
MS?U<^0]U6[MZ"-[NJ\7]#V7!=Z^3ZH)J]>VJ\I]/M-?^?WKD/G+!Y09W;7 +
MO=!FDP&>XYP^<W+"?'U-O@?%9YV1OGB"=B&:#XB_V2G^[2#F^;SCPMN:[LZ/
M"P-[Y&_^\QOYS>=G_E7'X5Z,$391A(^MW*_@GE6_P*]7;?4#N%?A[GF;S1CH
M*6>X#F$AM\1C!:=VQIY50;"["$8+@MU;.8HI+S!5%'\1FZ\5FR\>I"UBLXEV
M_^SY[<VT^^/GM[>UA%L^O]W%SKK(9Y4FS775C"/X^WD7*6\3?ZBG=6Q?%9#Z
M.I ZN9F7V9[N; M7G_QLM^OWKBO!;AIYSW<T[2/KFY0Z60U>=P]9?2I^??":
M]-<XK?XP;-KVCU4]\LWU-MNQGQ(S;K$SS?XX81]IFH>1@OG5.2L;YM&;G21X
MXF238Q@9+#WB26AD#&&(<6\\CH%9Y=8*>!'%/=$$>:HHXHY;9(6PB%'MK6)8
M>+>61P^R_E,GXS^#O&\['9Y0,Q!\AZ?\#U68MIGI7A#S0(E\>HBY8TR3U$K!
M4T V48$X$0IIEPCB40659!*4K9WOC,$S"E"((A,,<<,<TCQAQ RF3F( 1Z.W
MA&F?A3+)!EJ=%)(=25AJS2(_<>-[I7]C-6VJ282O?#V,U>B^59Z_SA_FE+]J
M/&D^U'DOU=V4R%>)$9P]G<]KMH6K3WZV^XQ\T6U$ON@1*M_O(USBZZX=<F5'
MH;+7^93C/[L/BD]WS#[=P74^.6I73B@I@PH><>TCXEYC9(*7B*F$-1&>.LRW
M$9Y:%4CX>1B[(\>C\&9%+K?DX5$Q !?SO#V\ F>%MN<(9UQ**ZB,*"H;$)>$
M(DVT0#)%SW0PFB>SC<C4/N%,#0@N :LM!JR*S?QPP&J%=_,91KCANIY=MX,J
MU*V'U9VVG2E=M^VL:[#AFW;:%NU3M$_1/KWV<<I80< F3BF(;!@;9"-H'P-6
ML9/612'6FS5M8$RO2NJ[-"^5,;I\F^41E-#W"W'=D@92N%C3!<\*;<\.SQ(@
M&/7)(14(6-.:8J2UPD@Q#T:VBDZ3M># )M;TGO&,###98?&Q8^#Z$H3>@T']
MYZ8)'^OAL*JOQ[:>Y*W@HEV*=BG:I=<NV&H?O$R(Y%0BKA5#FH&>T38QJHPW
M$:]E$6UB+2_$\*>E%&XQG8@(/J"\V,<%P0IMSP[!E*1*IL"1P,H@C@E%EE/X
M21CNN3>!!KP-^WB;"-956$+_C),F4UU30E^?-WB5V/(>3.$?,]=5MFWCM%TQ
MATOTN&B3HDT6)X62-Y*'7/O=<<1CI,@(*1"6.)CHK'+K'3<VL8=OM<B[]',S
MNORY_A##FTXT_SL.PX_-Y*]MW-;F)1X00L];P10\*[0]1SQC#&O (HJTDA(L
M7>&0\6 B!["33:**N$BW81WO$,^*L5SBQOLWEG\:3>WHLLY5=(O%7#1,T3"/
MYEN$D"R+#"7%-.+@ER,=(D8B:<-8-);@M>9)S[68;X6S5S$_ :RD&G1+'&:]
M\\.G>5>E1<QF6SD8 WGNIU8+RA7:GB/*\114$"$@+"4@5FZ*K*W4"$?-)2&!
M4;Q60>2Y=O1^4*Z8UR46O7_S.N^=5"!=N>=7T]IASG5VL[8>16#U8E\7S5,T
MSR(B[4ETD3 P0T5$'%N&7,06^6A$\%AI+^)6,C1L/<I2^6[T&RB-=^F[N31N
MO8P5'AA6HM$%RPIMSP[+DDPD4!D0M4(CKFU.--,8!<*\(C;QZ,56<C6>C67%
M0BX!Z)>UD+MFX<C9-N:*--?C.&K[4X'Q4_ZYE)$M>J7HE;E>H52)B(- R?B
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M:,=34D_%XBY(69#R@) R)(ZUYA1%3"7B5"MDJ.-(,<M(\,((K+=AS^\:*<E
M8E60\C#ZIM&O[)MVC!;]VRL[NH1WUZ/%Z<=<='I86U</2P>TTBOJ[.A\7K,M
M7'WRL]UG8(QM(S#&CE"-OO'SE@V3Z&/]P;IA2=LLSM_Q.'\[=L^\P(KCE*O1
MJ 2N%D[(=MV"....V<BI7"O=N%'I@)$'J&KC]['_]Z?10C#_LI3+;>\G2W;F
MU<T+J!7:GB.HA20"MU@AR;% 7!.#G.8!2?C+<9&8D]NI%/ "H$;I )LSQ[5]
MYGB>K>'\?A+'M@Z+LTY]^*G)4=;*SR83N&@>ERJ:IVB>HGD6IPBDTKG?F9$&
MS&D<(K)YRR,)0YB),=GUW8[MF--S<5VD-<TW/]Z,0K<QTE>OV;8N$@/#SUP5
M%: KM#U'H!,::Y\ M&0,''$"=K9-FJ.DJ>3"VD#26LG![9C8+P%T?$#-226F
MEV#U0=K<'0M7PV9TB0 WKHN!7?1.T3MWCP=0[HT3"@6,+>+6>&2$-4@YAX63
MFG"N=F-@+Q.,>N=W-XJ&X8&09WY>H$!;H>TY0IN@TO-@(DJY[@#WT0"T"8.L
M,MG:MISPK9Q\>B%H(VS SKU!9 E<[S/C8VQO;-<\8A0JZ_UD%F^CV47Q%,5S
M-(KGJ \ ,*.U"D*C* E!G&E04<)&)$RDU&O&6$J[S3!YW^/ FU%XTZ/ S[=)
MU%LWX/F "'Y*6JZ<J"J 6@#U@  5L%12K !+K04_(6@/X B&?\@Q=RI)@H]W
MF]VR3T 5<D"(+H!:@O#[\A]^6JEIMO ABG8KVNUHM-NN#7HM8V!1(6D#Z!+K
M'.B?J.$OY8(3R3"].X,^:YMER9ZXT$1;:RXGZ$F=\3TXQB^@=KJT+2;[HY!)
MN60R\8@$U1QQ*BER,46PP;51DECBQ8Y"^UN S*?F I:X1PGS[]%,_WF9)3.>
M-"FV+?";':X62"CZK>BWH]%ONTY,-\$2:10R1($V(1XC&[5"+BBBC+3"N:VT
MYUC70(O8T,V/S>3MT-;7[9M1F/\0_G?63G.GU7D6YU]B&R<?ME:RAPTH*\DT
M!>\*;<\.[QQA244C >\28%>( 1E#&%+PL5.:Y4+"N[&X7P[O-#NI.'G)43](
MNWN>HU[,[%VH'0>,%R?+L5Z(\;1JFV$=J@6MCD$.-Z3^ER=_&*KKJ$-1ACNA
MO4N(J>P(\&B099$C:PW%6$O&[(Y.J'; \6X<)W9:CRYWN&6<2R3LLKWU9_BT
M5RB8'5>\JJ!U0>N"UH>(UE$GB9-0&:,QXM13I%52B"N"C=0^&+FVU[K%,P'[
M0&LB!P+O\'#MR:%UZ7"X!R_GUSBM<BGQO+GPH0XQ5.ZF:A;B4&4F_=")0]6U
MHR>O.R&L1[/\[?RZ9E1\HQ*2*R&YN2[#%EOGL$'".=!@W'!D=' H..&P$H:3
MN)6>*2"Z;T%RW\\%][N;O[9Y WRIR]XL9??M4F3?+25V6[$X.N"E-DX!ND+;
M\P.Z1' (-$.54@YQGPAR"6.D ,.L#1; :RLM3PX"Z!0;8%7V'4J'P[U9Y+.V
M:SS^L#6.JE"W<U,<+BN6>(E[E;C7\<6]B/, D,$C0GU 7$>*M* 6:>J]QLS&
MD/PV?(4GZL_O5S!E$PWZM$B8'FA=MBW*MD6![P+?QPW?#J=@6.+(>Z9R$W?P
M@*24*!%O<*3$F/7VN)MX0 <%WV* \0[K&YT<?)=]C$/:QR@*MBC8LU*P.U:!
M@C.IL='(*N^S-Y)5H&<H4AN3EE8%MI4\JZ<' ;<7\!/R[/3<P47("WB>(O4+
M>/8ECHP522B"4HP"@#"E[#]XY!,W2<4DTW;2GO8.GE(/L-KAMO"I@.=V=U0>
MY,AUA^$+KL#!V_J9E:LT;#ZV59HTUU4]^A#;>V9^:1I?VFN7V9[J; M7G_QL
M]QDU(]N(FI$CC)J]\?^8U6W=6:1C>Y-/[+:#:A2G59/Z<)K-5TQB*)Y?R7L[
MFKRWH]Y3,LPJF8)!QF"/>$@B%R\QR!IG@L!66[?6<6Z3@-K[N;S_WKSI9?R[
M65N/8MO&%MS%=RE;V?-OPK:2A0=$GE3=P;*I7\"S@.<!@:?C ;-$%/+6Y28,
M@2)CO45">:<<=B0ENHV V@N )QG( IXOD(A\ML[!^]G$7UG@Z.P,]#&VCN>+
M-BO:K&BSO;@"2MI$14)4Z)0KD'MD*6?(,ZTLUX89XW;B"OQT*^U;TEZ"#SC>
M8=+O4:FO@I;'0N2"EL>#EMGT=Y@#Z$4+=CQF'+GHP:PW.(#Q+YPD9B>V__;1
MDLH!5\78+SL!^S/V)XV/,<QWU($S9Y/^H&$#:PX<7)R HM:.5JWM6/%0[ZE6
M3")&L ,SW5,PN7U$3!E0(E9+K]>Z7FQDIL]E]$<0T=] )G_II?0FU]UMAL/8
MC:E]E[:OC[@8,'I272\.3@(*NITN;8\:W6P(7BN+4;!*(RZ$RT$(CK!0AAC&
MO+)K08B-S.H70[=<F4_NL#+?,4A B:CO.Z(^GN3C:=.;RHY"%<&1'&>>+IJG
M:)ZCT3Q''2[RQ I%@D)>L@06.,;(6L<1F.\ZBL@U5EOI%+06+NHJSKZ?2__[
MH1U-0<7]L " ;>DT/1"[++)Q5!&D J#'0N0"H,<#H,Q[[AAFR#GJ$->,(J>5
M0L)[2HCF7,;=Y-KL!4 I'U!]4B&/$H(_;.^@8^NBOLH)ZW+">HM*RD2M/,7(
M4!41M]$@39E$G#)M@W(VNC4EM8W8_+NTT%)AE@^EQC=M&[>W/SQ@8H<-/T_E
M='4!S@*<!3@W+.[M*%/6$L1"3JE1*2*;9$32*465Y)&IM4W-;83]=PN<A,@"
MFX>T%U *UBW*?#]4Q:(HM:+4SDJI'75 S$=*M,$.&<X"XDQ2Y!A+*$C!$I$L
M"1%W6 KOIP6 ;%+-Z6FE7QD;<+G#)AB'J4'+SD,!ZP+6)P;61C/N'+@V7FF.
M..$1&>4,(CP%IQ51-)(=EM[;!UB+@1*ES\)+[7*<:3&^5(_LR)=B?*5LV?G2
M^;QF6[CZY&=;LH/WH$F_:R:3YB-HSK8"*W58CV)7A6\20UW2@DM6V_%DM>W8
M<]/<^Z@%1UBZO#.E!'*<!Y0<)<[SX /=^G&[GW-QIW?I;2>,V]K$!P=-X#,_
M=U) K-#V'$$L, (0%B*RD7+$#8"8B9@B%:B-0EE,M]/Y8=<@QA4>X','L9(>
MNX_#<_,T\&(<%[URQ'KER#=-C%'>8!2<<XB#RD&:48F$$40D&O-WVS"]_Q(7
MU>C?I6)ZETWJ@I4%*X\-*[$GA&,AD+*Y'%WT'!EIP.#G$4<6E&)^[7SQ)A;^
MKK&2*WYJ%GZI/'T\ICY@SW4U;.RH:*ZBN8KFVH?F(H)K+85$5@6%> H,.8X)
M<B0ZH[W3FJ[%IK[&RK\.*V>Z?P?Y_AG$>TO:R@S8+ON.'I6N*NAX+$0NZ'@\
MZ.AX<I%[BP(E$="1!V2-E,AXI:5C6BKBGV/7%W0\4$N^!.V?9\GWF:&Q&D;;
MQJIQ\#[;U70LNJOHKJ*[]J&[%-CA7'&&J$\><1(P,EA3)"5QTC)JHUS375]I
MV=\)1S6CRZS!WMIQ/;7#G[/@OUO*_=9J86!>=%I!S>,B<D'-XT'-&&5(P4>$
MDS6(<[#CC8D1V: =%2I%II]5 ?ME4)/@@IHEIK\_3^!.@YFZ;6>=,Y"3>)KK
MZR:_HO%_+TJM*+6C46J[SG/WCFBJ+0I"8,2UQ<AYK9'W6FJ-;>)BZWGN/\WE
M\EUZVTGE;UDHMZ9R#-YA]:7"[@7*3IBV1PUE3 5N;8Z48T Q3G!$.@2&DN),
M4*V\(&MY@\_-=M\EE+&!5F<.925\O@>C&=S"U98QQ5(NZN4HU<M1AW\<P<1J
M99!WAB#.J$$F&8.$X<I+K#S6:IN-8GYL)K=ROPOM10;XM-J=E8AY@<P"F0<$
MF=)0;B6SB&CO$<=*(LL!_G24(MA$O$M\FZUA=@Z9ANRPW/Y1 68)EN_![B^M
M8$H]T?.K)[KS UG6Q(0#DH:#'9^ZC';N4**.,Y)($&1M&_>Y\?05!=7)](^+
MZHB;E/W\K(8ZOTJ?!V<0%O0\1>H?"WH>M</  7NMY1EG.1C_R0'.<HZ1U$XE
MHKRUU&Q[@V"KV/RTDLQZP'>9JWB8.'TD.?JE$\VB$\U#)9R+.BWJM*C38U&G
MBEM0A8(@20FX.D$J9)(&S\=IJZ+6U!*]PTXT>]"D9B#HV7D\99^C8'7!ZA/#
M:L><(%0F)*WTB/.@D6:!(,4Q,53*I/167)^7PVJ*!Z9T#3N@/99-O)RC<&/J
MD9]TIXO!B^E<&CL*_0_Q'[/Z S Q^/M%/98T@*-) ]BQ\DG*.^]I1,PQ4"18
M8&3!=4 ZT'P<.&FLM^(H9,V3___A5@S_$MOII/;3&/(7;T;A[@<K5[Z/D[H!
M5=7+]O>Q_Q=^'\X"**X?/ODK.[J,?['3^$-*T6^K\AW# Z'8*>W['YSP%& \
M7=H>-3"&Y&3P!C#1Y1,+AFMDK%-(!:>2XXSBN)4,IJ,$1D(&3)S4Z>'#._]P
MDC;ZV\=L\LI.*Q=A%*.\[="D:MRQ=M%()9)U5I&L'6LU;T6RFC!DM):@H71
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MYH<(@/0ISQ^>^6J)39]VK?3VP.^/44O>P3*@P_SO3+2K96!E/O9ZE-N-@]@
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M)U$BC*-"/+B(# 7?@$KM.<7).WQ J1N"D $1.S[&<5J-B@ND%D@MD+HQI ;
MQY X\H)XQ#D@HTW6H.2XU8$X(S!=:^0C!!5<V'Q\P8&YKP/2/"@$_H$63*G
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M,H=LD. 4"D&LL($%+P\!V10IR%:0[3@H6Y!MV\BFO&<T2(&DX>"-YIK/EIN
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M%.4RQZ+57UN4[+[P&J43ME2D_(ZBU??!@#]VP\WQVL\. Z]A6PU/Y]B9H2&
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MD',_=)V8+4-0GKI1ZOA IG+F 00QRV2^%9E!QI,LCGGD>BL%,YZ<(P:K;G$
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M]0H9CCAM1 D*Z3L3KO>VGJ>M.#EUH;++34.DS #6,3D)DY.6_W:0_WY%PR0
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M]#JG_][? !D0EH]WPOZ!7ZRGXJL8CGY6#'V11%(0SG6&AS4V@/A)C5%K-_
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M^0PF+-^K,RRF>! F'>4=I_?J[V_L+DL++TO!",UC6];KI1%WH!+;[WVCP=
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MG&BFPLT:^ ;.Y=]SH%<H$.='G(NB(XV.+%'0L];$2V_-$-;"MLH'>$2>'HE
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M0!;J!!<<"8Z/SF]27<-V_^O+;U5]">__C)9#XR<V_38R?A]?C.E6<8TL P0
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MN&%928;?(TL@PYG&<"2)1;1] D-X%-2UC;;Z-HA"Q40+-:ARY4E> Y>1Y+P
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MI[<-KUT-C5LT]=?BS<,A?!/V^3Y)X%J 6.K>4.H^4&;X$S1J$T&?8+\@+-Y
M1&[IQ]*/I9^;G8Y.,B0*XM/1.='G(ET4&>6&ZF>X9ZD^.IGPN Z^I3A+<9;*
M9DZIJLR0\Q[M+2R)_J^("K()&_(H.?<_B4OG_V5.%WZ5,Y3XI\[BGI%?32+,
MGHHLN[).[0,K&/H+=.HY)JQYZYI!2P#$(Y#;#?!K$2S_6427CDME5EWWG>/0
MWSV7;<O+:/(F$-D('C3GU%]A[7/YPP-"@ZRU]X@CRJGP>K!4A7QJ0'F <^K9
MT,2<3\9)HU9;1_E%R_QITY#Z#I2^TW&[3WC#+>5N".6N;2.?.L&2W.;9K7Z.
M-+OAJ'U?6MZUGM-GHN4=%*,BRPT]3UVPBI[EEYO*/^S1:&FV(:NU-&MIUM*L
MW4A+L\][JS>.9C<<M:VC\?Y@666N5%KHU6P62VRWY)K+ R$VF*^N% 7R)#G1
M?1^RS0QCMP>QY0V6-UC>8'F#Y0V6-UC>T#B$V3C>\.P)Q'J9[P^6E !BJ<W:
M/3?-#L@!T':G+<D^]FIM2+,-:;:4:S=R@PG6^I.?+\UN.&HO43;A)]9IV]RJ
M=49'0"P%VH["+&_+B-I!TW!3F98)EFH!5-6NW]GR=E_5VP :D,#TX;G]_JAI
MW3M:=1M'S/:Q+P.VK;L"GVHA,!@6\+KG>I"[-RYGV,<\:G=G=[N_Y_5V^CO>
MUBO3KO!=RBG,*RJAH?KP$5"N@4(-_8QF?&4AP%<S7US3<J_T/:*ZOOEY0HTB
M?F!?!YV6CM71*26=>Y=0KK+7=7OZ.C>USU2G$N.]:^IA%E-\%E8I)M@,Q,D*
M;.,=PFRHG\APF$ENR!&$$?< #R>PZ+SJ9Q)F62%4-Q,U$'='Q[$DUV^%(:<R
MSK@5NEY%2S=\R1PLI#G1_5RPYGZ5Y8_YV9TM!Z 8X<MJ!*P53XV^K\O.]WKN
MT'NPK<(M4'D$L F[<_9IX7Y40 ^X^+R(G)^VL!9EN<X*F'-VK55URSDW$21P
M?NKO;7>V'K_XZ-IW0\-M84=XIRJ,6N_X:;GRXW+E0?.YLBKC4Y89-HH(QPF\
MA+VIUE%,> 9SFR\DV:YK-Z[HKP]@ZC$23A0JB/A2=XRIV+SJ=Q5(;*?%3;8R
M[!P%:*A*_9O]550G,T?"<("L/HT </@N\ZK[B>IMHOJ:: 3$&[9!TSJ[ VS=
M0^FDNX/A&+L#;(&42:UVCF.0MB;$O9I=:?_)[/HZ6 T_B1_>QXZ&H;]P^:=%
M)!VW.]AJN\Y7Q0%.(A&OLZ_"?4#$=6= \K=#^/@@#?_6RF U[4RFX7 %N#2@
MDGXC6RX\FG;1 FDKUNT,G4/0*>%X)'OISKL,%-14<I\;[&^)6JQ,YQ=ON_E,
M8#O"BWT8]7,Q >SQB5%_^+8M>P/7W7+;GK?7:_=WY$Y;#'?Z;;$W#(2[VQUT
M!\%+ZBT*.WPJA_]X>?A-]H>];5=NM[M=>+P?#&1[S]O>;GO;NW[?ZP[]0;?_
MTHG%!"8H_6 ?J1*)TCU(TX,@@4T(/D1B]-)A9@SGQ87J90"3CS*Y8*J^V.[V
M=P;#]E8O&+;[7;G;%F+':V_YKNRZVSL[/5?<=:J?D_@6LUT[^@B>5TG5-7#-
M^?NQ=&A WP?!6G]G:[ [\(-V=VM/M/L>_";ZVUY[Z.WN#+?DSEY_[\ZH8.+!
MUW02Y[=#6J\[D /?:P>][6Z[W]L%^MH301N.:6^PZ_5%U[]OI+W99->.#+E,
M4;]\"FB+JHHI2FAE0J0IMB2CENR VC#7]K+'7HN,6V'B\KD39B"'8<SMRD@Z
M[7=W\2 XE:,B8K/B6?N/-^OL6W8+ 97&OC<)U3!<3<5(MN,DD/J=ES5KRG](
M3[O8;_?>D>V%CTHL-@JH44SBN@UKBE;)>&2$/88\,Q4!R!?F&G5 9)A3R-3H
M!5)&5%XL\%W=V_;<K13MG4C!\VINKKK19EP&5*K)*TL9V<.XQU#]!L"4+],F
M<UBE&,+:]D5T+BXSU5/%W&^]@P1 VBT# VH[V8-[#=FPV]"3=S>GW'I,:9NL
MR1KV"WDQ#@=A_HT0K3EFC.V.\^+H8MR<_H8(I%NHUKUEPZW*"A\%!6?.EE)C
MOY<E+PS7OX>@[P= A",F&.=STGGQ J-"7KR7F9^&4V3&+]2_S6A\YW97[R2V
MM_2=>5D*=^H05C\WNRX<CG.2$O13J3I#Z;GYA^/>TXI%NO?UK_\,71T U^2Z
MX/8]'X2Z0V27V^VX?U\[=MTW,(0S3M&8, G:\L+M?G,[XWRR&$B8[S0/2/3E
M0/I)2HKI/D7#L'M_H?LO3 /G8,(65_3$G4IT),,?1Y-IE%R25GPP2B7IQRTG
MH'N+8AU:SN"2OC*0^3DV"#_Y]!L\EOX(?9FUG./8[]#M/T0&/U(!$,JRL-*=
M!>_AT^1GEISO3LX]=^/(N>>NCYP/$0Q# $2N(KD.QZ$<.D<7TN<0NB_LG7"F
M18JQ<Q1J9[0X/[KPQV@+<P[\7)G4>J+M]E^+-RTD>F7(GGV=1NMU/>T@.1/I
M0,0R:W^YB.0E?0SN>-VN9TG=DGI%ZM[FD;KWR*3^(8Q%[(<BLJ1N2;TQI.[!
MJ?[HM'X'.]9\:O<>ZV W:=+==?[LG'4..R5UNKVM[E(2WNMNWX6$S1"\]E8?
M(*OWA6Q"=.4A-\(2>B,)W>TV07Z_9_RZ SR.T?RMLFG>BUS \1S5VAFO?3&6
M6!I%+,>?SQZ=7)H"C__[]?2C<QQG.>5TO4_\@HQ/NF8M97SINX&^&R0PVSC)
M,7%+BA2C-/#!N83G#*0OB@P^DV<.C9:+$0=YH!DK0!,89D64W\ CF1_4XW56
M(UXKT&XFJB+IGAW^_NBDVYR3CJCDS!_+B2A)=T5BL2?=)I/+X<%'2RYU<CD4
MD:]C"#^&\7=,QK3$8XGG*O&\/_I@B:=./.\Q+#>TM&-I9PGM?#SXU=).G78^
MBH&,+-E8LKF&;$Y.CRS9U,GF))49_&D%-DL]UU-/WU).Y;E*8&'.B1@M,LJ]
MYJ0W%59F&MTP4@P_)'3^E8Y;!O[T9J/(;6X!NIJ/S74[KNN^JKO9,+CY0>+V
M-S]QY!&2L_[N$,('SEBF$NW,)0JO?2KK+##P>/!&@!=I'&;C>4!O9J+F\R&C
M6Z>D/C;RVE1;FVK[\A>O9U-MGVJJ;4VRVNFX_=Z,8+6TJMB525T/ WI\#MY2
M^FH&5P066LL:D1QX=OS;YX.OS<E:_?/TZ&QUCK_B!C6F)-*)$:N'00@IUK%-
M*?DF*P/V%D3QPFUWK]=OJ1='89:G^*DQZ%4!ENREZ(< ;H<9%O5+TEQ5O444
MA!M)3*$1 SD6T1!3>?!#%)RH'L"J;+*(X27Z'G"L<9+"<H-U2E5W8_KSD?/6
MA_:&I,EN[71V5T^4[7L=[S:ILNID(J!;D](-+ C.VNU)C= 3%A\D"]FG#$*1
MI^&%\PE^@]4[OZ5),:74PUL>:8N&ZEC[Z:8@^U,"A,4PBV$6PYH.V/<@H^T[
MSN?D!R?(N_4"IL\=[WZ]W+_E:;QZZA0;!-YF;YU_"ESO^XYS=AX.\Y;SJ?/^
MMB;XA01E_K/$9=GW@P*"4=O\_SH4MVAHT7!-:+B@[(3%1(N):\;$UR=I&/OA
M5$17T7'5!O06'RT^6OVJ$8"U^E4#]:NRJMOO'2[L]D#*E24JR[;7+$8L1&V+
M@Q8'UZI472GP93'18N+C*557Z\T!G[SO<_\1BV[<*]SX_PIX![Z/G3>Q"8U5
M22TU-TLE?3YH]13JV3^!]5LDLDADD:@)0'SNZ[=(9)'HWI!H>6[N3K_3=_=F
M4DCZWH-UIF],6J&%PJ-#@6AM13#8#,7GD:%8=X>M)4/QY[>#)+C\Y7]^?CO.
M)]$O_P502P,$%     @ "#AA6;A)@GL)Z@  ROL,  \   !M9"TR,#(T,#DS
M,"YX<V3LO7ESY$:2)_K_?HIXFAF;DCU2=:C5W=(<:SQ+G&%5LDF6>F?:UMK
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M<:O]7?8<]+#G=MEO79B'3[]_._>"^280S8[??U=^KN/<O5SXRAJ %X91(OZ
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M2KU,UU$<ST+X9AW%7C!;Z/FFA?7L2*UAY=\75E[W=T2PQ^-K[)*(/HG5J3C
MV"W!4 G5,8JC:=>ONZ7%37SC;=4-"[_A&^I?O*QI:+9!<[.&]?U0?1LKFF(E
M%56BR;ZN7:N3#MU3T,8Y!159',-P>4\QHN8AR1_CNJ8-:_A]80V1F-#4!3EU
M%L,E08H$2;ZN7ZWW9[6*0FETA1]2$5]8N[0RT="H8<U^5Z+\(1UM;,4?4YK2
MSO9ZZNJM:='\UZMP#CS#DW03>"&^?.*W-QL^?_1B^4MM0FO9NF$=BX8708,8
MTD20$<LJ_Z+)RS^\+FGC0133=DO7>EEXM.3>*G,,JYHT+%Z9!4:</+E2*4&B
M*;XN5\-RL43+G&<1[/]P2<,YL^_,J@8-2U5B?DF)J4O3(O>Z3OL:HV^B@*4K
MUJYIP]H5;3.EQFGR1A-\M73N;>F\1Y&]C;U3-6Q8NJ*QILGJ2=Y(RJ]KN+/Y
MTUZ[N@;U:_;[HK&FPA3ZNE0]V$3M16O7M&'YBA:7%O;1UZ7LQ:A2MIA-C1N6
M<T\#R^N"]J"I9Q[#5DT;%K-H:6FAM;\N96>A],3WQ<B\X"I<1'PE?GE.$X\%
M+>34NJ\;%KQHIBD77>%4FTZ(U0MY(_MY7?NND1<[;(']B#3LA**AIR%:XW5/
M#*?E-&Z&O;]NV 4E%J,F?>AU&PRV#3"9U]\$%..DS2];;X.ZKQNVP>[!0&@8
M5OW)R&I+87[=!WLJS.D*FC_/PA/0DC:<LW IGFHYN75:]2Y4&O9%ZRBDW'98
M8*LGT0J%2<)UY^1!B!MJB[R*D)WVB$99N KCA&^D1>712TXX_1PE9QY,./5/
M$D-EIYVS)^V&_50TO[7<3P90@J7C(0D,B(!&0L(H(7,Y)@*_LG;?ZT;;>Z,U
MRB0[?U6_.?[0WL[W*H(,: !,+X%B0VAE[X!>*#7LBOW,A]GKH^2+(]'\=;_T
MN5_2W^VU20J?-^R,&DMDZYV1,3F_;H9^-\,-<(<&2<J?V)RJ%J=;['VVN/&V
M$=]WG[2FW+"%BO;/_;:0&@]1 S(M'[9$S#6:UW!4KWNL>_SW+K;3'3]OV"TE
MQM.RJ/&L>,)>Q9-QXLIK%KKGF//:GAKV5-$,VUL\.GE3+B5_^ZH5]>-=+<JW
ME4W+'KH>Z39LLJ*5MYW/MD**KO?SOMYQ/6RMQD>N$X6&[5*T!K?=+J]J^<!9
M%KL\:ON2:=@=19OP=5-VQNM+-&A82/I>G*7\*<B4^ N,\BI$H_\<")RS8)-0
M5*LDY,T-Y:)9QLGDJK>&C582J]DB."7[9EE#-/ N,<%1@F N8A_F@IP:J5#F
M%!@0#%:V?[V^=HUYJ-T_NUQA74C5[ZX_%JW-K4*?7B\R)YNDATLF@]^UW_X:
M:A0-6[-H\A[KXLMBH+UN\EX3]QIE_#X(-6RUH@U]MW2_5YE_N(3 YJ"P?;]N
MV!254<&5:82_]6V _X,H]V)9 @7[;S?P^!R_O*4+HGZT-XM!UV9A\M9GJ[>J
MS5LO@*46A01^>N1TT1XD_Q^L+Q&C_-^^B=EJ'2@8_AY&!C\C=F84'ONRG,:>
MXZRD,_2HHY7'PNZ#SI 99LRBB^,573U0ON^ RV@,,MI'(,KGFP=Z;"9ISS'7
M4.HR<NR8QBOO.[KAT1K_(WI^"S?.PG#QS'S*CT./\^BYS:0'G)MOD?BQ^@=P
M\_Z/Q^_?'W\0T/K_4$YW;W:*R/QZ$/%F)2_@8Y;059&!UM4 _J&<4OV0]7C+
MYMY>]!_E*QC2):)R7GL/M,5UAW-M?X8[YD<L2_+^]V+ 9=2&&.X]Y3'M=\Q%
MDOL/?*<2"O;X5[($!7X@QE9H-NR8FNL,U ^V[??C<I'#SN[&4BFQ(?GK"V6^
MCNU^^YC^;.RP(P;L<-1YJD4)[S0A+2B/RGD9,'8GAJL)#LEG RIT'4>M/G4S
M]EJTY'8\M" QZ/M3CQU<^]JT^73(L5< Z=:-N?:3(<?:""];-^J6'SLZKZ5
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M&%)\ZI]N9?:Y>?5.Y@E[$D]"5=AH>P)C1+S%J:)7KD#5MQTSPE#?ET)!+:D
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MVPZ0EHTD>AS_1Y@Z"YFNZJ27-SL\W"OQ/[_(#2$]O_FBNH-TX11$Y)(%E*O
M[KQ86M5J=#]#2='K]A5%=R0R)E)**V.]\/V<!$'TC(DR4MQJ0KCH@_2$')=7
MH<HON<$0(#AX^Y<*[8EXCY>NP#7 "T,%J>"JR3%A8#@, 8."SE50T,5B00O+
MOB>1(7FX"F7T_@93VW1D5XMAEW\W:$V,BK-4W];1':X$,9EV^U_4X]71DI5-
M)_8N[_3"CF^^MF(Z5%C8WT&0]&&F0:_QS,NBI3&X0VTC3QQO5B:QNQ:^<+C^
M>O58L!4<!>F>G#/XL1*AMZKE)&!Y10:N)]T[IUO[+S5&YAT(#*!2U()!M(#(
M;_F]4]GTEBY%W4I9OK=2.,TUFT#D1J,Z$%?I W4),OW1GXS-LTE6KV[O="->
MK"A?8OHRCYZ31YQS+ZQ6ELI;CS;GM452K#),B D[KUB'W6B,'X.;JC!-\;=6
MRSYQ,RRL"GR"+<2+&N-YJZ_Z]*-@R0%1?@##2T1- :L*@8F'JZY%\,AX4OG$
M]TI]O'S7?.&RDTWRB#GPE9Z:NB]&/!E2,56E,NN-O!6-)Q'1DP*"M$CT;_QN
M?+?"5;B&Z_,:3D?POA:*H>Z+2:R,+((CPHS@U_Y&5"NJU6G:?CWF>Y*#E-26
M,W4T=,793/IK]9.S#[%14YY;8^96-!XSISZ/B%2CNE6U[C.^-H<E&-H8R=<U
M\+GMOIL$L! *+ *10)[;GVG@7T;\2UPIA+7ZML=%@!T:1\%&)D=*<W::<+J'
MT;@7DM.'%7ZP 8";P>FZ$!W7J5"L"BI>W-T,E;L3&MV?EA[$Z^KTHXK&X_G'
M<@@A:3YT%DFDR@?6]O.Q'8!6[95V;KVR#T8,7JJ$@BQMTJ<U6H<1<38O0P[/
M_'E"WLQ&=-S> 3I*)J^D0E"-E%+;>OPP\5JK:K;1A'0-K05LX88Z"SRV0NE/
M_6 0#524[2U,/'^JL7;U0+M71U&J^:%#5TA)L&E )V(^(MJRU<.&QU3+AK$.
M("WS).U+:LQ@:JO@>DNS4L-'4TS4K V*;/YN1%>@V"!F1\'5^F>6/)[!L0#!
MGIN $%15X/_[]]Y+I4]P=TK.P[^D-;\V]DLUF8S?2/@9A+&H?4V-W6B,6K<@
MI_1C*A8(*:@^R<($V5]8+:6N4;SNU3;3"9I8LK$T4FBD04SUI#?LJ+9?3^;8
M['A"QF<@M[-J#>3E;<<7/BUX]IM():RVKG]1_>GX6:ZIG:N"C[*68VK3:%HW
MCM\F;,OJ]DX?Z+M'&@1-$0>91A/!2+7+ \MK/E/@OL:/T)Z&TY6 /:#C[*28
MVB W5;6?I(DS?<QE;C3&"H%JN* ,D^"J\ZKWI]BC-FGN&1/%3D4UD5L,6IDM
MOL3E;LA=OAPY*:M5Q<KQGX:/T1/E(9[<VI>ZT,SI.5;7N,$+Q=>VM*A1;?,>
MM^\=>Y%Q,L^1%2 CXV),F$Q9@,PS--N*P)JJ&)S^2$_MUI(&D)I+IM*0TH'@
M!$)+V\0,W.^'"K8#R?'<"5&X3'1,'/13X]0O;>H8PCK-MFA7.2UM.9[*1;D2
M6;"RU#E<>Z!XU"M>-5],Q,9:APY<UG)4A3>?E)P**28IN1P8NT8QWI]FK]@M
M/'D\6<%U._="S(9 F.&K\"2$2_>1QLRKA YH^>%A&NV,92QC$H<O=EYE9T,8
M;:(1]CU%\[ZC21+(A <8ZY=P$V^\0&SUN&:F=J,Q>H:9#716_=I5M7:5B(AN
M:$Z]L\@O33ZT_SP%()5ZV\^4:IE4(%647. EF;$[PE^T)3JE,Y$)X\!<=6EL
MT=%*Z,/&"P\._3D58<4HXM;56.BWCSZ=YL;PA6[MQ2;T$7I2F2=/DOM''%_$
MI3ICP(PPQZ68$=R9W$2LC+GZ20W)_>V^=71E7D=8*ODQ"JL=L(4FXQO]A7FL
M5;Q@[2>CWR!]Y%&G\"$NLK;MWOI%(LY:?>"$HQI:@TA<UWY*"VO/(8>K/%QJ
M5ZTL&XF_%[=TNB;MUW$?XJ-FL;%$"[F90;9.\=B-QKBH$K&T[U69ONPFPV*'
M% 7VZG9])CID'CJ-6XW'M"2#H;KM ."2=49&4R:ZK:^V/[H3>5A-6&9#W<7Z
MCR8BF]G>6Q'2X'=P_Q8(C.>16Z$CZ.^JQ)I!S1*9+=IBLJD&E6_]^>A GB>A
M#?Y]R1:"A/7EP-"?>_??ZT4J;<.H$DF(N+*8UIJ&CAT. GB&23D3'98U'H="
M4\>5.#(EKF]XM.3>*@UHEK)3'F]QER_'E4 *I02+8)!V!IQP-&;,#)E$=77O
MU<DSPW0XWB328 %#K74\9=OT>.I_CF)1%#+689V54*>5+4=\@W,U@YHJB==\
MX+:D  OK2PID_C[:_'X).87W!RZ:CW"_HS%C%C:7DFGZJL],<Q%=?16J4@BI
MX44612C+,6_Z8@KH*_4NZ$*[L;,V:Q62]F"U^U)S^Y:;4)+R>K+%WU)1(ZJJ
M^%87<A/*WQ.Y)6F]R5HHE+9?C[>MR\LFUY[*^F]&8^5GN(F3QS,0B&Y 4!+Q
M<**X<RTO#1]-/@N^(=A]1RHC;D.KE#=:5D%Y#F@&=.,^:NG:; JJ':*KT9^E
M'+AW8PY$W4?C&<WP;E1B:JL"P(6V4WLF4HO>'CA2U13&C=HM*.FW%&TB>#*,
MMIZV*=?X>R XA6W:8,\M-AP=$Z:V/$+#U;D;#;?1_WET1@N]M#H'H.ZC,3/O
MO>62TZ6R):MTU.L*F([6GPV#^]]0N*^RY81B[AO+9K<";]Z-FF-%3E8[_A+&
M:SH7-O92>W=]6Z=#OF<)3NH5G$40PC9>@!G8 FP,(]4>V?H^DF>XDI%=*4S!
M&%(7SUYHYG0]+EY 6< TS=EB >I1>1A)3<,^#6$22!FN.EJ9DE;9;%0?:JIP
MY16S5JD].Y$8'P+W=&O5Q;OD]&\;&L[K*BVT^7**H3:[!]8,DV:(45LJ'9"V
MQ.+>)=6P#_)30\M7Y5:;1,9]J?1YZRE'%/4_>2'T[:/-JO+NJVD\(5,%AJOO
M:*BP/G&+U[#R@D"'"U8J%-E6X_FR[NZYN$"WZ7-1:P6M^6!$BXIQHY54>JXT
MHM1^--[K(8212V\N KIJWL"2AF.B*$7!$P8Q9095NY/JOQGO[@D"88PQ^0ZG
M4>C7GXG:3Z:6-F3TS-9F\#T(32'!JX&KLI;CVH2E[4,I;Q+=,8,>7JSG9)5[
MJC,5=R,\8IR%DAI1FZE_E$I:CJ_5E&DF.U<)SW\YNDS6JGY,1>,Q+W59P18T
MX/-H\Y L-D%18FS@:2<:4UFGTGB1G1:OED(9FTB-O*P"^"E<_MLW-#S^<O=-
MAG.X@:(-+X7D5N4 [B.L>X6VT;\&#X%NQZ. RBF"&7I^?OY.S!).T(=W[[Y_
MBW]^ZZO@5@FL_^_X<I%HDRQ@\4@2$<0#(0'0_>Y?WZ9]3XX+0>N;?]>$<.1(
MBB"M:0[\1SGP$+T*L%5RXX_"=.8''']IA1W<NG=>X'%\ZD,?A+--3...^TKW
M1-[XJJ]O"0N))[LCL>J/@'I/'F2/0^ZX 1E76S%E^-QF6'5#[FR&54^'R>\3
MY0]13-4.!N&7Z!5N6N"A^$T]X H5]%I[ZO9<2T.(_ 5)$4'K_TY_^'"%F(5Q
MRT-YA0-1[>?9*KK!HQ!^G$O)69C9.UXSHE,R6Q"[6P+]$NB8I#V3;-=$]'WP
MDZ&VJYR$*#<)7N,D_$5T.OB^ML2B$DN25BZ[['6KAY\.DYN@P,@10?)$T"=I
M!^0ONHO!URV;:H@&M#VY0D(DI00L *W!AU]=33#51GI_ZP5]DG9P4$R6BJB&
M*>Z,*4Q4Q'!UJ=+OJQH $8)4R%\DG<$W7+=AV_>9N['#4W5+UTH+D34&4;-1
M<>@B>7KV$# 9"=6?KK.02,(D$*<H,CT,*1(/P&=VQZ4=H$""74B=5'5"1"\D
M[>8@><W)7Q/B&4,J_URHOF>0#0KIQS)ZKB/_V"G!0$Z2=DNP7T)UQT3W#$+G
M"Y%]$]GYP<^&VOF_\5FPK^YI3D7J5S_Q?6@3WT0Q',__9FO$&]QSU25!HB@>
M$4F3 %&"5(?G!=-,I$>183@?O#5G**KP;7>F,J2/B"!.(DY4!X,RF#J 46*>
M)P*"6R6:[KPU([SR]?MDT5,;#I;M'IL< B]!#1N',/ZLX4R 2RPBOO)D J#0
MUWF&-RXK L/-(:H,#LYD"8972>9LE]M1]T"L+@Z4K:":HXRZCAT0T<.00GQM
M$?0^#&W"3V3U(&QL5A^#6]3ZYU"M8($S+\>9(S/9E[NTZL?=&LY%!"+"!0(\
MK3F+\WFFTHN_)\M?[DC:UW&L.R-6;T08;=+^R%]DCU_%-&1OXDOJ4PX7\,\1
M*-SHTW/)M@@Q?6(^ C^%"-^T'T?YTXHDB:%Y*%SH$WF8H[<?NK/9+U?GQ^]_
M='9L#!@"PI.(]&M5F[B+Q"B($D652++DC2+\K2/1L3?.@C9,'0PW]FX31*<_
M\E*SH).Q6_DPYL>?&=SZ?/ZXO:9/-.C@WK#\-(:F]+Z=_#*PKT. E/O,PYH5
M'SW0'2*\P&!PT7(+$M+';4CGXA\WZ#%":/;0_[0)$G:M -K-UU] HPD3@=ZA
MFO;R$!GZ)#\\(4"F R1KU:WXO1@CT8,D*14Y3(+C)'J@+MZ'B<VR]G%\#;-;
M.*-7X7J3Q.)4?N@T/>G!/"*2Z!$19,D'9UREL</UR(.9\&)$'KSN&L."5(\%
M66)W3:R^R<.6V.U4_T0,P&WLB_-IRL3*B#EX:#E7#R//E4@/5,&G)2$('>.Y
MD#A1U.T8A /C*FA@Q[+1#!XQDBNSU\FMC<2.A8L-R8$(#@2=>;A++&EGH*$S
M7]6]D39-X=MXWXN9T$LKS!"AF)"YW=]!\VOI665&Q".2Z8I8?3E2O(;DOL9Z
M6L/XT!RW*N#0U6)L=2*TA$PWKDW';CC/6$;JV!^:S5P0M,K2V',A\Z'=L'$E
MO</@PEZ4D[*H;18B-@%[HG#IIC+14,PAXLD-C[ XV(PKZ,@.2KDB)1A1U ;6
MQ?MB(!,(YIR+-/@SAWEMA:9^IKMO-NNU,^$/RO:&41"9P%>@[^B)ZYG+H#V#
M!\:9O2D->TRREP![04I]R/-5!6S<2:1.?7U';@-&S^F:TSF3'FFZ#JA*$[ +
MH'0[:"G](V)Z$+>)W8>SP]8_N\%NG!XBB]FCE](7S'D'SES6^# *>Q@NZ_E,
MV$G5&QM_HCZ;JQK/G4R0AK)^OF.B:!-!W(7M>@#N\E' 8W.9IM!E,'#]<Q%(
M)<N82F2';BEU0)WPE#SQ9:#66G1P1&+1Q>$Q&=C\692))$UN%']WA\9?J<?1
M9G N0#](C%VZ6C]=M$VY3S]'8:21J;LQI@GK@,%#8*3DF!TP&T&. T7RB-A$
M#X@?6YJL9\J1#)D",*A*P")\ -1D&$>RQ;RI!"025!/6J_TM.S:LA.J'R+ 1
MW=,1$7T="2G%='>HW)?G:ZE+4F06KU4?@E\Z-+^EH,,=C$&"EACZ3:2\"6ZL
M*.(IDV5T[5=,>*#*79ZB?$07EV],9']'VO-=ZN!-_9I'Y($N(MC@EQ%?4)8X
M<(@YFI7,FP*]B8Q#V,LBR)XAI*=\]YWD#HC^,-08S>O94.;RWW:+H,30-F%=
MSP<WN[)M%!.3K9K"0R5@I_8V.FX2=B^\9F4B;6JC+C.Q^^:L0FRU>%M+5_WP
M* XAEO/,(&N:4BFG$>?1,R;Z>&OX6[+MADT1BEM']D46JC.0'#3J.'GP KR;
M#IOGH)3=2\.NZ8F8KHCN:T#CAX#9EJC;D8+<5O6Q&["V[Q\Y[2<&$KLE8@P$
M>B'RGV881(Z#R$@5&(EHI,="Y&"(&(T+8]$8\Z6VSNL\[7"M',YD646"*&*I
M!R#2TY?_I/O>,"I#5Q$C@AH!<H-+K6E]FLI:@-<=@S9S25='Q'1U##+Z,7;F
M-BQS2)ZSMO\LI[$K3N$H6T?TDBTP_^=S%/X)-$Y1LD<6^]9%U8!\+V]"YCBJ
M7M&>0DR_1%IC=<_"WN#B8G,R&UHO_VW/@GV??WCW_@=D_7A<UJL%?U,]44&[
M=$0ZJ]#@3"\&0<8=WMEP/&?BWT0I\5A@94KH#]S\@4,$NR]W LX" _UN(NQS
M[@5WFP>TL\68C]\UM5A25^8V19_8'8R86SP$Y]EW[-,F9'.V!I;'XK)0BU&:
MVKK8_B5)>2-I-^"1,30ZL?SWQ%70S-"!<)(/JLV[,0ESPDWQUKSA=.TQ7X>)
M*7<1G#FKB&NWH$A!W\"BB)LF$NX95;Q8W:Q?">L9'USIJZEG1/4G)D3ZJV27
MCHZHF_FH%R":IN+ YZ#<4S?V@<@*S'W;SZI-%Y+\@7!5IO.XMEH-98WZ\.[#
M]\K8Y 2LPSR@O4 ;6;+ T& _/8R^1((Y@%&72"M.AFXL6:E5ME,(H+2KADAG
MPD,.,J/]//'1VA*./>2!Q1;8U5_"T%MAJ($J3/<?:%#_!:X&S'9[CGIYOE0?
MQ'1"1"]$=2,L\X,_9(,PFE5\V_#IX'$8A--@.BQ:@F:THJ;*1W=S'/K@K:(A
M@YO="IBTHO,9%W44PWE?J+0&NE73'7#OI>X24_PQ#9+8WU&2NU!T+^AF7^A^
MK*"000LI#<2B?K T:[,%,?2M2)[8E4]H(#8SHL0D>&T3DW>Q6@?1EM*"VZ,O
MDY4R59%-Z(/.2E5WZF\Z6)^LT0'B!(O$R63H+2^8E)WE\RU4!*?NLLPCY.:9
M00#S2QZM9++^!L:H7"-1&)^*\%$K+NSB!1Z.B/NPI_E6[%Y$C<,ZZE$ 72QU
M('E'0YB [0M@8-_J"%9F!9+]AN8E^X2_N193LH!1D718)!V7GBT[6%+$\EM#
M(7HLOZ%IM"\G-8EJ0XFYG*=S&17FTL7.PZ"C(BY2+^#. A;I2< B^2GE(<6(
MWCA1F[\4V,D9=+.":3@)?97_*$R[W:#]BL@/1\J0[4K#Z).KK*HH^>#TB8;#
M/^8_4R]('A'3<,:77JBRB6]EYW?BR[@3?H#L0*(FVEU@S*OHA*A>G 7?#\>R
M?4E.AV^KX.E56"CJTO%R-(XF%A)?0U\DIG*+BZJU/3"5]YI=A=DR-(,[B'KD
M)9<84;XZ;ES 'VFTY-[ZD<WAV4DX>]@(=(0NUTE*DM@T!S]$:(\Y0^C]CJ8D
M0<-AV-:%QS&M( :E22>/L7D7W4(31#5,AH8<$4'4D1N]%X:"!EX.@HFLU.!D
MW"A#2NS9((B>,2TG?UW) +ZK\&2%M:#V7!?3#3']')74!4/<XD*8PQ&171_Z
M5)1>XW8M\2<S29X>P1AW?&4M=4LI50BS Z8SWKA)C!N0V<I\1D<Y?R::5X7@
MQ!T?NC1661-T^.KUQDRFCH3A2(<2#1Z,;!5:PGA9!5^0;-.XV<Z>+=/!D0S)
MU9 -R383G>MLZ? ZG6/X5GFN>[?J)HW9_A=N0%6&8;* QJ3 V&V 4E>P,;JN
M+NZI3@G"6#07\<'A;7L8_%'O,NH@'7 *03[E =M2O1AU8@&GNRE[F8#*1GTM
M#<-;NEEM1%5'D*78G.W,DH0:NPA3,"O9 S&2_ANK$Z)Z 9D1/A')UVYRS8=B
M_"[Q>+(KZZ=TR<+PH+G/UG%MR?>!;O%@)S8/CS_[\C=,^I+6X#9]^! Q;KL@
M:Z,;7N+D.L%0ZC+D3-J(XW&KBN(R +^C$*O3.!0UE\)J'UQDXCXR&0F#ZQ=6
MW+)*XI0Y5[<TIOR)^I<1O]Q@\)Y&B.HEH4PGKRI$+MT9642<R.Z([N_@)Z Z
M#XW;;#-'_*;Z'I;&Z7#/I814D1TGM\9GFB!FEPA6]*E_NOT2H^W%:.8G\X0]
M"8VUBP@!O1!1_G*M^L'J5@;+D7BFD\-E-T@Y%2!H-Q:G;[ 7PL)OK7SSD\%Y
MM@I$Q*E3O9OON;1 Q,".HE[Y:*QVX<AE;HEU(CH!C16</M(P9D\TC5*"[31;
MW'LO70Z?+<7*2(A,9R03R"6*16"D+W3J2*(?>"J"CK-PX.SG4&^L65 9FYE9
MP/C&X7']'Y*K$"0[$?5PW0>$44K.:1!S2<6R6SJ/EB'[.[PJ/E8S6C!T-4BI
M5H'H^G")6=51X&\P<K\W3.'F0F_I&(D]2!5@HA&(?7$O6@,E:J1'#:C$XY6+
M&W_R@Q'G_3<YX5F,NA></2=.6KB)9=1\)W$*'>^2C#/!HW+F]ZC2E#<.Y_9G
M_EH0=;;<VH7[Y]:V"+?AU[DQN$^6[;>D#;-N,/E[9#!HR]LA,973<4J ](](
M.#Q+[77MCM;*/71NAQ;-X:<A8Q'#>5@$T7,LTTC*C"R#&4%7_E\_;S!<?[;X
MM D2=HTN>1 3;JC//,2D_\*7L/LP@OL&&<6*E4I*Z!@T+;M%C6V%'9- ]4S6
MNFNR$7V3.8:/KU7OLN S=#]D5+6K*=&G04[%;$%$AT3W2$R71/8I(^EUKT;\
M_ IFPCX0Z<Z0^NY^^V/H2\+D)WVB'J82B?BA6XP6P@3-;C#7)E5):""2HD-P
MP!)<A&ZU)BK $)S5?$M3M?6B*84GH^BHA?1GH9ET#"B666==:WK;*?GV^IZD
M")^V JG'0F##IUM #$>EK!&'M;]'G<#2C/C.L^C0J7;C\1D7(!,R/UP'O/?B
M1P3B"%TAR:O\1A/)?X!,5OL*UY[*0!T\<+;"IOLEY-0+T'3R<Q2@2OP1M'\T
M],Y"*Q:5LQC^9(,"[.T1L*8B[9L\RL[)$GK'C<WL\-50&L&3X8W@4YDE=2IF
M9U='>3S=,G#\(V)-I1HAP2$:/X)*V#[Q_V>C:SY["U@+%YX%@ZXS6Z!:<(E:
M04=5*P7LP9HKJ&L(J@[5J:SWX)S&<\[6G4HY9_P'N.R&Y,'PDJW9/"9#N53+
MCU'D/[,@@*?]"I2U<,F,?7CO]<HG+<')U-V(-SOMR!$&ZY!<VRM[XONBF*#
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M.R91VJVS2H9IH$!')XR!>;8R# ^ BR##@*S7>CLX R#D7X.(/5N<@53-$C1
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M.<"9S-_!C LF P4KI&=#R4#:Q]HDZ$B'/X!6D/V%U5+Z68NZA3JD%R_S1W2
MWH)FN"><:^XJ]E47J&P)Z#Y4KL0/-!W5;WO*U*G";H](/HX/(<;TP(AL@C.8
M^V7V"SEB4J+RVH^$'CC!D0\,)=SRL>AX+[5X)4>\C_9E+NL#QS/%5(0/AHE]
M._A]TQ<?E8^'PS7)'>U.:3F%B%MGY7JTW6ZV,#';-U',!,12QX@I8Q($K34-
M"-?4':Z40IO&8#D=4M<Q-24],O*",'#3@S\_/?"BUL=0RD;Y'0 #)0@CCE=!
MY;$8G!&Z=UG+*K 4E=)R,(RH3:7SCFS<E,$S=E,EZ^Z1!D$O0%J"DBOX+(R6
M21-E=!QM*@6F4 B@(G0)/$H[.3+AND)F.R*F)Y)V==!\9V+CD7EF,:\CW@D7
MS%/#_'IPYM/="J=# _U*.UH?]@$@2K)4'5D+ZN)P4Q5#M!)PB&DP;*<'P"*#
M@@9/E1DG*=H.N39R%9;7EET2V:?2TDPXLJ71R=:JK*'5^8#.%//"F])G]!HU
MQELT=<P67^(]$Z-S[K54?D$E=B$[(H'04CEV=1PMCC<Q52E 0_K2AN*X(*F=
MF&)NE(@>B.@"'470R?# WT,QFLG=WVU=!Y>0)"1\QYA1F87F3N7I-NI,,/;=
MW<7]W?"Q\4^4AWBZNU7O-62<:=!=1YZ-Y]>TAA<^E$Q^2]=8;2Y<HKJ^V?>&
M4K*'+D!@B!))=< ;Z8Z]2."PY\A"#)- 808WK PQ[!F:;0726"^P83 .C1KV
M'&71PA1&6 H:5H46)H8D\<:&?*U&FS(MP,!4*7PZ8#^#2Z?0Z%)XNBI<.CE5
M$MG. :S?:%-FWPZ__^[##_]4-T4?WGWXPU<]&UGSM6!7=#.2D"\C1VJD_!V"
M27Z4'(8"BDY77FW0;71XR5? ?GL51_;:J.,,'VGC;E9V4'>=;0E3GJ$-R(\(
M">Z*\&L78VB+>:2BD8G#<@4N9Z:J5D7M]%PX D;"F-]$(Q_#!QW@A-+<+R1V
M1)#<P'!"*"B?*Q$O+2)Y";_9._-34<O4D!0$!_=44JZL@32>+<Y!.(]9-SW+
MIH@;3M%TIG3UR%$..75DQK*AJ<*<UV,\ZK^0?_SNW7NRAHWWA*3_A;P_>O?N
M'?Y?,5+U7Q EA@KL2]<AN7OQG2];7X@SUK"7"KKA0A14(([*O??&H%VJOHG%
M4[ID87A87-J>]B;^G"20]\!3T(8=%_$J-SQZ8C[U3[=?8O3ZIO9<]'Y)# !X
MG60=;>J;,MV=XB5$<(ON&2MDO<'."0N_)99EVPS@B-A#(.D8'*VWTWDJ!F2)
M>,:U-5M1:@\WG9-CXMN3Y"[RP>GL!/UNH*]J;O*![&+?;.2\3&3/8,G*B">/
M)RMXN>9>B%5"0QCV57@2@M[Z2&/F]6)\%;T0W0W1_8@T*M,3^8NLP_!_!RW1
M.0R_ZB"TY-.5$-XE$MK$#F<2EN"+8=Z??H*ATX#G7#H4?CG^JS75Q0BFL Z_
MY04H:@YG5>D3Q$O(@U$;0 .6W[[.7JI8ULX=A=\[F[5[[R7-UH_O:)($L@XM
M\/XEW,0;+Q#R2-SAU&(\F=7)$;&ZD4=5]432K@Z:;UNP0N8]F_G8="58WRC6
MU\Y8/]W$#)YZ6>5;Q>GO;UC5U(A%SH%A]0P!>3CUSB)_7UT:21"D09#(\"!@
MQF+?+3XZ4Z+"42&C[H.WI2DAS9"YBO1P@."AV0 EIZ6"=2;O?/A=/P+D+FKY
MW/3M4"EW.S5!.BL[:^9I_PY%LY([,P/:=A($D0R5UH"JZ"-#00/N_W,J2NV@
M V^%3K4>;]HCDD+JZAY%_';:)Y&=?M4S5(9H.R36BXGP1V"7Q2;T9PN3_W*2
MW#\BRQ&7WORSB*\CS!' 8L+PGZZ00*9OZ;S'WO$G9E)_4(8$/1X! ".NQ$BX
M5-0H1 O\85!D()<3I$WCZ<0(T!LQ,?!3FD=$3K">*26B;YV6;'H7+;#_KV5>
MLH;AWO:-VXP>.15LKB#1^ZAR8;*6=)VGM>K#"P+'>5H]<:?# _+Y69J\!I0_
M&KS  HKFUW#/!S>/4=@-K$20(8*.H_0C(V^(A(1> .]3$4;0=(Y[WR=+Y1D6
M55D5+NKEY&6/LVCUP$)5R6,>+4,,0M"9;"* 2N8TH(C"J8^UU5/E _X&QP9D
MW@1&@:)(9XW8&@Z:*/6 B#TBE7!#])B$3< ./U/#.L*D'99056W)&N5O9'*S
MKYD$]F&&W,"9//!T%X*0X57&^*M>O$_W)4'\^-YNH8,AY;1^F=+FOI(P>Y2M
M1+2:@]CR?IDJ!(R_<\=,S1&TSQ8'?2M<:A0;^)&&HDB!4*72L]KEOC=WVCP=
M AHJ8M#:I0I.F'VK>;&Q[^ N"")X*01XJT-KSSBS5OL(9"YV.8 4'L@,X4BI
M[-:;,;CS)%JM6*(-X)G1]%:9U.I#8AK;O8P#TB8C[67P5*<25ZXBL+H,..^$
M4@%].A]B^D.WO8^.!@_/R<4+[,6(^W"(^59 P>_C+<D]^!FB$F!^^.*V_7"B
M]OTH'&2UYT]>@L6!MO@6=RU>F$7W("M%>G )K#^.RHT 1),4$LM!,%*+NI)9
MF '9:9-Y<_&BP63[@D#*[<K:ZN26)$6H'HGY*[.1H)0H-N0^'F>^U)YOG<ME
M1D#*4*:&]J:.-DV3JWB?-4N92A+==D'!UF;H.O.3]\N7O6P:%T&@(LCRS%'.
M!N=0M:I&W1*0C?X@D%M9Q*W#9;'*6I]#4Y/=.(12 Z43]M;?/5E!6L%MADM1
M#%E'PN'-T24.PNY#)L?A)(!.(!!Z1%=I!.9&Q$NY*?$X$._!GFP?*K^9ER;'
M])K3%=NL8$E]35XPS?0\S+'W(2/K64@32D/QW^T=>_D<A7_:> %;,.I?K-9!
MM*54Y%69R 7HY03-B,:B>,D6@H3U9>&+?A(2U&")'"U!R!/HE9ANB1ZQ B\P
MA?]P" +F*V.(50//T2C[U(&)=MHKH0[MZPJ,M@+V-?+^QQ]_CW-VW'+><:H_
MO'O_0^Z;D>;Y7.5K8GR'<%'M5T*G8*Y06: BJD5Z$"7AZ;-BQ)\B"T/7 +(1
M&>ZY%\HP-0DUUA62(:6GL,N&8B*&L8K-#-V8 +MHR;U56H!*^@_>=S%IDY0\
M4?2/K );1P.'%0[(94:M4K52Q.60 A>(\HO<].S$-/X '?F(%@T:N#CF)YQC
M00S<7:?;M(F*Y1%X0)D(R]E"<B/O8*DV=-D!QZ?8';&'1*PQ8:RNW4Z-2X,H
MI3<MCDT4JY9SK1+7U0!_.U.; =7(!..M//XK322>ABBHGMF4"7E^9/-'0M6C
M!T(S%\B *Y:@@IA$Q-D^I<$"YJ@;=!_0. 8B[NI3=!ET%@F%/8%*+@9_ ]MH
MR,@F>&Y_CN(U ]4WUJ5C]JP/DA,=#%E3DF;X4B$]<J-VT8%S86\K35/D?8@2
M09Z_8B%#%[C DU]0%P8]*8VEP<A"(OM,.R7Z&!G/CL$6A(\(D'9DV^F/M[SH
M6L[6X?"3-;8JINR \$&#ZE#$^P0;?;59]1&:I4@-?@UT'G;@=KQZVWP).05E
M&*3;CZ!C80#P++P*GZA*3.VR=U+2Y#$*A']MZ2&&2 B[R?1P1$(J*CGAUH+_
M_.,/?WA_1/[Q&/[O]S_\0>CM__C^W;L#FX>@, 5(5E5"(J(0LZ$]X,MT)HKG
M7:$Q!C/JTDAO^ -?[AYNFY,:)'G$A4'KE<C9LR+951\'Q)Y:M:^-K5R:2R8X
MVF5 OJ4M=0.)M%1&=Z T70=?8F!PRT&;*(,TWK(KJF[KZ L[Q-,AG*ZCV2@-
MLA@#/5>8S@R$,(*<)*#])H]8-58_1<7?4OK96W5!V$V)@Q0,I :.!M2K6ZR$
M*W)#X$9544^=ZN:4%*W%UT*FGZ1]#%PV9RA>2Q'C)6\8L7\L(O8=U<CQ?6$\
M]X(;C\&6//.$4MSI]4AI$B1ZS/")E[JVLYNX3[8R-\SXO/T, F_R>.9QJJQA
M=Y0_L3GM9M@11,F9J.*NZ!)%^$ YR\,LKA57L>**RSK1@V_%)X\%^!A=1OS.
M"^@=%MF0CQ]]2-)_]0#P(L);4HI'Q/1]O(CX<0R]FY \5P$^PW(?M&+\SF;\
MP#G.&E_N'B.>R/>"#:_OIK>KP=6ZCS!9*IRS@,(92PL#WT<M86UZ*726C@?=
M,ER/2!@^5+%G;5Z+Q"];80(-7E-]"O,8E$ZA&0P:5K-5IO'/.X('N:R>IS0
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M9GWAPW;U:!N1O<QOVRD4L\)SZR@:,P?RU*?119%TCEC1"T=Y,V">F</@HJZ
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M%BDL=9CUV<$DILQ256X\/N/"F2L]@-I&VJ#A5'TV"?:J!,,O(:=>@$+#SU&
MP"@?X0%%:7$66O8GSF+$3+%<HW7RZ%!]36(B3;S";($/V26B<=<]>'7M)\%0
M5KP^I_&<LW5U(E1%XXFPDO.'(0C0,PL" >J1>.&2&8FXG+OVWT^"X33)0-Q
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M=T\_ P5A2EQIJENGF>+ZK,Q*0=R^K\.,:3WE\(=&&^S.68ZP(HJS?J%>E&R
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M+( #9(,0(_/#5$WO@OM_?U=#^P!_-;[A7QS:O0_^7?QZ#_0]\2/O_;?K> _
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M)37K%Y70'S7,#"D#-^9)&I?*(I+*+6Y<@]J6A1KE->LXLQ:1!6U^P\Q],(M
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M!D GX-N#1HT'$V!2>F<-)N"XCF*L5@%>&I@O_.8$:6E[SJNG;4FT#N:F(BL
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M5D=/SO'>SSZ&LB;67TBPW:7P:H4GI+<EG[/]*Z&K3>-LS*^ZS5HX[KA-[.5
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M#;LYOH8L[APY#>WS,:/KG9> 1&3,.@P++>]C'/M?@S"\?0?U*>4\[H:P0-J
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M]*\L2;D)\"66/(O$28Y/!-[:">S^F="W8$UR8)_(.M[F5DQ^^M('V,0_BR4
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M)/?15>"O-D\DV+]F-.&L?K5YB)/TB;R1J%?5RW[^J$%O\9H0/[FC\;ZYBP%
M#%]J$K,\^\5-%OG,C,4RM4&AO$I?=N21>9-RU;)RO<%W3_ ?E:E^R'*S"P>T
M3=994,$R.Y</:E08!6?)/4!-$I![+&:" 54HUFDHF$G@E3;&2.G7*2-BK%T.
M,\&)+)IH"J3,A&#TC-3$<EP6Y^DZ1V8.NL2V54"K\V^@!MY(:N@]'TW6J2:4
MF6!#)4'&0\?LF8.!7:)J7"KRHZ &6RM$>SZ74D:T7 PS@5$F%$V G D=&S$[
MH<^E>:%[TF F,*M8FBW0EW#@6E=0G>(E]6C,!'II^/Q)X%\"$1B[>UH97 (?
MQ4Q08%2@>Q@.YD$.4Y2G[N,+,P;4%T+K\RKT.;G:-Q/813?A5.#G<04T^1T#
M TVK-"J)OP\U1HQDA-PAV&*,0D?63*!7B8?AX,\C=VX,9X*MRQ S/D:0E I^
M.M,$.'.WTG 7+&;4C$ 4"DO[S O76_@:!_FQ,:-G),*0O$@Q%^P?\44A$K&8
M"_&/=.@-$R/FNODC'K3*A8"Y//Z(*!#YX3'7OA\1](ZU=3:9\-=>LF/9_V]>
MR+MP18U*&\EY2M\JM] 3NXU8/+-Y8T8/JGY14OK68(Z[ $W8&VRHNT5%6*Q\
M@L-BEV5]=_'NQ)\J*Y>>M*33TS2%\!Q;_Y;==OG4[CZIYU,<D>,GC_Z;I'?P
M^$JNTFN/TF,0;56-F76S9A<0;"U'2^N6@4C#;.@TJ8YE+K9;#S>%<,2,$:.B
MEJ<SD2ZJ! -18VE9D4 J%XA6"6S7ASN%=&:"+:7+Y&SHFKWG<9!,,I;KL_:S
M6$NE038U[/:%NM1GXT/7)?:J/5V]P3[8.=S%]!FV7[<)E1DEAJWAM(I9H_=I
M9ZNJ:GTF,YV!)<=Y>]L2V(RG.P.POBPO\"L*<XU@())-7WLIV0('^Y6;%)7/
M4X.)EPB4^Y<U+_^[(90Q[;SY'PC?U>8NB+QH'3";<&GI3Q@0B?@K=>V8,7_"
M'<,)PZ+K=.'=_1"#PJ(\?^449X (D*O@+K+1WPC6["?<W_ OSR\L*SJCQUJL
M*<E6,<$A$-P[QT[D,0YA2VLO?,Y>610*T[MU !E-=@C<Q_B-T(B'3QQ@0S$E
M_FV4$@HO@*2KDFA ';"4.V<&H6FP@>-(V26Z(8<X"5*U2T,Q8W;FW)->(UV7
MO%;'GZE]830DF;\84&/*R-PG?SPT,6*BV,X$%RICWEC(F+VI;DH5JG73E*HR
M9N09QPI96%7D1#8#-Y,1M]&\*%H15*.2WDQ0IV).CG!W,9D=4_,RU>L),^JF
MYF12NL6<!(&"GLP>LIA3!E"@<<B3&7,V @*D*I_CLW%&WGD!Y=[C3YQODXX3
MLOIZ%5T],0JA@$3>6B_W22;?^GYA[?MUN@T_24B:5!10-XB[>H7KX:U3R?[U
M\]Q9\\M-?3A6?_X4$ IL97=\(&]$U/C)<K)[X)I7N;]3I3'?;HWE@#I%X>5N
M.(_@QG2V;CC)_;'<1X<L3?B=^%YIH5;-< _&AV.#-NXH^4]&HK6J1KK)3/=@
MB;9F?56Z,R\3+/<.22&;JE0QL\NEFHH@4,2 \QE.<G]*#3[V@S7G^^'$,Q$)
MF2S-O-!"OJC'S]=K^*TJO-35I]?S4>/!S.INI?FW;'=VNN9,4*6TLI\'5Q?C
M(31^*!<)9D:*_\QQ,NB%)B0ET5L",W)&K*!@>A$QH\.:/>N>7#I^T]/]9X(=
M0XX\,GHNA@E;/ .U$JOWO,+LNQQ;0)F^SV:.DTD$U ]S()AI!)2<+\W<QVVM
MW6E>W!?C&A0Y4G=>>D7)YYAGI@;$OTIK''QS&%ZXP_ A\%Y923\6&:-V$8I&
M8MBVO;/3<+(SX. JDN31._(H)6,SJVZ6T_Q<HTPLP4 DFVXV&C38>F/XB&;A
M?C<O&"JN\Z0;C8*T#>AX4O0]LZK&QNAKCAYW5_]+:,P/A_VAV(]HW#?;_IS>
MNV9 "T7RS"&WD]=-;&B%(6K,?&M]JZ<-G:B5-K-LBC_,.)AA:6(WK,&4#^"V
MU4PA",[NZ3TC,H;>_Y;^-G.#E3D.A-KBO.U3YZG/+;A"JK+<ZN$CO@!$/R0I
MPBT?BN2=_.UQ?R;S5QQM4T+W;&<L$4:Y?<G@$4GX(_S,,XF !W$I+7O#BH>-
M>96"-_(8 _L%/LG_KIK:-'[V)B-VEI115D5"Z_<L@8PD*>O:<[O9D'7: LCH
M NC60',K%-Q(.!3-Q@=<YRF2'9Z#]T%TKS2LC;'H[*Q>INI'H>8I5 +4C[UO
MU@Z#YZ[RKA<$(!&HF$$WJ16L574OW-1A^,H;1XV9*:YL6.5 '0<U9HQXJ$K3
M:5F0),QF)AA0A5>>AH)Y5(<9G:>*D889!>-QU5&TV=D8VJ[6ZSC+PV))\,;H
MX2KR/Y.RE6\=$E9_-KK%K1=W%FWK[:AL;Z83W85XU:4:"SQS\GF(O8B5+A'L
M6AD+-G"ULS85>Z2QGZW3%<WKLLA:G@F'N=AH74*&B&LAJ\?.;\ONTYY! GG;
M+25;;L!G?:0Y7]%$X^EF.0/G)^*%Z>[:H^01ML;*,.7X5J8(:R8Y;+C'L5KU
M? ?,_A+ 1K,DC?>$WD?K,/.!Q[#(:?@__\5[ET X9*41C5(_Q<DA2$&7*']<
M:FZ6CG1V",7=K:\N+R*JI"?EE#G:P2R5@E8TV%"I.Y/GCJ2#FTKRECV5%!)D
M)L"+WGHG0S_[3+G3+HQ6(,\4*T8Z4Q,1.E$^4SQ8*E[MCGX#] ',:#(/LCOM
M[=;A.1V^-%-3BO&%4BI@,XW!LN8F:C7N(DU$;;99C/AP9#;$U>;1.\;4<;]#
M"0N4&9F,IV%[3"O;&:JF('A&K^C6BXJ&$R61Q1F563L&+##B.[/D;L3_Y$7>
MEG6^I=(0(=5@U(A7A,@83T<-X$B4-45X3>V!,&2Q?;JS7\+98=75S)7VCMXP
M=VWX=@'U'SV:'CGFE+L6CW7GGB A.V[EEMMC9F=)LI7[!L_B.1B+]&]!>Z98
MZ/5*@8<9*>:-0 Q4*K'50"= ,:/'+*+$5EFPQ=,%6"//BZK9FRZ'<.AA6M%,
MC2ZG<6RY7C53,\PXZ)!H;3-O-G0:3CKJX&P,5'5$VX<L 7:1)-?Q_C6(./!3
M9 U^JU<U=;TJP3/X<\;($I@Y\0,OI<%Z15]V\0'^M7YD^BBSQ5ZM_Y,%M":F
M^@5L-7O$7=^0#:&4^T7R8G,"2XITV)3[$!H\% ,1[66B""9-\-63%VUET6SU
M=^??DO#UWOW6G77$>P=-+8A]A06Q/<;]5I6VP.XHEX;_0YQXX4<:9X?KT$N2
MO&,=TT84Z=6:61C!42==:^=='DCN0SA+18N+S"17@7/IJ4Y*U<\;U7!>R/J/
M7I+2F+!\GSB,M\>KR/]XC,B:_Z,4__#A)\!I\!#GJ*YF?Z%;F,J#0HJA,O?.
MU#\XIC85TW1WM0=.MO8B]@Z*"$WNHRLXG'1'DL"3P6@Z$15IROFA;#2J[8]R
MLZ9P395:M2D=Z_5SZY6FX!?/V6MR(*S^<7HTOO.*22/NL;IGG)64,2B?V#NF
M$!BRC1K/G((^X%%(X05^!\_ND/\DT*K%J\UP_IB]M52_*$.QR:01]_CD^?9D
M8#)IRE=[5S2:LP;S)9PQ;Y9@F>O281A_]:(UZ3YAKW?L50;R<L]BJB2\W'H9
MY]*J87"[CJ,D\ GE_R@;=</6O]<(+J,EW*5D>,>\"GY<4%FY;9+ S4EDZH5V
M&J:3>P(%=1L%OQ+_WH=-PZ.#!_OE]JCB;H'2VBS$F"39GOC7&9Q.E.8CS8]Y
MI-_#A,+F7BFH8=&VC)R&/TFT9I_S*UO#;HZO(8L[1TY#'WW,Z'KG)2 1&;,.
MPT++^QC'_M<@#&_?07U*.8^[(2QP-F#4H.*3X_Z&<U2-<37NHQ0D X/J'!>Q
M^6O.T'<?K>,]>0!NRJX#<P;Q&Y$1?W4H9$CRF:2K#1.>*2@0KUG*P_7C)W*
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M0VYZY#EI80B\B-$4,[#UM2/L@63CWZ.91]8-EMRMUT)1!$9<+$84<C<K+CO
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M>?HYGJ.LAD5?JP5Q7C$L6>_(WOO__G]02P,$%     @ "#AA67U!L J*:
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M,KE(+L@RL9:=N9!__OE$1\];#0),:W/XHT1'F9K#[S(4 Z.4E.*FG6Y1E2S
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M57"&2;G!K75T5><XCQ1N#QU$L"PXJF[^Q/.!QQ^6M2W1V('9GL$:X6,7JLA
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M&P?9[&.N[_U<3;BGK>.>CG<1]_0<CD!TGA08JF+;TBGGYU79WO].G33 1VN
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MT]L9$1^X?O9S I]KIHKJ:E_0T(WW]>2T,0&X_^M!&I+;7KU3UH*W<[=@+=C
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M!P+!+A^E5_>!>F:ABFP_(#\A_G )GV*'K=*\P[G1Z<)H+^Z9&7'70>>9YA_
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M5V%UM:\BJ.* \RHPE]9HN$G8.0W"CC/U.2&\;ZTNV@*;F:P]#S% <L9]KR"
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M])27N'%XN !/O21N"BHVK_S D-U93<='@8&YC[/E/>H:$9DZF"UOBCI?.B<
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MGQ_L_0P.W4!@A4CJXZAO4)"7\M+=O0A%6PD@@NN6JOC-E!8K0+D82Q=$"*U
MAWHH:U_*UZH$5AN]2(DZ@%O"NE'+(SV4*&7HBS-*"NZ#HXF3F%-921V059@9
M1%E33:6CT"^L("[$B4&RC -TR*-$4J$"<S:9EHJ3TF*W@A/+$!)+5 'I:AR-
M?R5 ACAG6![$T\;DCJW;96NRSM8[*\@&:>^N/7?F+O)]+ 51DCNC.8DL=TAG
MRMF(I]R*.6>0Q9(G4DD_HZCRIF9I!0GT"LRIR'_-="7G"UH^K3M4E+9 YKH0
M!:>IL2(X$+*_(6@,;A42&)] 02L#F6!F6Y$45Q!9H)P^;3#N:+I=FJ8'>X,Q
M5V50'L(P9!FF7W*,Z',WI%'+&/8.4EI=WIQ:!5IB091!5R5PB2G][2[<1>SY
MPAHH.\T^OFW"DGG>&U8:J(8"_>E2Y4\:/SMF;9=9 @6PPNPF]FF+LDZ+PI.;
M&?8)ND<QJ$G3TA+$5P*^FZK-C?/X@%Z/8F6.=NSK37ZV?UN9#-F*FK1F7ON>
M(H?"!BOMO>IRX=E!Y=>(NT5\3&H6V TBR'P8DEJ"9TS)*U#U;NN:?>/S1^F#
ME'Y&O'S>NS(O[[TK$UZ.B3FE&TOI("5;)=5218@5GQ#W;N2)2]\X)HO>6+>(
M-<,-K#//I?< 'U+JQ& X2P9"HH>AEGWD'@JC(^'%WY2SSI<,^*N4V(&P.I0Z
M#;NK![=NOSP)8&V=<L]<"OG!7E]A%H2.2&04[>O1#F$J 2E0QXF+'90)\"L*
M_*JL*(1^(9\+[^OF^_V?1*QZLZ/:5;U!;+C @@X66G,[">LT$,L@D3!;:U3A
MI\/8TY4Y#C\.4^A-K?,WOAK9A98[/GWVWDH?(\C,H@@T$-T0A OY$=XBUT1J
M5-&7U&.CQD AF.;#^F6XK;4.\D*9&>#3R<A4 L>OT11I]65"U.9S_+KH@?KV
M(*#[&6$5LS.<WSS!*6XWV%'KZ'C+WZ]N;33>S.*]>WZI%]P7)!]!#>*P24D?
MFG\!MP[=X>=\/[CZS>O7=),]PJ';^"YS[[EB>V]C*)[M2)R,)&3L[4+.SJN$
M\/%]H_M_/Q/[[ZH7'C@)&].Q&D_OIN3!.K[X64Y-?_F"JIZ;@[7AH<-3J>+.
MT>&I(43:")A7BKU8.5NU<I(J4S"-JLT+6O:Q>V6NNT*Z0O%93$\78?]\B,)A
MK+436'7,/F\N%(Q B\=R-.M^V=;&Z:P^1?^?>B9K>3)K9-<0+'4X!N<\MSZF
MTW+=ZP]P!*O;84(33+&O(IYA7A!S->$S%X[-]0[I[-WK;WJ'X=3>_P!02P,$
M%     @ "#AA61&9 C&.!   #A\   T   !M9"UE>#,R7S$N:'1M[5E1;]LV
M$'Y>?P778(4#6+9E-UDC>0&R+-VZH6W:;,!>*?%DW4:1*DG%=G_]CI+E)/;2
M(FX=9',"&+'$(^^^N^]X-&^<NT(>/V'C'+B@_VSLT$DX/OLS& U[X;C?/))
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M!\B#S>LZH(D!_G? ,P<FXG+*Y[9N1(_[OIM]_&3<K_O@_P!02P$"% ,4
M"  (.&%9MFT1<Y 6! !\U00 $@              @ $     :6UG,C8P,C<R
M-SDV7S N:G!G4$L! A0#%     @ "#AA65D!=-?+; $ ^B 7  \
M     ( !P!8$ &UD+3(P,C0P.3,P+FAT;5!+ 0(4 Q0    (  @X85FX28)[
M">H  ,K[#  /              "  ;B#!0!M9"TR,#(T,#DS,"YX<V102P$"
M% ,4    "  (.&%9?4&P"HIH  "I10, #0              @ 'N;08 ;60M
M97@Q,%\Q+FAT;5!+ 0(4 Q0    (  @X85D<B:AG^ <  *XW   -
M      "  :/6!@!M9"UE>#,Q7S$N:'1M4$L! A0#%     @ "#AA66R<;=G_
M!P  O#<   T              ( !QMX& &UD+65X,S%?,BYH=&U02P$"% ,4
M    "  (.&%9$9D",8X$   .'P  #0              @ 'PY@8 ;60M97@S
=,E\Q+FAT;5!+!08     !P ' *8!  "IZP8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>md-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20240930.xsd" xlink:type="simple"/>
    <context id="C_809640ed-b7ff-4176-8579-f511b0405d13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_85aec564-a952-4cd7-9508-5cbe268b1c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_884a565f-15d0-484c-a843-754c3a3fd51c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8893f8cd-4da1-451b-89f6-37ca8812969d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_89ef8a38-8113-41c1-8884-93ceeeec10b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8a373077-e7b6-4d74-ad52-6daa978d5cf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8bcf80cf-5670-466b-a111-7a4f4df2f96f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_8d0e1e7a-bcf8-46ca-91e1-c0bdbcb1a4a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8da3915f-acc7-4713-ba2c-89d5082ed5ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_91bb3025-d080-4133-988b-b4f0d0b089ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_97646255-9ce5-4a28-beb9-59eb7df4e021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_98c7bf66-2c4f-46e5-b8f2-acc2d7acc7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_9c587590-b2d8-42e3-8e9e-97f94e51d556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_9f3f07b8-2273-400e-9dac-e0d7b41207ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_9fe3e6f6-dfe4-49b2-b5b9-6a12b9a5ec2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a064a518-736d-4c03-94ce-b34a0a334113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_a5ff1526-329f-4f0e-adea-d07328710c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_a75a21da-6809-46e5-af03-95d29f9164a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_a760bed3-e7a4-433b-9d43-3760b6d240a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_a97a53d9-d7b3-4f52-bcbd-33dcc1fc5933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_adcf8579-3d6b-4b9f-8e99-6447b79239ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b044401a-b565-4c10-a46e-4df13e21403c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_b0a769b5-fd85-4a51-83ff-76f342c6430e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b33c435b-217f-44e6-b52c-795ccaa7b00b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4c72fe0-fa90-4fdf-a008-6fff4568447e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b8197466-b836-40f5-85ec-515f06dd7959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_b8fc85c6-2e4a-4259-af7d-66c68b0e250a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_bb151c97-9f7d-4189-b1ec-f8da6602d134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_bc533806-93ff-49e5-b0c8-9cf97c0129d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_bc621510-11b6-4741-b375-b503a329d672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_bd4aca94-0492-4f7f-9862-fa2bf57c6c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_c365d25d-3bf1-4fdb-a10e-5da8bba0e06b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_c3888977-2554-47aa-831d-fd567a5a82f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_c4f7fa0c-4852-41a3-8551-93e9d6ff41e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_c879f931-4318-47fc-90a7-3a99688432aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_c8c92c28-c7af-413c-ab11-7994e195cbdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cb429657-52b5-4ff8-a2fe-c7f05b728717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ccf152cf-ccd9-4e3b-ad6d-b551a5ad3dc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_cd2b3074-957c-47ae-bd82-52e354aedc65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_cf9e856d-4f62-44c9-bc0f-62baf73c9b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d17aad46-7efb-49af-8377-5895940b3823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_d4d03e6c-0505-4dfb-a0aa-1fb8302e51db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_d8733763-56e3-4062-ae80-9b406c362d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_d9374888-7c91-4cc7-a16b-1f318051fca5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dbb37038-35b4-4678-82a8-8d91cb359de4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_dc569cc7-6aeb-45b2-a43d-509db2773e16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e3929a3a-e631-4b36-ac48-9798696c3593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_e3d4fda8-e2c4-41b7-b7bb-a79d5f1f5fb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_e4f361e6-00e7-4dbe-9266-268c420fcb04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_e5b15b48-9344-4b59-8c84-5acf6a9e4f95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwentyFivePerecentUnsecuredSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_e677cfe7-2e92-47c1-bdb2-9ea23c33d51c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_e8baca31-7b2d-488d-8c77-f9c0d2500a82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_edc32faf-e353-493b-84f0-3902b6006c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_efbc84c8-00fb-4a9b-8009-81542e40749f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_f729b94a-bdc8-4113-a994-f4e604bdbebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_f9508b9c-3eec-4609-8305-3008f33d44f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_f9c9410e-b646-4864-81ca-3b62fc7d8849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_fae578a7-d0cf-4d45-9f18-19ac5559973c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_fc38c255-4fa4-44a0-a508-6debd99e834f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_fc7ad59c-2e25-40e7-af1a-51976aee8220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_fc9712c3-f658-44af-9601-750da0b09a7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fffa0abb-f44c-4f13-9801-32f57a3f6d0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_0310ccf0-c3d9-49e4-aadd-2e067003de46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_03aeeb1a-6712-41b8-b9d7-3904a46932d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_03faae58-4912-4ec2-812d-9cda8660c060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_040f5030-8668-48c5-8848-7595226a4f67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_04afc832-8f3e-408b-8423-2c62e6af5946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_050e4bfe-b9c5-4ca8-9e26-96b6ce67c09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_05ec53de-4d6b-4354-9ca4-75993de13e10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_09f36e04-ed7b-4580-81de-9e91190ac2c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_0a422510-3d44-47cf-88b2-48f0575a1143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a8c0d8a-e7ce-404f-9c3f-9a4becbd6264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_0b429a49-04e0-4af0-a34e-5f729e65b865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_117ba3bc-14b9-4031-9bd2-9c2358d754ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_1202300f-b9c8-495b-8286-dd386fb30e91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_14426c2a-51aa-4302-9c65-7d61956fde41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_185f6642-e06e-4f8e-82da-cc97ce9485fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_1c7a5188-9dfb-4b7b-9117-75232b52d800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_1eb0559c-65bc-419b-9342-1cc866cf8e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_2174c181-c272-4b4a-a55a-328ca7305cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_24781c95-cc49-4f39-8985-1dc5dfaea767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2552545a-460b-438d-84d7-f2a85377d43f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_2859086d-715d-44f6-833b-c4f773353b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_289f4f19-0840-473e-83b2-ff56e944f693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_28fa2519-8122-457f-8ba0-95ed99b3c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_2aac07cf-292c-417d-84aa-0cdee14fc3fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_2bf9eff0-56e4-43b2-93d7-2aa6cebf3f72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2c0855ff-d273-4bff-9e15-451242764f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2da96b5a-a862-41c6-bf8b-5603236a16d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2f2b7c65-5b1c-4fa7-82de-aeef631ca5d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_30923953-448c-4331-a85c-b787cb6bd620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_30fb370c-634f-4103-9fe0-f5ed7b584e16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31f10005-61d2-425a-98d1-6c46c15c52e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_33d9e07d-a996-482e-a2e3-ae221fbaed2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_345a8683-3a40-4392-9de5-24333799ced8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_34b50bdd-0dce-4d36-b6db-803f912a1615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_396c2856-16b5-4b29-9a6d-0cf8c4644545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_3aaa3335-768e-46db-93e1-0c4ef48e3199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_3adf6473-1204-48e7-8491-9b1ef9c81706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_3f03f9d7-2c71-47ee-a8a2-3847457e8827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_40ce43d6-de46-459b-bbd4-173babcdee2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_44ba766e-800a-4319-b85c-312bb5654756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_45ae435c-1042-4b5a-96ae-8bb41d0114d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_46499516-3d0b-4a41-8a39-4fc6b1dd499a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_4706aab8-b042-4ef2-a16d-8c4b37316242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_4a193a2f-b90e-43a7-8dd9-49f38c7c982f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_4c6acf44-78a8-4282-9b87-3142ddf448cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_50c28849-d475-4e33-b9af-f6b8058a8d67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_51656139-59ae-422c-baf9-a869db14153e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_52510259-ebc9-442f-9bd2-61734b97e057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_55792ef2-9526-43dd-a1b0-74ec9336243f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_5621fe56-862f-40f3-af0a-35de308efe0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_5694b95e-c7a4-4c1f-8ca3-731f364b3aab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_56ebd4fc-39c1-4956-8a5c-fcae4efff07b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_58c12c59-2a6c-435e-913c-34398f795390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_59042f13-1f1d-4792-8848-e80880b13fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:MaternalFetalMedicinePracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_5dd0ed8f-b21b-4d66-9790-efa9a58934b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_5fc55157-e10f-464a-8e86-f58de13c1556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-10-25</instant>
        </period>
    </context>
    <context id="C_60eae1e8-e969-481f-9fcc-b8bd60d6c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_670aadb1-d0ce-4bc5-9e7e-daa0c38d0f03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_67b3dbbf-e507-4f3c-9126-f4e687359ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_67fa25ce-537a-4741-a50f-8a52146562e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_69acc370-b79c-460d-aad7-0050c48e4b39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_6cd8e851-3986-4e06-8fd3-aaed9f13e169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_6ee00435-93bf-4611-b09d-2c2deb02faf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_6f592960-a202-4029-b088-c0a2bc84ee92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_70459c21-18a9-41b0-8deb-ec60bf6e856d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_725f7eeb-d657-453d-92fe-1caaa6092c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_73c5246d-4aad-43c5-87f0-58cbadc4d111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_75ee178e-6d00-479f-9b2a-a97ace384501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_79accd32-aa9b-4cab-864d-398239122d36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_7db712e2-9eb1-41c5-a6ef-4225a89f28c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Number">
        <measure>md:Number</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_04ceb4d0-3c0b-4d07-956f-8b518e80af23">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_5ee593a4-c36b-4805-94d8-fcc1170c801c">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2605e4f0-d7f3-4a91-83c9-443ed058d56a">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_0364beb5-1d96-41e0-a43e-51dfdf17c9fd">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      id="F_97cf0492-ca89-4c00-ab6e-b389cf4c47c8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      id="F_03fdf1ea-e076-45b4-a2b0-c8c20cef772a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_11e06b6b-0a67-4cde-955c-f3396d047128">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_c2241f61-e806-40e6-aa87-c672b133c30f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_bd7b144e-9ba2-4d93-bf15-11218cae2d34">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_ce9d2b0d-835f-4bf1-9be4-c9be96d6ab80">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_6dd7ac59-4fc2-40f3-b4ea-1fd66e514502">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2b1b56b4-dd4f-4f66-8c17-36445719f793">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_7fdd7519-930b-416c-bfd6-7afb802dc795">Pediatrix Medical Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_f57c7b35-1d2d-47b1-9c58-1e8082e36911">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_30ae48c3-ca1d-4257-982a-064eb805cf58">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2592c215-b5f0-4c1b-8136-1af69a28c1b6">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_f79dfae1-e4a9-44b9-a76e-751c779c88a2">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_4e884723-f30d-44a3-95fa-eb4bfabcafd9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_5fe3b197-bf69-488b-8637-efa0a2d401d0">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2d635d11-ffcf-4461-89c0-217e6c605cc1">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_14228d05-76b5-423d-a240-ab51d250ecdf">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_f07bddaf-f86a-410f-8b12-c10cf5778dba">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_5ed8dfda-ad1b-47ea-9503-5349555800bc">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_e5ebfe11-dcef-4636-96df-1d309a033e01">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_241d7c5f-9228-4702-a6ca-072698efff81">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_d2e9cd04-ca25-4300-9f07-44604e9c049c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_ddfe655c-734d-4c67-ab93-11905dc00d51">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_b8ad9e8a-9e8f-48a5-a7dd-e591fd952402">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_ea28f89d-79ea-4dd7-8452-c751f89036ca">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_1024017f-4d3a-493e-8a48-fbb355df1e47">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5fc55157-e10f-464a-8e86-f58de13c1556"
      decimals="0"
      id="F_fc6b57b2-81e0-4302-8e3a-48381b9ff203"
      unitRef="U_shares">85880487</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_4ee52ee2-9f31-4aa2-bce4-1c46ae497012"
      unitRef="U_USD">103831000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_27c9a7ba-7b09-475f-9547-200db1062f8d"
      unitRef="U_USD">73258000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_0723dd04-4afd-4aa2-9a11-257ce175f57d"
      unitRef="U_USD">116621000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_1de1e710-13b8-4dec-b8b5-3eb30ca5c02e"
      unitRef="U_USD">104485000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_9eceab14-78a1-4200-b5e9-08e0b4df8d59"
      unitRef="U_USD">286897000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_25d81d9f-2ae1-4410-9e79-7f8eb03cf21e"
      unitRef="U_USD">272313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_acf7d4b7-f71e-40e6-9660-b083c3717851"
      unitRef="U_USD">10188000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_447f4bd5-31bb-44d1-a055-c7060752210e"
      unitRef="U_USD">13525000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_af2b016c-026d-45b5-a485-de69fbfded24"
      unitRef="U_USD">1198000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_85b1eb99-7b64-40c3-93a6-3dd74fe4377f"
      unitRef="U_USD">7565000</us-gaap:IncomeTaxReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_02dad9e9-5c77-49bd-8d14-630debeba370"
      unitRef="U_USD">9480000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_f9535f83-2a56-4d29-af51-a616cdab2367"
      unitRef="U_USD">12308000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_155ac861-6fe9-4d8e-9592-d0def4913a8a"
      unitRef="U_USD">528215000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_210a4b02-c60b-4583-9724-53e2390edd4a"
      unitRef="U_USD">483454000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_05a1c517-e4f6-42ad-a6c1-4beb8cdc726b"
      unitRef="U_USD">41922000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_3f5d8a67-5e82-487a-9392-75153552ccfc"
      unitRef="U_USD">75639000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_b1daed31-a697-4f45-9089-4c3a2d7ad736"
      unitRef="U_USD">1239007000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_0e237540-56da-45a8-9042-61b7c474f647"
      unitRef="U_USD">1384166000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_01326e8f-d52d-49eb-af6e-2a36bdbc2cd1"
      unitRef="U_USD">13183000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_439f3195-c53c-4cdb-8ae1-3a404c3907d7"
      unitRef="U_USD">21240000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_cfa4cb2c-35e4-4540-a3bb-b6ab9b5ceaa8"
      unitRef="U_USD">56566000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_6e3e52e4-dfaf-4950-adc6-ddf08c7dabbe"
      unitRef="U_USD">70294000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_0ecb53e4-5da3-4f3a-847f-6e8d2e42fe62"
      unitRef="U_USD">119386000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_fbeb7ba6-58e8-4406-9a33-a2e12679fa93"
      unitRef="U_USD">102852000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_b9bbc4a9-6de1-40fd-bf55-036304836f15"
      unitRef="U_USD">78594000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_5ddf69ff-0f7c-49b3-9c2e-eade9fb0efb1"
      unitRef="U_USD">82165000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_ca789bfa-8869-4a9f-aed7-983b545b093b"
      unitRef="U_USD">2076873000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_95c2a5f1-681d-42bd-aaa4-f401d58efab8"
      unitRef="U_USD">2219810000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_af8ac6a9-851f-4fc2-8c04-363ed15b472f"
      unitRef="U_USD">333493000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_951bcb67-1162-4226-8dce-19005ba3ebd7"
      unitRef="U_USD">350798000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_9db7b7e5-6621-40b6-bcd5-ffdf9fcae932"
      unitRef="U_USD">19276000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_1289b31e-755d-4983-b274-f88997dc9c25"
      unitRef="U_USD">14913000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_711c041d-3be0-44d0-9b18-16c3eaf61f7e"
      unitRef="U_USD">16992000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_f0af8a90-dfe1-4a9e-a5b2-c9fcdbd5f68a"
      unitRef="U_USD">21076000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_dca941a1-f799-45a4-8eae-6f3399e4a4ef"
      unitRef="U_USD">3319000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_54276184-07dc-4d38-9669-c2ee21f36204"
      unitRef="U_USD">2159000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_e2ac0e77-906c-42ac-b8c9-9f7498e91d41"
      unitRef="U_USD">373080000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_e5038700-a890-43e8-afdd-55fe7c7e0e30"
      unitRef="U_USD">388946000</us-gaap:LiabilitiesCurrent>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_5a87dc5d-79d6-4186-b7cc-a106b14ebd44"
      unitRef="U_USD">607445000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_5f90e43a-7a83-49b7-9971-fca9bd0ff6c7"
      unitRef="U_USD">618421000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_80d31965-9c33-44d7-90f9-e0decaec475a"
      unitRef="U_USD">39940000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_75e8824a-9a3d-4df5-9d29-d301d1b28180"
      unitRef="U_USD">47238000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_f20ec315-12ee-412d-910e-379923edca01"
      unitRef="U_USD">255263000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_176a7283-424d-4657-bd74-b84f8ddffa77"
      unitRef="U_USD">251284000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_10951cf8-3fc1-4619-b4ad-c4d141cd22bd"
      unitRef="U_USD">35618000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_34636e5f-c668-4ad3-afeb-94682f535a65"
      unitRef="U_USD">34308000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_0d1f36fa-b553-4ab4-a01f-aff53f909e53"
      unitRef="U_USD">33035000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_35a1945f-bbd3-41b3-b730-ea6b78239fcc"
      unitRef="U_USD">30552000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_2c6aabef-6cbb-4abe-af3a-8b3503d947db"
      unitRef="U_USD">1344381000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_795a8fa1-9a7b-4360-ad89-2b34e2c913bc"
      unitRef="U_USD">1370749000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="2"
      id="F_3e357319-2166-4f67-8790-061db1c8635b"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="2"
      id="F_cc573127-202c-4e2b-b919-c84b18efacbe"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="INF"
      id="F_7d7379d6-4c6e-4170-82f4-5662c72166fd"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="INF"
      id="F_b29a17a1-d87f-424d-92d7-bda2cf986c64"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="INF"
      id="F_4ef769b8-7da8-45e5-8a43-80f927fa219f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="INF"
      id="F_91a45953-4b7c-446e-8f93-39b6b9d63a20"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_e9dcaabb-31f6-4880-ae23-5f81c61fb685"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_5ce996b7-fff9-49a2-b8ae-1bed4f29d9a2"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="2"
      id="F_596f9e2e-bf35-49f3-8071-75b7e8b0cc70"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="2"
      id="F_1edf0893-e77d-43e3-8d34-cfa8ef02b4af"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="INF"
      id="F_2f0b1b5c-e35d-463f-a136-b45d03ba2c0c"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="INF"
      id="F_6a12b67e-c027-4f41-ac5d-43fe450a541e"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="INF"
      id="F_e0752bf6-997c-46b0-8917-f7f60f7f810f"
      unitRef="U_shares">85865841</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="INF"
      id="F_b25846d6-c39a-4b1c-a127-0af316698c99"
      unitRef="U_shares">85865841</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="0"
      id="F_c297a4e8-e7c3-4826-bebe-610ef6c73495"
      unitRef="U_shares">84018023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="0"
      id="F_77189fe7-72b2-4a70-9ab9-4cc35652bad9"
      unitRef="U_shares">84018023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_ba6dd9c8-75ce-4980-bb31-131562681a67"
      unitRef="U_USD">859000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_f237b0ac-e77b-4d9b-a835-13d1fb2ecb97"
      unitRef="U_USD">840000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_f7aa934a-e3a3-4419-86fb-cbaa60f5e665"
      unitRef="U_USD">1010862000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_71750b27-2106-4bf3-bae5-9a1ac0158596"
      unitRef="U_USD">999906000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_6d1f70d6-a258-4a68-b805-ee775ff6d6d2"
      unitRef="U_USD">-209000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_9ab956f3-f1e6-479d-a927-a92a7fc908b2"
      unitRef="U_USD">-2214000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_e1b62756-c8fc-451d-bc2c-ad8c5b525310"
      unitRef="U_USD">-279020000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_addcb141-a1f4-4eb1-9557-8d2fea4dd332"
      unitRef="U_USD">-149471000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_a392af9b-ce57-4091-a983-1afa09dc630d"
      unitRef="U_USD">732492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_95d07c75-2761-4ddf-abe8-16dc2f296309"
      unitRef="U_USD">849061000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_550cab18-5c53-44be-bf77-a33eccf31e89"
      unitRef="U_USD">2076873000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_afd815bb-8909-4b5b-90ba-c7655b2d6e16"
      unitRef="U_USD">2219810000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_9243fa23-fb42-4b27-9ea6-0f99df60948c"
      unitRef="U_USD">511158000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_90c83378-7db1-435a-8a4a-91ec8fa41540"
      unitRef="U_USD">506612000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9a27342e-354f-431f-b3ec-4511bc111570"
      unitRef="U_USD">1510555000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_e4148e09-4fd0-4956-9edc-e5eb9a64ae17"
      unitRef="U_USD">1498197000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_8fc44ed2-4961-4e5b-905f-92e56a33dacf"
      unitRef="U_USD">364888000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_d41e3447-bfa6-4dc2-9658-2c9722bce16f"
      unitRef="U_USD">368404000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9d9c070c-98c5-4a50-9edd-d235556598b6"
      unitRef="U_USD">1091834000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_dc79784b-8cfb-44cf-ab49-6c5788a907d2"
      unitRef="U_USD">1084671000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_edc22020-7975-46a7-895b-8b814abe0edf"
      unitRef="U_USD">29449000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_dd2f2598-5318-477c-b452-d56204b4a103"
      unitRef="U_USD">31319000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_a3cc6c31-6096-479b-bc09-e0bc95d6e952"
      unitRef="U_USD">92903000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_0c4132f4-abad-42db-926e-f75c26bea65e"
      unitRef="U_USD">93128000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_ec5a6bad-dc90-4203-9c35-ec714ea0c840"
      unitRef="U_USD">58121000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_d534f0e1-bff6-4721-b593-7bb5982eec09"
      unitRef="U_USD">57406000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_1ed8b1ca-2dbe-4336-b6b6-815e94f5e620"
      unitRef="U_USD">174884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_40383417-04ea-4059-afa1-608dbd56ff3e"
      unitRef="U_USD">174478000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_9b195aff-52ff-41b9-9481-608ed38c62bf"
      unitRef="U_USD">6254000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_959dbcf0-2053-41f0-84c3-ff406558c0ac"
      unitRef="U_USD">9211000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_8daa1971-61ee-42c2-a896-6376f4ed0db5"
      unitRef="U_USD">25353000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_22bd1254-7128-4c93-bc79-4ba925ad2dc7"
      unitRef="U_USD">27109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_c338fff3-82fd-4b4c-8443-9180d1c41f4e"
      unitRef="U_USD">18560000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_0bd3e033-b83f-4073-963c-3a6db9bff28b"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_00e641cf-7afc-4fda-8877-f669a6ed2826"
      unitRef="U_USD">40619000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_a7618d7a-d8d3-449e-8e86-5c9942f901fd"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_e1f6d519-58cb-4166-b3e4-ec26370c271d"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_534b3cd3-51cd-49f3-9802-b10d0b8584e1"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_823e499a-96c0-4c2d-9add-a4f031f97983"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_ab82f566-1c01-4778-ab80-44d61fb8b541"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_b06589ae-e259-40b2-8dbe-f023fa2729d6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_a3e2c12b-3119-498e-a87e-45cbd23760f5"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_23b7f413-d7cf-4346-a33c-833b72302f52"
      unitRef="U_USD">20112000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_04c896d5-66db-49c6-a85e-768885242306"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_c90f127b-64d7-48de-afb5-6c56dd786fb2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_0c19df50-8fe0-44a0-aee6-a514f5bbf017"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_65dc921f-c25b-48c0-b0e5-581130ee283d"
      unitRef="U_USD">7679000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_4d1c8985-fd2e-49ea-aa92-e519f745849a"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_e71fbbbd-cab2-405c-b6fd-193142dc5a11"
      unitRef="U_USD">-59000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_b23cccf2-5ab6-4529-b2bc-ec1812e865c7"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_50acff3c-650c-4a7d-b120-781771c97485"
      unitRef="U_USD">-10932000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_ba170ca2-33b8-45ad-97b6-431577145271"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingExpenses
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_a02aad2d-ab9e-403b-acfe-35454b1014f3"
      unitRef="U_USD">477331000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_bdbeb39c-b317-4f64-8dcd-a5ba67c91a49"
      unitRef="U_USD">466340000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_e4e7d4c7-e10d-4b6f-b3e8-258d287ca2bc"
      unitRef="U_USD">1618559000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b3d2c6c4-4025-4029-8019-3c31b23bc600"
      unitRef="U_USD">1379386000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_bb11224e-01bc-407f-8692-4bd0a849d6a1"
      unitRef="U_USD">33827000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_b1e3ff46-5cc5-47b1-95af-8b30686c24c5"
      unitRef="U_USD">40272000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_312a3c35-3aff-40ea-861e-0cd12793a654"
      unitRef="U_USD">-108004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_2b43dd7e-3462-4291-a95a-25a2b03c4fc8"
      unitRef="U_USD">118811000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_22b08fa5-35de-4a1a-89d7-015c4b7735e1"
      unitRef="U_USD">1089000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_ced4f766-317c-4be7-97da-ed154d9cc905"
      unitRef="U_USD">273000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_cb38734a-9126-445a-9272-1d22e3bbeb78"
      unitRef="U_USD">2941000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_07d126fb-4145-4d57-8ccd-45b503fea900"
      unitRef="U_USD">2096000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_ff4ab45c-10ac-4a23-b7fb-667493ff26df"
      unitRef="U_USD">10126000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_355ef0b6-dc2d-4c25-a2bb-ed24a6e813c4"
      unitRef="U_USD">10374000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_92a46e29-248a-4b7c-b91d-5e0b923e416e"
      unitRef="U_USD">31033000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_181c7469-5198-4034-8b61-9fea8de9abd9"
      unitRef="U_USD">31994000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_4e01f941-5a2f-4a95-936e-4079ff03aa7f"
      unitRef="U_USD">445000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_7128dbf0-96cb-4a53-a4bd-771a3ce5272f"
      unitRef="U_USD">661000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_e5217329-9c15-48aa-8f0e-52ccf1d70716"
      unitRef="U_USD">1427000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_6d5fb3fe-9e51-454a-afe1-f9ce5b52991a"
      unitRef="U_USD">1578000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_1d6a78bc-2943-4c66-a9e1-687d35386c73"
      unitRef="U_USD">-8592000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_62c50ff4-77c4-4f41-87c5-c0cc9307b7c9"
      unitRef="U_USD">-9440000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9555e640-a87a-4a1b-96e9-80855f2686a7"
      unitRef="U_USD">-26665000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_169748e8-9c7c-4075-8c56-31db1fbac81f"
      unitRef="U_USD">-28320000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_5f7d3a60-1ab8-46cf-8f30-50134cd64532"
      unitRef="U_USD">25235000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_8920078f-f3e4-40cb-921f-1788f712e7e4"
      unitRef="U_USD">30832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_1140302e-795c-427d-b113-60a73406f6b7"
      unitRef="U_USD">-134669000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_d5fdc864-a601-4502-92b2-34f910bd5805"
      unitRef="U_USD">90491000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_a675820e-6455-4af4-8442-34361ccdeeb8"
      unitRef="U_USD">5794000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_8a0cd06f-befa-43c3-b4b0-40201fdea52e"
      unitRef="U_USD">9441000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_fe4e0f18-1181-464d-ad3d-2657ad4ad2ac"
      unitRef="U_USD">-5120000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_deed8b59-3cec-448b-9454-67574ae92168"
      unitRef="U_USD">26612000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_182fff8d-a9ac-4f61-afa3-924ec352549c"
      unitRef="U_USD">19441000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_3404cd50-173a-419e-983a-b62cf05caf1a"
      unitRef="U_USD">21391000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_57e20d45-7071-4b8f-af49-cbdba2fb95cf"
      unitRef="U_USD">-129549000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_6547994e-4aed-480e-82c0-7b8d5308e01f"
      unitRef="U_USD">63879000</us-gaap:ProfitLoss>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_1737a2c6-2a62-4b5c-8f0c-6defa8594de8"
      unitRef="U_USD">571000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_7280c3de-a1f0-411b-8a65-18033418c1b6"
      unitRef="U_USD">657000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_859cd922-276e-433b-8263-81c598c582eb"
      unitRef="U_USD">100000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_aae55aa3-a26f-4bb1-8f22-d023a2486cdd"
      unitRef="U_USD">1745000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_ed1ae2c8-d84b-4954-88fe-11d90385d58f"
      unitRef="U_USD">1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_fa213146-ac7e-4ad1-b699-4071ac7fed97"
      unitRef="U_USD">2005000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_9a62d6a7-a613-4ba2-885e-8fca7c544aa9"
      unitRef="U_USD">218000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_35644fd7-fc30-4e88-8e8b-aa1f626b00f3"
      unitRef="U_USD">21186000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_06ac8cb8-90a9-4abb-a36b-9424474ca5ca"
      unitRef="U_USD">21392000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_630dd46f-31c3-4975-8f4e-679ff749f5e1"
      unitRef="U_USD">-127544000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b5be0016-2c29-4f27-9e75-da2bb1bad174"
      unitRef="U_USD">64097000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="2"
      id="F_406f60a6-1c7a-4339-8491-06e88e2c75e0"
      unitRef="U_USDollarShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="2"
      id="F_68ed4890-617f-4240-8e17-3ce46e45d54b"
      unitRef="U_USDollarShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="2"
      id="F_b0f245bc-52ed-42ec-b757-a8681961dc73"
      unitRef="U_USDollarShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="2"
      id="F_228c1f79-7b3d-46db-a135-d03864992471"
      unitRef="U_USDollarShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="2"
      id="F_eef37e3e-c3dd-4fda-98b7-308948649d36"
      unitRef="U_USDollarShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="2"
      id="F_7545d10e-a861-4975-94f3-77160acb52d7"
      unitRef="U_USDollarShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="2"
      id="F_7fe52162-4589-4a0f-829e-302d0f590b13"
      unitRef="U_USDollarShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="2"
      id="F_9c99103b-9654-404a-9bd3-370779079253"
      unitRef="U_USDollarShare">0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_2a3e1aff-04ca-4a1e-9bd4-f48cb7fede12"
      unitRef="U_shares">83891000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_60e36c40-0425-467b-b8fc-8c47a977547c"
      unitRef="U_shares">82543000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9936538f-2050-41cc-8405-1dba1ff022b9"
      unitRef="U_shares">83223000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_73dfb7ee-bc20-4658-8f55-ad7e1942731b"
      unitRef="U_shares">82127000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_82e8b708-da14-4388-bf51-a600d94ed0ee"
      unitRef="U_shares">84523000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_7254651a-2f19-4815-aa08-9993bb5d8e87"
      unitRef="U_shares">82950000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_34a29fcf-4433-4bd6-980f-63709abd4069"
      unitRef="U_shares">83223000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_401ebc78-8be9-4239-9a63-65414781766b"
      unitRef="U_shares">82492000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="C_8893f8cd-4da1-451b-89f6-37ca8812969d"
      decimals="-3"
      id="F_f9007875-fb54-491b-8e5b-d0fe57a3dd12"
      unitRef="U_shares">84018000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8893f8cd-4da1-451b-89f6-37ca8812969d"
      decimals="-3"
      id="F_881a5d29-115e-4b24-a745-aed0a399b153"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_05ec53de-4d6b-4354-9ca4-75993de13e10"
      decimals="-3"
      id="F_08145efc-4c9b-4f5b-8b6c-7d0829b8efe1"
      unitRef="U_USD">999906000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_30fb370c-634f-4103-9fe0-f5ed7b584e16"
      decimals="-3"
      id="F_79fd8498-c106-4632-8b7a-ec9392d99799"
      unitRef="U_USD">-2214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_efbc84c8-00fb-4a9b-8009-81542e40749f"
      decimals="-3"
      id="F_f4addcf9-e34f-4425-a9b4-bf994faf5832"
      unitRef="U_USD">-149471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_5c91febd-2c45-4024-8e01-f1f9b186e61b"
      unitRef="U_USD">849061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_884a565f-15d0-484c-a843-754c3a3fd51c"
      decimals="-3"
      id="F_d9b6a21c-ab7c-4b11-92a5-23397dab5df8"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"
      decimals="-3"
      id="F_34eceb20-e58c-4ff2-923a-43d95ceeb4ec"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2bf9eff0-56e4-43b2-93d7-2aa6cebf3f72"
      decimals="-3"
      id="F_282b6570-c6c0-4291-9af1-90427c00bdaa"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"
      decimals="-3"
      id="F_5fbf4de2-e785-4c6d-bd46-65e9e4cf34f7"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"
      decimals="-3"
      id="F_8daabeca-a4f5-40ee-aa45-9ccb0f6aa33c"
      unitRef="U_shares">108000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"
      decimals="-3"
      id="F_5d458556-469e-42b5-9d01-a2d5b3d447df"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057"
      decimals="-3"
      id="F_4972c95e-f110-40f1-ac24-2e1f32e7572f"
      unitRef="U_USD">859000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"
      decimals="-3"
      id="F_557e8e15-1399-4afa-b9f7-d604ac0629de"
      unitRef="U_USD">860000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"
      decimals="-3"
      id="F_a346f2f1-a075-4125-ac53-5c11318dcc96"
      unitRef="U_shares">-21000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057"
      decimals="-3"
      id="F_c4985001-1706-4c79-8de8-46802bbe089f"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"
      decimals="-3"
      id="F_bf5a9758-229d-4d42-abe8-b862d1bfc777"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"
      decimals="-3"
      id="F_6832143b-08e6-44d6-a403-de2f7a8ba19a"
      unitRef="U_shares">97000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_ff6548aa-dc9c-45a8-86f5-5abc61455b6b"
      decimals="-3"
      id="F_a97e1f52-62b5-46b3-b26e-b6050e2ffae9"
      unitRef="U_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_52510259-ebc9-442f-9bd2-61734b97e057"
      decimals="-3"
      id="F_4d82e574-839e-480a-a6f6-a0514d307dbd"
      unitRef="U_USD">886000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_2da96b5a-a862-41c6-bf8b-5603236a16d4"
      decimals="-3"
      id="F_7e5d9b90-760c-4681-8d2e-567930434513"
      unitRef="U_USD">887000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_cd2b3074-957c-47ae-bd82-52e354aedc65"
      decimals="-3"
      id="F_30789c1d-7ee0-4b58-85b8-dd39eeb89842"
      unitRef="U_shares">84008000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cd2b3074-957c-47ae-bd82-52e354aedc65"
      decimals="-3"
      id="F_1293010d-c7c7-4bd7-95f0-69b57d4547e0"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_89ef8a38-8113-41c1-8884-93ceeeec10b6"
      decimals="-3"
      id="F_c8e15f8f-e42a-424a-9e86-3d25cae44a32"
      unitRef="U_USD">1002946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fc9712c3-f658-44af-9601-750da0b09a7e"
      decimals="-3"
      id="F_2594f3be-ae58-4367-a5b1-264049affb7f"
      unitRef="U_USD">-2154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8d0e1e7a-bcf8-46ca-91e1-c0bdbcb1a4a4"
      decimals="-3"
      id="F_78cc7bce-c5e2-4dec-ab59-f0362da20a67"
      unitRef="U_USD">-145436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8a373077-e7b6-4d74-ad52-6daa978d5cf3"
      decimals="-3"
      id="F_4e0bf102-7c8e-45a7-b5d8-67e985c48867"
      unitRef="U_USD">856196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_cf9e856d-4f62-44c9-bc0f-62baf73c9b06"
      decimals="-3"
      id="F_e9f06f47-9329-4c13-af4d-97383a3fa759"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-3"
      id="F_3ca1c6fc-aa50-4513-ab12-a2df85379179"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e8baca31-7b2d-488d-8c77-f9c0d2500a82"
      decimals="-3"
      id="F_4712b0fe-fdc0-4581-ada8-5bd3b6a6bf67"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-3"
      id="F_3f9ad690-afd4-4849-bd79-7b23fa8300d0"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_24083caf-a8db-4220-a6cc-5010b7eb64e2"
      unitRef="U_shares">139000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_13f9a7bb-140b-4ce9-9030-d81d7af8e494"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a"
      decimals="-3"
      id="F_864f3a2d-3418-496f-9fbb-f0063cb73db2"
      unitRef="U_USD">1147000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-3"
      id="F_327bf89c-0d97-491b-85c5-fd72a1708d51"
      unitRef="U_USD">1149000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_34004f60-7397-4fef-a9bf-6e12c9acd0b2"
      unitRef="U_shares">1630000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_c0eca4fb-e5af-4ea3-8347-2f865d3b31f6"
      unitRef="U_USD">16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a"
      decimals="-3"
      id="F_d15e3af2-9c07-40e3-8b0b-682c6dd80aa5"
      unitRef="U_USD">-16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_25c54fa5-9e9b-48f5-9c1e-5e5531cb5526"
      unitRef="U_shares">-22000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a"
      decimals="-3"
      id="F_c550671c-3480-4659-9676-82f119d2add7"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-3"
      id="F_88e438ec-2a52-4f7f-aa51-a50ead7267ec"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_f729b94a-bdc8-4113-a994-f4e604bdbebe"
      decimals="-3"
      id="F_9aefec75-7239-454b-a74e-1b5469a466aa"
      unitRef="U_shares">2000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_ab502aa8-05b3-48f4-a006-56ed6fb87a6a"
      decimals="-3"
      id="F_07c1b30f-e61a-40dd-acda-a0cb4839a886"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-3"
      id="F_572567db-b486-41ba-bb96-6b462be89b22"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_31f10005-61d2-425a-98d1-6c46c15c52e5"
      decimals="-3"
      id="F_4a7e5428-efdd-40ce-84fa-81034963872e"
      unitRef="U_shares">85753000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_31f10005-61d2-425a-98d1-6c46c15c52e5"
      decimals="-3"
      id="F_2c27a870-6c01-4afe-a256-01408fe00979"
      unitRef="U_USD">858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b4c72fe0-fa90-4fdf-a008-6fff4568447e"
      decimals="-3"
      id="F_94972ec0-b477-4715-905f-852e8b9bd6a8"
      unitRef="U_USD">1006018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_98c7bf66-2c4f-46e5-b8f2-acc2d7acc7bb"
      decimals="-3"
      id="F_3fc5daf7-0230-4cc8-87e9-e08180c5a81b"
      unitRef="U_USD">-1954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fae578a7-d0cf-4d45-9f18-19ac5559973c"
      decimals="-3"
      id="F_4168e834-1c15-4445-9d10-8845130fa233"
      unitRef="U_USD">-298461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3adf6473-1204-48e7-8491-9b1ef9c81706"
      decimals="-3"
      id="F_38b211d4-9d0d-46ec-9f65-9cbedddf3155"
      unitRef="U_USD">706461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_59042f13-1f1d-4792-8848-e80880b13fd6"
      decimals="-3"
      id="F_ce9303b2-9267-4f86-bbd8-04dcf77f9e2c"
      unitRef="U_USD">19441000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_3a697997-ac78-4c6e-b6dd-a9965efd2095"
      unitRef="U_USD">19441000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_85aec564-a952-4cd7-9508-5cbe268b1c48"
      decimals="-3"
      id="F_34ed1fb1-8ec6-4040-979d-ec54f1edd9e6"
      unitRef="U_USD">1745000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_8cedf1c3-1a50-4384-81d7-bcec090ec2e8"
      unitRef="U_USD">1745000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2"
      decimals="-3"
      id="F_0d26a0d9-261b-4588-b452-ac46067b5cc4"
      unitRef="U_shares">149000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2"
      decimals="-3"
      id="F_94fdd05b-677e-46d3-94c2-4330bbbb6c4f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa"
      decimals="-3"
      id="F_964c8e93-52cd-4d1f-9fac-17f3abfd959e"
      unitRef="U_USD">896000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_9cc96f57-2c6d-44b9-8777-f10f408fa3ad"
      unitRef="U_USD">897000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2"
      decimals="-3"
      id="F_09e81e1b-7f16-4764-90d4-44bf06f6dec2"
      unitRef="U_shares">-13000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa"
      decimals="-3"
      id="F_dead753f-78ef-4673-8d64-a0df18268409"
      unitRef="U_USD">4110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_f356b541-1188-4829-a8ce-7392136d5c79"
      unitRef="U_USD">4110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_a760bed3-e7a4-433b-9d43-3760b6d240a2"
      decimals="-3"
      id="F_106b04f9-9d61-4d4d-b0b4-0501935cfe12"
      unitRef="U_shares">23000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_185f6642-e06e-4f8e-82da-cc97ce9485fa"
      decimals="-3"
      id="F_122ffad3-94a8-46f9-96ec-91a220cd9391"
      unitRef="U_USD">162000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_a7aa2926-d28b-47d3-a433-f38b41a078cd"
      unitRef="U_USD">162000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_9c587590-b2d8-42e3-8e9e-97f94e51d556"
      decimals="-3"
      id="F_d76fb465-a47a-416f-8ae0-06cd34da87c7"
      unitRef="U_shares">85866000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9c587590-b2d8-42e3-8e9e-97f94e51d556"
      decimals="-3"
      id="F_0646d7eb-73a6-445a-9895-01c57b5a4f13"
      unitRef="U_USD">859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0b429a49-04e0-4af0-a34e-5f729e65b865"
      decimals="-3"
      id="F_dd0ecdd2-9a53-4b5e-a42a-44866849f6be"
      unitRef="U_USD">1010862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1202300f-b9c8-495b-8286-dd386fb30e91"
      decimals="-3"
      id="F_9c7701c2-fd73-43b8-b0ca-f358c0592b03"
      unitRef="U_USD">-209000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_33d9e07d-a996-482e-a2e3-ae221fbaed2a"
      decimals="-3"
      id="F_a2a714a7-f1cb-473a-a104-476980c8b7f4"
      unitRef="U_USD">-279020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_553bd1aa-9480-4035-86d6-47fe00f656ce"
      unitRef="U_USD">732492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_24781c95-cc49-4f39-8985-1dc5dfaea767"
      decimals="-3"
      id="F_8b234f00-bb37-4308-a629-2c2aaaf6f5f0"
      unitRef="U_shares">82947000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_24781c95-cc49-4f39-8985-1dc5dfaea767"
      decimals="-3"
      id="F_8006be46-d43f-4c1c-bc8e-c112e95fe699"
      unitRef="U_USD">829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_adcf8579-3d6b-4b9f-8e99-6447b79239ec"
      decimals="-3"
      id="F_75f51249-6324-4a0f-beb6-26bbff8546f8"
      unitRef="U_USD">983601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0a422510-3d44-47cf-88b2-48f0575a1143"
      decimals="-3"
      id="F_a2eb333e-3810-460a-80db-dd1967da46e9"
      unitRef="U_USD">-3735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b0a769b5-fd85-4a51-83ff-76f342c6430e"
      decimals="-3"
      id="F_1f158c8f-e3fc-43cd-9f0c-b5535b3f1de8"
      unitRef="U_USD">-89063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_03faae58-4912-4ec2-812d-9cda8660c060"
      decimals="-3"
      id="F_16ecc3d2-b7ae-454a-b1e1-df258b3a6f01"
      unitRef="U_USD">891632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_5dd0ed8f-b21b-4d66-9790-efa9a58934b9"
      decimals="-3"
      id="F_29f02917-c667-4610-81a9-e0cb95db6a42"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"
      decimals="-3"
      id="F_28184a9a-b1a4-4da8-9500-3e79e9ab8e35"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_dc569cc7-6aeb-45b2-a43d-509db2773e16"
      decimals="-3"
      id="F_924981a6-1f5c-4277-81a2-6f1966a86e88"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"
      decimals="-3"
      id="F_86a5c2b3-8ea8-456f-babb-a6733b1e24b9"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_d7afd49c-1004-4d4b-a597-088cfb2d8ac5"
      unitRef="U_shares">86000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"
      decimals="-3"
      id="F_753f76ce-6ebd-465d-afda-b58aa8ff10da"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"
      decimals="-3"
      id="F_8a967808-cd65-4565-93f8-10330c7d34ab"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_43e6d331-5736-4451-b3a1-3aa2904c1cd6"
      unitRef="U_shares">871000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_36ee32f2-09e2-44f1-84bb-19fca4b3a261"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"
      decimals="-3"
      id="F_93eae6bc-e8fe-441d-b60b-d854ba10bae9"
      unitRef="U_USD">-9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_90e1c45d-1c45-42e8-9ce7-9122608663db"
      unitRef="U_shares">-221000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_61b2c33f-01b4-4230-a80c-9fde39d7c9ad"
      unitRef="U_USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"
      decimals="-3"
      id="F_c4beb80f-bb8f-4fd9-9c36-91c84081bb6b"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"
      decimals="-3"
      id="F_fbe79cb9-25a2-4ff9-b410-02ee93b32571"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"
      decimals="-3"
      id="F_006cabe5-26c9-48e7-aeba-9426d998e4fe"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_1ee18f6e-83b2-4532-bfa6-08cf8414bede"
      decimals="-3"
      id="F_7a355f07-d90f-4159-9f92-21d89b4b04c8"
      unitRef="U_shares">49000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_cb429657-52b5-4ff8-a2fe-c7f05b728717"
      decimals="-3"
      id="F_9a28e255-f92c-4c5b-9663-f17f1b53ffe9"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_f0a6bcb8-e61c-4153-bca5-6df21e0cac16"
      decimals="-3"
      id="F_2a603d32-ae24-49a2-9c10-c5bf32a71dbb"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_6ee00435-93bf-4611-b09d-2c2deb02faf4"
      decimals="-3"
      id="F_7b5ed819-f71b-4d36-99b9-709320a2492b"
      unitRef="U_shares">83634000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6ee00435-93bf-4611-b09d-2c2deb02faf4"
      decimals="-3"
      id="F_e6886f71-1792-4bc9-baf7-a57ae98445fa"
      unitRef="U_USD">836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_56ebd4fc-39c1-4956-8a5c-fcae4efff07b"
      decimals="-3"
      id="F_22e44de4-64e5-4af3-8c98-a5b30000a19f"
      unitRef="U_USD">986923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_28fa2519-8122-457f-8ba0-95ed99b3c132"
      decimals="-3"
      id="F_ebd0d21c-bc2f-4ffd-961c-a1ff78e1ddc5"
      unitRef="U_USD">-3131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_30923953-448c-4331-a85c-b787cb6bd620"
      decimals="-3"
      id="F_ffc5adea-b61b-468f-99d2-64cd0da3d0e9"
      unitRef="U_USD">-74857000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6cd8e851-3986-4e06-8fd3-aaed9f13e169"
      decimals="-3"
      id="F_c468695d-547e-48f3-baf1-44391332f59e"
      unitRef="U_USD">909771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f2b7c65-5b1c-4fa7-82de-aeef631ca5d1"
      decimals="-3"
      id="F_ef728f33-da10-49e1-9835-84704cc5a663"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693"
      decimals="-3"
      id="F_2b332763-70d1-4750-b94d-d3ce5e2d5276"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c3888977-2554-47aa-831d-fd567a5a82f3"
      decimals="-3"
      id="F_89f284e1-21db-4da6-a778-893c6f579bb5"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693"
      decimals="-3"
      id="F_b13d9adf-5ea7-44b1-8731-af65d89dc0ee"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_5c195e58-dcc6-4503-baa0-236a7cfac1f4"
      unitRef="U_shares">126000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_860d0a94-b36c-4c84-823f-f64b4414bccf"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_79accd32-aa9b-4cab-864d-398239122d36"
      decimals="-3"
      id="F_40113e71-9bb8-4a5a-acd4-edb2042be8cc"
      unitRef="U_USD">1593000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693"
      decimals="-3"
      id="F_a748bf60-c3a0-475f-bbc0-15fc38322a3c"
      unitRef="U_USD">1594000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_0acb138c-6536-4b47-8553-e918668b857a"
      unitRef="U_shares">93000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_e824f0fb-10e4-4e35-82c1-5eacb2b4a052"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_79accd32-aa9b-4cab-864d-398239122d36"
      decimals="-3"
      id="F_a80e7efd-83b9-44f9-a848-2bd66e15fd75"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_fc4087c3-9f95-4ad7-8237-922261c864d7"
      unitRef="U_shares">-11000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_79accd32-aa9b-4cab-864d-398239122d36"
      decimals="-3"
      id="F_6df3fed1-b765-40c5-8c5e-e4c60512390a"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693"
      decimals="-3"
      id="F_372a764f-5d71-4813-a2aa-2d697f8e6353"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_84300ee9-2b0b-431b-ac4e-6f4cc5887581"
      decimals="-3"
      id="F_499d4dff-5e7d-461b-9899-7272b636fa91"
      unitRef="U_shares">1000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_79accd32-aa9b-4cab-864d-398239122d36"
      decimals="-3"
      id="F_246a600f-ebce-42a2-a283-e9e2f49234c7"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_289f4f19-0840-473e-83b2-ff56e944f693"
      decimals="-3"
      id="F_4317b774-32eb-421f-bf37-f99a0c412643"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb"
      decimals="-3"
      id="F_c426526c-be83-4d52-93b0-5a21d086e56f"
      unitRef="U_shares">83841000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8c4c0e65-2d0d-4709-bebe-b7b75de8bddb"
      decimals="-3"
      id="F_a15e0199-e9ce-41c7-b65b-eb617ba8e757"
      unitRef="U_USD">838000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f9c9410e-b646-4864-81ca-3b62fc7d8849"
      decimals="-3"
      id="F_c0ba5f67-055a-432b-9f14-d0b289c6f39f"
      unitRef="U_USD">991630000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_40ce43d6-de46-459b-bbd4-173babcdee2c"
      decimals="-3"
      id="F_de69b6ec-6446-476a-835d-09ae3058a8dc"
      unitRef="U_USD">-3518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d8733763-56e3-4062-ae80-9b406c362d7b"
      decimals="-3"
      id="F_fb4ad4f2-902b-4fce-a99d-03a5dbdb9b03"
      unitRef="U_USD">-46575000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_75ee178e-6d00-479f-9b2a-a97ace384501"
      decimals="-3"
      id="F_32a30e91-3484-46cd-93f7-32ab684d75eb"
      unitRef="U_USD">942375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_670aadb1-d0ce-4bc5-9e7e-daa0c38d0f03"
      decimals="-3"
      id="F_5b00dbec-1924-4132-b290-f382621adef7"
      unitRef="U_USD">21391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_f288d4da-e299-4ae4-824d-419a9c505ceb"
      unitRef="U_USD">21391000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e3929a3a-e631-4b36-ac48-9798696c3593"
      decimals="-3"
      id="F_f40430a3-a602-49d1-b3c4-96ed525f0190"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_f6d3a1f5-cfa5-4629-aa57-125aa985561b"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d"
      decimals="-3"
      id="F_a57ffeac-9c87-47db-b48a-852f786ac3a0"
      unitRef="U_shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d"
      decimals="-3"
      id="F_7018933c-fa88-4f31-8fb0-9ebc0eb239d5"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242"
      decimals="-3"
      id="F_5f4a0c3d-7f6e-49ac-bae9-3274e99ee70a"
      unitRef="U_USD">1186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_090239b0-0626-4da8-8822-517e46d7ff4c"
      unitRef="U_USD">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d"
      decimals="-3"
      id="F_cde5a612-9ad0-4ac7-85ad-57489cd04075"
      unitRef="U_shares">-1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242"
      decimals="-3"
      id="F_c6f3ced9-c611-4a38-94cc-7b774f774897"
      unitRef="U_USD">3164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_b6a002df-51a2-4c35-873c-1078621e1416"
      unitRef="U_USD">3164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_54be8c98-bb02-4dc3-ace3-2dd32ea5c17d"
      decimals="-3"
      id="F_162f8642-91df-4bd9-84ce-9015dc41809c"
      unitRef="U_shares">11000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_4706aab8-b042-4ef2-a16d-8c4b37316242"
      decimals="-3"
      id="F_5fcb6e73-3ae8-49dd-a26f-f15c4c25ffee"
      unitRef="U_USD">133000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_4eab5345-81f8-41f4-84e2-4de03d7e5a9f"
      unitRef="U_USD">133000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_a064a518-736d-4c03-94ce-b34a0a334113"
      decimals="-3"
      id="F_8e74cfb0-26a3-48d1-9aa3-ab9e732701b5"
      unitRef="U_shares">83929000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a064a518-736d-4c03-94ce-b34a0a334113"
      decimals="-3"
      id="F_1eeb4b47-3385-44c4-bf2a-70e6e4231648"
      unitRef="U_USD">839000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_51656139-59ae-422c-baf9-a869db14153e"
      decimals="-3"
      id="F_3f673304-778d-4df7-b108-06404452a7f6"
      unitRef="U_USD">995847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_67b3dbbf-e507-4f3c-9126-f4e687359ae4"
      decimals="-3"
      id="F_57c02a51-427b-4132-b99e-54006970306d"
      unitRef="U_USD">-3517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4c6acf44-78a8-4282-9b87-3142ddf448cd"
      decimals="-3"
      id="F_d6a3e822-a942-4e01-bed1-41fd4fefd79a"
      unitRef="U_USD">-25184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a"
      decimals="-3"
      id="F_97a93635-059e-496c-8618-d36e7d92b466"
      unitRef="U_USD">967985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_90fafb30-906c-4f58-9913-34c9c0ed3a7b"
      unitRef="U_USD">-129549000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_62a654fd-af25-4157-8bf1-4e7d7f6f523d"
      unitRef="U_USD">63879000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_5766d7dc-48ce-4c80-9dc6-37f0815c2b04"
      unitRef="U_USD">25353000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_466a526e-e7ad-4612-8185-6fec38d984f9"
      unitRef="U_USD">27109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_b79a5172-ffd5-4b49-ae85-9a73b6abe55f"
      unitRef="U_USD">703000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_fb492cfb-7d1d-4820-8870-73c5267eb814"
      unitRef="U_USD">1015000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_0a8cdc6f-14fd-4873-831d-8af3279c9e0d"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_76276fd4-5079-4012-a429-4594c4c9d2d0"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9fc964d8-d3b4-4ee2-9565-060d9eba7b9a"
      unitRef="U_USD">20112000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_330855a2-8766-495b-9c12-d0129f271be2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_bddfa3e3-f738-4ff0-8de0-5f8933e9a106"
      unitRef="U_USD">7679000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_4fd7d5dd-0662-4126-8a68-0e84611d320b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_9c1ebe13-de5e-40a3-be0a-ce95dc078c5e"
      unitRef="U_USD">-10932000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_f6f1d26d-2a58-48ad-8a80-d13c71af4ec5"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_2275e0d5-f9cd-4c3c-8c29-99cd4008701a"
      unitRef="U_USD">9129000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_92237417-7b9e-4b42-b485-e96934d5595e"
      unitRef="U_USD">9299000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_94dee9be-1e79-41e0-9940-e2372d8b6031"
      unitRef="U_USD">-15880000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_4d8f7c49-d54e-4614-88c6-643f6e4fba0d"
      unitRef="U_USD">10589000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_6869cc85-2c85-4a09-9c68-df5c61ec17a3"
      unitRef="U_USD">2006000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_df408842-e026-4287-92b4-73a31dc59508"
      unitRef="U_USD">1607000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_c50740f2-d07f-490f-a612-8434b3ae4260"
      unitRef="U_USD">-635000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_df5d4a07-6405-4819-b84d-684db45f3b6b"
      unitRef="U_USD">-22095000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_92678b49-969f-40de-a287-f59139eefa08"
      unitRef="U_USD">-5945000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_5808cf81-6ed4-4105-af84-f82645aad1f6"
      unitRef="U_USD">-4290000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_424c9b57-d00a-4a9c-95a9-7bb05b681447"
      unitRef="U_USD">-30569000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_526c4d9e-f485-4ce9-9559-a795808a414d"
      unitRef="U_USD">-13343000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_39887d58-e611-438b-85ae-59e22c8333ff"
      unitRef="U_USD">-34154000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_d5862071-4aa5-4d8c-a53b-dd1f6261faa5"
      unitRef="U_USD">-56118000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_386ed3e7-6ad3-4abb-a5e8-a57bdb5f938f"
      unitRef="U_USD">7527000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_24636f4e-5284-4262-befe-8489761a1c5d"
      unitRef="U_USD">-5154000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_99da1697-9173-41c0-ae87-bd71796a5bba"
      unitRef="U_USD">13239000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b13f7e96-91f2-4ded-9913-73f7b7834fba"
      unitRef="U_USD">838000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_94b58cbf-3773-44e9-a3e4-aa92008633a8"
      unitRef="U_USD">-22032000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_e8f60f57-a3e0-42c2-87f7-4710968cd96f"
      unitRef="U_USD">-16500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_0a0abb09-5bb7-4494-98db-db5b075941e3"
      unitRef="U_USD">82445000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_f10dd24a-a77b-4cf1-bf00-7272aada3288"
      unitRef="U_USD">73078000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_1bcfffdc-12cd-48e2-852a-82cc803aedfc"
      unitRef="U_USD">-8882000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b0fd93f4-cc37-4611-b666-f1c90e2199a3"
      unitRef="U_USD">-5003000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_54368098-a7cc-4b41-b6c3-e2aef86a7d38"
      unitRef="U_USD">73563000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_d9a5f571-fee5-4bff-b66c-cf49f7ef6f6f"
      unitRef="U_USD">68075000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_93a76fd9-990c-4df5-bd79-a9b9d50a8ab6"
      unitRef="U_USD">8167000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b4d03f17-cab1-43d2-9aca-57cb7b0b1ff2"
      unitRef="U_USD">1667000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_976af25f-258f-4abc-a243-c387a489399b"
      unitRef="U_USD">54402000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_4d03b042-4ea3-4034-becf-e90db7b5b619"
      unitRef="U_USD">26477000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_2cc28736-310b-4ac2-a5ce-3792b6a86c8d"
      unitRef="U_USD">45324000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_addc87a0-da78-455b-a244-05791933c7ab"
      unitRef="U_USD">16560000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_c1a571d7-c63f-4b00-aab4-ac28e5e4807a"
      unitRef="U_USD">18582000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_3cc4b303-bb2b-4832-b877-5cc2118446e2"
      unitRef="U_USD">24284000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_39e87c20-927e-4ae9-8236-4238ad7baeb2"
      unitRef="U_USD">2359000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_fb237aa1-3d42-47fe-af6e-6b772764e37d"
      unitRef="U_USD">116000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_ce21890b-943d-4362-b33f-d653f163f55e"
      unitRef="U_USD">-33468000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_9834bb42-c784-414e-97b9-14fdb87172e1"
      unitRef="U_USD">-35752000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_84cce854-06b2-4775-b44d-fb21bc4dcd2d"
      unitRef="U_USD">235500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_d31854de-ae24-4975-9e02-7d2ae57a026f"
      unitRef="U_USD">470000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_98997c90-dbbb-4006-8326-59515f2e7c90"
      unitRef="U_USD">235500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_0c114055-7aa3-4ec4-969e-a4e0e3d773ca"
      unitRef="U_USD">474000000</us-gaap:RepaymentsOfLinesOfCredit>
    <md:PaymentsToTermLoan
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_15488656-a7d7-4fd3-b401-b1eb98cb882f"
      unitRef="U_USD">9375000</md:PaymentsToTermLoan>
    <md:PaymentsToTermLoan
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b4fbe4ca-d21e-4f4d-a966-9c786b38671c"
      unitRef="U_USD">9375000</md:PaymentsToTermLoan>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_705c4743-2cfc-41d0-9082-661b6a32ae6c"
      unitRef="U_USD">2045000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_ee6dfdce-0fa9-44af-99ee-ad8b257fe38b"
      unitRef="U_USD">2105000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_8cb1828a-d550-48a0-bc88-cc86880af45d"
      unitRef="U_USD">2906000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_37d4aa4d-a0a0-410e-8dd3-f7435287c510"
      unitRef="U_USD">3876000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_b101a879-cb91-4329-9f99-5947c607c087"
      unitRef="U_USD">1060000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_6924a63a-18cc-4076-a45a-8e65daf1cbf4"
      unitRef="U_USD">919000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_0ca9ef0d-6941-4f01-b14b-f2b431f1d51b"
      unitRef="U_USD">52000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_451baa41-c243-4fba-a440-68b7f17caa29"
      unitRef="U_USD">-8445000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_74a84f51-6211-4d67-9f8d-6b8a7e882a18"
      unitRef="U_USD">-9522000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_b3b5126f-6a6c-44d8-83d1-74019266f789"
      unitRef="U_USD">-20968000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_f7cbcc2e-3b33-4050-aa84-8d2a32af8088"
      unitRef="U_USD">30573000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_dfb6dc93-4ba0-4948-9ab7-7db7fb4320e4"
      unitRef="U_USD">11355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_ca5fa813-9886-498d-9511-90d211e5162b"
      unitRef="U_USD">73258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_03faae58-4912-4ec2-812d-9cda8660c060"
      decimals="-3"
      id="F_c67660c7-df86-43ef-98b3-6d8266e743b9"
      unitRef="U_USD">9824000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_8cabbef7-c1d4-4cd6-8080-e80ec19cb883"
      unitRef="U_USD">103831000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f7e5ef4c-7f47-49d2-9ca4-4f2dc8538d6a"
      decimals="-3"
      id="F_6c647b93-81bf-435c-a6db-83de8e79ae01"
      unitRef="U_USD">21179000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_a832276b-8241-47d8-b463-41f35d1e5289">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;            Basis of Presentation:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#x201c;PMG&#x201d;) together with the accounts of PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#x201c;Pediatrix&#x201d; and the &#x201c;Company&#x201d; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Compan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;y is a party to a joint venture in which it owns a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form 10-K (the &#x201c;Form 10-K&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_a75a21da-6809-46e5-af03-95d29f9164a1"
      decimals="3"
      id="F_dde27613-b583-40e4-87ad-be433f315919"
      unitRef="U_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_44362b54-de59-4d3a-90c6-7311bd4919c2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.            Cash Equivalents and Investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2024 and December 31, 2023, the Company's cash equivalents consisted entirely of money market funds totaling $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.833%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.389%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_34b50bdd-0dce-4d36-b6db-803f912a1615"
      decimals="-5"
      id="F_e86f400d-8f19-4a04-b519-b5342e696d15"
      unitRef="U_USD">700000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_a97a53d9-d7b3-4f52-bcbd-33dcc1fc5933"
      decimals="-5"
      id="F_e413be99-1ab3-403e-8c77-05af2d2b2713"
      unitRef="U_USD">2800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_4b014ad5-5dbe-4cc2-b8f4-5a9dd3a90264">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.833%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.389%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1c7a5188-9dfb-4b7b-9117-75232b52d800"
      decimals="-3"
      id="F_06c0d111-f25e-4d77-9956-0fb98e9a6aef"
      unitRef="U_USD">50602000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_97646255-9ce5-4a28-beb9-59eb7df4e021"
      decimals="-3"
      id="F_6a3af728-8bb0-4ba6-b80e-455c018f0af6"
      unitRef="U_USD">57878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_91bb3025-d080-4133-988b-b4f0d0b089ec"
      decimals="-3"
      id="F_fbd97f8e-4af0-455d-8451-05ff6b5ba80c"
      unitRef="U_USD">35105000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b33c435b-217f-44e6-b52c-795ccaa7b00b"
      decimals="-3"
      id="F_80b27ef4-b570-4300-a2ad-daab902135dc"
      unitRef="U_USD">22674000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9f3f07b8-2273-400e-9dac-e0d7b41207ad"
      decimals="-3"
      id="F_4fbe65b1-975b-4e7c-b713-3799b6d51183"
      unitRef="U_USD">21508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_04afc832-8f3e-408b-8423-2c62e6af5946"
      decimals="-3"
      id="F_fabce886-e16e-4049-8026-b40223f5f142"
      unitRef="U_USD">14649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d4d03e6c-0505-4dfb-a0aa-1fb8302e51db"
      decimals="-3"
      id="F_cc60bd7d-c03a-4b44-9b3e-98a1dd965b69"
      unitRef="U_USD">6673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8bcf80cf-5670-466b-a111-7a4f4df2f96f"
      decimals="-3"
      id="F_a0bd4118-b54a-444d-b9d3-df37e2535776"
      unitRef="U_USD">5670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c4f7fa0c-4852-41a3-8551-93e9d6ff41e3"
      decimals="-3"
      id="F_049fcb44-5d9a-4a8e-b95e-553a77bc6427"
      unitRef="U_USD">2733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d9374888-7c91-4cc7-a16b-1f318051fca5"
      decimals="-3"
      id="F_8516f9eb-213c-44d1-9d1b-d3b4a90ef70c"
      unitRef="U_USD">3614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_f1dc4727-3e88-4648-99b2-acdbb17af4d1"
      unitRef="U_USD">116621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_1ca08e92-ca6d-4880-bf28-8634240ca9e2"
      unitRef="U_USD">104485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_df3da8f3-c5d7-4f92-82b6-c905a5f6701c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.            Fair Value Measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.889000000000003%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2deac78c-f340-4383-b25e-685b60749b9a">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.889000000000003%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8"
      decimals="-3"
      id="F_223bac66-6302-48de-908c-ca680557b952"
      unitRef="U_USD">711000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_2c0855ff-d273-4bff-9e15-451242764f8c"
      decimals="-3"
      id="F_64a5002d-e412-4f84-8f09-68a492b90c17"
      unitRef="U_USD">2814000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f9508b9c-3eec-4609-8305-3008f33d44f3"
      decimals="-3"
      id="F_af3aa034-a34a-4551-92f2-05425829d379"
      unitRef="U_USD">116621000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_bd4aca94-0492-4f7f-9862-fa2bf57c6c59"
      decimals="-3"
      id="F_96af9a3f-409a-470c-a865-b969e6867a6d"
      unitRef="U_USD">104485000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_c8e17a0c-c35a-49e9-a6e6-9928d41ab7d8"
      decimals="-3"
      id="F_98271640-192b-4e99-be86-c7e6bee9b5b4"
      unitRef="U_USD">18708000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_2c0855ff-d273-4bff-9e15-451242764f8c"
      decimals="-3"
      id="F_f162285d-6436-4673-9871-5657c66b4f87"
      unitRef="U_USD">17687000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_f069ce59-d1ea-461c-9c11-6cccd63e6a21">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="C_345a8683-3a40-4392-9de5-24333799ced8"
      decimals="-3"
      id="F_be603f8c-c937-4d4d-8bc6-c12d31716995"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_345a8683-3a40-4392-9de5-24333799ced8"
      decimals="-3"
      id="F_68f61f22-171c-454c-8536-04a826b34bcf"
      unitRef="U_USD">388240000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4"
      decimals="-3"
      id="F_40ac39db-6924-4f45-a6e3-21d714ef0041"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_14af2d30-6df1-452a-81e8-1c3fefb18fe4"
      decimals="-3"
      id="F_b9e2dcbc-8e32-4706-ae0f-24b6b014888d"
      unitRef="U_USD">357000000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_ceee724a-0c39-4117-b23d-234b417d2c71">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts Receivable and Net Revenue:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.29%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.075%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.204%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,469,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,379,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,182,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,106,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;286,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.215%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.131%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.33%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.329%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.442%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,293,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,290,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;215,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;511,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,510,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.578%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_85fbe446-c63b-447f-9d5f-6e322127af68">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.29%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.075%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.204%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,469,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,379,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,182,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,106,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;286,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_7751a1b2-4eea-4f02-9569-f2a09be425cc"
      unitRef="U_USD">1469676000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_e871cb83-ad34-421f-894c-d9fdce8fd846"
      unitRef="U_USD">1379213000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_65be70a7-d954-4075-94bf-a491bd61b13c"
      unitRef="U_USD">1182779000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_b0ad1d72-bf43-4376-b265-f973cb46c9fd"
      unitRef="U_USD">1106900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_883a52d3-9438-4ad7-8d74-73f164d249de"
      unitRef="U_USD">286897000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_e5826253-2740-4f63-a7b8-1b85ecf15c3a"
      unitRef="U_USD">272313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_efa7c735-657d-4f29-a64c-88405dcd4191">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.215%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.131%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.222%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.33%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.329%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.442%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,293,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,290,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;215,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;511,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,510,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e677cfe7-2e92-47c1-bdb2-9ea23c33d51c"
      decimals="-3"
      id="F_261c8b12-cf4c-41c9-9b61-ff27ef0ee09b"
      unitRef="U_USD">438675000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_67fa25ce-537a-4741-a50f-8a52146562e2"
      decimals="-3"
      id="F_617420ae-eae8-444a-a595-bd562156f31c"
      unitRef="U_USD">437321000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_3f03f9d7-2c71-47ee-a8a2-3847457e8827"
      decimals="-3"
      id="F_571f6c6a-aff9-4636-961c-cbd07e7923c3"
      unitRef="U_USD">1293353000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_dbb37038-35b4-4678-82a8-8d91cb359de4"
      decimals="-3"
      id="F_3ee942b4-6c0e-4cac-8627-9a03c168093e"
      unitRef="U_USD">1290888000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_69acc370-b79c-460d-aad7-0050c48e4b39"
      decimals="-3"
      id="F_ce71abcf-721f-42ad-831f-2bc741e32010"
      unitRef="U_USD">72413000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_50c28849-d475-4e33-b9af-f6b8058a8d67"
      decimals="-3"
      id="F_640a73b3-0379-4f49-bc9d-ede44334d438"
      unitRef="U_USD">68712000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_a5ff1526-329f-4f0e-adea-d07328710c94"
      decimals="-3"
      id="F_99f2edfe-570b-4914-82db-ce5c5639184b"
      unitRef="U_USD">215129000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_44ba766e-800a-4319-b85c-312bb5654756"
      decimals="-3"
      id="F_2ac0a52b-2271-42d2-98e5-f3764ef884dd"
      unitRef="U_USD">204286000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_d17aad46-7efb-49af-8377-5895940b3823"
      decimals="-3"
      id="F_e0292ffc-069f-4fe0-8799-7ab0f44e9504"
      unitRef="U_USD">70000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_725f7eeb-d657-453d-92fe-1caaa6092c16"
      decimals="-3"
      id="F_0b7fccc3-1550-45b9-a6ed-c914fbf13c86"
      unitRef="U_USD">579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_5694b95e-c7a4-4c1f-8ca3-731f364b3aab"
      decimals="-3"
      id="F_aacfd200-dc66-4052-9e00-8a1678fced81"
      unitRef="U_USD">2073000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_73c5246d-4aad-43c5-87f0-58cbadc4d111"
      decimals="-3"
      id="F_2bc14e35-c384-4a02-a5d6-122f2ab3c390"
      unitRef="U_USD">3023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_c0178574-8205-4504-9450-41cfea327829"
      unitRef="U_USD">511158000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_cd4f3df4-c51c-4466-afa9-fb4a8d1b9502"
      unitRef="U_USD">506612000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_f07c6e5d-0de5-40b1-b644-9aecfb42b030"
      unitRef="U_USD">1510555000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_cd730396-8f14-46f7-83bb-712b9cb45e2f"
      unitRef="U_USD">1498197000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_2731b9a5-f183-42f9-804a-0fc9f6832f76">&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.578%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_2aac07cf-292c-417d-84aa-0cdee14fc3fb"
      decimals="2"
      id="F_a1a60b14-90e2-4241-8eeb-4ed142dfc3cf"
      unitRef="U_pure">0.72</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_4a193a2f-b90e-43a7-8dd9-49f38c7c982f"
      decimals="2"
      id="F_fdffd6a6-6768-428a-91cc-95bcdd83eb0d"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_ccf152cf-ccd9-4e3b-ad6d-b551a5ad3dc6"
      decimals="2"
      id="F_a9e32a25-e195-459b-b7d9-c0beacb70f76"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_fc7ad59c-2e25-40e7-af1a-51976aee8220"
      decimals="2"
      id="F_7cc32d65-6942-46ed-a49d-598165d81b89"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_e3d4fda8-e2c4-41b7-b7bb-a79d5f1f5fb3"
      decimals="2"
      id="F_6fb79a2f-28dd-4713-bfc5-add7a87eb153"
      unitRef="U_pure">0.23</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_9fe3e6f6-dfe4-49b2-b5b9-6a12b9a5ec2b"
      decimals="2"
      id="F_736da600-edc9-4ad2-8cca-ec6c426354fa"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_c879f931-4318-47fc-90a7-3a99688432aa"
      decimals="2"
      id="F_f7d63c32-89eb-41e9-941a-8e73e57a715c"
      unitRef="U_pure">0.24</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_fffa0abb-f44c-4f13-9801-32f57a3f6d0e"
      decimals="2"
      id="F_d82ca19a-ee39-4c1c-b801-139b36759a94"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_0a8c0d8a-e7ce-404f-9c3f-9a4becbd6264"
      decimals="2"
      id="F_a483f393-3019-4130-a1b9-33062438d8f6"
      unitRef="U_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_040f5030-8668-48c5-8848-7595226a4f67"
      decimals="2"
      id="F_57f007d8-1f24-426e-83ca-acda6fd09652"
      unitRef="U_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_117ba3bc-14b9-4031-9bd2-9c2358d754ba"
      decimals="2"
      id="F_683acf1c-1bec-4a2e-a7c5-45851613f982"
      unitRef="U_pure">0.03</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_c365d25d-3bf1-4fdb-a10e-5da8bba0e06b"
      decimals="2"
      id="F_07b62f6e-36aa-428f-8278-904686bba96c"
      unitRef="U_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_8da3915f-acc7-4713-ba2c-89d5082ed5ab"
      decimals="2"
      id="F_4f33d521-ca01-4b5e-ae5b-6d64ba24f960"
      unitRef="U_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_7db712e2-9eb1-41c5-a6ef-4225a89f28c2"
      decimals="2"
      id="F_2d5622e9-a873-46d8-bbaa-3c6ecefad317"
      unitRef="U_pure">0.03</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_03aeeb1a-6712-41b8-b9d7-3904a46932d1"
      decimals="2"
      id="F_0c7c2835-17cd-4ed0-aa94-2693c06456cf"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_14426c2a-51aa-4302-9c65-7d61956fde41"
      decimals="2"
      id="F_02534b3f-51bb-406f-8557-042e1afa6921"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="INF"
      id="F_a34f64dc-2692-496b-9ed2-c549f8acaa8e"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="INF"
      id="F_6a2f2de1-22ff-4e07-9efa-1eb0e684feef"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="INF"
      id="F_a5709941-fe58-46c0-93a9-3eb8715ec5a9"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="INF"
      id="F_da27774e-6542-43fa-87e7-63ab614cb9b4"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_eb4ea482-7965-410d-a381-2c501efa25f2">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. 	Business Combinations:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company completed the acquisition of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; maternal-fetal medicine practice for total consideration of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was paid in cash at closing and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as a contingent consideration liability. The acquisition expanded the Company&#x2019;s national network of physician practices across women&#x2019;s and children&#x2019;s services. In connection with this acquisition, the Company recorded tax deductible goodwill of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, fixed assets of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and other intangible assets consisting primarily of physician and hospital agreements of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <md:NumberOfMaternalFetalMedicinePracticesAcquired
      contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6"
      decimals="0"
      id="F_c7c7d09a-550d-4caf-9bba-ecf02ff04da3"
      unitRef="U_Number">1</md:NumberOfMaternalFetalMedicinePracticesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6"
      decimals="-5"
      id="F_a8d5b35e-12e2-4142-9cc4-53aebf3584f6"
      unitRef="U_USD">9700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_5b2d83cf-ad29-4c6d-8b42-45a9b5e1e3b6"
      decimals="-5"
      id="F_9a95086f-4a94-4498-a881-6a9813c67e35"
      unitRef="U_USD">6500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="C_bb151c97-9f7d-4189-b1ec-f8da6602d134"
      decimals="-5"
      id="F_40818292-ba13-4946-ab6c-3c28ca64fe7a"
      unitRef="U_USD">3200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-5"
      id="F_5d877e25-93be-4565-bebc-ad9d03e99867"
      unitRef="U_USD">9100000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-5"
      id="F_d0eb7358-0d2b-4d20-abfb-cc0c55ab80e2"
      unitRef="U_USD">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-5"
      id="F_02eb03f1-453f-42a4-8f77-12942378f218"
      unitRef="U_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_99a088e5-08d4-451d-b4a2-6f0512cfef2e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill, Long-Lived Asset Impairments and Loss on Disposal of Businesses:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The practice exits are expected to be completed by December 31, 2024. Accordingly, a recoverability assessment for each individual physician practice was performed, and the estimated future cash flows related to the physician practices did not support the carrying value of the specifically identified individual long-lived assets. As a result, during the nine months ended September 30, 2024, the Company recorded fixed asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, intangible asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and operating lease right-of-use asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The operating lease right-of-use impairments are recorded within the transformational and restructuring related expenses line item.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company made the decision to exit its primary and urgent care service line based on a review of the cost and time that would be required to build the platform to scale.  The Company divested one of its two previously acquired primary and urgent care practices during the second quarter and divested the second practice during the third quarter. The total loss on disposal of these two businesses was $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company's book equity value. As the Company consists of only one reporting unit, and is publicly traded, management estimates the fair value of its reporting unit utilizing the Company&#x2019;s market capitalization, multiplying the number of actual shares of common stock outstanding on June 30, 2024 by its stock price on June 30, 2024 and applying an additional premium to give effect to the Company&#x2019;s best estimate of a control premium. With respect to the estimated control premium used in its analysis, the Company believes that it is reasonable to expect that a market participant would pay a premium to obtain a controlling interest in the Company. The Company considered information from the public markets for premiums on acquisitions in its industry and also considered other factors, such as the value that may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;This assessment resulted in a non-cash impairment charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, representing the amount by which the Company's book value exceeded its implied fair value, based on its market capitalization plus an estimated control premium. Consideration was first given to other individual and group long-lived assets, and no impairment was considered necessary on such assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recognition of this non-cash charge against goodwill resulted in a tax benefit which generated an additional deferred tax asset of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that increased the Company's book value. An incremental non-cash charge was required to reduce the Company's book value to its previously determined fair value. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, the Company recorded the incremental non-cash charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for a total non-cash charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. A &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% change in the control premium used would have impacted the non-cash impairment charge by approximately $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_44a0ceb8-9c76-4097-96f8-4e6966e2b3f0"
      unitRef="U_USD">20100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_42ed736c-c777-43c4-ae8f-e303ba7c97bf"
      unitRef="U_USD">7700000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_80bffd3f-75d5-41fb-a401-05d4c3a98925"
      unitRef="U_USD">10600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_ca8f08cb-6406-4aa7-bfd1-ce1bb8f78a46"
      decimals="-5"
      id="F_a04c77ab-6525-4269-b493-5afde007a2c6"
      unitRef="U_USD">-10600000</us-gaap:GainLossOnSaleOfBusiness>
    <md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_89273fd2-a4c8-4f3c-b741-8cdf617bb498"
      unitRef="U_USD">130000000</md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-5"
      id="F_70f14755-5750-485c-aaba-ce977f53fc40"
      unitRef="U_USD">24200000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <md:IncrementalNonCashCharge
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_afb52448-4616-4583-93e0-df91fcee42dd"
      unitRef="U_USD">24200000</md:IncrementalNonCashCharge>
    <md:NonCashCharge
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_96aaeee7-90fa-41af-96e4-85c524602359"
      unitRef="U_USD">154200000</md:NonCashCharge>
    <md:ChangeInRateOfControlPremium
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="2"
      id="F_15afec53-fabe-4a03-a5c3-2b29fb9efb91"
      unitRef="U_pure">0.01</md:ChangeInRateOfControlPremium>
    <md:ChangeInNonCashImpairmentCharges
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_14efe4c2-7597-4dd1-a521-33838779b83a"
      unitRef="U_USD">7700000</md:ChangeInNonCashImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_83c1a651-5f3e-40c0-b0b8-b37ed2938660">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.            Accounts Payable and Accrued Expenses:	&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;162,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net decrease in accrued salaries and incentive compensation of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, from December 31, 2023 to September 30, 2024, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_6f7e8fb0-0b81-4b1c-b2c0-d26404fe1861">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;162,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_22e0179b-05a2-4c10-8c02-61aeca790cdd"
      unitRef="U_USD">47367000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_e9b2c3de-b671-486b-9237-1bc11a0bb8de"
      unitRef="U_USD">34588000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_225bd0a1-1400-4ba4-ab3b-fc94c217c6fb"
      unitRef="U_USD">162554000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_fcd761e2-2747-442c-8e8a-feb8e9d09017"
      unitRef="U_USD">193112000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_de0bfb08-71b4-4ce3-ac9c-1aa54332d765"
      unitRef="U_USD">34327000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_85a45e46-ad29-4873-afb5-22c05418f28d"
      unitRef="U_USD">36545000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_7c7e382f-474b-4b79-8df2-4b3457936733"
      unitRef="U_USD">28966000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_5e318a0e-b709-4d42-aef4-8fcbdfd44ee0"
      unitRef="U_USD">32039000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_451b9699-9c87-4723-b06e-6d794dcbe56f"
      unitRef="U_USD">2789000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_12f74a41-e9d7-4ee9-8d20-fa749b12c115"
      unitRef="U_USD">8262000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_242658e0-339f-4898-931f-2fe10e09fea2"
      unitRef="U_USD">57490000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_85c8eff7-15ec-4653-a5ea-62389a27f100"
      unitRef="U_USD">46252000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="-3"
      id="F_8bc170b6-981a-42e7-8c6b-4fd66e21d3a4"
      unitRef="U_USD">333493000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-3"
      id="F_6fc8dbd2-0a5b-4263-a7e2-fc34e75e42e8"
      unitRef="U_USD">350798000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_69fcf467-eed0-4e35-a1ea-898447fd5a35"
      unitRef="U_USD">30600000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <md:LineOfCreditAndLongTermDebtTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_0d0a6c88-4db9-4ba5-8e39-6ce21bf40599">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;          &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Line of Credit and Long-Term Debt:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 11, 2022, the Company issued $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  The Company used the net proceeds from the issuance of the &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; Notes, together with $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million drawn under the Revolving Credit Line (as defined below), $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Term A Loan (as defined below) and approximately $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash on hand, to redeem (the &#x201c;Redemption&#x201d;) the &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% senior unsecured notes due 2027 (the "2027 Notes"), which had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest on the 2030 Notes accrues at the rate of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum, or $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and is &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company's obligations under the 2030 &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Also in connection with the Redemption, the Company amended its credit agreement (the &#x201c;Credit Agreement&#x201d;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unsecured revolving credit facility, including a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million term A loan facility (&#x201c;Term A Loan&#x201d;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on the Company's consolidated net leverage ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At September 30, 2024, the Company had an outstanding principal balance on the Amended Credit Agreement of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;218.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, composed of the Term A Loan.  There was no outstanding balance under the Revolving Credit Line at September 30, 2024. The Company had $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available on its Amended Credit Agreement at September 30, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At September 30, 2024, the Company had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the 2030 Notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:LineOfCreditAndLongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275"
      decimals="-5"
      id="F_771cf373-3137-4a8c-bdd7-c1682819013a"
      unitRef="U_USD">400000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_bf06072e-ecfc-44d1-9c1f-5ea4ff03d275"
      decimals="5"
      id="F_256ec109-48a8-46c2-908d-60a80a9bca4c"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <md:DebtInstrumentMaturityYear
      contextRef="C_70459c21-18a9-41b0-8deb-ec60bf6e856d"
      id="F_2d3a7e01-338f-4ec5-bf80-511948440683">2030</md:DebtInstrumentMaturityYear>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_45ae435c-1042-4b5a-96ae-8bb41d0114d8"
      decimals="-5"
      id="F_4f5c6c44-41c6-4fbb-9071-397a9d0ecc7c"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d"
      decimals="-5"
      id="F_9b807895-064e-4893-891a-2620f0925969"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:Cash
      contextRef="C_ff275f9a-86d5-4413-bca9-3018fc01ec3d"
      decimals="-5"
      id="F_c03e249c-8d2c-4b99-8552-0fd6b60e3dc4"
      unitRef="U_USD">308000000</us-gaap:Cash>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_e5b15b48-9344-4b59-8c84-5acf6a9e4f95"
      decimals="4"
      id="F_eea626ee-095c-4932-8f1a-5f67c8de98d2"
      unitRef="U_pure">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="C_bc621510-11b6-4741-b375-b503a329d672"
      decimals="-8"
      id="F_899a9dc8-949b-47ee-9d4f-9a0e6fda3100"
      unitRef="U_USD">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="5"
      id="F_76671459-cbcb-4326-9182-193be94106f5"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="C_6f592960-a202-4029-b088-c0a2bc84ee92"
      decimals="-5"
      id="F_c1752cc9-11ee-4904-ad66-5192c3f2a275"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_56d20411-dc8e-4635-b269-37de63cefa43">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_dcb71d25-5578-4998-b004-10403784d848">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</us-gaap:DebtInstrumentDescription>
    <md:PurchasePrice
      contextRef="C_a30c4ca9-d086-4fdd-81c1-77b3a5a940ca"
      decimals="2"
      id="F_55bbec7a-5a31-4d10-9276-df0b15f0c38e"
      unitRef="U_pure">1.01</md:PurchasePrice>
    <us-gaap:UnsecuredDebt
      contextRef="C_55792ef2-9526-43dd-a1b0-74ec9336243f"
      decimals="-6"
      id="F_d9a5b84f-740c-41c3-9edf-7098ff7184cd"
      unitRef="U_USD">450000000</us-gaap:UnsecuredDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_58c12c59-2a6c-435e-913c-34398f795390"
      decimals="-5"
      id="F_877be97d-4941-454c-a1f2-28118b702712"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_b044401a-b565-4c10-a46e-4df13e21403c"
      decimals="-6"
      id="F_42c8b1c1-b2b4-4962-985f-aa47125a37f3"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:DescriptionOfInterestRateRiskExposure
      contextRef="C_bc533806-93ff-49e5-b0c8-9cf97c0129d7"
      id="F_5ba46954-fcd3-486d-9e9d-2c9cea039e63">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</us-gaap:DescriptionOfInterestRateRiskExposure>
    <us-gaap:LongTermDebt
      contextRef="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7"
      decimals="-5"
      id="F_60f5d1d6-32d1-4318-b5a9-4254a1b16c02"
      unitRef="U_USD">218800000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_79660855-4d0f-4723-ba46-1bac8c3a5cd7"
      decimals="-5"
      id="F_13503252-c020-46ef-a782-620c9d207c3c"
      unitRef="U_USD">450000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="C_46499516-3d0b-4a41-8a39-4fc6b1dd499a"
      decimals="-5"
      id="F_e1ad7b08-7deb-4147-a3d6-c5257dd065af"
      unitRef="U_USD">400000000</us-gaap:LongTermDebt>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_1d227a5e-fcb7-4251-80c8-e856085bd2cd">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common and Common Equivalent Shares:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to a loss for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million incremental shares are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_eccf6c99-f520-4c34-84c0-da95a8cfdeea">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to a loss for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt; million incremental shares are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_b4eaab1c-1c34-41ae-a1e7-b0d3c2024c76"
      unitRef="U_shares">83891000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_c18afdc1-56ee-4b0f-b810-87c515c49856"
      unitRef="U_shares">82543000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_2554557e-f92a-47ce-bed0-f9399057f0c8"
      unitRef="U_shares">83223000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_3bd0e605-0872-4a24-b362-dc7ef04412be"
      unitRef="U_shares">82127000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="INF"
      id="F_554f20a0-098b-4a43-8639-8d7377037c50"
      unitRef="U_shares">632000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="INF"
      id="F_28c3128d-bf1c-4211-afdf-739d332083af"
      unitRef="U_shares">407000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="INF"
      id="F_3dbe5509-4bef-474c-989c-13ffc8dc1751"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="INF"
      id="F_20724637-3d05-4be7-a24a-1b65bee504db"
      unitRef="U_shares">365000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-3"
      id="F_4e79cdbe-f2f5-4dc5-bb32-c759d8e471c4"
      unitRef="U_shares">84523000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-3"
      id="F_355fa24e-89f6-4ef6-b2d5-80856bfe532f"
      unitRef="U_shares">82950000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-3"
      id="F_2b44df58-ecd8-4af6-8c02-c8a9e1a7b7f6"
      unitRef="U_shares">83223000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-3"
      id="F_89c6b747-f615-493c-9fd1-4e6a99c8735f"
      unitRef="U_shares">82492000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="INF"
      id="F_ddcd6c3c-dace-4aae-832f-ee7dac18f863"
      unitRef="U_shares">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="INF"
      id="F_7f4bc9af-38d7-48e8-8b26-b29b1a54bb50"
      unitRef="U_shares">888000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="INF"
      id="F_cf88c7e6-2a52-422e-82bb-66401ad4566f"
      unitRef="U_shares">389000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="INF"
      id="F_9d0169f2-4dbe-4cfe-85a0-6bff2c4c2a35"
      unitRef="U_shares">1201000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_347e3e6b-5614-48cd-b55a-84c0cf54e9a7"
      unitRef="U_shares">400000</md:IncrementalSharesNotIncludedDueToAntiDilutiveEffect>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_fe92d13d-2a4f-4a16-be18-73ac642c3bab">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Incentive Plans and Stock Purchase Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant and generally become exercisable on a pro rata basis over a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Company&#x2019;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company's common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares were issued under the ESPP. At September 30, 2024, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares reserved for issuance under the ESPP. At September 30, 2024, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the aggregate reserved for issuance under the SPP.  &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been issued under the SPP since 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and nine months ended September 30, 2024 and 2023, the Company recognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_396c2856-16b5-4b29-9a6d-0cf8c4644545"
      id="F_f226a157-c348-44ff-8442-3d9f81cd9276">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0310ccf0-c3d9-49e4-aadd-2e067003de46"
      id="F_1e7e9d72-d2ee-4888-add7-71e939145d3b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_809640ed-b7ff-4176-8579-f511b0405d13"
      id="F_d2fe5dbf-2f23-4411-a066-a79786e8e13d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b8197466-b836-40f5-85ec-515f06dd7959"
      decimals="-5"
      id="F_eb3b4712-4f72-4849-af36-5f1bcca950e9"
      unitRef="U_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5621fe56-862f-40f3-af0a-35de308efe0c"
      decimals="-5"
      id="F_ce70bf30-9075-48a3-a032-91ac2623a00c"
      unitRef="U_shares">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_60eae1e8-e969-481f-9fcc-b8bd60d6c306"
      decimals="2"
      id="F_1a097956-aeda-46a9-89c1-c58db7f14dad"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_3aaa3335-768e-46db-93e1-0c4ef48e3199"
      decimals="2"
      id="F_5b47cf04-da52-4cd6-aa33-08ca274f6eee"
      unitRef="U_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0310ccf0-c3d9-49e4-aadd-2e067003de46"
      decimals="-5"
      id="F_10d13776-b123-445d-880f-4b9dc874e673"
      unitRef="U_shares">400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_050e4bfe-b9c5-4ca8-9e26-96b6ce67c09c"
      decimals="-5"
      id="F_05f7e257-0613-472a-85cf-3b2acdc7f196"
      unitRef="U_shares">1700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2859086d-715d-44f6-833b-c4f773353b3c"
      decimals="INF"
      id="F_d581b3e9-931b-418c-9785-3e6ec0386d78"
      unitRef="U_shares">61000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_fc38c255-4fa4-44a0-a508-6debd99e834f"
      decimals="-6"
      id="F_4a34b9b8-b2b0-4741-a2ec-9a56fe57329a"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      decimals="-5"
      id="F_411cfb91-75fa-4375-a6e5-2a73e8a917ec"
      unitRef="U_USD">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="-5"
      id="F_19b01f9d-546b-4d25-8104-de4cb50dbf3f"
      unitRef="U_USD">7500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2552545a-460b-438d-84d7-f2a85377d43f"
      decimals="-5"
      id="F_2166a6c3-eaa7-499e-8005-bab65f926a64"
      unitRef="U_USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_edc32faf-e353-493b-84f0-3902b6006c98"
      decimals="-5"
      id="F_5c84efb4-6c49-470c-976f-2a7f7e40a8fd"
      unitRef="U_USD">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_1b93cefb-1a72-41b6-a8a7-a40e8e18196c">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock Repurchase Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were purchased under this program during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remained available for repurchase as of December 31, 2023. Under this share repurchase program, during the nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company purchased a nominal number of shares of its common stock for $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remaining available for repurchase under this authorization as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.&lt;/span&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      decimals="INF"
      id="F_cf06eb72-42a3-4d19-856a-9d99bc3b535c"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_1eb0559c-65bc-419b-9342-1cc866cf8e35"
      decimals="-5"
      id="F_49507eb3-7aef-4555-b6d8-6f79dfa58207"
      unitRef="U_USD">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_c8c92c28-c7af-413c-ab11-7994e195cbdf"
      decimals="-5"
      id="F_e0890b37-53ae-4d42-996a-1e56b2b06dbe"
      unitRef="U_USD">4600000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_b8fc85c6-2e4a-4259-af7d-66c68b0e250a"
      decimals="-5"
      id="F_6f486979-c651-48a2-bed2-678baf8b4efa"
      unitRef="U_USD">1100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_09f36e04-ed7b-4580-81de-9e91190ac2c5"
      decimals="-5"
      id="F_2e288d0d-888d-43ef-b77f-8d0a3a485e38"
      unitRef="U_USD">3500000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_2174c181-c272-4b4a-a55a-328ca7305cbd"
      id="F_0a62fd7b-e90c-4673-b4d6-34d9fe75b4b7">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies:	&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2024 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      id="F_6e3b1151-2293-47e7-af74-a9fda180b0bd">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      id="F_ca6047bf-53df-40e8-aa72-5c1e0167731a">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      id="F_c75b8bcd-059a-42cd-a462-f287f5e7949a">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_e4f361e6-00e7-4dbe-9266-268c420fcb04"
      id="F_c20bebc2-d360-4387-a9ad-1602b824a0ca">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_28c3128d-bf1c-4211-afdf-739d332083af"
          xlink:label="F_28c3128d-bf1c-4211-afdf-739d332083af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3dbe5509-4bef-474c-989c-13ffc8dc1751"
          xlink:label="F_3dbe5509-4bef-474c-989c-13ffc8dc1751"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_554f20a0-098b-4a43-8639-8d7377037c50"
          xlink:label="F_554f20a0-098b-4a43-8639-8d7377037c50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_20724637-3d05-4be7-a24a-1b65bee504db"
          xlink:label="F_20724637-3d05-4be7-a24a-1b65bee504db"
          xlink:type="locator"/>
        <link:footnote id="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xlink:label="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Due to a loss for the </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">, </xhtml:span><xhtml:span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> million incremental shares are not included because the effect would be antidilutive.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_28c3128d-bf1c-4211-afdf-739d332083af"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3dbe5509-4bef-474c-989c-13ffc8dc1751"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_554f20a0-098b-4a43-8639-8d7377037c50"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_20724637-3d05-4be7-a24a-1b65bee504db"
          xlink:to="FNT_744c8b1e-b9b8-41e6-bb9a-b20ca1c97fb6"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
